cisapride/JJ motor/NN Effects/NNPS function/VBP patients/NNS syndrome/NN irritable/JJ
cisapride/JJ motor/NN Effects/NNPS function/VBP patients/NNS syndrome/NN bowel/NN
cisapride/JJ motor/NN Effects/NNPS function/VBP patients/NNS syndrome/NN
cisapride/NN agent/NN treatment/NN symptoms/NNS bowel/NN irritable/JJ
cisapride/NN agent/NN treatment/NN symptoms/NNS bowel/NN
cisapride/NN agent/NN treatment/NN long/JJ syndrome/NN
cisapride/NN agent/NN treatment/NN long/JJ syndrome/NN IBS/NNP
cisapride/NN h/VB underwent/VBD patients/NNS IBS/NNP constipation/NN n/NN diarrhoea/NN
cisapride/NN h/VB underwent/VBD patients/NNS IBS/NNP
cisapride/NN h/VB underwent/VBD patients/NNS IBS/NNP constipation/NN
cisapride/NN groups/NNS observed/VBN patients/NNS RESULTS/NNS diarrhoea/NN
cisapride/NN //VBZ treated/VBN diarrhoea/JJ
cisapride/NN //VBZ treated/VBN diarrhoea/JJ
cisapride/NN sec/NN 2/CD 3/NNP longer/JJR duration/NN 6/CD cisapride/NN //VBZ treated/VBN diarrhoea/JJ
cisapride/NNP 001/CD 0/CD +/JJ +/JJ 2/CD lower/JJR frequency/NN 6/CD cisapride/NN //VBZ treated/VBN diarrhoea/JJ
cisapride/NN constipation/NN patients/NNS IBS/NNP
cisapride/NN mm/NN 14/CD patients/NNS IBS/NNP
cisapride/NN lower/JJR scores/NNS relating/VBG severity/NN constipation/NN
cisapride/NN constipation/NN
cisapride/NN mm/NN 14/CD patients/NNS constipation/NN cisapride/NN lower/JJR scores/NNS relating/VBG severity/NN constipation/NN
cisapride/NN mm/NN 14/CD patients/NNS constipation/NN
cisapride/JJ score/NN had/VBD Diarrhoea/NNP
cisapride/NN mm/NN Diarrhoea/NNP
cisapride/JJ score/NN had/VBD patients/NNS IBS/NNP
cisapride/NN mm/NN Diarrhoea/NNP had/VBD patients/NNS IBS/NNP
cisapride/JJ score/NN had/VBD score/NN pain/NN
cisapride/NN mm/NN Diarrhoea/NNP had/VBD score/NN pain/NN
Cisapride/NNP affects/VBZ characteristics/NNS symptoms/NNS IBS/NNP
pilocarpine/NN effects/NNS evaluate/VB designed/VBN models/NNS arrhythmia/NN
pilocarpine/NN delayed/VBD decreased/VBD course/NN tachycardia/NN ventricular/NN
pilocarpine/NN delayed/VBD decreased/VBD course/NN tachycardia/NN
pilocarpine/NN delayed/VBD decreased/VBD course/NN tachycardia/NN and/CC
pilocarpine/NN delayed/VBD decreased/VBD course/NN tachycardia/NN fibrillation/NN
pilocarpine/NN delayed/VBD onset/NN arrhythmias/NNS
pilocarpine/NN delayed/VBD reduced/VBD score/NN arrhythmia/NN
pilocarpine/NN delayed/VBD increased/VBD time/NN rats/NNS arrhythmic/JJ
pilocarpine/NN produced/VBD rat/NN arrhythmic/JJ
cisplatin/NN striking/JJ BACKGROUND/NNP rate/NN effects/NNS neurotoxic/JJ
CDDP/NNP BACKGROUND/NNP rate/NN effects/NNS neurotoxic/JJ
carboplatin/NN advantages/NNS striking/JJ BACKGROUND/NNP rate/NN effects/NNS neurotoxic/JJ
CBDCA/NNP advantages/NNS striking/JJ BACKGROUND/NNP rate/NN effects/NNS neurotoxic/JJ
CBDCA/NNP higher/JJR schedules/NNS drugs/NNS neurotoxic/JJ
CDDP/NNP caused/VBN those/DT similar/JJ neurotoxic/JJ
CDDP/NNP caused/VBN those/DT similar/JJ probable/JJ induced/VBN neurotoxicity/NN
CBDCA/NNP neurotoxic/JJ
CBDCA/NNP neurotoxic/JJ similar/JJ probable/JJ induced/VBN neurotoxicity/NN
propranolol/JJ toxicity/NN
propranolol/JJ toxicity/NN result/NN developed/VBD an/DT Alzheimer/NNP
propranolol/JJ toxicity/NN
propranolol/JJ toxicity/NN result/NN developed/VBD an/DT Alzheimer/NNP dementia/NN
warfarin/NN model/NN hemorrhage/VB
Warfarin/NNP associated/VBN type/NN stroke/NN
PCC/NNP suggesting/VBG treatment/NN ICH/NNP
glutamate/NN subtype/NN modulates/VBZ models/NNS disease/NN Parkinson/NNP
glutamate/NN subtype/NN modulates/VBZ models/NNS disease/NN Parkinson/NNP '/POS
glutamate/NN subtype/NN modulates/VBZ models/NNS disease/NN s/JJ
glutamate/NN subtype/NN modulates/VBZ models/NNS disease/NN
glutamate/NN receptors/NNS modulate/VBP represent/VBP treatment/NN disease/NN Parkinson/NNP
glutamate/NN receptors/NNS modulate/VBP represent/VBP treatment/NN disease/NN Parkinson/NNP '/POS
glutamate/NN receptors/NNS modulate/VBP represent/VBP treatment/NN disease/NN s/JJ
glutamate/NN receptors/NNS modulate/VBP represent/VBP treatment/NN disease/NN
glutamate/NN receptors/NNS modulate/VBP represent/VBP treatment/NN disease/NN PD/NNP
N/NNP effects/NNS tested/VBN models/NNS PD/NNP
N/NNP dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
'/POS N/NNP dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
dibenzhydrylethane/JJ dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
-/NNP dibenzhydrylethane/JJ dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
1/CD -/NNP dibenzhydrylethane/JJ dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
2/CD -/NNP dibenzhydrylethane/JJ dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
diamine/NN dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
AMN/NNP dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
082/CD AMN/NNP dihydrochloride/NN effects/NNS tested/VBN models/NNS PD/NNP
AMN/NNP 0/CD administration/NN oral/JJ reverses/VBZ haloperidol/NN induced/VBN catalepsy/RB
082/CD AMN/NNP 0/CD administration/NN oral/JJ reverses/VBZ haloperidol/NN induced/VBN catalepsy/RB
AMN/NNP 082/NNP reverses/VBZ mg/NN lesioned/VBD task/NN used/VBN evaluate/VB symptoms/NNS akinetic/JJ
082/NNP reverses/VBZ mg/NN lesioned/VBD task/NN used/VBN evaluate/VB symptoms/NNS akinetic/JJ
6/CD cue/NN respond/VB reverses/VBZ mg/NN lesioned/VBD task/NN used/VBN evaluate/VB symptoms/NNS akinetic/JJ
OHDA/NNP cue/NN respond/VB reverses/VBZ mg/NN lesioned/VBD task/NN used/VBN evaluate/VB symptoms/NNS akinetic/JJ
AMN/NNP 082/NNP reverses/VBZ mg/NN lesioned/VBD task/NN used/VBN evaluate/VB symptoms/NNS patients/NNS PD/NNP
082/NNP reverses/VBZ mg/NN lesioned/VBD task/NN used/VBN evaluate/VB symptoms/NNS patients/NNS PD/NNP
6/CD cue/NN respond/VB reverses/VBZ mg/NN lesioned/VBD task/NN used/VBN evaluate/VB symptoms/NNS patients/NNS PD/NNP
OHDA/NNP cue/NN respond/VB reverses/VBZ mg/NN lesioned/VBD task/NN used/VBN evaluate/VB symptoms/NNS patients/NNS PD/NNP
AMN/NNP 082/NNP reduces/VBZ duration/NN induced/VBN catalepsy/RB
082/NNP reduces/VBZ duration/NN induced/VBN catalepsy/RB
AMN/NNP doses/NNS have/VBP effect/NN models/NNS PD/NNP
082/CD AMN/NNP doses/NNS have/VBP effect/NN models/NNS PD/NNP
isoflurane/JJ anesthesia/NN hypertensive/VBP
2/CD determined/VBN extent/NN injury/NN neuronal/JJ
2/CD determined/VBN extent/NN injury/NN
3/LS 5/CD 2/CD determined/VBN extent/NN injury/NN neuronal/JJ
3/LS 5/CD 2/CD determined/VBN extent/NN injury/NN
5/CD 2/CD determined/VBN extent/NN injury/NN neuronal/JJ
5/CD 2/CD determined/VBN extent/NN injury/NN
triphenyltetrazolium/NN 5/CD 2/CD determined/VBN extent/NN injury/NN neuronal/JJ
triphenyltetrazolium/NN 5/CD 2/CD determined/VBN extent/NN injury/NN
phenylephrine/NN indicate/VBP instituted/VBD aggravate/VB edema/NN
phenylephrine/NN indicate/VBP instituted/VBD aggravate/VB improves/VBZ edema/NN
phenylephrine/NN indicate/VBP instituted/VBD aggravate/VB core/NN ischemic/JJ
phenylephrine/NN indicate/VBP instituted/VBD aggravate/VB improves/VBZ periphery/NN territory/NN ischemic/JJ
phenylephrine/NN indicate/VBP instituted/VBD aggravate/VB reduces/VBZ area/NN dysfunction/NN neuronal/JJ
phenylephrine/NN indicate/VBP instituted/VBD aggravate/VB reduces/VBZ area/NN dysfunction/NN
phenylephrine/NN indicate/VBP instituted/VBD aggravate/VB MCAO/NNP
captopril/NN sensitivity/NN Contribution/NNP treated/VBN rats/NNS hypertensive/JJ
captopril/NN treated/VBD rats/NNS hypertensive/JJ
captopril/NN treated/VBD contributes/VBZ importantly/RB effect/NN hypertensive/JJ
hexamethonium/NN infusion/NN resulted/VBD decline/NN eliminated/VBD increase/NN
hexamethonium/NN infusion/NN resulted/VBD decline/NN eliminated/VBD MAP/NNP in/IN
hexamethonium/NN infusion/NN resulted/VBD decline/NN eliminated/VBD MAP/NNP
cyproterone/NN women/NNS thromboembolism/VBP risk/NN venous/NNS
cyproterone/NN women/NNS thromboembolism/VBP
acetate/JJ cyproterone/NN women/NNS thromboembolism/VBP risk/NN venous/NNS
acetate/JJ cyproterone/NN women/NNS thromboembolism/VBP
ethinylestradiol/JJ acetate/JJ cyproterone/NN women/NNS thromboembolism/VBP risk/NN venous/NNS
ethinylestradiol/JJ acetate/JJ cyproterone/NN women/NNS thromboembolism/VBP
cyproterone/JJ ethinylestradiol/NN women/NNS thromboembolism/NN venous/JJ
cyproterone/JJ ethinylestradiol/NN women/NNS thromboembolism/NN
acetate/NN ethinylestradiol/NN women/NNS thromboembolism/NN venous/JJ
acetate/NN ethinylestradiol/NN women/NNS thromboembolism/NN
cyproterone/JJ ethinylestradiol/NN women/NNS thromboembolism/NN VTE/NNP
acetate/NN ethinylestradiol/NN women/NNS thromboembolism/NN VTE/NNP
CPA/NNP EE/NNP ethinylestradiol/NN women/NNS thromboembolism/NN venous/JJ
CPA/NNP EE/NNP ethinylestradiol/NN women/NNS thromboembolism/NN
CPA/NNP EE/NNP ethinylestradiol/NN women/NNS thromboembolism/NN VTE/NNP
ethinylestradiol/NN women/NNS thromboembolism/NN venous/JJ
ethinylestradiol/NN women/NNS thromboembolism/NN
ethinylestradiol/NN women/NNS thromboembolism/NN VTE/NNP
EE/NNP ethinylestradiol/NN women/NNS thromboembolism/NN venous/JJ
EE/NNP ethinylestradiol/NN women/NNS thromboembolism/NN
EE/NNP ethinylestradiol/NN women/NNS thromboembolism/NN VTE/NNP
levonorgestrel/NN women/NNS years/NNS COCs/NNP 1/CD women/NNS risk/NN VTE/NNP
CPA/NNP EE/NNP women/NNS risk/NN VTE/NNP
EE/NNP women/NNS risk/NN VTE/NNP
CPA/NNP EE/NNP taking/VBG similar/JJ risk/NN VTE/NNP
EE/NNP taking/VBG similar/JJ risk/NN VTE/NNP
Haloperidol/NNP induced/VBN parkinsonian/NN
AIDA/NNP doses/NNS 5/CD microg/NN rigidity/NN muscle/NN
AIDA/NNP doses/NNS 5/CD microg/NN rigidity/NN
AZT/NNP induced/VBN anemia/NN patients/NNS AIDS/NNP
AZT/NNP therapy/NNP induced/VBN anemia/NN patients/NNS AIDS/NNP
morphine/NN induced/VBN interval/NN ischemia/NN spinal/JJ
morphine/NN induced/VBN interval/NN ischemia/NN cord/NN
morphine/NN induced/VBN interval/NN ischemia/NN
N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN spinal/JJ
N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN cord/NN
N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN
methyl/NN N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN spinal/JJ
methyl/NN N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN cord/NN
methyl/NN N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN
D/NNP N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN spinal/JJ
D/NNP N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN cord/NN
D/NNP N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN
aspartate/JJ receptors/NNS N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN spinal/JJ
aspartate/JJ receptors/NNS N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN cord/NN
aspartate/JJ receptors/NNS N/NNP activation/NN contribute/VB degeneration/NN neurons/NNS induced/VBN interval/NN ischemia/NN
morphine/NN interval/NN occlusion/NN aortic/JJ
morphine/NN interval/NN occlusion/NN
N/JJ receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN aortic/JJ
N/JJ receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN
methyl/NN receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN aortic/JJ
methyl/NN receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN
d/SYM methyl/NN receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN aortic/JJ
d/SYM methyl/NN receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN
aspartate/JJ receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN aortic/JJ
aspartate/JJ receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN
NMDA/NNP receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN aortic/JJ
NMDA/NNP receptors/NNS activation/NN degeneration/NN relationship/NN investigated/VBD morphine/NN interval/NN occlusion/NN
MK/NNP induced/VBN paraparesis/NNS spastic/JJ
MK/NNP induced/VBN paraparesis/NNS
801/CD MK/NNP induced/VBN paraparesis/NNS spastic/JJ
801/CD MK/NNP induced/VBN paraparesis/NNS
MK/NNP reduced/VBD paraparesis/NNS spastic/JJ
MK/NNP reduced/VBD paraparesis/NNS
801/CD reduced/VBD paraparesis/NNS spastic/JJ
801/CD reduced/VBD paraparesis/NNS
NMDA/NNP activation/NN involved/VBN glutamate/NNP increase/NN induces/VBZ paraparesis/NNS spastic/JJ
NMDA/NNP activation/NN involved/VBN glutamate/NNP increase/NN induces/VBZ paraparesis/NNS
glutamate/NNP increase/NN induces/VBZ paraparesis/NNS spastic/JJ
glutamate/NNP increase/NN induces/VBZ paraparesis/NNS
NMDA/NNP activation/NN ischemia/NN setting/NN neurotoxic/JJ
NMDA/NNP activation/NN ischemia/NN spinal/JJ
NMDA/NNP activation/NN ischemia/NN cord/NN
NMDA/NNP activation/NN ischemia/NN
interferon/NN therapy/NN hemolysis/NNS
ribavirin/NNP reduction/NN timing/NN C/NNP chronic/JJ
ribavirin/NNP reduction/NN timing/NN C/NNP hepatitis/NNP
ribavirin/NNP reduction/NN timing/NN C/NNP
ribavirin/NN interferon/NN therapy/NN hemolysis/NNS patients/NNS timing/NN C/NNP chronic/JJ
ribavirin/NN interferon/NN therapy/NN hemolysis/NNS patients/NNS timing/NN C/NNP hepatitis/NNP
ribavirin/NN interferon/NN therapy/NN hemolysis/NNS patients/NNS timing/NN C/NNP
ribavirin/NNP reduction/NN timing/NN patients/NNS hemolysis/NNS
ribavirin/NN interferon/NN therapy/NN hemolysis/NNS
interferon/NN therapy/NN hemolysis/NNS patients/NNS timing/NN C/NNP chronic/JJ
interferon/NN therapy/NN hemolysis/NNS patients/NNS timing/NN C/NNP hepatitis/NNP
interferon/NN therapy/NN hemolysis/NNS patients/NNS timing/NN C/NNP
ribavirin/NNP reduction/NN timing/NN examined/VBN patients/NNS hemolysis/NNS
ribavirin/NNP reduction/NN patients/NNS 10/CD continue/VB </NN g/NN values/NNS decreased/VBN anemia/CD
rifampicin/NN administration/NN developed/VBN failure/NN renal/JJ
rifampicin/NN administration/NN developed/VBN failure/NN
Cocaine/NNP use/NN associated/VBN vasoconstriction/NN vasculitis/NNS
Cocaine/NNP use/NN associated/VBN complications/NNS neurovascular/NN
Cocaine/NNP use/NN associated/VBN complications/NNS
cocaine/NN use/NN associated/VBN SAH/NNP underwent/VBD patients/NNS found/VBN evidence/NN narrowing/NN evidence/NN narrowing/NN vasculitis/NNS
fluorouracil/NNP therapy/NN associated/VBN toxicity/NN cardiac/JJ
fluorouracil/NNP therapy/NN associated/VBN toxicity/NN
5/CD therapy/NN associated/VBN toxicity/NN cardiac/JJ
5/CD therapy/NN associated/VBN toxicity/NN
FU/NNP 5/CD therapy/NN associated/VBN toxicity/NN cardiac/JJ
FU/NNP 5/CD therapy/NN associated/VBN toxicity/NN
5/CD infusion/NNP treatment/NN tumors/NNS
FU/NNP infusion/NNP treatment/NN tumors/NNS
5/CD infusion/NN associated/VBN patients/NNS disease/NN coronary/JJ
5/CD infusion/NN associated/VBN patients/NNS disease/NN artery/NN
5/CD infusion/NN associated/VBN patients/NNS disease/NN
-/NNP infusion/NN associated/VBN patients/NNS disease/NN coronary/JJ
-/NNP infusion/NN associated/VBN patients/NNS disease/NN artery/NN
-/NNP infusion/NN associated/VBN patients/NNS disease/NN
FU/NNP infusion/NN associated/VBN patients/NNS disease/NN coronary/JJ
FU/NNP infusion/NN associated/VBN patients/NNS disease/NN artery/NN
FU/NNP infusion/NN associated/VBN patients/NNS disease/NN
captopril/JJ overdose/NN due/JJ reversal/NN hypotension/NN
Naloxone/JJ reversal/NN hypotension/NN
Naloxone/JJ reversal/NN due/JJ overdose/NN
captopril/JJ overdose/NN
captopril/NN actions/NNS hypotensive/JJ
naloxone/NN shown/VBN block/VB actions/NNS hypotensive/JJ
captopril/JJ overdose/NN manifested/VBN hypotension/NN
naloxone/NN administration/NN resolved/VBN overdose/NN manifested/VBN hypotension/NN
naloxone/NN administration/NN resolved/VBN overdose/NN
captopril/JJ overdose/NN
captopril/NN case/NN hypotension/NN
naloxone/NN treated/VBN hypotension/NN
captopril/NN resulting/VBG hypotension/NN
naloxone/NN reversal/NN hypotension/NN
Amphotericin/NNP B/NNP induced/VBN AIDS/NNP
B/NNP induced/VBN AIDS/NNP
amphotericin/JJ infusion/NN patent/NN AIDS/NNP
B/NN infusion/NN patent/NN AIDS/NNP
amphotericin/NNP B/NNP infusion/NN experienced/VBD seizures/NNS grand/JJ
amphotericin/NNP B/NNP infusion/NN experienced/VBD seizures/NNS mal/NN
amphotericin/NNP B/NNP infusion/NN experienced/VBD seizures/NNS
B/NNP infusion/NN experienced/VBD seizures/NNS grand/JJ
B/NNP infusion/NN experienced/VBD seizures/NNS mal/NN
B/NNP infusion/NN experienced/VBD seizures/NNS
lorazepam/NN phenytoin/NN administration/NN persisted/VBD seizures/NNS
phenytoin/NN administration/NN persisted/VBD seizures/NNS
alcohol/NN cause/VB seizures/NNS
alcohol/NN cause/VB had/VBD history/NN abuse/NN alcohol/NN
alcohol/NN cause/VB had/VBD history/NN abuse/NN
Didanosine/NNP has/VBZ potential/NN inducing/VBG seizures/NNS
amphotericin/NNP B/NNP cause/NN seizures/NNS patient/NN AIDS/NNP
B/NNP cause/NN seizures/NNS patient/NN AIDS/NNP
lamivudine/JJ monotherapy/NN cirrhosis/NNS
lamivudine/JJ monotherapy/NN cirrhosis/NNS improvement/NN patient/NN virus/NN hepatitis/NNP
lamivudine/JJ monotherapy/NN cirrhosis/NNS improvement/NN patient/NN virus/NN B/NNP
lamivudine/NN administration/NN cirrhosis/NNS
ritanserin/NN Microinjection/NNP improves/VBZ scopolamine/NN amnesia/NN
ritanserin/NN effect/NN amnesia/NN
ritanserin/NN microinjection/NN improves/VBZ amnesia/NN
aminoglycoside/JJ treatment/NN effects/NNS Nephrotoxic/JJ
aminoglycosides/NNS act/VB nephrotoxicants/NNS level/NN inducing/VBG impairment/NN
aminoglycosides/NNS act/VB nephrotoxicants/NNS level/NN inducing/VBG impairment/NN reabsorption/NN of/IN
aminoglycosides/NNS act/VB nephrotoxicants/NNS level/NN inducing/VBG impairment/NN reabsorption/NN renal/JJ
aminoglycosides/NNS act/VB nephrotoxicants/NNS level/NN inducing/VBG impairment/NN reabsorption/NN
D/NNP developed/VBD patients/NNS arthritis/NN rheumatoid/JJ
D/NNP developed/VBD patients/NNS arthritis/NN
penicillamine/NN D/NNP developed/VBD patients/NNS arthritis/NN rheumatoid/JJ
penicillamine/NN D/NNP developed/VBD patients/NNS arthritis/NN
glyceryl/JJ trinitrate/NN Effect/NN sphincter/NN
glyceryl/JJ trinitrate/NN Effect/NN spasm/NNP of/IN
glyceryl/JJ trinitrate/NN Effect/NN spasm/NNP Oddi/NNP
glyceryl/JJ trinitrate/NN Effect/NN spasm/NNP
trinitrate/NN Effect/NN sphincter/NN
trinitrate/NN Effect/NN spasm/NNP of/IN
trinitrate/NN Effect/NN spasm/NNP Oddi/NNP
trinitrate/NN Effect/NN spasm/NNP
morphine/VBP Effect/NN sphincter/NN
morphine/VBP Effect/NN spasm/NNP of/IN
morphine/VBP Effect/NN spasm/NNP Oddi/NNP
morphine/VBP Effect/NN spasm/NNP
prostigmine/NN evoked/VBN spasm/NNP Effect/NN sphincter/NN
prostigmine/NN evoked/VBN spasm/NNP of/IN
prostigmine/NN evoked/VBN spasm/NNP Oddi/NNP
prostigmine/NN evoked/VBN spasm/NNP
glyceryl/JJ trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN
glyceryl/JJ trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP of/IN
glyceryl/JJ trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP Oddi/NNP
glyceryl/JJ trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP
trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN
trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP of/IN
trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP Oddi/NNP
trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP
morphine/NN trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN
morphine/NN trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP of/IN
morphine/NN trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP Oddi/NNP
morphine/NN trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP
glyceryl/JJ trinitrate/NN effect/NN induced/VBN evaluated/VBN patients/NNS sphincter/NN
glyceryl/JJ trinitrate/NN effect/NN induced/VBN evaluated/VBN patients/NNS sphincter/NN dyskinesia/NNP of/IN
glyceryl/JJ trinitrate/NN effect/NN induced/VBN evaluated/VBN patients/NNS sphincter/NN dyskinesia/NNP Oddi/NNP
glyceryl/JJ trinitrate/NN effect/NN induced/VBN evaluated/VBN patients/NNS sphincter/NN dyskinesia/NNP
trinitrate/NN effect/NN induced/VBN evaluated/VBN patients/NNS sphincter/NN
trinitrate/NN effect/NN induced/VBN evaluated/VBN patients/NNS sphincter/NN dyskinesia/NNP of/IN
trinitrate/NN effect/NN induced/VBN evaluated/VBN patients/NNS sphincter/NN dyskinesia/NNP Oddi/NNP
trinitrate/NN effect/NN induced/VBN evaluated/VBN patients/NNS sphincter/NN dyskinesia/NNP
prostigmine/NN morphine/NN trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN
prostigmine/NN morphine/NN trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP of/IN
prostigmine/NN morphine/NN trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP Oddi/NNP
prostigmine/NN morphine/NN trinitrate/NN effect/NN induced/VBN evaluated/VBN sphincter/NN spasm/NNP
morphine/JJ administration/NN prostigmine/NN induced/VBN Sphincter/NNP
morphine/JJ administration/NN prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP of/IN
morphine/JJ administration/NN prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP Oddi/NNP
morphine/JJ administration/NN prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP
morphine/NN subcutaneously/NN intramuscularly/NN 0/NNP prostigmine/NN induced/VBN Sphincter/NNP
morphine/NN subcutaneously/NN intramuscularly/NN 0/NNP prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP of/IN
morphine/NN subcutaneously/NN intramuscularly/NN 0/NNP prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP Oddi/NNP
morphine/NN subcutaneously/NN intramuscularly/NN 0/NNP prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP
prostigmine/NN induced/VBN Sphincter/NNP
prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP of/IN
prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP Oddi/NNP
prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP
prostigmine/NN intramuscularly/NN 0/NNP prostigmine/NN induced/VBN Sphincter/NNP
prostigmine/NN intramuscularly/NN 0/NNP prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP of/IN
prostigmine/NN intramuscularly/NN 0/NNP prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP Oddi/NNP
prostigmine/NN intramuscularly/NN 0/NNP prostigmine/NN induced/VBN Sphincter/NNP spasm/NNP
glyceryl/JJ trinitrate/NN effectiveness/NN evidence/NN sphincter/NN
glyceryl/JJ trinitrate/NN effectiveness/NN evidence/NN sphincter/NN spasm/NNP of/IN
glyceryl/JJ trinitrate/NN effectiveness/NN evidence/NN sphincter/NN spasm/NNP Oddi/NNP
glyceryl/JJ trinitrate/NN effectiveness/NN evidence/NN sphincter/NN spasm/NNP
trinitrate/NN effectiveness/NN evidence/NN sphincter/NN
trinitrate/NN effectiveness/NN evidence/NN sphincter/NN spasm/NNP of/IN
trinitrate/NN effectiveness/NN evidence/NN sphincter/NN spasm/NNP Oddi/NNP
trinitrate/NN effectiveness/NN evidence/NN sphincter/NN spasm/NNP
morphine/NN trinitrate/NN effectiveness/NN evidence/NN sphincter/NN
morphine/NN trinitrate/NN effectiveness/NN evidence/NN sphincter/NN spasm/NNP of/IN
morphine/NN trinitrate/NN effectiveness/NN evidence/NN sphincter/NN spasm/NNP Oddi/NNP
morphine/NN trinitrate/NN effectiveness/NN evidence/NN sphincter/NN spasm/NNP
glyceryl/JJ trinitrate/NN able/JJ relevance/NN treatment/NN sphincter/NN
glyceryl/JJ trinitrate/NN able/JJ relevance/NN treatment/NN sphincter/NN dyskinesia/NNP of/IN
glyceryl/JJ trinitrate/NN able/JJ relevance/NN treatment/NN sphincter/NN dyskinesia/NNP Oddi/NNP
glyceryl/JJ trinitrate/NN able/JJ relevance/NN treatment/NN sphincter/NN dyskinesia/NNP
trinitrate/NN able/JJ relevance/NN treatment/NN sphincter/NN
trinitrate/NN able/JJ relevance/NN treatment/NN sphincter/NN dyskinesia/NNP of/IN
trinitrate/NN able/JJ relevance/NN treatment/NN sphincter/NN dyskinesia/NNP Oddi/NNP
trinitrate/NN able/JJ relevance/NN treatment/NN sphincter/NN dyskinesia/NNP
Ethambutol/NNP used/VBN treatment/NN tuberculosis/NNP
dobutamine/JJ stress/NN spasm/NN due/JJ ischemia/NN Myocardial/JJ
dobutamine/JJ stress/NN spasm/NN due/JJ ischemia/NN
Dobutamine/JJ echocardiography/NN test/NN ischemia/NN myocardial/JJ
Dobutamine/JJ echocardiography/NN test/NN ischemia/NN
dobutamine/NN induced/VBN ischemia/NN myocardial/JJ
dobutamine/NN induced/VBN ischemia/NN
acetylcholine/NN injection/NN induced/VBN documented/VBN stenosis/NNS coronary/JJ
acetylcholine/NN injection/NN induced/VBN documented/VBN stenosis/NNS artery/NN
acetylcholine/NN injection/NN induced/VBN documented/VBN stenosis/NNS
milrinone/NN treatment/NN Vasopressin/NNP hypotension/NN failure/NN heart/NN
milrinone/NN treatment/NN Vasopressin/NNP hypotension/NN failure/NN
Vasopressin/NNP hypotension/NN failure/NN heart/NN
Vasopressin/NNP hypotension/NN failure/NN
milrinone/NN treatment/NN failure/NN heart/NN
milrinone/NN treatment/NN failure/NN
milrinone/NN treatment/NN hypotension/NN failure/NN heart/NN
milrinone/NN treatment/NN hypotension/NN failure/NN
milrinone/NN effect/NN inhibiting/VBG restored/VBD patients/NNS failure/NN heart/NN
milrinone/NN effect/NN inhibiting/VBG restored/VBD patients/NNS failure/NN
vasopressin/NN doses/NNS restored/VBD patients/NNS failure/NN heart/NN
vasopressin/NN doses/NNS restored/VBD patients/NNS failure/NN
amphetamine/NN reflects/VBZ rotation/NN lesion/NN substantia/NN
amphetamine/NN reflects/VBZ rotation/NN lesion/NN nigra/NN
amphetamine/NN reflects/VBZ rotation/NN lesion/NN
6/CD reported/VBN period/NN rotation/NN contralateral/JJ
6/CD reported/VBN period/NN rotation/NN
OHDA/NNP SN/NNP 6/CD reported/VBN period/NN rotation/NN contralateral/JJ
OHDA/NNP SN/NNP 6/CD reported/VBN period/NN rotation/NN
6/CD reported/VBN precede/VB circling/NN ipsilateral/JJ
6/CD reported/VBN precede/VB circling/NN
OHDA/NNP SN/NNP 6/CD reported/VBN precede/VB circling/NN ipsilateral/JJ
OHDA/NNP SN/NNP 6/CD reported/VBN precede/VB circling/NN
6/CD SN/NNP
6/CD SN/NNP lesion/NN
OHDA/NNP SN/NNP
OHDA/NNP SN/NNP lesion/NN
macrolides/NNS experience/NN recorded/VBN function/VBP side/NN established/VBN gastroenteritis/NNS
erythromycin/NN administration/NN demonstrated/VBN Cardiotoxicity/NNP
macrolides/NNS reported/VBN demonstrated/VBN Cardiotoxicity/NNP
clarithromycin/NN doses/NNS occurred/VBD case/NN dysrhythmias/NNS ventricular/NN
clarithromycin/NN doses/NNS occurred/VBD case/NN dysrhythmias/NNS
Phenobarbital/NNP dyskinesia/NN neurologically/NN
Phenobarbital/NNP child/NN impaired/VBN
phenobarbital/JJ therapy/NN starting/VBG seizures/NNS
phenobarbital/JJ therapy/NN starting/VBG developed/VBN impairment/NN neurologic/JJ
phenobarbital/JJ therapy/NN starting/VBG developed/VBN impairment/NN
Phenobarbital/NNP added/VBN list/NN cause/VB disorders/NNS movement/NN
Phenobarbital/NNP added/VBN list/NN cause/VB disorders/NNS
CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
3717/CD CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
N/NNP CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
10/CD N/NNP CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
propargyl/JJ N/NNP CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
-/NNP propargyl/JJ N/NNP CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
5/CD -/NNP propargyl/JJ N/NNP CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
8/CD -/NNP propargyl/JJ N/NNP CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
dideazafolic/JJ acid/NN N/NNP CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
acid/NN N/NNP CB/NNP synthase/NN mediated/VBN cytotoxicity/JJ
CB/NNP fold/VBP determinant/NN cytotoxicity/NN
3717/CD CB/NNP fold/VBP determinant/NN cytotoxicity/NN
CB/NNP cytotoxicity/NN
3717/CD cytotoxicity/NN
CB/NNP studies/NNS seen/VBN cancer/NN cancer/NN ovarian/NN
CB/NNP studies/NNS seen/VBN cancer/NN cancer/NN
3717/CD CB/NNP studies/NNS seen/VBN cancer/NN cancer/NN ovarian/NN
3717/CD CB/NNP studies/NNS seen/VBN cancer/NN cancer/NN
CB/NNP studies/NNS seen/VBN cancer/NN mesothelioma/NN
3717/CD CB/NNP studies/NNS seen/VBN cancer/NN mesothelioma/NN
CB/NNP studies/NNS seen/VBN cancer/NN breast/NN
CB/NNP studies/NNS seen/VBN cancer/NN
3717/CD CB/NNP studies/NNS seen/VBN cancer/NN breast/NN
3717/CD CB/NNP studies/NNS seen/VBN cancer/NN
CB/NNP studies/NNS seen/VBN cancer/NN hepatoma/NN
3717/CD CB/NNP studies/NNS seen/VBN cancer/NN hepatoma/NN
sodium/NN density/NN subunits/VBZ dependence/NN inactivation/NN susceptibility/NN seizures/NNS
sodium/NN beta/NN lacking/VBG mice/NNS seizures/NNS
NAD/NNP diet/NN Influence/NNP precursors/NNS hepatotoxicity/NN
poly/JJ polymerase/NN inhibitor/NN amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG acetaminophen/NN hepatitis/NN
ADP/NNP polymerase/NN inhibitor/NN amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG acetaminophen/NN hepatitis/NN
ribose/NN ADP/NNP polymerase/NN inhibitor/NN amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG acetaminophen/NN hepatitis/NN
poly/JJ polymerase/NN inhibitor/NN amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN liver/NN
poly/JJ polymerase/NN inhibitor/NN amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN
ADP/NNP polymerase/NN inhibitor/NN amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN liver/NN
ADP/NNP polymerase/NN inhibitor/NN amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN
ribose/NN ADP/NNP polymerase/NN inhibitor/NN amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN liver/NN
ribose/NN ADP/NNP polymerase/NN inhibitor/NN amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN
nicotinic/JJ amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG acetaminophen/NN hepatitis/NN
acid/JJ amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG acetaminophen/NN hepatitis/NN
amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG acetaminophen/NN hepatitis/NN
nicotinic/JJ amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN liver/NN
nicotinic/JJ amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN
acid/JJ amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN liver/NN
acid/JJ amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN
amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN liver/NN
amide/NN effects/NNS demonstrated/VBD mice/NNS suffering/VBG suggesting/VBG involves/VBZ injury/NN
NAD/NNP precursors/NNS diet/NN substrate/NN acts/VBZ hepatitis/NNP
oxaloacetate/JJ transaminase/JJ transaminase/NN quantified/VBN injuries/NNS Liver/NNP
oxaloacetate/JJ transaminase/JJ transaminase/NN quantified/VBN injuries/NNS
pyruvate/JJ transaminase/NN quantified/VBN injuries/NNS Liver/NNP
pyruvate/JJ transaminase/NN quantified/VBN injuries/NNS
glutamate/NN activities/NNS quantified/VBN injuries/NNS Liver/NNP
glutamate/NN activities/NNS quantified/VBN injuries/NNS
glutamate/JJ transaminase/JJ transaminase/NN quantified/VBN injuries/NNS Liver/NNP
glutamate/JJ transaminase/JJ transaminase/NN quantified/VBN injuries/NNS
NAA/NNP given/VBN observed/JJ reduction/NN hepatitis/NN
NAD/NNP depletion/NN reduced/VBN' reduced/VBN AAP/NNP hepatitis/NNP
NAA/NNP reduced/VBN AAP/NNP hepatitis/NNP
NAA/NNP application/NN see/VBP avoid/VB damage/NN hepatic/JJ
NAA/NNP application/NN see/VBP avoid/VB damage/NN
aryl/NN induced/VBN catalepsy/RB
piperazine/VBP Reversal/NNP induced/VBN catalepsy/RB
buspirone/NN drug/NN reverses/VBZ induced/VBN catalepsy/RB
buspirone/NN analogues/NNS series/NN tested/VBN ability/NN reverse/VB catalepsy/RB
aryl/NN series/NN tested/VBN ability/NN reverse/VB catalepsy/RB
piperazine/JJ analogues/NNS series/NN tested/VBN ability/NN reverse/VB catalepsy/RB
5/CD buspirone/NN analogues/NNS series/NN tested/VBN ability/NN reverse/VB catalepsy/RB
hydroxytryptaminergic/JJ agonists/NNS tested/VBN ability/NN reverse/VB catalepsy/RB
agonists/NNS tested/VBN ability/NN reverse/VB catalepsy/RB
5/CD affinity/NN drugs/NNS hydroxytryptamine/NN able/JJ reverse/VB catalepsy/RB
hydroxytryptamine/NN able/JJ reverse/VB catalepsy/RB
5/CD inhibition/NN receptors/NNP reversal/NN catalepsy/NN
HT/NNP receptors/NNP reversal/NN catalepsy/NN
Cyclophosphamide/NNP induced/VBN behavioral/VBG model/NN pain/NN visceral/JJ
Cyclophosphamide/NNP induced/VBN behavioral/VBG model/NN pain/NN
acrolein/NN produce/VB known/VBN agent/NN Cyclophosphamide/NNP used/VBN induce/VB cystitis/NNS
Morphine/JJ dose/NN reversed/VBN disorders/NNS behavioral/JJ
Morphine/JJ dose/NN reversed/VBN disorders/NNS
morphine/NN administration/NN time/NN observed/JJ modifications/NNS edema/NN
CP/NNP model/NN induced/VBN model/NN pain/NN visceral/JJ
CP/NNP model/NN induced/VBN model/NN pain/NN
iodine/NN induced/VBN cardiomyopathy/RB
125/CD iodine/NN induced/VBN cardiomyopathy/RB
metaiodobenzylguanidine/VBP Detection/NNP induced/VBN cardiomyopathy/RB
adriamycin/NN treatment/NN duration/NN analyzed/VBN degree/NN degeneration/NN vacuolar/NN
adriamycin/NN treatment/NN duration/NN analyzed/VBN degree/NN degeneration/NN
adriamycin/NN treatment/NN duration/NN analyzed/VBN degree/NN degeneration/NN cells/NNS of/IN
adriamycin/NN treatment/NN duration/NN analyzed/VBN degree/NN degeneration/NN cells/NNS myocardial/JJ
adriamycin/NN treatment/NN duration/NN analyzed/VBN degree/NN degeneration/NN cells/NNS
adriamycin/NN detection/NN method/NN indicates/VBZ appearance/NN presence/NN impairment/NN scattered/JJ degeneration/NN vacuolar/NN
adriamycin/NN detection/NN method/NN indicates/VBZ appearance/NN presence/NN impairment/NN scattered/JJ degeneration/NN
MIBG/NNP method/NN indicates/VBZ appearance/NN presence/NN impairment/NN myocardial/JJ
MIBG/NNP method/NN indicates/VBZ appearance/NN presence/NN impairment/NN
MIBG/NNP method/NN detection/NN adriamycin/NN induced/VBN cardiomyopathy/RB
MIBG/NNP method/NN indicates/VBZ appearance/NN presence/NN impairment/NN scattered/JJ degeneration/NN vacuolar/NN
MIBG/NNP method/NN indicates/VBZ appearance/NN presence/NN impairment/NN scattered/JJ degeneration/NN
ergot/NN history/NN discussion/NN includes/VBZ discovery/NN epidemics/NNS gangrene/NN
ergot/NN preparations/NNS continue/VBP play/VB persists/VBZ fire/NN danger/NN Anthony/NNP St/NNP
ergot/NN preparations/NNS continue/VBP play/VB persists/VBZ fire/NN danger/NN Anthony/NNP
ergot/NN preparations/NNS continue/VBP play/VB persists/VBZ fire/NN danger/NN '/POS
ergot/NN preparations/NNS continue/VBP play/VB persists/VBZ fire/NN s/JJ
ergot/NN preparations/NNS continue/VBP play/VB persists/VBZ fire/NN
calcium/NN blockers/NNS advent/NN continue/VBP play/VB therapy/NN migraine/JJ
calcium/NN blockers/NNS advent/NN continue/VBP play/VB persists/VBZ fire/NN danger/NN Anthony/NNP St/NNP
calcium/NN blockers/NNS advent/NN continue/VBP play/VB persists/VBZ fire/NN danger/NN Anthony/NNP
calcium/NN blockers/NNS advent/NN continue/VBP play/VB persists/VBZ fire/NN danger/NN '/POS
calcium/NN blockers/NNS advent/NN continue/VBP play/VB persists/VBZ fire/NN s/JJ
calcium/NN blockers/NNS advent/NN continue/VBP play/VB persists/VBZ fire/NN
carbamazepine/JJ therapy/NN institution/NN atonic/JJ Myoclonic/NNP
carbamazepine/JJ therapy/NN institution/NN atonic/JJ
carbamazepine/JJ therapy/NN institution/NN atonic/JJ and/CC
carbamazepine/JJ therapy/NN institution/NN atonic/JJ seizures/NNS absence/NN
carbamazepine/JJ therapy/NN institution/NN atonic/JJ seizures/NNS
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN atypical/JJ myoclonic/JJ
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN atypical/JJ
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN and/CC
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN //NNS
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN or/CC
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN seizures/NNS atonic/NN
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN seizures/NNS motor/NN minor/JJ
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN seizures/NNS motor/NN
carbamazepine/NN treated/VBN years/NNS aged/VBN children/NNS had/VBD reaction/NN characterized/VBN onset/NN absence/NN seizures/NNS
carbamazepine/NN epilepsy/NN
carbamazepine/NN discontinued/VBN returned/VBD had/VBD resolve/VB seizures/NNS
carbamazepine/NN discontinued/VBN returned/VBD had/VBD persist/VB seizures/NNS
propranolol/NN bendrofluazide/NN reactions/NNS treatment/NN hypertension/NN
bendrofluazide/NN reactions/NNS treatment/NN hypertension/NN
propranolol/NN bendrofluazide/NN one/CD allocated/VBN Participants/NNS trial/NN hypertension/NN
bendrofluazide/NN one/CD allocated/VBN Participants/NNS trial/NN hypertension/NN
propranolol/JJ taking/VBG phenomenon/NN include/VBP tolerance/NN gout/NN
bendrofluazide/JJ treatment/NN associated/VBN men/NNS gout/NN tolerance/NN include/VBP phenomenon/NN Raynaud/NNP
bendrofluazide/JJ treatment/NN associated/VBN men/NNS gout/NN tolerance/NN include/VBP phenomenon/NN Raynaud/NNP '/POS
bendrofluazide/JJ treatment/NN associated/VBN men/NNS gout/NN tolerance/NN include/VBP phenomenon/NN s/VBZ
bendrofluazide/JJ treatment/NN associated/VBN men/NNS gout/NN tolerance/NN include/VBP phenomenon/NN
bendrofluazide/JJ treatment/NN associated/VBN men/NNS gout/NN tolerance/NN include/VBP phenomenon/NN dyspnoea/NN
propranolol/JJ taking/VBG phenomenon/NN include/VBP tolerance/NN impaired/VBN
propranolol/JJ taking/VBG phenomenon/NN include/VBP tolerance/NN glucose/NN
propranolol/JJ taking/VBG phenomenon/NN include/VBP tolerance/NN
propranolol/JJ group/NN occurred/VBN known/VBN disease/NN corneal/JJ
propranolol/JJ group/NN occurred/VBN known/VBN disease/NN
Dexmedetomidine/NNP associated/VBN mortality/NN OR/NNP infarction/NN myocardial/JJ
Dexmedetomidine/NNP associated/VBN mortality/NN OR/NNP infarction/NN
Dexmedetomidine/NNP associated/VBN mortality/NN OR/NNP ischaemia/NN myocardial/JJ
Dexmedetomidine/NNP associated/VBN mortality/NN OR/NNP ischaemia/NN
Clarithromycin/NNP associated/VBN failure/NN chronic/JJ
Clarithromycin/NNP associated/VBN failure/NN renal/JJ
Clarithromycin/NNP associated/VBN failure/NN
macrolide/NN antibiotic/NN occurring/VBG hallucinations/NNS visual/JJ
macrolide/NN antibiotic/NN occurring/VBG hallucinations/NNS
clarithromycin/NN face/NN failure/NN chronic/JJ
clarithromycin/NN face/NN failure/NN renal/JJ
clarithromycin/NN face/NN failure/NN
aluminum/NN intoxication/NN combination/NN dose/NN clarithromycin/NN face/NN failure/NN chronic/JJ
aluminum/NN intoxication/NN combination/NN dose/NN clarithromycin/NN face/NN failure/NN renal/JJ
aluminum/NN intoxication/NN combination/NN dose/NN clarithromycin/NN face/NN failure/NN
aluminum/NN intoxication/NN combination/NN facilitated/VBN appearance/NN effect/NN neurotoxic/JJ
clarithromycin/NN dose/NN combination/NN facilitated/VBN appearance/NN effect/NN neurotoxic/JJ
Warfarin/NNP induced/VBN vasculitis/NNS leukocytoclastic/JJ
Warfarin/NNP induced/VBN vasculitis/NNS
warfarin/VB LV/NNP
warfarin/NN receiving/VBG developed/VBN eruptions/NNS skin/NN
warfarin/NN receiving/VBG developed/VBN eruptions/NNS
warfarin/NN discontinued/VBN available/JJ results/NNS biopsies/NNS skin/NN
warfarin/NN discontinued/VBN available/JJ results/NNS biopsies/NNS lesion/NN
warfarin/NN therapy/NN associated/VBN reaction/NN late/JJ LV/NNP
paracetamol/NNP survivors/NNS transplant/NN induced/VBN injury/NN acute/JJ
paracetamol/NNP survivors/NNS transplant/NN induced/VBN injury/NN liver/NN
paracetamol/NNP survivors/NNS transplant/NN induced/VBN injury/NN
paracetamol/NNS caused/VBN induced/VBN injury/NN liver/NN
paracetamol/NNS caused/VBN induced/VBN injury/NN
paracetamol/NNS caused/VBN higher/JJR age/VBP age/NN died/VBD disease/NN liver/NN
paracetamol/NNS caused/VBN higher/JJR age/VBP age/NN died/VBD disease/NN
heparin/NN induced/VBN aggregation/NN platelet/JJ
heparin/NN induced/VBN aggregation/NN
heparin/NN require/VBP aggregation/NN platelet/JJ
heparin/NN require/VBP aggregation/NN
chlorpropamide/NN treated/VBN diabetes/NN 65/CD year/NN woman/NN adult/NN
chlorpropamide/NN treated/VBN diabetes/NN onset/NN
chlorpropamide/NN treated/VBN diabetes/NN
Diabenese/NNP diabetes/NN 65/CD year/NN woman/NN adult/NN
Diabenese/NNP diabetes/NN onset/NN
Diabenese/NNP diabetes/NN
chlorpropamide/JJ therapy/NN discontinuation/NN resolved/VBN neuropathy/NN had/VBD diabetes/NN 65/CD year/NN woman/NN adult/NN
chlorpropamide/JJ therapy/NN discontinuation/NN resolved/VBN neuropathy/NN had/VBD diabetes/NN onset/NN
chlorpropamide/JJ therapy/NN discontinuation/NN resolved/VBN neuropathy/NN had/VBD diabetes/NN
dexamethasone/NN saline/NN pretreated/VBN patients/NNS determined/VBN myalgia/NN
dexamethasone/JJ group/NN patients/NNS complained/VBD differ/VB Incidence/NN myalgia/NN
dexamethasone/JJ group/NN patients/NNS complained/VBD myalgia/NN
dexamethasone/JJ group/NN patients/NNS complained/VBD reported/VBN myalgia/NN
dexamethasone/NN Administration/NNP IMPLICATIONS/NNS induced/VBN myalgia/NN postoperative/JJ
dexamethasone/NN Administration/NNP IMPLICATIONS/NNS induced/VBN myalgia/NN
dexamethasone/NN Pretreatment/NNP justified/JJ prevent/VB myalgia/NN postoperative/JJ
dexamethasone/NN Pretreatment/NNP justified/JJ prevent/VB myalgia/NN
estrogens/NNS exogenous/VBZ had/VBD disease/NN Hodgkin/NNP
estrogens/NNS exogenous/VBZ had/VBD disease/NN
estrogens/NNS exogenous/VBZ had/VBD failure/NN ovarian/NN
estrogens/NNS exogenous/VBZ had/VBD failure/NN
estrogens/NNS failure/NN ovarian/NN
estrogens/NNS failure/NN
estrogens/NNS failure/NN therapy/NN cancer/NN
pilocarpine/JJ model/NN characterized/VBN period/NN epilepticus/NNS status/NN
pilocarpine/JJ model/NN characterized/VBN period/NN epilepticus/NNS
PILO/NNP model/NN characterized/VBN period/NN epilepticus/NNS status/NN
PILO/NNP model/NN characterized/VBN period/NN epilepticus/NNS
pilocarpine/JJ model/NN characterized/VBN period/NN epilepticus/NNS followed/VBN seizures/NNS
PILO/NNP model/NN characterized/VBN period/NN epilepticus/NNS followed/VBN seizures/NNS
pilocarpine/JJ model/NN epilepsy/NN
PILO/NNP model/NN epilepsy/NN
pilocarpine/JJ model/NN characterized/VBN period/NN epilepticus/NNS followed/VBN seizures/NNS damage/NN brain/NN
pilocarpine/JJ model/NN characterized/VBN period/NN epilepticus/NNS followed/VBN seizures/NNS damage/NN
PILO/NNP model/NN characterized/VBN period/NN epilepticus/NNS followed/VBN seizures/NNS damage/NN brain/NN
PILO/NNP model/NN characterized/VBN period/NN epilepticus/NNS followed/VBN seizures/NNS damage/NN
hydrogen/NN production/NN superoxide/NN failure/NN acute/JJ
hydrogen/NN production/NN superoxide/NN failure/NN liver/NN
hydrogen/NN production/NN superoxide/NN failure/NN
peroxide/NN production/NN superoxide/NN failure/NN acute/JJ
peroxide/NN production/NN superoxide/NN failure/NN liver/NN
peroxide/NN production/NN superoxide/NN failure/NN
superoxide/NN failure/NN acute/JJ
superoxide/NN failure/NN liver/NN
superoxide/NN failure/NN
hydrogen/NN superoxide/NN production/NN Defects/NNS implicated/VBN incidence/NN infections/NNS bacterial/JJ
hydrogen/NN superoxide/NN production/NN Defects/NNS implicated/VBN incidence/NN infections/NNS
peroxide/NN production/NN Defects/NNS implicated/VBN incidence/NN infections/NNS bacterial/JJ
peroxide/NN production/NN Defects/NNS implicated/VBN incidence/NN infections/NNS
hydrogen/NN superoxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN acute/JJ
hydrogen/NN superoxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN liver/NN
hydrogen/NN superoxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN
peroxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN acute/JJ
peroxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN liver/NN
peroxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN
hydrogen/NN superoxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN ALF/NNP
peroxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN ALF/NNP
superoxide/NN production/NN Defects/NNS implicated/VBN incidence/NN infections/NNS bacterial/JJ
superoxide/NN production/NN Defects/NNS implicated/VBN incidence/NN infections/NNS
superoxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN acute/JJ
superoxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN liver/NN
superoxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN
superoxide/NN production/NN Defects/NNS implicated/VBN patients/NNS failure/NN ALF/NNP
oxygen/NN production/NN patients/NNS ALF/NNP
oxygen/NN production/NN patients/NNS ALF/NNP due/JJ overdose/NN
paracetamol/NNP overdose/NN
hydrogen/NN Superoxide/NN production/NN neutrophils/NNS ALF/NNP
peroxide/NN production/NN neutrophils/NNS ALF/NNP
hydrogen/NN Superoxide/NN production/NN neutrophils/NNS stimulated/VBN zymosan/NN opsonized/VBN serum/NNP ALF/NNP
peroxide/NN production/NN neutrophils/NNS stimulated/VBN zymosan/NN opsonized/VBN serum/NNP ALF/NNP
Superoxide/NN production/NN neutrophils/NNS ALF/NNP
Superoxide/NN production/NN neutrophils/NNS stimulated/VBN zymosan/NN opsonized/VBN serum/NNP ALF/NNP
hydrogen/NN Superoxide/NN production/NN neutrophils/NNS stimulated/VBN patients/NNS ALF/NNP
peroxide/NN production/NN neutrophils/NNS stimulated/VBN patients/NNS ALF/NNP
formyl/JJ phenylalanine/NN stimulated/VBN patients/NNS ALF/NNP
methionyl/NN phenylalanine/NN stimulated/VBN patients/NNS ALF/NNP
leucyl/NN methionyl/NN phenylalanine/NN stimulated/VBN patients/NNS ALF/NNP
phenylalanine/NN stimulated/VBN patients/NNS ALF/NNP
fMLP/NN phenylalanine/NN stimulated/VBN patients/NNS ALF/NNP
Superoxide/NN production/NN neutrophils/NNS stimulated/VBN patients/NNS ALF/NNP
paracetamol/NNP overdose/NNP
dopamine/JJ agonist/NN hyperprolactinemia/NN
cabergoline/NN induced/VBN hyperprolactinemia/NN
cabergoline/NN treated/VBN hyperprolactinemia/NN
risperidone/NN males/NNS Manual/NNP bipolar/NNP
risperidone/NN males/NNS disorder/JJ
risperidone/NN males/NNS Manual/NNP bipolar/NNP Mental/NNP
risperidone/NN males/NNS Manual/NNP bipolar/NNP Disorders/NNP
cabergoline/NN treated/VBN RESULTS/NNS males/NNS disorder/JJ psychoses/JJ
cabergoline/NN treated/VBN RESULTS/NNS males/NNS Manual/NNP bipolar/NNP Mental/NNP
cabergoline/NN treated/VBN RESULTS/NNS males/NNS Manual/NNP bipolar/NNP Disorders/NNP
cabergoline/NN treated/VBN RESULTS/NNS males/NNS Manual/NNP bipolar/NNP
cabergoline/NN treated/VBN RESULTS/NNS males/NNS disorder/JJ
risperidone/NN males/NNS disorder/JJ psychoses/JJ
Cabergoline/NNP useful/JJ treatment/NN hyperprolactinemia/NN
tacrine/NN treated/VBN showed/VBD outcome/NN CNS/NNP onset/NN epileptic/JJ
tacrine/NN induced/VBN processes/NNS severity/NN model/NN epilepsy/NN
lithium/NN model/NN epilepsy/NN
penicillin/NN analysis/NN activity/NN epileptiform/NN
penicillin/NN analysis/NN activity/NN
Penicillin/NN model/NN model/NN research/NN epilepsy/NN
penicillin/NN analysis/NN activity/NN epileptiform/NN
penicillin/NN analysis/NN activity/NN
penicillin/NN activity/NN analyzed/VBN periods/NNS epileptiform/NN
penicillin/NN activity/NN analyzed/VBN periods/NNS activity/NN
diclofenac/JJ tolerability/NN results/NNS tolerability/NN etoricoxib/NN patients/NNS rheumatoid/JJ
diclofenac/JJ tolerability/NN results/NNS tolerability/NN etoricoxib/NN patients/NNS arthritis/NN
sodium/NN tolerability/NN results/NNS tolerability/NN etoricoxib/NN patients/NNS rheumatoid/JJ
sodium/NN tolerability/NN results/NNS tolerability/NN etoricoxib/NN patients/NNS arthritis/NN
etoricoxib/NN patients/NNS rheumatoid/JJ
etoricoxib/NN patients/NNS arthritis/NN
etoricoxib/JJ tolerability/NN results/NNS tolerability/NN etoricoxib/NN patients/NNS rheumatoid/JJ
etoricoxib/JJ tolerability/NN results/NNS tolerability/NN etoricoxib/NN patients/NNS arthritis/NN
diclofenac/NN etoricoxib/NN compare/VB patients/NNS arthritis/NN rheumatoid/JJ
diclofenac/NN etoricoxib/NN compare/VB patients/NNS arthritis/NN
diclofenac/NN etoricoxib/NN compare/VB patients/NNS arthritis/NN RA/NNP
etoricoxib/NN compare/VB patients/NNS arthritis/NN rheumatoid/JJ
etoricoxib/NN compare/VB patients/NNS arthritis/NN
etoricoxib/NN compare/VB patients/NNS arthritis/NN RA/NNP
diclofenac/JJ mg/NN daily/NN received/VBD diagnosed/VBD enrolled/VBN RA/NNP
etoricoxib/NN daily/NN received/VBD diagnosed/VBD enrolled/VBN RA/NNP
etoricoxib/NN lower/JJR rate/NN due/JJ AEs/NNP GI/NNP
etoricoxib/NN lower/JJR rate/NN due/JJ AEs/NNP
diclofenac/NN etoricoxib/NN higher/JJR incidence/NN discontinuations/NNS related/VBN oedema/JJ
diclofenac/NN etoricoxib/NN %/NN 0/NNP 001/NNP 01/NNP oedema/NN
diclofenac/NN etoricoxib/NN higher/JJR incidence/NN discontinuations/NNS hypertension/NN
diclofenac/NN etoricoxib/NN %/NN 0/NNP 001/NNP hypertension/NN
Etoricoxib/NNP mg/NN demonstrated/VBN discontinuing/VBG treatment/NN higher/JJR AEs/NNP GI/NNP
Etoricoxib/NNP mg/NN demonstrated/VBN discontinuing/VBG treatment/NN higher/JJR AEs/NNP
Etoricoxib/NNP mg/NN demonstrated/VBN discontinuing/VBG treatment/NN higher/JJR common/JJ discontinuations/NNS AEs/NNP GI/NNP
Etoricoxib/NNP mg/NN demonstrated/VBN discontinuing/VBG treatment/NN higher/JJR common/JJ discontinuations/NNS AEs/NNP
etoricoxib/NN higher/JJR AEs/NNP GI/NNP
etoricoxib/NN higher/JJR AEs/NNP
etoricoxib/NN higher/JJR common/JJ discontinuations/NNS AEs/NNP GI/NNP
etoricoxib/NN higher/JJR common/JJ discontinuations/NNS AEs/NNP
hepatitis/NNP vaccine/NN injections/NNS injections/NNS globulin/NN hepatitis/NNP
hepatitis/NNP vaccine/NN injections/NNS injections/NNS globulin/NN B/NNP
B/NNP vaccine/NN injections/NNS injections/NNS globulin/NN hepatitis/NNP
B/NNP vaccine/NN injections/NNS injections/NNS globulin/NN B/NNP
vaccine/NN injections/NNS injections/NNS globulin/NN hepatitis/NNP
vaccine/NN injections/NNS injections/NNS globulin/NN B/NNP
Metformin/NNP hydrochloride/NNP discontinued/VBN resolved/VBN jaundice/NN
hydrochloride/NNP discontinued/VBN resolved/VBN jaundice/NN
metformin/NN initiation/NN wk/NN jaundice/NN
metformin/NN example/NN represents/VBZ believe/VBP onset/NN wk/NN jaundice/NN
metformin/NN initiation/NN wk/NN onset/NN believe/VBP reported/VBD associated/VBN hepatotoxicity/RB
metformin/NN example/NN represents/VBZ believe/VBP reported/VBD associated/VBN hepatotoxicity/RB
Amiodarone/VB toxicity/NN pulmonary/JJ
Amiodarone/VB toxicity/NN
amiodarone/NN toxicity/NN thought/VBN result/VB injury/NN related/VBN accumulation/NN pneumonitis/NNS hypersensitivity/JJ
amiodarone/NN toxicity/NN thought/VBN result/VB injury/NN related/VBN accumulation/NN pneumonitis/NNS
amiodarone/NN toxicity/NN pulmonary/JJ
amiodarone/NN toxicity/NN
amiodarone/NN induced/VBN toxicity/NN pulmonary/JJ
amiodarone/NN induced/VBN toxicity/NN
etoposide/NN enhancing/VBG protects/VBZ myelosuppression/NN
daunorubicin/NN etoposide/NN enhancing/VBG protects/VBZ myelosuppression/NN
doxorubicin/NN etoposide/NN enhancing/VBG protects/VBZ myelosuppression/NN
Dexrazoxane/NNP protects/VBZ myelosuppression/NN
daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN cardiac/JJ
daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN
etoposide/NN daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN
etoposide/NN daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN cardiac/JJ
etoposide/NN daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN
daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN
epipodophyllotoxin/NN etoposide/NN daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN
doxorubicin/NN daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN cardiac/JJ
doxorubicin/NN daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN
epipodophyllotoxin/NN etoposide/NN daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN cardiac/JJ
epipodophyllotoxin/NN etoposide/NN daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN
doxorubicin/NN daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN
anthracyclines/JJ daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN
anthracyclines/JJ daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN cardiac/JJ
anthracyclines/JJ daunorubicin/NN cleavage/NN limit/VBP myelosuppression/NN toxicity/NN
anthracycline/NN induced/VBN cardiotoxicity/RB
Dexrazoxane/NNP recommended/VBN anthracycline/NN induced/VBN cardiotoxicity/RB
ICRF/NNP Dexrazoxane/NNP recommended/VBN anthracycline/NN induced/VBN cardiotoxicity/RB
187/CD ICRF/NNP Dexrazoxane/NNP recommended/VBN anthracycline/NN induced/VBN cardiotoxicity/RB
dexrazoxane/NN coadministration/NN toxicity/NN hematologic/JJ
dexrazoxane/NN coadministration/NN toxicity/NN
dexrazoxane/NN determined/VBN investigated/VBN toxicity/NN hematologic/JJ
dexrazoxane/NN determined/VBN investigated/VBN toxicity/NN
etoposide/NN daunorubicin/NN reduced/VBD antagonized/VBD dexrazoxane/VB myelosuppression/NN cytotoxicity/NN
etoposide/NN daunorubicin/NN reduced/VBD loss/NN myelosuppression/NN
etoposide/NN daunorubicin/NN reduced/VBD antagonized/VBD dexrazoxane/VB myelosuppression/NN
dexrazoxane/NN doses/NNS reduced/VBD loss/NN myelosuppression/NN weight/NN
dexrazoxane/NN doses/NNS reduced/VBD loss/NN
dexrazoxane/NN doses/NNS reduced/VBD antagonized/VBD dexrazoxane/VB myelosuppression/NN loss/NN weight/NN
dexrazoxane/NN doses/NNS reduced/VBD antagonized/VBD dexrazoxane/VB myelosuppression/NN loss/NN
dexrazoxane/VB antagonized/VBD reduced/VBD loss/NN myelosuppression/NN weight/NN
dexrazoxane/VB antagonized/VBD reduced/VBD loss/NN
dexrazoxane/VB myelosuppression/NN loss/NN weight/NN
dexrazoxane/VB myelosuppression/NN loss/NN
daunorubicin/NN reduced/VBD loss/NN myelosuppression/NN
daunorubicin/NN reduced/VBD antagonized/VBD dexrazoxane/VB myelosuppression/NN
doxorubicin/NN cytotoxicity/NN
doxorubicin/NN cytotoxicity/NN myelosuppression/NN dexrazoxane/VB antagonized/VBD reduced/VBD loss/NN myelosuppression/NN
doxorubicin/NN cytotoxicity/NN myelosuppression/NN
dexrazoxane/NN doses/NNS reduced/VBD antagonized/VBD dexrazoxane/VB myelosuppression/NN cytotoxicity/NN
dexrazoxane/VB myelosuppression/NN cytotoxicity/NN
daunorubicin/NN reduced/VBD antagonized/VBD dexrazoxane/VB myelosuppression/NN cytotoxicity/NN
dexrazoxane/NN doses/NNS reduced/VBD loss/NN myelosuppression/NN
dexrazoxane/NN doses/NNS reduced/VBD antagonized/VBD dexrazoxane/VB myelosuppression/NN
dexrazoxane/VB antagonized/VBD reduced/VBD loss/NN myelosuppression/NN
dexrazoxane/VB myelosuppression/NN
etoposide/NN doses/NNS combining/VBG metastases/NNS
dexrazoxane/JJ doses/NNS combining/VBG metastases/NNS patients/NNS trials/NNS ongoing/JJ aim/NN improving/VBG toxicity/NN hematologic/JJ
dexrazoxane/JJ doses/NNS combining/VBG metastases/NNS patients/NNS trials/NNS ongoing/JJ aim/NN improving/VBG toxicity/NN
dexrazoxane/JJ doses/NNS combining/VBG metastases/NNS
amiodarone/NN presenting/VBG coma/NN myxedemic/JJ
amiodarone/NN presenting/VBG coma/NN
amiodarone/NN patient/NN congestive/JJ
amiodarone/NN patient/NN heart/NN
amiodarone/NN patient/NN failure/NN
amiodarone/NN secondary/JJ report/NN coma/NN myxedema/NN
amiodarone/NN secondary/JJ report/NN coma/NN
amiodarone/NN secondary/JJ hypothyroidism/NN failure/NN patient/JJ heart/NN congestive/JJ
amiodarone/NN secondary/JJ hypothyroidism/NN failure/NN patient/JJ heart/NN
amiodarone/NN secondary/JJ hypothyroidism/NN failure/NN
amiodarone/NN secondary/JJ hypothyroidism/NN failure/NN CHF/NNP
amiodarone/NN therapy/NN coma/NN myxedema/NN
amiodarone/NN therapy/NN coma/NN
amiodarone/NN CHF/NNP
amiodarone/NN usage/NN given/VBN patients/NNS CHF/NNP
magnesium/NN supplementation/NN importance/NN furosemide/NN Tetany/JJ rhabdomyolysis/JJ
magnesium/NN supplementation/NN importance/NN furosemide/NN Tetany/JJ
calcium/NN potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS associated/VBN hypomagnesemia/NN
potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS associated/VBN hypomagnesemia/NN
calcium/NN potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS associated/VBN cause/VB hypokalemia/NN
calcium/NN potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS muscle/NN
calcium/NN potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS
calcium/NN potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS associated/VBN cause/VB weakness/NN muscle/NN
calcium/NN potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS associated/VBN cause/VB weakness/NN
calcium/NN potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS tetany/NN
potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS tetany/NN
potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS associated/VBN cause/VB hypokalemia/NN
potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS muscle/NN
potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS
potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS associated/VBN cause/VB weakness/NN muscle/NN
potassium/NN supplementation/NN corrected/VBN cannot/VBP spasms/NNS associated/VBN cause/VB weakness/NN
magnesium/NN depletion/NN effects/NNS noted/VBN reported/VBN observed/JJ hypocalcemia/NN
magnesium/NN depletion/NN effects/NNS noted/VBN reported/VBN hypokalemia/NNP
ribavirin/NNP strategies/NNS anemia/NN treatment/NN C/NNP hepatitis/NNP
ribavirin/NNP strategies/NNS anemia/NN treatment/NN C/NNP
interferon/NN published/VBN OBJECTIVES/NNS alpha/VBD treatment/NN C/NNP chronic/JJ
interferon/NN published/VBN OBJECTIVES/NNS alpha/VBD treatment/NN C/NNP hepatitis/NNP
interferon/NN published/VBN OBJECTIVES/NNS alpha/VBD treatment/NN C/NNP
alpha/VBD treatment/NN C/NNP chronic/JJ
alpha/VBD treatment/NN C/NNP hepatitis/NNP
alpha/VBD treatment/NN C/NNP
interferon/NN published/VBN OBJECTIVES/NNS alpha/VBD treatment/NN C/NNP CHC/NNP
alpha/VBD treatment/NN C/NNP CHC/NNP
ribavirin/NNS therapy/NN effectiveness/NN efficacy/NN demonstrated/VBN published/VBN OBJECTIVES/NNS alpha/VBD treatment/NN C/NNP chronic/JJ
ribavirin/NNS therapy/NN effectiveness/NN efficacy/NN demonstrated/VBN published/VBN OBJECTIVES/NNS alpha/VBD treatment/NN C/NNP hepatitis/NNP
ribavirin/NNS therapy/NN effectiveness/NN efficacy/NN demonstrated/VBN published/VBN OBJECTIVES/NNS alpha/VBD treatment/NN C/NNP
ribavirin/NNS therapy/NN effectiveness/NN efficacy/NN demonstrated/VBN published/VBN OBJECTIVES/NNS alpha/VBD treatment/NN C/NNP CHC/NNP
phenobarbital/NN action/NN carcinogenic/JJ
diethylnitrosamine/NN given/VBN phenobarbital/NN action/NN carcinogenic/JJ
phenobarbital/NN carcinogenesis/NNS
PB/NNP phenobarbital/NN carcinogenesis/NNS
diethylnitrosamine/NN administered/VBN carcinogenesis/NNS
DEN/NNP phenobarbital/NN carcinogenesis/NNS
PB/NNP or/CC weeks/NNS treated/VBN schedule/NN hepatocarcinogenesis/NNS
DEN/NNP weeks/NNS treated/VBN schedule/NN hepatocarcinogenesis/NNS
DEN/NNP PB/NNP or/CC weeks/NNS treated/VBN schedule/NN hepatocarcinogenesis/NNS
PB/NNP given/VBN reduced/VBN number/NN size/NN foci/NNS preneoplastic/JJ
PB/NNP given/VBN reduced/VBN number/NN size/NN foci/NNS
DEN/NNP PB/NNP prolonged/JJ decreased/VBD incidence/NN tumor/NN
DEN/NNP obtained/VBN results/NNS decreased/VBD incidence/NN tumor/NN
PB/NNP prolonged/JJ decreased/VBD incidence/NN tumor/NN
PB/NNP promotes/VBZ carcinogenesis/NNS
DEN/NNP treatment/NN administered/VBN promotes/VBZ carcinogenesis/NNS
DEN/NNP given/VBN reduces/VBZ PB/NNP promotes/VBZ carcinogenesis/NNS
androgens/NNS role/NN favored/VBN pathogenesis/NNS apnea/NN sleep/NN
androgens/NNS role/NN favored/VBN pathogenesis/NNS apnea/NN
Valproate/NNP mg/NN month/NN improved/VBD subthalamotomy/NN developed/VBD had/VBD hemianopsia/NN homonymous/NN
Valproate/NNP mg/NN month/NN improved/VBD subthalamotomy/NN developed/VBD had/VBD hemianopsia/NN
serotonin/JJ blockers/NNS induced/VBN treatment/NN effects/NNS sexual/JJ
serotonin/JJ blockers/NNS induced/VBN treatment/NN effects/NNS side/NN
serotonin/JJ blockers/NNS induced/VBN treatment/NN effects/NNS
Yohimbine/JJ treatment/NN effects/NNS sexual/JJ
Yohimbine/JJ treatment/NN effects/NNS side/NN
Yohimbine/JJ treatment/NN effects/NNS
yohimbine/NN facilitates/VBZ helpful/JJ treatment/NN impotence/NN male/JJ
yohimbine/NN facilitates/VBZ helpful/JJ treatment/NN impotence/NN
yohimbine/NN used/VBN treat/VB effects/NNS sexual/JJ
yohimbine/NN used/VBN treat/VB effects/NNS side/NN
yohimbine/NN used/VBN treat/VB effects/NNS
serotonin/JJ blockers/NNS caused/VBD study/NN evaluated/VBN treatment/NN effects/NNS sexual/JJ
serotonin/JJ blockers/NNS caused/VBD study/NN evaluated/VBN treatment/NN effects/NNS side/NN
serotonin/JJ blockers/NNS caused/VBD study/NN evaluated/VBN treatment/NN effects/NNS
yohimbine/JJ evaluated/VBN treatment/NN effects/NNS sexual/JJ
yohimbine/JJ evaluated/VBN treatment/NN effects/NNS side/NN
yohimbine/JJ evaluated/VBN treatment/NN effects/NNS
yohimbine/NN given/VBN suffered/VBD patients/NNS disorder/NN obsessive/JJ
yohimbine/NN given/VBN suffered/VBD patients/NNS disorder/NN compulsive/JJ
yohimbine/NN given/VBN suffered/VBD patients/NNS disorder/NN
yohimbine/NN given/VBN suffered/VBD patients/NNS disorder/NN disorders/NNS affective/JJ
yohimbine/NN given/VBN suffered/VBD patients/NNS disorder/NN disorders/NNS
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD patients/NNS disorder/NN obsessive/JJ
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD patients/NNS disorder/NN compulsive/JJ
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD patients/NNS disorder/NN
yohimbine/NN given/VBN suffered/VBD patients/NNS disorder/NN anxiety/NN
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD patients/NNS disorder/NN anxiety/NN
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD effects/NNS sexual/JJ
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD effects/NNS side/NN
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD effects/NNS
yohimbine/NN given/VBN suffered/VBD patients/NNS disorder/NN trichotillomania/NN
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD patients/NNS disorder/NN trichotillomania/NN
yohimbine/NN given/VBN suffered/VBD effects/NNS sexual/JJ
yohimbine/NN given/VBN suffered/VBD effects/NNS side/NN
yohimbine/NN given/VBN suffered/VBD effects/NNS
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD patients/NNS disorder/NN disorders/NNS affective/JJ
serotonin/JJ blockers/NNS treatment/NN given/VBN suffered/VBD patients/NNS disorder/NN disorders/NNS
yohimbine/NN effects/NNS included/VBD sweating/NN anxiety/NN
serotonin/JJ blockers/NNS caused/VBN effects/NNS sexual/JJ
serotonin/JJ blockers/NNS caused/VBN effects/NNS side/NN
serotonin/JJ blockers/NNS caused/VBN effects/NNS
yohimbine/NN treatment/NN effects/NNS sexual/JJ
yohimbine/NN treatment/NN effects/NNS side/NN
yohimbine/NN treatment/NN effects/NNS
folic/JJ acid/NN activity/NN induces/VBZ SLE/NNP acid/NN epilepsy/NN
acid/NN activity/NN induces/VBZ SLE/NNP acid/NN epilepsy/NN
folic/JJ acid/NN epilepsy/NN
acid/NN epilepsy/NN
folic/JJ acid/NN effect/NN study/VB containing/VBG determine/VB rate/NN defects/NNS birth/NN
folic/JJ acid/NN effect/NN study/VB containing/VBG determine/VB rate/NN defects/NNS
acid/NN effect/NN study/VB containing/VBG determine/VB rate/NN defects/NNS birth/NN
acid/NN effect/NN study/VB containing/VBG determine/VB rate/NN defects/NNS
folic/JJ acid/NN effect/NN study/VB containing/VBG supplementation/NN women/NNS epileptic/JJ
acid/NN effect/NN study/VB containing/VBG supplementation/NN women/NNS epileptic/JJ
folic/JJ acid/NN effect/NN study/VB containing/VBG determine/VB rate/NN defects/NNS epilepsy/NN
acid/NN effect/NN study/VB containing/VBG determine/VB rate/NN defects/NNS epilepsy/NN
folic/JJ acid/NN women/NNS epileptic/JJ
acid/NN women/NNS epileptic/JJ
folic/JJ acid/NN women/NNS developed/VBD epilepsy/NN
acid/NN women/NNS developed/VBD epilepsy/NN
carbamazepine/NN treated/VBN woman/NN epileptic/JJ
folic/JJ acid/NN carbamazepine/NN treated/VBN woman/NN epileptic/JJ
acid/NN carbamazepine/NN treated/VBN woman/NN epileptic/JJ
folic/JJ acid/NN dose/NN barrier/NN triggered/VBD disease/NN autoimmune/JJ
folic/JJ acid/NN dose/NN barrier/NN triggered/VBD disease/NN
acid/NN dose/NN barrier/NN triggered/VBD disease/NN autoimmune/JJ
acid/NN dose/NN barrier/NN triggered/VBD disease/NN
folic/JJ acid/NN dose/NN barrier/NN triggered/VBD disease/NN CONCLUSIONS/NNS patient/NN epileptic/JJ
acid/NN dose/NN barrier/NN triggered/VBD disease/NN CONCLUSIONS/NNS patient/NN epileptic/JJ
folic/JJ acid/NN dose/NN all/DT disease/NN autoimmune/JJ
folic/JJ acid/NN dose/NN all/DT disease/NN
acid/NN dose/NN all/DT disease/NN autoimmune/JJ
acid/NN dose/NN all/DT disease/NN
folic/JJ acid/NN healthy/JJ women/NNS epileptic/JJ
acid/NN healthy/JJ women/NNS epileptic/JJ
folic/JJ acid/NN dose/NN increase/VB risk/NN seizures/NNS epileptic/JJ
folic/JJ acid/NN dose/NN increase/VB risk/NN seizures/NNS
acid/NN dose/NN increase/VB risk/NN seizures/NNS epileptic/JJ
acid/NN dose/NN increase/VB risk/NN seizures/NNS
epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN patient/NN haemorrhage/NN subarachnoid/JJ
epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN patient/NN haemorrhage/NN
aminocaproic/JJ acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN patient/NN haemorrhage/NN subarachnoid/JJ
aminocaproic/JJ acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN patient/NN haemorrhage/NN
acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN patient/NN haemorrhage/NN subarachnoid/JJ
acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN patient/NN haemorrhage/NN
epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN SAH/NNP
aminocaproic/JJ acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN SAH/NNP
acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN SAH/NNP
EACA/NNP acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN patient/NN haemorrhage/NN subarachnoid/JJ
EACA/NNP acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN patient/NN haemorrhage/NN
EACA/NNP acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG case/NN SAH/NNP
epsilon/NN due/JJ treatment/NN necrotizing/VBG
epsilon/NN due/JJ myopathy/RB
aminocaproic/JJ acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG
aminocaproic/JJ acid/NN epsilon/NN due/JJ myopathy/RB
acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG
acid/NN epsilon/NN due/JJ myopathy/RB
EACA/NNP acid/NN epsilon/NN due/JJ treatment/NN necrotizing/VBG
EACA/NNP acid/NN epsilon/NN due/JJ myopathy/RB
Valproate/NNP induced/VBN hyperglycinemia/NN nonketotic/JJ
Valproate/NNP induced/VBN hyperglycinemia/NN
glycine/JJ system/NN defect/NN leads/VBZ disorder/NN
glycine/JJ system/NN defect/NN leads/VBZ disorder/NN metabolism/NN of/IN
glycine/JJ system/NN defect/NN leads/VBZ disorder/NN metabolism/NN amino/JJ
glycine/JJ system/NN defect/NN leads/VBZ disorder/NN metabolism/NN acid/JJ
glycine/JJ system/NN defect/NN leads/VBZ disorder/NN metabolism/NN
glycine/NN accumulation/NN leads/VBZ disorder/NN
glycine/NN accumulation/NN leads/VBZ disorder/NN metabolism/NN of/IN
glycine/NN accumulation/NN leads/VBZ disorder/NN metabolism/NN amino/JJ
glycine/NN accumulation/NN leads/VBZ disorder/NN metabolism/NN acid/JJ
glycine/NN accumulation/NN leads/VBZ disorder/NN metabolism/NN
glycine/JJ system/NN defect/NN leads/VBZ disorder/NN hyperglycinemia/NNP Nonketotic/NNP
glycine/JJ system/NN defect/NN leads/VBZ disorder/NN hyperglycinemia/NNP
glycine/NN accumulation/NN leads/VBZ disorder/NN hyperglycinemia/NNP Nonketotic/NNP
glycine/NN accumulation/NN leads/VBZ disorder/NN hyperglycinemia/NNP
valproate/JJ therapy/NN initiation/NN have/VB found/VBN delay/NN retardation/NN mental/JJ
valproate/JJ therapy/NN initiation/NN have/VB found/VBN delay/NN retardation/NN
valproate/JJ therapy/NN initiation/NN have/VB hyperglycinemia/NN nonketotic/JJ
valproate/JJ therapy/NN initiation/NN have/VB hyperglycinemia/NN
valproate/JJ therapy/NN initiation/NN have/VB found/VBN delay/NN language/NN
valproate/JJ therapy/NN initiation/NN have/VB found/VBN delay/NN
nimesulide/NN Tolerability/NNP urticaria/NN
paracetamol/NN nimesulide/NN Tolerability/NNP urticaria/NN
NSAID/NNP Tolerability/NNP urticaria/NN
nimesulide/NN paracetamol/JJ number/NN history/NN induced/VBN urticaria/NN
paracetamol/JJ number/NN history/NN induced/VBN urticaria/NN
NSAID/NNP history/NN induced/VBN urticaria/NN
nimesulide/NN procedure/NN applied/VBN patients/NNS history/NN angioedema/NN urticaria/NN
paracetamol/NN nimesulide/NN procedure/NN applied/VBN patients/NNS history/NN angioedema/NN urticaria/NN
NSAID/NNP angioedema/NN urticaria/NN
NSAID/NNP history/NN subjects/NNS %/NN urticaria/NN
NSAID/NNP history/NN subjects/NNS %/NN induced/VBN angioedema/NN urticaria/JJ
NSAID/NNP history/NN subjects/NNS %/NN induced/VBN alone/RB with/IN urticaria/NN
nimesulide/NN tolerability/NN confirm/VBP patients/NNS experienced/VBD angioedema/NN urticaria/NN
paracetamol/NN nimesulide/NN tolerability/NN confirm/VBP patients/NNS experienced/VBD angioedema/NN urticaria/NN
NSAIDs/NNP caused/VBN angioedema/NN urticaria/NN
NSAID/NNP history/NN increased/JJ' increased/JJ history/NN urticaria/NN
carboplatin/NN rhabdomyosarcoma/NN embryonal/JJ
carboplatin/NN rhabdomyosarcoma/NN
amphotericin/NNP B/NNP prevention/NN drug/NN it/PRP hypokalemia/NN patients/NNS cancer/NN
B/NNP prevention/NN drug/NN it/PRP hypokalemia/NN patients/NNS cancer/NN
Spironolactone/NNP it/PRP hypokalemia/NN patients/NNS cancer/NN
Spironolactone/NNP it/PRP hypokalemia/NN
amphotericin/NNP B/NNP effect/NN Nephrotoxicity/NNP
B/NNP effect/NN Nephrotoxicity/NNP
AmB/NNP B/NNP effect/NN Nephrotoxicity/NNP
potassium/NN wasting/NN responsible/JJ seems/VBZ toxicity/NNS
AmB/NNP treatment/NN effect/NN wasting/NN responsible/JJ seems/VBZ toxicity/NNS
Potassium/JJ depletion/NN potentiates/VBZ toxicity/NN
AmB/NNP toxicity/NN
AmB/NNP treatment/NN patients/NNS neutropenic/JJ
spironolactone/NN ability/NN assess/VB reduce/VB prevent/VB patients/NNS neutropenic/JJ
spironolactone/NN ability/NN assess/VB reduce/VB prevent/VB hypokalemia/NN
potassium/NN requirements/NNS reduce/VB prevent/VB hypokalemia/NN
potassium/NN requirements/NNS reduce/VB prevent/VB patients/NNS neutropenic/JJ
AmB/NN receive/VB randomized/VBN patients/NNS disorders/NNS hematological/JJ
AmB/NN receive/VB randomized/VBN patients/NNS disorders/NNS
AmB/NNP mg/VBP randomized/VBN patients/NNS disorders/NNS hematological/JJ
AmB/NNP mg/VBP randomized/VBN patients/NNS disorders/NNS
spironolactone/NN AmB/NNP mg/VBP daily/JJ developing/VBG proven/JJ infection/NN fungal/JJ
spironolactone/NN AmB/NNP mg/VBP daily/JJ developing/VBG proven/JJ infection/NN
AmB/NN receive/VB randomized/VBN mg/VBP daily/JJ developing/VBG proven/JJ infection/NN fungal/JJ
AmB/NN receive/VB randomized/VBN mg/VBP daily/JJ developing/VBG proven/JJ infection/NN
AmB/NNP mg/VBP daily/JJ developing/VBG proven/JJ infection/NN fungal/JJ
AmB/NNP mg/VBP daily/JJ developing/VBG proven/JJ infection/NN
spironolactone/NN AmB/NNP mg/VBP randomized/VBN patients/NNS disorders/NNS hematological/JJ
spironolactone/NN AmB/NNP mg/VBP randomized/VBN patients/NNS disorders/NNS
AmB/NNP treatment/NN patients/NNS neutropenic/JJ
spironolactone/NN reduce/VB prevent/VB reducing/VBG patients/NNS neutropenic/JJ
spironolactone/NN reduce/VB prevent/VB hypokalemia/NN
potassium/NN requirements/NNS reduce/VB prevent/VB hypokalemia/NN
potassium/NN loss/NN reducing/VBG prevent/VB hypokalemia/NN
potassium/NN requirements/NNS reduce/VB prevent/VB reducing/VBG patients/NNS neutropenic/JJ
potassium/NN loss/NN reducing/VBG patients/NNS neutropenic/JJ
enflurane/NN delineated/VBN foci/NNS Epileptic/JJ
enflurane/NN prove/VB activator/NN foci/NNS epileptic/JJ
sulfasalazine/NN arthritis/NN
benztropine/NN Ethopropazine/NN parkinsonism/NN
Ethopropazine/NN parkinsonism/NN
fluphenazine/JJ enanthate/NN outpatients/NNS schizophrenic/JJ
enanthate/NN outpatients/NNS schizophrenic/JJ
ethopropazine/NN compared/VBN benztropine/VB treatment/NN parkinsonism/NN induced/VBN enanthate/NN outpatients/NNS schizophrenic/JJ
benztropine/VB treatment/NN parkinsonism/NN induced/VBN enanthate/NN outpatients/NNS schizophrenic/JJ
benztropine/VB treatment/NN parkinsonism/NN
ethopropazine/NN compared/VBN benztropine/VB treatment/NN parkinsonism/NN
procyclidine/NN efficacious/JJ found/VBN effective/JJ symptoms/NNS parkinsonian/NN
procyclidine/NN efficacious/JJ found/VBN effective/JJ symptoms/NNS
benztropine/NN Ethopropazine/NN found/VBN effective/JJ symptoms/NNS parkinsonian/NN
benztropine/NN Ethopropazine/NN found/VBN effective/JJ symptoms/NNS
Ethopropazine/NN found/VBN effective/JJ symptoms/NNS parkinsonian/NN
Ethopropazine/NN found/VBN effective/JJ symptoms/NNS
procyclindine/JJ treatment/NN condition/NN had/VBD increase/NN dyskinesia/NN tardive/JJ
procyclindine/JJ treatment/NN condition/NN had/VBD increase/NN dyskinesia/NN
ethopropazine/JJ patients/NNS anxiety/NN
procyclindine/JJ treatment/NN condition/NN anxiety/NN depression/NN
ethopropazine/JJ patients/NNS anxiety/NN depression/NN
ethopropazine/JJ patients/NNS anxiety/NN condition/NN had/VBD increase/NN dyskinesia/NN tardive/JJ
ethopropazine/JJ patients/NNS anxiety/NN condition/NN had/VBD increase/NN dyskinesia/NN
procyclindine/JJ treatment/NN condition/NN anxiety/NN
benztropine/NN drug/NN choice/NN treatment/NN neuroleptic/JJ symptoms/NNS parkinsonian/NN
benztropine/NN drug/NN choice/NN treatment/NN neuroleptic/JJ symptoms/NNS
Doxorubicin/NNP induces/VBZ self/NN nephropathy/NN
Doxorubicin/NNP induces/VBZ self/NN nephropathy/NN characterized/VBN glomerular/NN
Doxorubicin/NNP induces/VBZ self/NN nephropathy/NN characterized/VBN and/CC
Doxorubicin/NNP induces/VBZ self/NN nephropathy/NN characterized/VBN lesions/NNS late/RB
Doxorubicin/NNP induces/VBZ self/NN nephropathy/NN characterized/VBN lesions/NNS onset/JJ
Doxorubicin/NNP induces/VBZ self/NN nephropathy/NN characterized/VBN lesions/NNS tubular/JJ
Doxorubicin/NNP induces/VBZ self/NN nephropathy/NN characterized/VBN lesions/NNS
citrate/JJ activity/NN glomerular/NN
citrate/JJ activity/NN glomerular/NN and/CC
citrate/JJ activity/NN glomerular/NN lesions/NNS tubular/JJ
citrate/JJ activity/NN glomerular/NN lesions/NNS
superoxide/NN function/NN encoded/VBN reduction/NN induced/VBN lesions/NNS renal/JJ
superoxide/NN function/NN encoded/VBN reduction/NN induced/VBN lesions/NNS
doxorubicin/NN encoded/VBN reduction/NN induced/VBN lesions/NNS renal/JJ
doxorubicin/NN encoded/VBN reduction/NN induced/VBN lesions/NNS
oxprenolol/NN mediated/VBD hypokalemia/NN
oxprenolol/NN efficacy/NN investigated/VBD antagonizing/VBG hypokalemia/NN
oxprenolol/JJ pretreatment/NN concentrations/NNS spite/NN antagonized/VBN hypokalemia/NN
thalidomide/NN study/NN carcinoma/NN renal/JJ
thalidomide/NN study/NN carcinoma/NN cell/NN
thalidomide/NN study/NN carcinoma/NN
thalidomide/NN toxicity/NN
thalidomide/NN toxicity/NN evaluate/VB patients/NNS cancer/NN renal/JJ
thalidomide/NN toxicity/NN evaluate/VB patients/NNS cancer/NN cell/NN
thalidomide/NN toxicity/NN evaluate/VB patients/NNS cancer/NN
thalidomide/NN carcinoma/NN renal/JJ
thalidomide/NN carcinoma/NN cell/NN
thalidomide/NN carcinoma/NN
thalidomide/NN carcinoma/NN renal/JJ
thalidomide/NN carcinoma/NN cell/NN
thalidomide/NN carcinoma/NN
amlodipine/NN telmisartan/NN combination/NN hypertension/NN
amlodipine/NN hypertension/NN
telmisartan/NN combination/NN hypertension/NN
amlodipine/VB mg/CD monotherapy/NN patients/NNS hypertension/NNP
amlodipine/JJ 5/CD mg/CD monotherapy/NN patients/NNS hypertension/NNP
telmisartan/NN +/NN efficacy/NN amlodipine/VB mg/CD monotherapy/NN patients/NNS hypertension/NNP
warfarin/NN juice/NN haemopericardium/NN
warfarin/NN dosage/NN maintaining/VBG consumed/VBN man/NN report/VBP case/NN haemorrhage/NN
ketamine/JJ induced/NN analgesia/JJ
morphine/JJ ketamine/JJ induced/NN analgesia/JJ
morphine/NN ketamine/NN predominance/NN reflected/VBD Latency/NNP loss/NN righting/VBG reflex/NN rigidity/NN
ketamine/NN predominance/NN reflected/VBD Latency/NNP loss/NN righting/VBG reflex/NN rigidity/NN
Naloxone/NNP inhibited/VBD effects/NNS cataleptic/JJ
naloxone/NN ID/NN asymmetry/NN latency/NN rigidity/NN
naloxone/NN ID/NN asymmetry/NN latency/NN differences/NNS argue/VB suggest/VBP mechanisms/NNS catalepsy/NN
carboplatin/NN cancer/NN ovarian/NN
carboplatin/NN cancer/NN
Paclitaxel/NNP combined/VBN carboplatin/NN cancer/NN ovarian/NN
Paclitaxel/NNP combined/VBN carboplatin/NN cancer/NN
carboplatin/NN administered/VBN women/NNS cancer/NN ovarian/NN
carboplatin/NN administered/VBN women/NNS cancer/NN
paclitaxel/NN dose/NN determine/VB study/VBP phase/NN infusion/NN combination/NN carboplatin/NN administered/VBN women/NNS cancer/NN ovarian/NN
paclitaxel/NN dose/NN determine/VB study/VBP phase/NN infusion/NN combination/NN carboplatin/NN administered/VBN women/NNS cancer/NN
Taxol/NNP Bristol/NNP paclitaxel/NN dose/NN determine/VB study/VBP phase/NN infusion/NN combination/NN carboplatin/NN administered/VBN women/NNS cancer/NN ovarian/NN
Taxol/NNP Bristol/NNP paclitaxel/NN dose/NN determine/VB study/VBP phase/NN infusion/NN combination/NN carboplatin/NN administered/VBN women/NNS cancer/NN
paclitaxel/JJ doses/NNS escalated/VBN phase/NN infusion/NN combination/NN carboplatin/NN administered/VBN women/NNS cancer/NN ovarian/NN
paclitaxel/JJ doses/NNS escalated/VBN phase/NN infusion/NN combination/NN carboplatin/NN administered/VBN women/NNS cancer/NN
interferon/NN therapy/NN treatment/NN infection/NN HCV/NNP
interferon/NN therapy/NN treatment/NN infection/NN
ribavirin/NNP interferon/NN therapy/NN treatment/NN infection/NN HCV/NNP
ribavirin/NNP interferon/NN therapy/NN treatment/NN infection/NN
ribavirin/NNP result/NN decrease/VB problematic/JJ patients/NNS those/DT comorbid/VBN disorders/NNS renal/JJ
ribavirin/NNP result/NN decrease/VB problematic/JJ patients/NNS those/DT comorbid/VBN disorders/NNS renal/JJ or/CC
ribavirin/NNP result/NN decrease/VB problematic/JJ patients/NNS those/DT comorbid/VBN disorders/NNS renal/JJ cardiovascular/JJ
ribavirin/NNP result/NN decrease/VB problematic/JJ patients/NNS those/DT comorbid/VBN disorders/NNS
ribavirin/NNP result/NN hemolysis/NNS
ribavirin/NNP result/NN decrease/VB problematic/JJ patients/NNS infection/NN HCV/NNP
ribavirin/NNP result/NN decrease/VB problematic/JJ patients/NNS infection/NN
ribavirin/NNP result/NN decrease/VB problematic/JJ anemia/NN
ribavirin/NNP anemia/NN
ribavirin/NNP associated/VBN anemia/NN
Viramidine/RB has/VBZ potential/NN maintain/VB decreasing/VBG risk/NN anemia/NN hemolytic/JJ
Viramidine/RB has/VBZ potential/NN maintain/VB decreasing/VBG risk/NN anemia/NN
Viramidine/RB has/VBZ potential/NN maintain/VB decreasing/VBG patients/NNS C/NNP chronic/JJ
Viramidine/RB has/VBZ potential/NN maintain/VB decreasing/VBG patients/NNS C/NNP hepatitis/NNP
Viramidine/RB has/VBZ potential/NN maintain/VB decreasing/VBG patients/NNS C/NNP
ribavirin/NNP prodrug/NN liver/NN has/VBZ potential/NN maintain/VB decreasing/VBG patients/NNS C/NNP chronic/JJ
ribavirin/NNP prodrug/NN liver/NN has/VBZ potential/NN maintain/VB decreasing/VBG patients/NNS C/NNP hepatitis/NNP
ribavirin/NNP prodrug/NN liver/NN has/VBZ potential/NN maintain/VB decreasing/VBG patients/NNS C/NNP
ribavirin/NNP efficacy/NN maintain/VB decreasing/VBG patients/NNS C/NNP chronic/JJ
ribavirin/NNP efficacy/NN maintain/VB decreasing/VBG patients/NNS C/NNP hepatitis/NNP
ribavirin/NNP efficacy/NN maintain/VB decreasing/VBG patients/NNS C/NNP
vancomycin/NN course/NN osteomyelitis/NNS
tenofovir/NN AIDS/NNP patients/NNS failure/NN Acute/VB
tenofovir/NN AIDS/NNP patients/NNS failure/NN renal/JJ
tenofovir/NN AIDS/NNP patients/NNS failure/NN
tenofovir/NN AIDS/NNP
vancomycin/NN course/NN receiving/VBG Acute/VB failure/NN patients/NNS AIDS/NNP
tenofovir/NN AIDS/NNP patients/NNS failure/NN Acute/VB receiving/VBG course/NN osteomyelitis/NNS
tenofovir/NN fumarate/NN receiving/VBG patients/NNS developed/VBD failure/NN Renal/JJ
tenofovir/NN fumarate/NN receiving/VBG patients/NNS developed/VBD failure/NN
disoproxil/JJ fumarate/NN receiving/VBG patients/NNS developed/VBD failure/NN Renal/JJ
disoproxil/JJ fumarate/NN receiving/VBG patients/NNS developed/VBD failure/NN
fumarate/NN receiving/VBG patients/NNS developed/VBD failure/NN Renal/JJ
fumarate/NN receiving/VBG patients/NNS developed/VBD failure/NN
vancomycin/NN therapy/NN course/NN developed/VBD failure/NN Renal/JJ
vancomycin/NN therapy/NN course/NN developed/VBD failure/NN
Tenofovir/NNP implicated/VBN development/NN syndrome/NN Fanconi/NNP
Tenofovir/NNP implicated/VBN development/NN syndrome/NN
Tenofovir/NNP implicated/VBN development/NN insufficiency/NN renal/JJ
Tenofovir/NNP implicated/VBN development/NN insufficiency/NN
Vancomycin/NNP infrequent/JJ nephrotoxicity/RB
Vancomycin/NNP infrequent/JJ result/VB agent/NN nephrotoxic/JJ
vancomycin/NN administration/NN raise/VB risk/NN failure/NN renal/JJ
vancomycin/NN administration/NN raise/VB risk/NN failure/NN
tenofovir/NN raise/VB risk/NN failure/NN renal/JJ
tenofovir/NN raise/VB risk/NN failure/NN
CC/NNP received/VBN presented/VBN pain/NN chest/NN
CC/NNP received/VBN presented/VBN pain/NN
CC/NNP complication/NN Thrombosis/NNS
Thorazine/NNP receiving/VBG developed/VBD tachycardia/NNP Supraventricular/NNP
Thorazine/NNP receiving/VBG developed/VBD tachycardia/NNP
chlorpromazine/NN Thorazine/NNP receiving/VBG developed/VBD tachycardia/NNP Supraventricular/NNP
chlorpromazine/NN Thorazine/NNP receiving/VBG developed/VBD tachycardia/NNP
lidocaine/NN administration/NN responded/VBD arrhythmias/NNS ventricular/NN
lidocaine/NN administration/NN responded/VBD arrhythmias/NNS
propranolol/NN instances/NNS required/VBN responded/VBD arrhythmias/NNS ventricular/NN
propranolol/NN instances/NNS required/VBN responded/VBD arrhythmias/NNS
phenothiazines/JJ drugs/NNS receiving/VBG patients/NNS quantify/VB risk/NN complications/NNS cardiac/JJ
phenothiazines/JJ drugs/NNS receiving/VBG patients/NNS quantify/VB risk/NN complications/NNS
Tramadol/NNP opioid/NN used/VBN treat/VB pain/NN
Tramadol/NNP opioid/NN used/VBN treat/VB pain/NN pain/NN
Tramadol/NNP opioid/NN used/VBN treat/VB pain/NN cancer/NN
paroxetine/JJ hydrochloride/NN patient/NN tetraparetic/JJ
dosulepine/JJ paroxetine/JJ hydrochloride/NN patient/NN pain/NN chronic/JJ
dosulepine/JJ paroxetine/JJ hydrochloride/NN patient/NN pain/NN
hydrochloride/NN patient/NN pain/NN chronic/JJ
hydrochloride/NN patient/NN pain/NN
dosulepine/JJ paroxetine/JJ hydrochloride/NN patient/NN tetraparetic/JJ
hydrochloride/NN patient/NN tetraparetic/JJ
paroxetine/JJ hydrochloride/NN patient/NN pain/NN chronic/JJ
paroxetine/JJ hydrochloride/NN patient/NN pain/NN
anthracycline/NN derivative/JJ induced/VBN cardiomyopathy/RB
SM/NNP derivative/JJ induced/VBN cardiomyopathy/RB
5887/CD SM/NNP derivative/JJ induced/VBN cardiomyopathy/RB
SM/NNP potential/NN cardiotoxic/JJ
5887/CD potential/NN cardiotoxic/JJ
SM/NNP potential/NN pre/NN cardiotoxicity/NN
5887/CD potential/NN pre/NN cardiotoxicity/NN
SM/NNP effect/NN 5887/CD potential/NN cardiotoxic/JJ
5887/CD potential/NN cardiotoxic/JJ
SM/NNP effect/NN 5887/CD potential/NN pre/NN cardiotoxicity/NN
5887/CD potential/NN pre/NN cardiotoxicity/NN
doxorubicin/NN induced/VBN potential/NN cardiotoxic/JJ
doxorubicin/NN induced/VBN potential/NN pre/NN cardiotoxicity/NN
SM/NNP sacrificed/VBN animals/NNS cardiomyopathy/NN
5887/CD administration/NN show/VB demonstrated/VBD changes/NNS decrease/NN cardiomyopathy/NN
SM/NNP effect/NN cardiotoxic/JJ
5887/CD effect/NN cardiotoxic/JJ
SM/NNP effect/NN examine/VB cardiomyopathy/NN
5887/CD effect/NN examine/VB cardiomyopathy/NN
doxorubicin/NN cardiomyopathy/NN examine/VB effect/NN cardiotoxic/JJ
doxorubicin/NN treatment/NN enhanced/VBN changes/NNS cardiotoxic/JJ
SM/NNP progress/VB grade/NN cardiomyopathy/NN
5887/CD treatment/NN SM/NNP progress/VB grade/NN cardiomyopathy/NN
SM/NNP have/VB potential/NN cardiotoxicity/NN
5887/CD have/VB potential/NN cardiotoxicity/NN
SM/NNP induced/VBN cardiotoxicity/RB
5887/CD have/VB SM/NNP induced/VBN cardiotoxicity/RB
doxorubicin/NN effect/NN potential/NN cardiotoxicity/NN
doxorubicin/NN effect/NN potential/NN have/VB SM/NNP induced/VBN cardiotoxicity/RB
metoprolol/NN antagonism/NN hypokalemia/NN
diphenylhydantoin/NN toxicity/NN
DPH/NNP toxicity/NNP
DPH/NNP toxicity/NNP manifest/VB liable/JJ patients/NNS damage/NN cerebral/JJ
DPH/NNP toxicity/NNP manifest/VB liable/JJ patients/NNS damage/NN
iopentol/NN lower/JJR Frequencies/NNS fibrillation/NN ventricular/NN
iopentol/NN lower/JJR Frequencies/NNS fibrillation/NN
iohexol/NN iopentol/NN lower/JJR Frequencies/NNS fibrillation/NN ventricular/NN
iohexol/NN iopentol/NN lower/JJR Frequencies/NNS fibrillation/NN
levobupivacaine/NN bupivacaine/JJ rats/NNS toxicity/NN
bupivacaine/JJ rats/NNS toxicity/NN
ropivacaine/JJ bupivacaine/JJ rats/NNS toxicity/NN
levobupivacaine/NN bupivacaine/NN toxicity/NN
bupivacaine/NN toxicity/NN
ropivacaine/NN bupivacaine/NN toxicity/NN
bupivacaine/NN those/DT larger/JJR similar/JJ doses/NNS seizures/NNS
bupivacaine/NN those/DT larger/JJR smaller/JJR doses/NNS levobupivacaine/NN produced/VBD dysrhythmias/JJ asystole/JJ
bupivacaine/NN those/DT larger/JJR smaller/JJR doses/NNS levobupivacaine/NN produced/VBD dysrhythmias/JJ
levobupivacaine/NN toxicity/NN
levobupivacaine/NN bupivacaine/NN induced/VBN that/DT treatment/NN susceptible/JJ appears/VBZ conclude/VBP intermediate/JJ toxicity/NN
bupivacaine/NN ropivacaine/NN that/DT intermediate/JJ conclude/VBP appears/VBZ arrest/NN cardiac/JJ
bupivacaine/NN ropivacaine/NN that/DT intermediate/JJ conclude/VBP appears/VBZ arrest/NN
bupivacaine/NN induced/VBN that/DT treatment/NN susceptible/JJ appears/VBZ arrest/NN cardiac/JJ
bupivacaine/NN induced/VBN that/DT treatment/NN susceptible/JJ appears/VBZ arrest/NN
bupivacaine/NN ropivacaine/NN that/DT intermediate/JJ toxicity/NN
bupivacaine/NN induced/VBN that/DT treatment/NN susceptible/JJ appears/VBZ conclude/VBP intermediate/JJ toxicity/NN
ropivacaine/NN that/DT intermediate/JJ toxicity/NN
ropivacaine/NN rate/NN administered/VBN intermediate/JJ toxicity/NN
tacrolimus/NNS treatment/NN associated/VBN dermatitis/NNS
tacrolimus/VBZ describe/VBP eruptions/VBZ
tacrolimus/VBZ ointment/NN dermatitis/NNS facial/JJ
tacrolimus/VBZ ointment/NN dermatitis/NNS
tacrolimus/VBZ describe/VBP herein/VB patients/NNS developed/VBD rosacea/NN
tacrolimus/VBZ describe/VBP eruptions/VBZ dermatitis/NNS
tacrolimus/NNS immunomodulators/NNS use/NN regarded/VBN cause/NN dermatitis/NNS
Heparin/NNP induced/VBN thrombocytopenia/NN thrombosis/NN
heparin/NN resistance/NN count/NN a/DT
heparin/NN resistance/NN count/NN falling/VBG
heparin/NN resistance/NN count/NN platelet/NN
heparin/NN resistance/NN count/NN
heparin/NN added/VBN plasma/NN revealed/VBN count/NN a/DT
heparin/NN added/VBN plasma/NN revealed/VBN count/NN falling/VBG
heparin/NN added/VBN plasma/NN revealed/VBN count/NN platelet/NN
heparin/NN added/VBN plasma/NN revealed/VBN count/NN
heparin/NN receiving/VBG indicated/VBN testing/NN platelet/JJ
heparin/NN receiving/VBG indicated/VBN testing/NN aggregation/NN
calcium/NN chloride/NN injected/VBN mydriasis/NNS tremor/NN
chloride/NN injected/VBN mydriasis/NNS tremor/NN
calcium/NN chloride/NN injected/VBN mydriasis/NNS clonic/NNS
calcium/NN chloride/NN injected/VBN mydriasis/NNS produced/VBD convulsions/NNS tonic/NN
calcium/NN chloride/NN injected/VBN mydriasis/NNS produced/VBD convulsions/NNS
chloride/NN injected/VBN mydriasis/NNS clonic/NNS
chloride/NN injected/VBN mydriasis/NNS produced/VBD convulsions/NNS tonic/NN
chloride/NN injected/VBN mydriasis/NNS produced/VBD convulsions/NNS
calcium/NN chloride/NN injected/VBN mydriasis/NNS
chloride/NN injected/VBN mydriasis/NNS
calcium/NN chloride/NN changed/VBN hand/NN tremor/NN
chloride/NN changed/VBN hand/NN tremor/NN
calcium/NN chloride/NN changed/VBN hand/NN clonic/NN
calcium/NN chloride/NN changed/VBN convulsions/NNS tonic/NN
calcium/NN chloride/NN changed/VBN convulsions/NNS
chloride/NN changed/VBN hand/NN clonic/NN
chloride/NN changed/VBN convulsions/NNS tonic/NN
chloride/NN changed/VBN convulsions/NNS
calcium/NN chloride/NN changed/VBN hand/NN mydriasis/NNS
chloride/NN changed/VBN hand/NN mydriasis/NNS
calcium/NN chloride/NN dissociate/VB phenomena/NNS mydriasis/NNS tremor/NN
chloride/NN dissociate/VB phenomena/NNS mydriasis/NNS tremor/NN
calcium/NN chloride/NN dissociate/VB phenomena/NNS mydriasis/NNS clonic/NN
calcium/NN chloride/NN dissociate/VB phenomena/NNS convulsions/NNS tonic/NN
calcium/NN chloride/NN dissociate/VB phenomena/NNS convulsions/NNS
chloride/NN dissociate/VB phenomena/NNS mydriasis/NNS clonic/NN
chloride/NN dissociate/VB phenomena/NNS convulsions/NNS tonic/NN
chloride/NN dissociate/VB phenomena/NNS convulsions/NNS
calcium/NN chloride/NN dissociate/VB phenomena/NNS mydriasis/NNS
chloride/NN dissociate/VB phenomena/NNS mydriasis/NNS
dexamethasone/NN myeloma/NN
cyclophosphamide/NN definition/NN XI/NNP dexamethasone/NN myeloma/NN
bortezomib/NN definition/NN XI/NNP dexamethasone/NN myeloma/NN
dexamethasone/VB transplantation/NN patients/NNS myeloma/NN multiple/JJ
dexamethasone/VB transplantation/NN patients/NNS myeloma/NN
dexamethasone/VB transplantation/NN patients/NNS myeloma/NN MM/NNP
cyclophosphamide/NN dose/NN evaluate/VB dexamethasone/VB transplantation/NN patients/NNS myeloma/NN multiple/JJ
cyclophosphamide/NN dose/NN evaluate/VB dexamethasone/VB transplantation/NN patients/NNS myeloma/NN
cyclophosphamide/NN dose/NN evaluate/VB dexamethasone/VB transplantation/NN patients/NNS myeloma/NN MM/NNP
bortezomib/NN evaluate/VB dexamethasone/VB transplantation/NN patients/NNS myeloma/NN multiple/JJ
bortezomib/NN evaluate/VB dexamethasone/VB transplantation/NN patients/NNS myeloma/NN
bortezomib/NN evaluate/VB dexamethasone/VB transplantation/NN patients/NNS myeloma/NN MM/NNP
dexamethasone/NN combination/NN bortezomib/NN treatment/NN patients/NNS MM/NNP
cyclophosphamide/JJ m/NN combination/NN bortezomib/NN treatment/NN patients/NNS MM/NNP
bortezomib/NN treatment/NN patients/NNS MM/NNP
metoprolol/JJ treatment/NN SR/NNP block/VBP shock/NN cardiogenic/JJ
metoprolol/JJ treatment/NN SR/NNP block/VBP shock/NN
verapamil/NNP SR/NNP block/VBP shock/NN cardiogenic/JJ
verapamil/NNP SR/NNP block/VBP shock/NN
atropine/JJ doses/NNS uses/NNS block/NN heart/NN
atropine/JJ doses/NNS uses/NNS block/NN
dopamine/NN agents/NNS doses/NNS uses/NNS block/NN heart/NN
dopamine/NN agents/NNS doses/NNS uses/NNS block/NN
dopamine/NN agents/NNS doses/NNS uses/NNS block/NN remain/VB hypotensive/NN
dobutamine/NN dopamine/NN agents/NNS doses/NNS uses/NNS block/NN heart/NN
dobutamine/NN dopamine/NN agents/NNS doses/NNS uses/NNS block/NN
atropine/JJ doses/NNS uses/NNS block/NN remain/VB hypotensive/NN
dobutamine/NN dopamine/NN agents/NNS doses/NNS uses/NNS block/NN remain/VB hypotensive/NN
calcium/NN chloride/NN use/NN resolved/VBN hypotension/NN
chloride/NN use/NN resolved/VBN hypotension/NN
calcium/NN chloride/NN use/NN resolved/VBN hypotension/NN block/NN heart/NN
calcium/NN chloride/NN use/NN resolved/VBN hypotension/NN block/NN
chloride/NN use/NN resolved/VBN hypotension/NN block/NN heart/NN
chloride/NN use/NN resolved/VBN hypotension/NN block/NN
paclitaxel/NN cancer/NN Chemotherapy/NNP non/NN
paclitaxel/NN cancer/NN small/JJ
paclitaxel/NN cancer/NN cell/NN
paclitaxel/NN cancer/NN lung/NN
paclitaxel/NN cancer/NN
Paclitaxel/NNP demonstrated/VBN types/NNS ovarian/NN
Paclitaxel/NNP demonstrated/VBN types/NNS and/CC
Paclitaxel/NNP demonstrated/VBN types/NNS carcinoma/NN breast/NN
Paclitaxel/NNP demonstrated/VBN types/NNS carcinoma/NN
Taxol/NNP Bristol/NNP Paclitaxel/NNP demonstrated/VBN types/NNS ovarian/NN
Taxol/NNP Bristol/NNP Paclitaxel/NNP demonstrated/VBN types/NNS and/CC
Taxol/NNP Bristol/NNP Paclitaxel/NNP demonstrated/VBN types/NNS carcinoma/NN breast/NN
Taxol/NNP Bristol/NNP Paclitaxel/NNP demonstrated/VBN types/NNS carcinoma/NN
Paclitaxel/NNP demonstrated/VBN types/NNS tumor/NN
Taxol/NNP Bristol/NNP Paclitaxel/NNP demonstrated/VBN types/NNS tumor/NN
paclitaxel/NN infusions/NNS trials/NNS patients/NNS IIIB/NNS non/NNP
paclitaxel/NN infusions/NNS trials/NNS cell/NN small/JJ
paclitaxel/NN infusions/NNS trials/NNS cell/NN
paclitaxel/NN infusions/NNS trials/NNS cell/NN cancer/NN lung/NN
paclitaxel/NN infusions/NNS trials/NNS cell/NN cancer/NN
paclitaxel/NN infusions/NNS trials/NNS NSCLC/NNP
paclitaxel/JJ infusion/NN efficacy/NN investigated/VBD IIIB/NNP NSCLC/NNP
paclitaxel/JJ infusion/NN efficacy/NN toxicity/NN
Paclitaxel/NNP agent/NN 3/CD infusion/NN proving/VBG effective/JJ superior/JJ terms/NNS incidence/NN toxicity/NN
paclitaxel/NN combined/VBN drugs/NNS active/JJ NSCLC/NNP
paclitaxel/NN comparing/VBG studies/NNS remain/VBP indicated/VBN studies/NNS paclitaxel/NN combined/VBN drugs/NNS active/JJ NSCLC/NNP
Cyclosporin/NNP A/NNP caused/VBD reduction/NN hypertrophy/NN
A/NNP caused/VBD reduction/NN hypertrophy/NN
CsA/NNP A/NNP caused/VBD reduction/NN hypertrophy/NN
macrolide/JJ rapamycin/NN A/NNP caused/VBD reduction/NN hypertrophy/NN
rapamycin/NN A/NNP caused/VBD reduction/NN hypertrophy/NN
Fujimycine/NNP A/NNP caused/VBD reduction/NN hypertrophy/NN
FK/NNP Fujimycine/NNP A/NNP caused/VBD reduction/NN hypertrophy/NN
506/CD FK/NNP Fujimycine/NNP A/NNP caused/VBD reduction/NN hypertrophy/NN
FK/NNP CsA/NNPS toxicity/NN
506/NNP toxicity/NN
CsA/NNPS toxicity/NN
timolol/NN Comparison/NNP response/NN patients/NNS treatment/NN glaucoma/NN
timolol/NN trial/NN DESIGN/NNP rate/NN patients/NNS treated/VBN glaucoma/NN
timolol/JJ solution/NN timolol/NN trial/NN DESIGN/NNP rate/NN patients/NNS treated/VBN glaucoma/NN
timolol/JJ suspension/NN trial/NN DESIGN/NNP rate/NN patients/NNS treated/VBN glaucoma/NN
timolol/JJ gellan/NN conjunctiva/NN forms/NNS suspension/NN trial/NN DESIGN/NNP rate/NN patients/NNS treated/VBN glaucoma/NN
timolol/JJ solution/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ
timolol/JJ solution/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ glaucoma/NN angle/NN
timolol/JJ solution/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ glaucoma/NN
timolol/JJ gellan/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ
timolol/JJ gellan/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ glaucoma/NN angle/NN
timolol/JJ gellan/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ glaucoma/NN
timolol/JJ solution/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ glaucoma/NN hypertension/NN ocular/NN
timolol/JJ solution/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ glaucoma/NN hypertension/NN
timolol/JJ gellan/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ glaucoma/NN hypertension/NN ocular/NN
timolol/JJ gellan/NN placebo/NN masked/VBN Forty/VBG randomized/VBN patients/NNS years/NNS open/JJ glaucoma/NN hypertension/NN
HCBD/NNP produced/VBN damage/NN discriminated/VBN both/DT damage/NN glomerular/NN
HCBD/NNP produced/VBN damage/NN discriminated/VBN both/DT damage/NN
BEA/NNP HCBD/NNP produced/VBN damage/NN discriminated/VBN both/DT damage/NN glomerular/NN
BEA/NNP HCBD/NNP produced/VBN damage/NN discriminated/VBN both/DT damage/NN
PAN/NNP produced/VBN damage/NN glomerular/NN
PAN/NNP produced/VBN damage/NN
droperidol/NN dose/NN administration/NN minutes/NNS developed/VBN protrusion/NN year/NN man/NN allergies/NNS drug/NN
droperidol/NN dose/NN administration/NN minutes/NNS developed/VBN protrusion/NN year/NN man/NN allergies/NNS
droperidol/NN dose/NN administration/NN minutes/NNS developed/VBN protrusion/NN year/NN man/NN allergies/NNS angioedema/NN tongue/NN
droperidol/NN dose/NN administration/NN minutes/NNS developed/VBN protrusion/NN year/NN man/NN allergies/NNS angioedema/NN tongue/NN swelling/VBG
ethambutol/NN map/VB pattern/NN degeneration/NN axonal/JJ
ethambutol/NN map/VB pattern/NN degeneration/NN
Ethambutol/NNP agent/NN used/VBN treat/VB tuberculosis/NNP
EMB/NNP management/NN terms/NNS important/JJ manage/VB patients/NNS impairment/NN renal/JJ
EMB/NNP management/NN terms/NNS important/JJ manage/VB patients/NNS impairment/NN
ethambutol/JJ dosing/NN manage/VB patients/NNS impairment/NN renal/JJ
ethambutol/JJ dosing/NN manage/VB patients/NNS impairment/NN
Metformin/NNP prevents/VBZ pathway/NN induced/VBN nephropathy/RB
gentamicin/JJ pathway/NN induced/VBN nephropathy/RB
metformin/NN diminish/VB prevent/VB dysfunction/NN vascular/NN
metformin/NN diminish/VB prevent/VB dysfunction/NN
gentamicin/NN toxicity/NN
Metformin/NN treatment/NN blocked/VBD gentamicin/NN failure/NN acute/JJ
Metformin/NN treatment/NN blocked/VBD gentamicin/NN failure/NN renal/JJ
Metformin/NN treatment/NN blocked/VBD gentamicin/NN failure/NN
metformin/NN correction/NN markers/NNS dysfunction/NN kidney/NN
metformin/NN correction/NN markers/NNS dysfunction/NN
metformin/NN effects/NNS lessen/VB nephrotoxicity/RB
gentamicin/NN lessen/VB nephrotoxicity/RB
sodium/NN administration/NN toxicity/NN Treatment/NNP sulphonate/NN patients/NNS cancer/NN lung/NN
sodium/NN administration/NN toxicity/NN Treatment/NNP sulphonate/NN patients/NNS cancer/NN
2/CD sodium/NN administration/NN toxicity/NN Treatment/NNP sulphonate/NN patients/NNS cancer/NN lung/NN
2/CD sodium/NN administration/NN toxicity/NN Treatment/NNP sulphonate/NN patients/NNS cancer/NN
mercaptoethane/JJ sulphonate/NN patients/NNS cancer/NN lung/NN
mercaptoethane/JJ sulphonate/NN patients/NNS cancer/NN
sulphonate/NN patients/NNS cancer/NN lung/NN
sulphonate/NN patients/NNS cancer/NN
MESNA/NNP sulphonate/NN patients/NNS cancer/NN lung/NN
MESNA/NNP sulphonate/NN patients/NNS cancer/NN
sodium/NN administration/NN toxicity/NN urothelial/JJ
sodium/NN administration/NN toxicity/NN
2/CD sodium/NN administration/NN toxicity/NN urothelial/JJ
2/CD sodium/NN administration/NN toxicity/NN
mercaptoethane/JJ sulphonate/NN Treatment/NNP toxicity/NN urothelial/JJ
mercaptoethane/JJ sulphonate/NN Treatment/NNP toxicity/NN
sulphonate/NN Treatment/NNP toxicity/NN urothelial/JJ
sulphonate/NN Treatment/NNP toxicity/NN
MESNA/NNP sulphonate/NN Treatment/NNP toxicity/NN urothelial/JJ
MESNA/NNP sulphonate/NN Treatment/NNP toxicity/NN
ifosfamide/NN Treatment/NNP sulphonate/NN patients/NNS cancer/NN lung/NN
ifosfamide/NN Treatment/NNP sulphonate/NN patients/NNS cancer/NN
sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN lung/NN
sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN
2/CD sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN lung/NN
2/CD sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN
mercaptoethane/JJ sulphonate/JJ sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN lung/NN
mercaptoethane/JJ sulphonate/JJ sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN
sulphonate/JJ sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN lung/NN
sulphonate/JJ sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN
MESNA/NNP sulphonate/JJ sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN lung/NN
MESNA/NNP sulphonate/JJ sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN
thiol/JJ compound/NN administration/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN lung/NN
thiol/JJ compound/NN administration/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN
sodium/NN sulphonate/JJ toxicity/NN urothelial/JJ
sodium/NN sulphonate/JJ toxicity/NN
2/CD sodium/NN sulphonate/JJ toxicity/NN urothelial/JJ
2/CD sodium/NN sulphonate/JJ toxicity/NN
mercaptoethane/JJ sulphonate/JJ toxicity/NN urothelial/JJ
mercaptoethane/JJ sulphonate/JJ toxicity/NN
sulphonate/JJ toxicity/NN urothelial/JJ
sulphonate/JJ toxicity/NN
MESNA/NNP sulphonate/JJ toxicity/NN urothelial/JJ
MESNA/NNP sulphonate/JJ toxicity/NN
ifosfamide/NN induced/VBN toxicity/NN sulphonate/JJ sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN lung/NN
ifosfamide/NN induced/VBN toxicity/NN sulphonate/JJ sodium/NN effect/NN tested/VBN group/NN patients/NNS cancer/NN
IF/NNP effect/NN tested/VBN group/NN patients/NNS cancer/NN lung/NN
IF/NNP effect/NN tested/VBN group/NN patients/NNS cancer/NN
IF/NNP treatment/NN tested/VBN group/NN patients/NNS cancer/NN lung/NN
IF/NNP treatment/NN tested/VBN group/NN patients/NNS cancer/NN
thiol/JJ compound/NN administration/NN effect/NN sodium/NN sulphonate/JJ toxicity/NN urothelial/JJ
thiol/JJ compound/NN administration/NN effect/NN sodium/NN sulphonate/JJ toxicity/NN
MESNA/NNP series/NN differences/NNS were/VBD toxicity/NN
methylprednisolone/NN do/VB injury/NN spinal/JJ
methylprednisolone/NN do/VB injury/NN cord/NN
methylprednisolone/NN do/VB injury/NN
methylprednisolone/NN became/VBD Studies/NNP Spinal/NNP
methylprednisolone/NN became/VBD Studies/NNP Cord/NNP
methylprednisolone/NN became/VBD Studies/NNP Injury/NNP
methylprednisolone/NN became/VBD injury/NN spinal/JJ
methylprednisolone/NN became/VBD injury/NN cord/NN
methylprednisolone/NN became/VBD injury/NN
corticosteroid/JJ myopathy/NN
steroid/JJ myopathy/NN recovers/VBZ recording/NN protection/NN offers/VBZ injury/NN spinal/JJ
steroid/JJ myopathy/NN recovers/VBZ recording/NN protection/NN offers/VBZ injury/NN cord/NN
steroid/JJ myopathy/NN recovers/VBZ recording/NN protection/NN offers/VBZ injury/NN
steroid/JJ myopathy/NN recovery/NN recording/NN protection/NN offers/VBZ injury/NN spinal/JJ
steroid/JJ myopathy/NN recovery/NN recording/NN protection/NN offers/VBZ injury/NN cord/NN
steroid/JJ myopathy/NN recovery/NN recording/NN protection/NN offers/VBZ injury/NN
steroid/JJ myopathy/NN
steroid/JJ myopathy/NN recovers/VBZ recording/NN recovery/NN myopathy/NN
steroid/JJ myopathy/NN recovery/NN recording/NN recovers/VBZ myopathy/NN
steroid/JJ myopathy/NN
methylprednisolone/NN offers/VBZ injury/NN spinal/JJ
methylprednisolone/NN offers/VBZ injury/NN cord/NN
methylprednisolone/NN offers/VBZ injury/NN
corticosteroid/JJ myopathy/NN
tamoxifen/NN use/NN tumors/NNS
tamoxifen/NN treated/VBN year/NN 52/CD CASE/NN breast/NN
tamoxifen/NN treated/VBN year/NN 52/CD CASE/NN breast/NN carcinoma/NN
estrogen/JJ receptor/NN tamoxifen/NN treated/VBN year/NN 52/CD CASE/NN breast/NN
estrogen/JJ receptor/NN tamoxifen/NN treated/VBN year/NN 52/CD CASE/NN breast/NN carcinoma/NN
tamoxifen/NN Patients/NNS CONCLUSION/NNP induced/VBD risk/NN tumors/NNS granulosa/NN
tamoxifen/NN Patients/NNS CONCLUSION/NNP induced/VBD risk/NN tumors/NNS cell/NN
tamoxifen/NN Patients/NNS CONCLUSION/NNP induced/VBD risk/NN tumors/NNS
tamoxifen/NN metabolism/NN alterations/NNS tumors/NNS granulosa/NN
tamoxifen/NN metabolism/NN alterations/NNS tumors/NNS cell/NN
tamoxifen/NN metabolism/NN alterations/NNS tumors/NNS
quetiapine/NN symptoms/NNS extrapyramidal/JJ
quetiapine/NN symptoms/NNS
quetiapine/NN symptoms/NNS EPS/NNP
quetiapine/NN studies/NNS patients/NNS mania/NN bipolar/NNP
quetiapine/NN studies/NNS patients/NNS mania/NN
quetiapine/NN evaluate/VB symptoms/NNS akathisia/NN
quetiapine/NN evaluate/VB symptoms/NNS extrapyramidal/JJ
quetiapine/NN evaluate/VB symptoms/NNS
quetiapine/NN evaluate/VB symptoms/NNS EPS/NNP
quetiapine/NN patients/NNS mania/NN bipolar/NNP
quetiapine/NN patients/NNS mania/NN
quetiapine/NN different/JJ monotherapy/NN events/NNS akathisia/NN
quetiapine/NN different/JJ monotherapy/NN related/VBD RESULTS/NNS incidence/NN EPS/NNP
QTP/NNP Li/NNP events/NNS DVP/NNP EPS/NNP
DVP/NNP EPS/NNP
DVP/NNP different/JJ DVP/NNP EPS/NNP
DVP/NNP low/JJ' low/JJ incidence/NN akathisia/NN
DVP/NNP DVP/NNP low/JJ' low/JJ incidence/NN akathisia/NN
quetiapine/JJ monotherapy/NN low/JJ incidence/NN akathisia/NN
QTP/NNP DVP/NNP low/JJ' low/JJ incidence/NN akathisia/NN
Li/NNP DVP/NNP low/JJ' low/JJ incidence/NN akathisia/NN
Li/NNP DVP/NNP DVP/NNP low/JJ' low/JJ incidence/NN akathisia/NN
quetiapine/NN associated/VBN incidence/NN tremor/NN
quetiapine/NN associated/VBN contributed/VBN tremor/NN
quetiapine/NN associated/VBN contributed/VBN rate/NN tremor/NN
quetiapine/NN induced/VBN incidence/NN akathisia/NN
quetiapine/NN induced/VBN incidence/NN akathisia/NN syndrome/NN extrapyramidal/JJ
quetiapine/NN induced/VBN incidence/NN akathisia/NN syndrome/NN
quetiapine/NN induced/VBN incidence/NN akathisia/NN tremor/NN
quetiapine/JJ therapy/NN incidence/NN EPS/NNP akathisia/NN
quetiapine/JJ therapy/NN incidence/NN EPS/NNP
quetiapine/JJ therapy/NN incidence/NN similar/JJ mania/NN bipolar/NNP
quetiapine/JJ therapy/NN incidence/NN similar/JJ mania/NN
Steroid/JJ treatment/NN meshwork/VBP similar/JJ those/DT reported/VBN glaucoma/NN glaucoma/NN open/JJ
Steroid/JJ treatment/NN meshwork/VBP similar/JJ those/DT reported/VBN glaucoma/NN glaucoma/NN angle/NN
Steroid/JJ treatment/NN meshwork/VBP similar/JJ those/DT reported/VBN glaucoma/NN glaucoma/NN
Steroid/JJ treatment/NN meshwork/VBP similar/JJ those/DT reported/VBN glaucoma/NN corticosteroid/JJ
Steroid/JJ treatment/NN meshwork/VBP similar/JJ those/DT reported/VBN glaucoma/NN
Remifentanil/JJ pretreatment/NN reduces/VBZ myoclonus/NNS
remifentanil/NN kg/NN pretreatment/NN effect/NN compare/VB incidence/NN myoclonus/NNS
remifentanil/JJ group/NN lower/JJR incidence/NN myoclonus/NNS
remifentanil/JJ microg/NN Pretreatment/NNP CONCLUSION/NNP reduced/VBD effects/NNS sedation/NN apnea/NN
etomidate/JJ induction/NN reduced/VBD effects/NNS sedation/NN nausea/NN
remifentanil/JJ microg/NN Pretreatment/NNP CONCLUSION/NNP reduced/VBD myoclonus/NNS
etomidate/JJ induction/NN reduced/VBD effects/NNS sedation/NN pruritus/NNS
remifentanil/JJ microg/NN Pretreatment/NNP CONCLUSION/NNP reduced/VBD effects/NNS sedation/NN pruritus/NNS
etomidate/JJ induction/NN reduced/VBD effects/NNS sedation/NN apnea/NN
remifentanil/JJ microg/NN Pretreatment/NNP CONCLUSION/NNP reduced/VBD effects/NNS sedation/NN nausea/NN
nitric/JJ production/NN Association/NNP model/NN nephropathy/NN
oxide/NN production/NN Association/NNP model/NN nephropathy/NN
NO/DT association/NN role/NN studied/VBN apoptosis/NNS model/NN syndrome/NN nephrotic/JJ
NO/DT association/NN role/NN studied/VBN apoptosis/NNS model/NN syndrome/NN
ADR/NNP groups/NNS groups/NNS nephropathy/JJ
ADR/NNP revealed/VBN areas/NNS proliferation/NN mesangial/JJ
ADR/NNP revealed/VBN areas/NNS proliferation/NN
ADR/NNP revealed/VBN areas/NNS proliferation/NN inflammation/NN tubulointerstitial/JJ
ADR/NNP revealed/VBN areas/NNS proliferation/NN inflammation/NN
ADR/NNP increased/VBN group/NN nephropathy/JJ
nitrite/NN levels/NNS increased/VBN group/NN nephropathy/JJ
acetylcholine/JJ phenylephrine/JJ responses/NNS impaired/JJ group/NN nephropathy/NN
ADR/JJ group/NN nephropathy/NN
phenylephrine/JJ responses/NNS impaired/JJ group/NN nephropathy/NN
ADR/JJ group/NN nephropathy/NN
ADR/NNP pathogenesis/NNS important/JJ nephrosis/JJ
NO/NNS interactions/NNS important/JJ nephrosis/JJ
paracetamol/NNP overdose/NN
paracetamol/NNP overdose/NN survived/VBD increased/VBN patients/NNS failure/NN due/JJ hepatitis/NN viral/JJ
paracetamol/NNP overdose/NN survived/VBD increased/VBN patients/NNS failure/NN due/JJ hepatitis/NN
PPA/NNP abuse/NN linked/VBN involved/VBN overdose/NN
PPA/NNP abuse/NN linked/VBN injury/NN myocardial/JJ
PPA/NNP abuse/NN linked/VBN injury/NN
Dexatrim/NNP case/NN injury/NN myocardial/JJ
Dexatrim/NNP case/NN injury/NN
PPA/NNP Dexatrim/NNP case/NN injury/NN myocardial/JJ
PPA/NNP Dexatrim/NNP case/NN injury/NN
PPA/NNP injury/NN myocardial/JJ
PPA/NNP injury/NN
Reserpine/NNP produced/VBD dyskinesia/NN orofacial/JJ
Reserpine/NNP produced/VBD dyskinesia/NN
Reserpine/NNP produced/VBD tremor/NN suggestive/NN disease/NN Parkinson/NNP
Reserpine/NNP produced/VBD tremor/NN suggestive/NN disease/NN Parkinson/NNP '/POS
Reserpine/NNP produced/VBD tremor/NN suggestive/NN disease/NN s/JJ
Reserpine/NNP produced/VBD tremor/NN suggestive/NN disease/NN
MK/NNP 801/CD administered/VBN induced/VBN catalepsy/RB
801/CD administered/VBN induced/VBN catalepsy/RB
MK/NNP injection/NN produced/VBN increase/NN tremor/NN
801/CD injection/NN produced/VBN increase/NN tremor/NN
apomophine/JJ injection/NN followed/VBN administered/VBN Reserpine/NNP produce/VB dyskinesia/NN oral/JJ
apomophine/JJ injection/NN followed/VBN administered/VBN Reserpine/NNP produce/VB dyskinesia/NN
Reserpine/NNP produce/VB dyskinesia/NN oral/JJ
Reserpine/NNP produce/VB dyskinesia/NN
MK/NNP 801/CD attenuated/VBD catalepsy/NN
801/CD attenuated/VBD catalepsy/NN
MK/NNP 801/CD attenuated/VBD catalepsy/NN tremor/NN
801/CD attenuated/VBD catalepsy/NN tremor/NN
MK/NNP increases/NNS tremor/NN catalepsy/NN
801/CD increases/NNS tremor/NN catalepsy/NN
MK/NNP increases/NNS tremor/NN
801/CD increases/NNS tremor/NN
reserpine/NN produces/VBZ considered/VBN parkinsonian/NN
NMDA/NNP produced/VBN blockage/NN restore/VB signs/NNS vacuous/NNS chewing/VBG movements/NNS catalepsy/NN
NMDA/NNP produced/VBN blockage/NN restore/VB signs/NNS vacuous/NNS chewing/VBG movements/NNS tremor/NN
magnesium/NN toxicity/NN
nifedipine/NN potentiate/VB toxicity/NN
apomorphine/NN dose/NN administration/NN dyskinesia/NN study/NN included/VBN patients/NNS had/VBD disease/NN Parkinson/NNP
apomorphine/NN dose/NN administration/NN dyskinesia/NN study/NN included/VBN patients/NNS had/VBD disease/NN Parkinson/NNP '/POS
apomorphine/NN dose/NN administration/NN dyskinesia/NN study/NN included/VBN patients/NNS had/VBD disease/NN s/JJ
apomorphine/NN dose/NN administration/NN dyskinesia/NN study/NN included/VBN patients/NNS had/VBD disease/NN
poly/JJ polymerase/NNS Activation/NNP contributes/VBZ development/NN failure/NN heart/NN
poly/JJ polymerase/NNS Activation/NNP contributes/VBZ development/NN failure/NN
ADP/NNP polymerase/NNS Activation/NNP contributes/VBZ development/NN failure/NN heart/NN
ADP/NNP polymerase/NNS Activation/NNP contributes/VBZ development/NN failure/NN
ribose/NN ADP/NNP polymerase/NNS Activation/NNP contributes/VBZ development/NN failure/NN heart/NN
ribose/NN ADP/NNP polymerase/NNS Activation/NNP contributes/VBZ development/NN failure/NN
anthracycline/NN antibiotic/NN factor/NN implicated/VBN cardiotoxicity/NN
doxorubicin/NN cardiotoxicity/NN
DOX/NNP doxorubicin/NN cardiotoxicity/NN
DOX/NNP induced/VBN cardiotoxicity/RB
DOX/NNP induced/VBN dysfunction/NN cardiac/JJ
DOX/NNP induced/VBN dysfunction/NN
PJ/NNP deletion/NN Using/VBG demonstrate/VBP development/NN dysfunction/NN cardiac/JJ
PJ/NNP deletion/NN Using/VBG demonstrate/VBP development/NN dysfunction/NN
34/CD PJ/NNP deletion/NN Using/VBG demonstrate/VBP development/NN dysfunction/NN cardiac/JJ
34/CD PJ/NNP deletion/NN Using/VBG demonstrate/VBP development/NN dysfunction/NN
PJ/NNP Treatment/NNP improved/VBD dysfunction/NN cardiac/JJ
PJ/NNP Treatment/NNP improved/VBD dysfunction/NN
34/CD PJ/NNP Treatment/NNP improved/VBD dysfunction/NN cardiac/JJ
34/CD PJ/NNP Treatment/NNP improved/VBD dysfunction/NN
DOX/NNP cardiotoxicity/NN
DOX/NNP treatment/NN associated/VBN complications/NNS cardiac/JJ
DOX/NNP treatment/NN associated/VBN complications/NNS
fentanyl/NN dose/NN received/VBD period/NN case/NN rigidity/NN leading/VBG respiratory/VB
fentanyl/NN dose/NN received/VBD period/NN case/NN rigidity/NN leading/VBG respiratory/VB described/VBN failure/NN
oxytocin/NN administration/NN associated/VBN intoxication/NNP abortion/NN
oxytocin/NN administration/NN intoxication/VBN described/VBN abortions/NNS
Oxytocin/NN administration/NN advocated/VBN carried/VBN report/VB asthenia/NN
Oxytocin/NN administration/NN advocated/VBN carried/VBN report/VB asthenia/NN irritability/NN
Oxytocin/NN administration/NN advocated/VBN abortions/NNS
Oxytocin/NN administration/NN advocated/VBN carried/VBN report/VB asthenia/NN headaches/NNS
Dopamine/NNP essential/JJ development/NN methamphetamine/NN induced/VBN neurotoxicity/RB
dopamine/NN mediates/VBZ methamphetamine/NN toxicity/NN
dopamine/NN mediates/VBZ drugs/NNS interfere/VBP toxicity/NN
dopamine/NN mediates/VBZ drugs/NNS interfere/VBP enhance/VB toxicity/NN
DA/NNP dopamine/NN mediates/VBZ methamphetamine/NN toxicity/NN
DA/NNP dopamine/NN mediates/VBZ drugs/NNS interfere/VBP toxicity/NN
DA/NNP dopamine/NN mediates/VBZ drugs/NNS interfere/VBP enhance/VB toxicity/NN
DA/NNP toxicity/NN interfere/VBP drugs/NNS mediates/VBZ methamphetamine/NN toxicity/NN
DA/NNP toxicity/NN
DA/NNP toxicity/NN interfere/VBP enhance/VB toxicity/NN
DA/NNP neurotransmission/NN increase/VB drugs/NNS enhance/VB interfere/VBP drugs/NNS mediates/VBZ methamphetamine/NN toxicity/NN
DA/NNP neurotransmission/NN increase/VB drugs/NNS enhance/VB interfere/VBP toxicity/NN
DA/NNP neurotransmission/NN increase/VB drugs/NNS enhance/VB toxicity/NN
methamphetamine/NN toxicity/NN
methamphetamine/NN mediates/VBZ drugs/NNS interfere/VBP toxicity/NN
methamphetamine/NN mediates/VBZ drugs/NNS interfere/VBP enhance/VB toxicity/NN
METH/NNP methamphetamine/NN toxicity/NN
METH/NNP methamphetamine/NN mediates/VBZ drugs/NNS interfere/VBP toxicity/NN
METH/NNP methamphetamine/NN mediates/VBZ drugs/NNS interfere/VBP enhance/VB toxicity/NN
DA/NNP confounded/VBN neurotoxicity/RB
L/NNP ability/NN dihydroxyphenylalanine/VBP show/VBP confounded/VBN neurotoxicity/RB
dihydroxyphenylalanine/VBP show/VBP confounded/VBN neurotoxicity/RB
alpha/NNP tyrosine/NN effect/NN reverse/VB dihydroxyphenylalanine/VBP show/VBP confounded/VBN neurotoxicity/RB
methyl/NN tyrosine/NN effect/NN reverse/VB dihydroxyphenylalanine/VBP show/VBP confounded/VBN neurotoxicity/RB
para/NN methyl/NN tyrosine/NN effect/NN reverse/VB dihydroxyphenylalanine/VBP show/VBP confounded/VBN neurotoxicity/RB
tyrosine/NN effect/NN reverse/VB dihydroxyphenylalanine/VBP show/VBP confounded/VBN neurotoxicity/RB
DA/NN deficient/VBN engineered/VBN mice/NNS develop/VBP METH/VB neurotoxicity/RB
METH/NNP deficits/NNS dopaminergic/JJ
METH/NNP deficits/NNS
DA/NN deficits/NNS develop/VB METH/NNP deficits/NNS dopaminergic/JJ
DA/NN deficits/NNS develop/VB METH/NNP deficits/NNS
DA/NNP essential/JJ neurotoxicity/RB
DA/NNP mechanisms/NNS warrant/VBP suggest/VBP demonstrate/VBP essential/JJ neurotoxicity/RB
morphine/NN doubled/VBD increased/VBD incoordination/NN
NH/CD 4/CD Ac/NNS blocked/VBN reversed/VBD depression/NN
4/CD Ac/NNS blocked/VBN reversed/VBD depression/NN
Ac/NNS blocked/VBN reversed/VBD depression/NN
catecholamine/NN release/NN blocked/VBN reversed/VBD depression/NN
acetaldehyde/NN release/NN blocked/VBN reversed/VBD depression/NN
calcium/NN Addition/NNP reversed/VBD depression/NN
calcium/VBZ reversed/VBD depression/NN
NH/CD 4/CD activity/NN analgesia/JJ
4/CD activity/NN analgesia/JJ
Ac/JJ activity/NN analgesia/JJ
NH/JJ verapamil/JJ mg/NN activity/NN analgesia/JJ
4/CD Ac/JJ verapamil/NN mg/NN activity/NN analgesia/JJ
Ac/JJ verapamil/NN mg/NN activity/NN analgesia/JJ
verapamil/NN mg/NN activity/NN analgesia/JJ diazepam/JJ incoordination/NN
verapamil/JJ mg/NN activity/NN analgesia/JJ diazepam/JJ incoordination/NN
diazepam/JJ analgesia/JJ
amphetamine/JJ analgesia/JJ diazepam/JJ incoordination/NN
verapamil/NN mg/NN activity/NN analgesia/JJ
verapamil/JJ mg/NN activity/NN analgesia/JJ
morphine/JJ analgesia/JJ diazepam/JJ incoordination/NN
amphetamine/JJ analgesia/JJ
metrazol/NN action/NN affected/VBD verapamil/NN mg/NN activity/NN analgesia/JJ diazepam/JJ incoordination/NN
metrazol/NN action/NN affected/VBD verapamil/NN mg/NN activity/NN analgesia/JJ
morphine/JJ analgesia/JJ
calcium/NN channel/NN exerts/VBZ hyperammonemia/NN
salicylates/NNS calcium/NN treated/VBN arthritis/NN rheumatoid/JJ
salicylates/NNS calcium/NN treated/VBN arthritis/NN
naproxen/NN therapy/NN institution/NN developed/VBD year/NN man/NN arthritis/NN rheumatoid/JJ
naproxen/NN therapy/NN institution/NN developed/VBD year/NN man/NN arthritis/NN
fenoprofen/JJ calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS renal/JJ
fenoprofen/JJ calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS papillary/NN
fenoprofen/JJ calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS
calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS renal/JJ
calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS papillary/NN
calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS
fenoprofen/JJ calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS RPN/NNP
calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS RPN/NNP
sulindac/JJ calcium/NN treated/VBN arthritis/NN rheumatoid/JJ
sulindac/JJ calcium/NN treated/VBN arthritis/NN
salicylates/NNS calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS renal/JJ
salicylates/NNS calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS papillary/NN
salicylates/NNS calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS
salicylates/NNS calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS RPN/NNP
fenoprofen/JJ calcium/NN treated/VBN arthritis/NN rheumatoid/JJ
fenoprofen/JJ calcium/NN treated/VBN arthritis/NN
calcium/NN treated/VBN arthritis/NN rheumatoid/JJ
calcium/NN treated/VBN arthritis/NN
sulindac/JJ calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS renal/JJ
sulindac/JJ calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS papillary/NN
sulindac/JJ calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS
sulindac/JJ calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS RPN/NNP
gold/JJ salts/NNS calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS renal/JJ
gold/JJ salts/NNS calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS papillary/NN
gold/JJ salts/NNS calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS
gold/JJ salts/NNS calcium/NN treated/VBN arthritis/NN man/NN year/NN developed/VBD necrosis/NNS RPN/NNP
gold/JJ salts/NNS calcium/NN treated/VBN arthritis/NN rheumatoid/JJ
gold/JJ salts/NNS calcium/NN treated/VBN arthritis/NN
sulindac/NN advantages/NNS discuss/VB antiinflammatory/VB linking/VBG RPN/NNP
sulindac/NN advantages/NNS discuss/VB patients/NNS experienced/VBN toxicity/NN renal/JJ
sulindac/NN advantages/NNS discuss/VB patients/NNS experienced/VBN toxicity/NN
All/DT induced/VBN leukemia/NN acute/JJ
All/DT induced/VBN leukemia/NN promyelocytic/JJ
All/DT induced/VBN leukemia/NN
trans/NNS All/DT induced/VBN leukemia/NN acute/JJ
trans/NNS All/DT induced/VBN leukemia/NN promyelocytic/JJ
trans/NNS All/DT induced/VBN leukemia/NN
retinoic/JJ acid/NN trans/NNS All/DT induced/VBN leukemia/NN acute/JJ
retinoic/JJ acid/NN trans/NNS All/DT induced/VBN leukemia/NN promyelocytic/JJ
retinoic/JJ acid/NN trans/NNS All/DT induced/VBN leukemia/NN
acid/NN trans/NNS All/DT induced/VBN leukemia/NN acute/JJ
acid/NN trans/NNS All/DT induced/VBN leukemia/NN promyelocytic/JJ
acid/NN trans/NNS All/DT induced/VBN leukemia/NN
all/DT acid/NN associated/VBN leukemia/NN acute/JJ
all/DT acid/NN associated/VBN leukemia/NN promyelocytic/JJ
all/DT acid/NN associated/VBN leukemia/NN
trans/JJ acid/NN associated/VBN leukemia/NN acute/JJ
trans/JJ acid/NN associated/VBN leukemia/NN promyelocytic/JJ
trans/JJ acid/NN associated/VBN leukemia/NN
retinoic/JJ acid/NN associated/VBN leukemia/NN acute/JJ
retinoic/JJ acid/NN associated/VBN leukemia/NN promyelocytic/JJ
retinoic/JJ acid/NN associated/VBN leukemia/NN
acid/NN associated/VBN leukemia/NN acute/JJ
acid/NN associated/VBN leukemia/NN promyelocytic/JJ
acid/NN associated/VBN leukemia/NN
all/DT acid/NN associated/VBN nodosum/NNP APL/NNP
trans/JJ acid/NN associated/VBN nodosum/NNP APL/NNP
retinoic/JJ acid/NN associated/VBN nodosum/NNP APL/NNP
acid/NN associated/VBN nodosum/NNP APL/NNP
ATRA/NNP acid/NN associated/VBN leukemia/NN acute/JJ
ATRA/NNP acid/NN associated/VBN leukemia/NN promyelocytic/JJ
ATRA/NNP acid/NN associated/VBN leukemia/NN
ATRA/NNP acid/NN associated/VBN nodosum/NNP APL/NNP
ATRA/NNP therapy/NN developed/VBD patients/NNS APL/NNP
ATRA/NNP therapy/NN developed/VBD nodules/NNS painful/JJ
steroid/NN use/NN effective/JJ induced/VBN nodosum/NN erythema/NN
steroid/NN use/NN effective/JJ induced/VBN nodosum/NN
ziprasidone/NN dose/NN developed/VBD history/NN schizophrenia/NN
hydrocortisone/NN rise/NN associated/VBN output/NN increased/JJ
hydrocortisone/NN rise/NN associated/VBN output/NN cardiac/JJ
hydrocortisone/NN rise/NN associated/VBN output/NN
alcohol/NN intake/NN admitted/VBD Five/CD patients/NNS pain/NN
alcohol/NN intake/NN admitted/VBD Five/CD patients/NNS seven/CD patients/NNS pain/NN
tamoxifen/NN used/VBN treatment/NN breast/NN
tamoxifen/NN used/VBN treatment/NN cancer/NN
tamoxifen/NN used/VBN proposed/VBN prevention/NN cancer/NN breast/NN
tamoxifen/NN used/VBN proposed/VBN prevention/NN cancer/NN
tamoxifen/NN use/NN investigated/VBN women/NNS treated/VBN cancer/NN breast/NN
tamoxifen/NN use/NN investigated/VBN women/NNS treated/VBN cancer/NN
tamoxifen/NN received/VBN had/VBD Women/NNP had/VBD disease/NN advanced/JJ
tamoxifen/NN received/VBN had/VBD Women/NNP had/VBD disease/NN
tamoxifen/NN role/NN suggest/VBP used/VBD proposed/VBN prevention/NN breast/NN
tamoxifen/NN role/NN suggest/VBP used/VBD proposed/VBN prevention/NN cancer/NN
tamoxifen/NN cancer/NN breast/NN
tamoxifen/NN cancer/NN
tamoxifen/NN treatment/NN cancer/NN breast/NN
tamoxifen/NN treatment/NN cancer/NN
Nitric/JJ expression/NN hypertension/NN
oxide/NN expression/NN hypertension/NN
oxygen/NN species/NNS reduced/VBN hypertension/NN
nitrotyrosine/NN sequestration/NN increased/VBN reduced/VBN hypertension/NN
NO/DT metabolites/NNS excretion/NN reduced/VBN hypertension/NN
NO/DT sequestration/NN increased/VBN reduced/VBN hypertension/NN
NO/DT expression/NN depressed/VB due/JJ reduction/NN NOx/NN hypertension/NN
MDA/NN concentration/NN lowered/VBD ameliorated/VBD hypertension/NN
Vitamin/NNP supplementation/NN ameliorated/VBD hypertension/NN
E/NNP supplementation/NN ameliorated/VBD hypertension/NN
NO/DT inactivation/NN actions/NNS stress/NN associated/VBN hypertension/NN
CYP/NNP observed/VBD increased/VBN mice/NNP inflammation/NN bladder/NN
CYP/NNP observed/VBD increased/VBN mice/NNP inflammation/NN
RAPA/NNP conversion/NN effects/NNS evaluate/VB patients/NNS undergoing/VBG cyclosporine/NN toxicity/NN
tacrolimus/NNS cyclosporine/NN toxicity/NN
Tac/NNP tacrolimus/NNS cyclosporine/NN toxicity/NN
cyclosporine/NN toxicity/NN
CsA/NNP cyclosporine/NN toxicity/NN
CsA/NN CsA/NN hepatotoxicity/NN
CsA/NN hepatotoxicity/NN
Tac/NN nephrotoxicity/NN CsA/NN CsA/NN disorder/NN posttransplant/JJ
Tac/NN nephrotoxicity/NN CsA/NN CsA/NN disorder/NN lymphoproliferative/NN
Tac/NN nephrotoxicity/NN CsA/NN CsA/NN disorder/NN
Tac/NN nephrotoxicity/NN CsA/NN CsA/NN disorder/NN PTLD/NNP
Tac/NN toxicity/NN CsA/NN disorder/NN posttransplant/JJ
Tac/NN toxicity/NN CsA/NN disorder/NN lymphoproliferative/NN
Tac/NN toxicity/NN CsA/NN disorder/NN
Tac/NN toxicity/NN CsA/NN disorder/NN PTLD/NNP
CsA/NN CsA/NN dysmorphism/NN facial/JJ
CsA/NN CsA/NN dysmorphism/NN
CsA/NN dysmorphism/NN facial/JJ
CsA/NN dysmorphism/NN
Tac/NN nephrotoxicity/NN CsA/NN CsA/NN hepatotoxicity/NN
Tac/NN toxicity/NN CsA/NN hepatotoxicity/NN
Tac/NN nephrotoxicity/NN CsA/NN CsA/NN dysmorphism/NN facial/JJ
Tac/NN nephrotoxicity/NN CsA/NN CsA/NN dysmorphism/NN
Tac/NN toxicity/NN CsA/NN dysmorphism/NN facial/JJ
Tac/NN toxicity/NN CsA/NN dysmorphism/NN
Tac/NN nephrotoxicity/NN CsA/NN CsA/NN toxicity/NN
Tac/NN toxicity/NN
CsA/NN CsA/NN toxicity/NN
CsA/NN toxicity/NN
CsA/NN CsA/NN disorder/NN posttransplant/JJ
CsA/NN CsA/NN disorder/NN lymphoproliferative/NN
CsA/NN CsA/NN disorder/NN
CsA/NN CsA/NN disorder/NN PTLD/NNP
CsA/NN disorder/NN posttransplant/JJ
CsA/NN disorder/NN lymphoproliferative/NN
CsA/NN disorder/NN
CsA/NN disorder/NN PTLD/NNP
creatinine/NN +/NNP decrease/NN was/VBD nephrotoxicity/NN
RAPA/NNP discontinued/VBN patients/NNS pneumonia/NN ulcers/NNS aphtous/NNS
RAPA/NNP discontinued/VBN patients/NNS pneumonia/NN ulcers/NNS
RAPA/NNP discontinued/VBN patients/NNS pneumonia/NN PTLD/NNP
RAPA/NNP discontinued/VBN patients/NNS pneumonia/NN
RAPA/NNP levels/NNS converting/VBG monitored/VBN However/RB given/VBN immunosuppression/NN antiviral/JJ prophylaxis/NNS Pneumocystis/NNS
RAPA/NNP levels/NNS converting/VBG monitored/VBN However/RB given/VBN immunosuppression/NN antiviral/JJ prophylaxis/NNS carinii/NN
RAPA/NNP levels/NNS converting/VBG monitored/VBN However/RB given/VBN immunosuppression/NN antiviral/JJ prophylaxis/NNS pneumonia/NN
heroin/NN dependence/NN methadone/NN treated/VBN patients/NNS prolongation/VBN Syncope/NNP
heroin/NN dependence/NN methadone/NN treated/VBN patients/NNS prolongation/VBN Syncope/NNP QT/NNP
heroin/NN dependence/NN methadone/NN treated/VBN patients/NNS prolongation/VBN
methadone/JJ users/NNS reported/VBN Prolongation/NNP interval/NN ECG/NNP patients/NNS pointes/NNS torsade/JJ
methadone/JJ users/NNS reported/VBN Prolongation/NNP interval/NN ECG/NNP patients/NNS pointes/NNS de/NNP
methadone/JJ users/NNS reported/VBN Prolongation/NNP interval/NN ECG/NNP patients/NNS pointes/NNS
methadone/JJ users/NNS reported/VBN Prolongation/NNP TdP/NNP
heroin/NN addicts/NNS faint/JJ attribute/VB underestimate/VB incidence/NN TdP/NNP
methadone/NN effect/NN caused/VBN attribute/VB underestimate/VB incidence/NN TdP/NNP
heroin/NN addicts/NNS faint/JJ attribute/VB episodes/NNS syncope/NN
heroin/NN addicts/NNS population/NN associated/VBN prolongation/NNP reporting/NN syncope/NN
heroin/NN addicts/NNS population/NN associated/VBN prolongation/NNP QT/NNP
heroin/NN addicts/NNS population/NN associated/VBN prolongation/NNP
acetylcholine/JJ expression/NN caused/VBN dysfunction/NN muscle/NN
acetylcholine/JJ expression/NN caused/VBN dysfunction/NN
Prednisolone/NNP induced/VBN caused/VBN more/RBR atrophy/RB
acetylcholine/JJ expression/NN caused/VBN more/RBR atrophy/RB
d/NNP curves/NNS fatigability/NN nerve/NN tensions/NNS tensions/NNS tetanic/JJ
tubocurarine/NN fatigability/NN nerve/NN tensions/NNS tensions/NNS tetanic/JJ
prednisolone/NN dysfunction/NN neuromuscular/NN
prednisolone/NN dysfunction/NN
acetylcholine/JJ expression/NN changes/NNS dose/NN' dose/NN atrophy/NN muscle/NN
acetylcholine/JJ expression/NN changes/NNS dose/NN' dose/NN atrophy/NN
uric/JJ acid/NN dL/NN buffer/NN compared/VBN effects/NNS nephrotoxic/JJ
acid/NN dL/NN buffer/NN compared/VBN effects/NNS nephrotoxic/JJ
suprofen/NN mg/NN dose/NN effects/NNS nephrotoxic/JJ
uric/JJ acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS acute/JJ
uric/JJ acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS
uric/JJ acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS function/NN in/IN
uric/JJ acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS function/NN renal/JJ
uric/JJ acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS function/NN
acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS acute/JJ
acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS
acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS function/NN in/IN
acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS function/NN renal/JJ
acid/NN distribution/NN altering/VBG causes/VBZ declines/NNS function/NN
Atorvastatin/NNP prevented/VBD dexamethasone/NN induced/VBN hypertension/NN
atorvastatin/NN effects/NNS assess/VB hypertension/NN
atorva/NNP atorvastatin/NN effects/NNS assess/VB hypertension/NN
atorva/NN kg/NN treated/VBN day/NN hypertension/NN
Atorva/NNP reversed/VBD dex/NN hypertension/NN
atorva/NN 441/NNP </NNP 0001/CD 392/CD +/JJ superoxide/NN hypertension/NN
superoxide/NN hypertension/NN
atorvastatin/NN prevented/VBD dexamethasone/NN induced/VBN hypertension/NN
captopril/NN Effect/NN proteinuria/NN rats/NNS hypertensive/NN
captopril/NN Effect/NN proteinuria/NN
aminonucleoside/JJ existing/VBG captopril/NN Effect/NN proteinuria/NN rats/NNS hypertensive/NN
captopril/JJ treatment/NN patients/NNS hypertensive/JJ
captopril/JJ treatment/NN effect/NN Proteinuria/NNP
captopril/NN reproducing/VBG abnormality/NN renal/JJ
captopril/NN reproducing/VBG abnormality/NN
captopril/NN administration/NN failed/VBD aggravate/VB pre/NN proteinuria/NN
captopril/JJ treatment/NN failed/VBD potentiate/VB development/NN proteinuria/NN
Glyceryl/JJ trinitrate/NN induces/VBZ aura/NN sufferers/NNS migraine/NN
Glyceryl/JJ trinitrate/NN induces/VBZ aura/NN sufferers/NNS migraine/NN aura/NN with/IN
Glyceryl/JJ trinitrate/NN induces/VBZ aura/NN sufferers/NNS migraine/NN aura/NN
trinitrate/NN induces/VBZ aura/NN sufferers/NNS migraine/NN
trinitrate/NN induces/VBZ aura/NN sufferers/NNS migraine/NN aura/NN with/IN
trinitrate/NN induces/VBZ aura/NN sufferers/NNS migraine/NN aura/NN
nitric/JJ oxide/NN involved/VBN mechanisms/NNS pain/NN
oxide/NN involved/VBN mechanisms/NNS pain/NN
NO/RB oxide/NN involved/VBN mechanisms/NNS pain/NN
glyceryl/JJ trinitrate/NN infusion/NN examined/VBD response/NN headache/NN
trinitrate/NN infusion/NN examined/VBD response/NN headache/NN
GTN/NNP trinitrate/NN infusion/NN examined/VBD response/NN headache/NN
glyceryl/JJ trinitrate/NN infusion/NN examined/VBD clarify/VB true/JJ migraine/NN
glyceryl/JJ trinitrate/NN infusion/NN examined/VBD clarify/VB true/JJ migraine/NN aura/NN with/IN
glyceryl/JJ trinitrate/NN infusion/NN examined/VBD clarify/VB true/JJ migraine/NN aura/NN
trinitrate/NN infusion/NN examined/VBD clarify/VB true/JJ migraine/NN
trinitrate/NN infusion/NN examined/VBD clarify/VB true/JJ migraine/NN aura/NN with/IN
trinitrate/NN infusion/NN examined/VBD clarify/VB true/JJ migraine/NN aura/NN
glyceryl/JJ trinitrate/NN infusion/NN examined/VBD sufferers/NNS migraine/NN
glyceryl/JJ trinitrate/NN infusion/NN examined/VBD sufferers/NNS migraine/NN aura/NN with/IN
glyceryl/JJ trinitrate/NN infusion/NN examined/VBD sufferers/NNS migraine/NN aura/NN
trinitrate/NN infusion/NN examined/VBD sufferers/NNS migraine/NN
trinitrate/NN infusion/NN examined/VBD sufferers/NNS migraine/NN aura/NN with/IN
trinitrate/NN infusion/NN examined/VBD sufferers/NNS migraine/NN aura/NN
GTN/NNP trinitrate/NN infusion/NN examined/VBD clarify/VB true/JJ migraine/NN
GTN/NNP trinitrate/NN infusion/NN examined/VBD clarify/VB true/JJ migraine/NN aura/NN with/IN
GTN/NNP trinitrate/NN infusion/NN examined/VBD clarify/VB true/JJ migraine/NN aura/NN
GTN/NNP trinitrate/NN infusion/NN examined/VBD sufferers/NNS migraine/NN
GTN/NNP trinitrate/NN infusion/NN examined/VBD sufferers/NNS migraine/NN aura/NN with/IN
GTN/NNP trinitrate/NN infusion/NN examined/VBD sufferers/NNS migraine/NN aura/NN
GTN/NNP infusion/NNP during/IN controls/NNS severe/JJ migraineurs/NNS
GTN/NNP infusion/NNP during/IN controls/NNS severe/JJ Headache/NNP
GTN/NNP induced/VBN headache/NN disappeared/VBN occurred/VBD migraineurs/NNS
GTN/NNP induced/VBN headache/NN
GTN/NNP induced/VBN headache/NN disappeared/VBN occurred/VBD intensity/NN headache/NN
NO/NNP involved/VBN mechanisms/NNS migraine/NN
NO/NNP involved/VBN aura/NN with/IN
NO/NNP involved/VBN aura/NN
NO/NNP involved/VBN mechanisms/NNS pain/NN
NO/RB liberate/VB shown/VBN cortical/NN spreading/VBG depression/NN
NO/RB liberate/VB shown/VBN help/VB spreading/VBG depression/NN
NO/RB liberate/VB shown/VBN help/VB spreading/VBG migraine/NN
NO/RB liberate/VB shown/VBN help/VB spreading/VBG migraine/NN aura/NN with/IN
NO/RB liberate/VB shown/VBN help/VB spreading/VBG migraine/NN aura/NN
NO/RB liberate/VB shown/VBN help/VB spreading/VBG depression/NN headache/NN
timolol/NN hypokalemia/NN
timolol/NN drug/NN tended/VBD correct/VB hypokalemia/NN
alpha/NNS induced/VBN Peroxisomes/NNS lesions/NNS liver/NN
alpha/NNS induced/VBN Peroxisomes/NNS lesions/NNS
benzene/JJ hexachloride/NN examined/VBN induced/VBN Peroxisomes/NNS lesions/NNS liver/NN
benzene/JJ hexachloride/NN examined/VBN induced/VBN Peroxisomes/NNS lesions/NNS
hexachloride/NN examined/VBN induced/VBN Peroxisomes/NNS lesions/NNS liver/NN
hexachloride/NN examined/VBN induced/VBN Peroxisomes/NNS lesions/NNS
ethyl/JJ p/NN respond/VB were/VBD most/JJS hepatomas/NNS
alpha/NN p/NN respond/VB were/VBD most/JJS hepatomas/NNS
p/NN respond/VB were/VBD most/JJS hepatomas/NNS
chlorophenoxyisobutyrate/JJ p/NN respond/VB were/VBD most/JJS hepatomas/NNS
ethyl/JJ p/NN respond/VB were/VBD differentiated/VBD tumors/NNS
alpha/NN p/NN respond/VB were/VBD differentiated/VBD tumors/NNS
p/NN respond/VB were/VBD differentiated/VBD tumors/NNS
chlorophenoxyisobutyrate/JJ p/NN respond/VB were/VBD differentiated/VBD tumors/NNS
ethyl/JJ p/NN respond/VB cells/NNS tumor/NN
alpha/NN p/NN respond/VB cells/NNS tumor/NN
p/NN respond/VB cells/NNS tumor/NN
chlorophenoxyisobutyrate/JJ p/NN respond/VB cells/NNS tumor/NN
Morphine/NNP alter/VB hyperalgesia/NN
sertraline/NN effect/NN Absence/NNP sensitization/NN impairment/NN cognitive/JJ
sertraline/NN effect/NN Absence/NNP sensitization/NN impairment/NN
sertraline/NN administration/NN worsened/VBN profile/NN impairment/NN cognitive/JJ
sertraline/NN administration/NN worsened/VBN profile/NN impairment/NN
adriamycin/NN mitochondria/NN impairment/NN cardiomyopathy/NN
adriamycin/NN cancer/NN
ADR/NNP adriamycin/NN cancer/NN
adriamycin/NN use/NN limited/VBN due/JJ toxicity/NN cardiovascular/JJ
adriamycin/NN use/NN limited/VBN due/JJ toxicity/NN
ADR/NNP adriamycin/NN use/NN limited/VBN due/JJ toxicity/NN cardiovascular/JJ
ADR/NNP adriamycin/NN use/NN limited/VBN due/JJ toxicity/NN
ADR/NNP treatment/NN caused/VBD arrhythmias/NNS cardiovascular/JJ
ADR/NNP treatment/NN caused/VBD arrhythmias/NNS
ADR/NNP treatment/NN caused/VBD indicated/VBD underwent/VBD swelling/CD
estradiol/NN progesterone/NN use/NN left/VBD forty/NN year/NN woman/NN developed/VBN headache/NN vomiting/NN
estradiol/NN progesterone/NN use/NN left/VBD forty/NN year/NN woman/NN developed/VBN headache/NN nausea/NN
progesterone/NN use/NN left/VBD hemiparesis/NNS seizure/NN
estradiol/NN progesterone/NN use/NN left/VBD forty/NN year/NN woman/NN developed/VBN headache/NN
progesterone/NN use/NN left/VBD hemiparesis/NNS
progesterone/NN use/NN left/VBD forty/NN year/NN woman/NN developed/VBN headache/NN
estradiol/NN progesterone/NN use/NN left/VBD hemiparesis/NNS
estradiol/NN progesterone/NN use/NN left/VBD hemiparesis/NNS seizure/NN
progesterone/NN use/NN left/VBD forty/NN year/NN woman/NN developed/VBN headache/NN vomiting/NN
progesterone/NN use/NN left/VBD forty/NN year/NN woman/NN developed/VBN headache/NN nausea/NN
estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS
estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP of/IN
estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP both/PDT
estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP the/DT
estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP
estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP and/CC
estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP sinus/NNS the/DT
estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP sinus/NNS venous/JJ
estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP sinus/NNS
progesterone/NN estradiol/NN DM/NN
estradiol/NN DM/NN
progesterone/NN estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS
progesterone/NN estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP of/IN
progesterone/NN estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP both/PDT
progesterone/NN estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP the/DT
progesterone/NN estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP
progesterone/NN estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP and/CC
progesterone/NN estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP sinus/NNS the/DT
progesterone/NN estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP sinus/NNS venous/JJ
progesterone/NN estradiol/NN use/NN increased/VBD thrombogenicity/NN provided/VBD thrombosis/NNS ICA/NNP sinus/NNS
tamoxifen/NN trial/NN participating/VBG Patients/NNS group/NN women/NNS cancer/NN breast/NN
tamoxifen/NN trial/NN participating/VBG Patients/NNS group/NN women/NNS cancer/NN
anastrozole/NN trial/NN participating/VBG Patients/NNS group/NN women/NNS cancer/NN breast/NN
anastrozole/NN trial/NN participating/VBG Patients/NNS group/NN women/NNS cancer/NN
metoclopramide/NN induced/VBN preexisting/VBG block/NN left/NN
metoclopramide/NN induced/VBN preexisting/VBG block/NN bundle/NN
metoclopramide/NN induced/VBN preexisting/VBG block/NN branch/NN
metoclopramide/NN induced/VBN preexisting/VBG block/NN
metoclopramide/NN administration/NN developed/VBD block/NN left/VBD
metoclopramide/NN administration/NN developed/VBD block/NN bundle/NN
metoclopramide/NN administration/NN developed/VBD block/NN branch/NN
metoclopramide/NN administration/NN developed/VBD block/NN
ifosfamide/VBP patient/NN breast/NN
ifosfamide/VBP patient/NN cancer/NN
ifosfamide/JJ sixty/NN developed/VBD cancer/NN breast/NN
ifosfamide/JJ sixty/NN developed/VBD cancer/NN
cisplatin/NN treated/VBN cancer/NN developed/VBD anuria/NN
ifosfamide/JJ sixty/NN developed/VBD failure/NN renal/JJ
ifosfamide/JJ sixty/NN developed/VBD failure/NN
cisplatin/NN treated/VBN cancer/NN developed/VBD failure/NN renal/JJ
cisplatin/NN treated/VBN cancer/NN developed/VBD failure/NN
cisplatin/NN treated/VBN cancer/NN breast/NN
cisplatin/NN treated/VBN cancer/NN
cisplatin/NN received/VBN perfusion/NN occurring/VBG due/JJ anuria/NN
ifosfamide/VB due/JJ occurring/VBG perfusion/NN due/JJ hypotension/NN
cisplatin/NN received/VBN perfusion/NN due/JJ hypotension/NN
glycopyrronium/NN Use/NNP kg/NN induced/VBN bradycardias/NNS
cephalosporins/NNS receiving/VBG patients/NNS described/VBN anemia/NN hemolytic/JJ
cephalosporins/NNS receiving/VBG patients/NNS described/VBN anemia/NN
penicillins/JJ cephalosporins/NNS receiving/VBG patients/NNS described/VBN anemia/NN hemolytic/JJ
penicillins/JJ cephalosporins/NNS receiving/VBG patients/NNS described/VBN anemia/NN
cefotetan/NN receiving/VBG developed/VBD anemia/NN
4/CD chloride/NN Effect/NN therapy/NN toxicity/NN
aminopyridine/JJ therapy/NN toxicity/NN
desipramine/JJ toxicity/NN
calcium/NN chloride/NN Effect/NN therapy/NN toxicity/NN
chloride/NN Effect/NN therapy/NN toxicity/NN
calcium/NN blockade/NN role/NN hypotension/NN
calcium/NN overdose/NN
NaHCO/NNP RESULTS/NNS reversed/VBD prolongation/NN hypotension/NN
3/CD NaHCO/NNP RESULTS/NNS reversed/VBD prolongation/NN hypotension/NN
CaCl/NNP group/NN incidence/NN arrhythmias/NNS seizures/NNS
2/CD group/NN incidence/NN arrhythmias/NNS seizures/NNS
4/CD CaCl/NNP administration/NN CONCLUSION/NNP reverse/VB antidepressant/NN hypotension/NN
aminopyridine/RB reverse/VB antidepressant/NN hypotension/NN
CaCl/NNP administration/NN CONCLUSION/NNP reverse/VB antidepressant/NN hypotension/NN
2/CD CaCl/NNP administration/NN CONCLUSION/NNP reverse/VB antidepressant/NN hypotension/NN
CaCl/JJ therapy/NN worsen/VB cardiovascular/JJ
CaCl/JJ therapy/NN worsen/VB cardiovascular/JJ and/CC
CaCl/JJ therapy/NN worsen/VB cardiovascular/JJ toxicity/NNS central/JJ
CaCl/JJ therapy/NN worsen/VB cardiovascular/JJ toxicity/NNS nervous/JJ
CaCl/JJ therapy/NN worsen/VB cardiovascular/JJ toxicity/NNS system/NN
CaCl/JJ therapy/NN worsen/VB cardiovascular/JJ toxicity/NNS
2/CD therapy/NN worsen/VB cardiovascular/JJ
2/CD therapy/NN worsen/VB cardiovascular/JJ and/CC
2/CD therapy/NN worsen/VB cardiovascular/JJ toxicity/NNS central/JJ
2/CD therapy/NN worsen/VB cardiovascular/JJ toxicity/NNS nervous/JJ
2/CD therapy/NN worsen/VB cardiovascular/JJ toxicity/NNS system/NN
2/CD therapy/NN worsen/VB cardiovascular/JJ toxicity/NNS
calcium/NN inhibition/NN role/NN hypotension/NN
ouabain/NN Effects/NNPS supply/VBP patients/NNS disease/NN coronary/JJ
ouabain/NN Effects/NNPS supply/VBP patients/NNS disease/NN artery/NN
ouabain/NN Effects/NNPS supply/VBP patients/NNS disease/NN
oxygen/NN ouabain/NN Effects/NNPS supply/VBP patients/NNS disease/NN coronary/JJ
oxygen/NN ouabain/NN Effects/NNPS supply/VBP patients/NNS disease/NN artery/NN
oxygen/NN ouabain/NN Effects/NNPS supply/VBP patients/NNS disease/NN
digitalis/NN glycosides/NNS effects/NNS interest/NN presence/NN disease/NN coronary/JJ
digitalis/NN glycosides/NNS effects/NNS interest/NN presence/NN disease/NN artery/NN
digitalis/NN glycosides/NNS effects/NNS interest/NN presence/NN disease/NN
glycosides/NNS effects/NNS interest/NN presence/NN disease/NN coronary/JJ
glycosides/NNS effects/NNS interest/NN presence/NN disease/NN artery/NN
glycosides/NNS effects/NNS interest/NN presence/NN disease/NN
oxygen/NN supply/NN glycosides/NNS effects/NNS interest/NN presence/NN disease/NN coronary/JJ
oxygen/NN supply/NN glycosides/NNS effects/NNS interest/NN presence/NN disease/NN artery/NN
oxygen/NN supply/NN glycosides/NNS effects/NNS interest/NN presence/NN disease/NN
ouabain/NN effects/NNS assessed/VBD patients/NNS disease/NN coronary/JJ
ouabain/NN effects/NNS assessed/VBD patients/NNS disease/NN artery/NN
ouabain/NN effects/NNS assessed/VBD patients/NNS disease/NN
ouabain/NN effects/NNS assessed/VBD failure/NN congestive/JJ
ouabain/NN effects/NNS assessed/VBD failure/NN heart/NN
ouabain/NN effects/NNS assessed/VBD failure/NN
ouabain/NN administration/NN falls/VBZ conclude/VBP disease/NN coronary/JJ
ouabain/NN administration/NN falls/VBZ conclude/VBP disease/NN artery/NN
ouabain/NN administration/NN falls/VBZ conclude/VBP disease/NN
ouabain/NN administration/NN falls/VBZ conclude/VBP disease/NN failure/NN congestive/JJ
ouabain/NN administration/NN falls/VBZ conclude/VBP disease/NN failure/NN heart/NN
ouabain/NN administration/NN falls/VBZ conclude/VBP disease/NN failure/NN
Oxytocin/NNP attributed/VBN loss/NN blood/NN
Oxytocin/NNP attributed/VBN loss/NN
oxytocin/NN response/NN Hypotension/NNP associated/VBN decrease/NN increase/NN volume/NN stroke/NN
pentamidine/JJ tachycardia/NN ventricular/NN
pentamidine/JJ tachycardia/NN
Pentamidine/JJ isethionate/NN associated/VBN tachyarrhythmias/NNS ventricular/NN
Pentamidine/JJ isethionate/NN associated/VBN tachyarrhythmias/NNS
isethionate/NN associated/VBN tachyarrhythmias/NNS ventricular/NN
isethionate/NN associated/VBN tachyarrhythmias/NNS
magnesium/NN levels/NNS serum/VB related/VBN induce/VB hypomagnesemia/NN
Pentamidine/NNP induced/VBN related/VBN induce/VB hypomagnesemia/NN
magnesium/NN levels/NNS serum/VB related/VBN pointes/NNS torsade/JJ
magnesium/NN levels/NNS serum/VB related/VBN pointes/NNS de/NNP
magnesium/NN levels/NNS serum/VB related/VBN pointes/NNS
magnesium/NN supplementation/NN advocated/VBN observed/JJ prolongation/NN QTc/NNP
magnesium/NN supplementation/NN advocated/VBN observed/JJ prolongation/NN interval/JJ
magnesium/NN supplementation/NN advocated/VBN observed/JJ prolongation/NN
calcium/NN chloride/NN induced/VBN tetany/RB
chloride/NN induced/VBN tetany/RB
diltiazem/NN infusion/NN developed/VBD arrest/NN respiratory/JJ
diltiazem/NN infusion/NN developed/VBD arrest/NN
calcium/NN chloride/NN administration/NN resolved/VBD tetany/NN
chloride/NN administration/NN resolved/VBD tetany/NN
calcium/NN chloride/NN remedy/NN accompany/VB life/NN tetany/NN
chloride/NN remedy/NN accompany/VB life/NN tetany/NN
remifentanil/JJ propofol/JJ controlled/VBN Reduction/NN pain/NN
remifentanil/NN infusing/VBG prevented/VBN pain/NN
remifentanil/NN prevent/VB pain/NN
Remifentanil/NNP assessed/VBN evaluated/VBN pain/NN
remifentanil/JJ infusion/NN assessed/VBN evaluated/VBN pain/NN
remifentanil/NN propofol/NN TCI/NNP anaesthesia/NN induction/NN achieved/VBN reduction/NN pain/NN
remifentanil/JJ ml/NN administration/NN achieved/VBN reduction/NN pain/NN
anthracyclines/NNS cyclophosphamide/NN used/VBN example/NN patients/NNS systemic/JJ
anthracyclines/NNS cyclophosphamide/NN used/VBN example/NN patients/NNS sclerosis/NN
cyclophosphamide/NN used/VBN example/NN patients/NNS systemic/JJ
cyclophosphamide/NN used/VBN example/NN patients/NNS sclerosis/NN
mitoxantrone/NN cyclophosphamide/NN used/VBN example/NN patients/NNS systemic/JJ
mitoxantrone/NN cyclophosphamide/NN used/VBN example/NN patients/NNS sclerosis/NN
anthracyclines/NNS cyclophosphamide/NN used/VBN damage/NN heart/NN
anthracyclines/NNS cyclophosphamide/NN used/VBN damage/NN
bupropion/VBN release/NN associated/VBN deprivation/NN sleep/NN
bupropion/VBN release/NN associated/VBN deprivation/NN
bupropion/NN use/VBP sleep/VBP
bupropion/NN use/VBP deprivation/NN
bupropion/NN risk/NN add/VB deprivation/NN sleep/NN
bupropion/NN risk/NN add/VB deprivation/NN
methadone/NN responses/NNS Pain/NN
methadone/NN stabilized/VBN addicts/NNS opioid/JJ
methadone/NN stabilized/VBN addicts/NNS
methadone/NN stabilized/VBN addicts/NNS sample/NN tolerance/NN pain/NN
ketorolac/JJ agents/NNS pressor/VBP examined/VBN pain/NN
hydromorphone/VB doses/NNS administration/NN examined/VBN pain/NN
choline/JJ acetyltransferase/NN activates/VBZ MC/NNP induced/VBN amnesia/NN
Daidzein/NNP activates/VBZ MC/NNP induced/VBN amnesia/NN
acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN Alzheimer/NNP
acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN Alzheimer/NNP '/POS
acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN s/JJ
acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN
acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN AD/NNP
ACh/NNP acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN Alzheimer/NNP
ACh/NNP acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN Alzheimer/NNP '/POS
ACh/NNP acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN s/JJ
ACh/NNP acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN
ACh/NNP acetylcholine/NN production/NN augmentation/NN transmission/NN enhances/VBZ activator/NN factor/NN treatment/NN disease/NN AD/NNP
choline/JJ acetyltransferase/JJ activator/NN factor/NN treatment/NN disease/NN Alzheimer/NNP
choline/JJ acetyltransferase/JJ activator/NN factor/NN treatment/NN disease/NN Alzheimer/NNP '/POS
choline/JJ acetyltransferase/JJ activator/NN factor/NN treatment/NN disease/NN s/JJ
choline/JJ acetyltransferase/JJ activator/NN factor/NN treatment/NN disease/NN
choline/JJ acetyltransferase/JJ activator/NN factor/NN treatment/NN disease/NN AD/NNP
scopolamine/NN thunbergiana/NNP impairments/NNS
scopolamine/NN thunbergiana/NNP impairments/NNS learning/NN of/IN
scopolamine/NN thunbergiana/NNP impairments/NNS learning/NN
scopolamine/NN thunbergiana/NNP impairments/NNS learning/NN and/CC
scopolamine/NN thunbergiana/NNP impairments/NNS learning/NN memory/NN
daidzein/NN effects/NNS investigate/VB thunbergiana/NNP impairments/NNS
daidzein/NN effects/NNS investigate/VB thunbergiana/NNP impairments/NNS learning/NN of/IN
daidzein/NN effects/NNS investigate/VB thunbergiana/NNP impairments/NNS learning/NN
daidzein/NN effects/NNS investigate/VB thunbergiana/NNP impairments/NNS learning/NN and/CC
daidzein/NN effects/NNS investigate/VB thunbergiana/NNP impairments/NNS learning/NN memory/NN
daidzein/NN Administration/NNP shown/VBN reverse/VB test/NN scopolamine/JJ induced/VBN amnesia/NN
acetylcholine/JJ biosynthesis/NNS role/NN play/VB ameliorates/VBZ scopolamine/JJ amnesia/JJ
daidzein/NN play/VB ameliorates/VBZ scopolamine/JJ amnesia/JJ
phenobarbital/JJ therapy/NN term/NN Hepatonecrosis/NNS
PB/NNP treated/VBN epilepsy/NN
PB/NNP one/CD consequence/NN arrest/NN cardiac/JJ
PB/NNP one/CD consequence/NN arrest/NN
PB/NNP other/JJ bronchopneumonia/NN
PB/NNP diagnosis/NN dysfunction/NN chronic/JJ
PB/NNP diagnosis/NN dysfunction/NN hepatic/JJ
PB/NNP diagnosis/NN dysfunction/NN enzyme/NN
PB/NNP diagnosis/NN dysfunction/NN
sirolimus/NNS mofetil/NN mycophenolate/VB have/VBP nephrotoxicity/NN
rapamycin/NN mofetil/NN mycophenolate/VB have/VBP nephrotoxicity/NN
mycophenolate/VB have/VBP nephrotoxicity/NN
mofetil/NN mycophenolate/VB have/VBP nephrotoxicity/NN
adenosine/NN characterization/NN antagonist/NN disease/NN Parkinson/NNP
adenosine/NN characterization/NN antagonist/NN disease/NN Parkinson/NNP '/POS
adenosine/NN characterization/NN antagonist/NN disease/NN s/JJ
adenosine/NN characterization/NN antagonist/NN disease/NN
A/DT A/NN adenosine/NN characterization/NN antagonist/NN disease/NN Parkinson/NNP
A/DT A/NN adenosine/NN characterization/NN antagonist/NN disease/NN Parkinson/NNP '/POS
A/DT A/NN adenosine/NN characterization/NN antagonist/NN disease/NN s/JJ
A/DT A/NN adenosine/NN characterization/NN antagonist/NN disease/NN
2/CD A/NN adenosine/NN characterization/NN antagonist/NN disease/NN Parkinson/NNP
2/CD A/NN adenosine/NN characterization/NN antagonist/NN disease/NN Parkinson/NNP '/POS
2/CD A/NN adenosine/NN characterization/NN antagonist/NN disease/NN s/JJ
2/CD A/NN adenosine/NN characterization/NN antagonist/NN disease/NN
A/NN adenosine/NN characterization/NN antagonist/NN disease/NN Parkinson/NNP
A/NN adenosine/NN characterization/NN antagonist/NN disease/NN Parkinson/NNP '/POS
A/NN adenosine/NN characterization/NN antagonist/NN disease/NN s/JJ
A/NN adenosine/NN characterization/NN antagonist/NN disease/NN
A/DT antagonist/NN disease/NN Parkinson/NNP
A/DT antagonist/NN disease/NN Parkinson/NNP '/POS
A/DT antagonist/NN disease/NN s/JJ
A/DT antagonist/NN disease/NN
1/CD antagonist/NN disease/NN Parkinson/NNP
1/CD antagonist/NN disease/NN Parkinson/NNP '/POS
1/CD antagonist/NN disease/NN s/JJ
1/CD antagonist/NN disease/NN
receptor/NN antagonist/NN disease/NN Parkinson/NNP
receptor/NN antagonist/NN disease/NN Parkinson/NNP '/POS
receptor/NN antagonist/NN disease/NN s/JJ
receptor/NN antagonist/NN disease/NN
antagonist/NN disease/NN Parkinson/NNP
antagonist/NN disease/NN Parkinson/NNP '/POS
antagonist/NN disease/NN s/JJ
antagonist/NN disease/NN
adenosine/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN Parkinson/NNP
adenosine/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN Parkinson/NNP '/POS
adenosine/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN s/JJ
adenosine/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN
A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN Parkinson/NNP
A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN Parkinson/NNP '/POS
A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN s/JJ
A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN
2/CD A/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN Parkinson/NNP
2/CD A/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN Parkinson/NNP '/POS
2/CD A/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN s/JJ
2/CD A/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN
A/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN Parkinson/NNP
A/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN Parkinson/NNP '/POS
A/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN s/JJ
A/NN A/NN characterization/NN described/VBN antagonist/NN models/NNS disease/NN
A/DT antagonist/NN models/NNS disease/NN Parkinson/NNP
A/DT antagonist/NN models/NNS disease/NN Parkinson/NNP '/POS
A/DT antagonist/NN models/NNS disease/NN s/JJ
A/DT antagonist/NN models/NNS disease/NN
1/CD antagonist/NN models/NNS disease/NN Parkinson/NNP
1/CD antagonist/NN models/NNS disease/NN Parkinson/NNP '/POS
1/CD antagonist/NN models/NNS disease/NN s/JJ
1/CD antagonist/NN models/NNS disease/NN
receptor/NN antagonist/NN models/NNS disease/NN Parkinson/NNP
receptor/NN antagonist/NN models/NNS disease/NN Parkinson/NNP '/POS
receptor/NN antagonist/NN models/NNS disease/NN s/JJ
receptor/NN antagonist/NN models/NNS disease/NN
antagonist/NN models/NNS disease/NN Parkinson/NNP
antagonist/NN models/NNS disease/NN Parkinson/NNP '/POS
antagonist/NN models/NNS disease/NN s/JJ
antagonist/NN models/NNS disease/NN
haloperidol/NN models/NNS akinesia/NN
MPTP/NNP rotation/NN models/NNS akinesia/NN
MPTP/NNP rotation/NN models/NNS catalepsy/NN
reserpine/NN model/NN catalepsy/NN
6/CD rat/NN akinesia/NN models/NNS catalepsy/NN
hydroxydopamine/JJ model/NN models/NNS catalepsy/NN
6/CD hydroxydopamine/JJ model/NN models/NNS catalepsy/NN
OHDA/NNP 6/CD hydroxydopamine/JJ model/NN models/NNS catalepsy/NN
reserpine/NN model/NN catalepsy/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP
reserpine/NN model/NN catalepsy/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP '/POS
reserpine/NN model/NN catalepsy/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN s/JJ
reserpine/NN model/NN catalepsy/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN
MPTP/NNP rotation/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP
MPTP/NNP rotation/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP '/POS
MPTP/NNP rotation/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN s/JJ
MPTP/NNP rotation/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN
haloperidol/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP
haloperidol/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP '/POS
haloperidol/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN s/JJ
haloperidol/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN
6/CD rat/NN akinesia/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP
6/CD rat/NN akinesia/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP '/POS
6/CD rat/NN akinesia/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN s/JJ
6/CD rat/NN akinesia/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN
hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP
hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP '/POS
hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN s/JJ
hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN
6/CD hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP
6/CD hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP '/POS
6/CD hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN s/JJ
6/CD hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN
OHDA/NNP 6/CD hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP
OHDA/NNP 6/CD hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN Parkinson/NNP '/POS
OHDA/NNP 6/CD hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN s/JJ
OHDA/NNP 6/CD hydroxydopamine/JJ model/NN models/NNS mouse/NN =/VBZ 17/CD has/VBZ number/NN models/NNS disease/NN
6/CD rat/NN akinesia/NN
hydroxydopamine/JJ model/NN models/NNS akinesia/NN
6/CD hydroxydopamine/JJ model/NN models/NNS akinesia/NN
OHDA/NNP 6/CD hydroxydopamine/JJ model/NN models/NNS akinesia/NN
Gentamicin/NNP nephropathy/VBP
penicillin/NN gentamicin/NN died/VBD failure/NN acute/JJ
penicillin/NN gentamicin/NN died/VBD failure/NN renal/JJ
penicillin/NN gentamicin/NN died/VBD failure/NN
gentamicin/NN concentration/NN reached/VBN developed/VBD anuria/NN
caffeine/NN administration/NN developed/VBD patient/NN history/NN disease/NN arrhythmia/NN
caffeine/NN administration/NN developed/VBD patient/NN history/NN disease/NN cardiac/JJ
caffeine/NN administration/NN developed/VBD patient/NN history/NN disease/NN
caffeine/NN tolerated/JJ aware/JJ potential/NN arrhythmias/NNS ventricular/NN
caffeine/NN tolerated/JJ aware/JJ potential/NN arrhythmias/NNS
Carbamazepine/NNP induced/VBN dysfunction/NN cardiac/JJ
Carbamazepine/NNP induced/VBN dysfunction/NN
carbamazepine/NN associated/VBN dysfunction/NN cardiac/JJ
carbamazepine/NN associated/VBN dysfunction/NN
carbamazepine/NN overdose/NN
carbamazepine/NN used/VBN treatment/NN neurologic/JJ conditions/NNS psychiatric/JJ
cyclophosphamide/NN therapy/NN complication/NN cystitis/NNS Hemorrhagic/JJ
cyclophosphamide/NN therapy/NN complication/NN cystitis/NNS
mesna/NN neutralizes/VBZ metabolite/NN causes/VBZ cystitis/NNS hemorrhagic/JJ
mesna/NN neutralizes/VBZ metabolite/NN causes/VBZ cystitis/NNS
cyclophosphamide/NN metabolite/NN causes/VBZ cystitis/NNS hemorrhagic/JJ
cyclophosphamide/NN metabolite/NN causes/VBZ cystitis/NNS
mesna/NN uroprophylaxis/NNS received/VBD patients/NNS two/CD had/VBD cystitis/NNS hemorrhagic/JJ
mesna/NN uroprophylaxis/NNS received/VBD patients/NNS two/CD had/VBD cystitis/NNS
vitamin/NNP C/NNP increase/VB women/NNS diabetes/NN
C/NNP increase/VB women/NNS diabetes/NN
vitamin/NNP C/NNP persons/NNS diabetic/JJ
C/NNP persons/NNS diabetic/JJ
vitamin/NNP C/NNP intake/NN promote/VB atherosclerosis/NNS
C/NNP intake/NN promote/VB atherosclerosis/NNS
vitamin/NNP intake/NN relation/NN studied/VBD women/NNS reported/VBD diabetic/JJ
C/NNP intake/NN relation/NN studied/VBD women/NNS reported/VBD diabetic/JJ
vitamin/NNP intake/NN relation/NN stroke/NN
C/NNP intake/NN relation/NN stroke/NN
vitamin/NNP intake/NN relation/NN artery/NN coronary/JJ
vitamin/NNP intake/NN relation/NN artery/NN
vitamin/NNP intake/NN relation/NN artery/NN disease/NN
C/NNP intake/NN relation/NN artery/NN coronary/JJ
C/NNP intake/NN relation/NN artery/NN
C/NNP intake/NN relation/NN artery/NN disease/NN
vitamin/NNP E/NNP folate/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS cardiovascular/JJ
vitamin/NNP E/NNP folate/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS disease/NN
E/NNP folate/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS cardiovascular/JJ
E/NNP folate/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS disease/NN
vitamin/NNP E/NNP folate/NN intakes/NNS carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN cardiovascular/JJ
vitamin/NNP E/NNP folate/NN intakes/NNS carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN
E/NNP folate/NN intakes/NNS carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN cardiovascular/JJ
E/NNP folate/NN intakes/NNS carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN
beta/NN folate/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS cardiovascular/JJ
beta/NN folate/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS disease/NN
carotene/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS cardiovascular/JJ
carotene/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS disease/NN
beta/NN folate/NN intakes/NNS carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN cardiovascular/JJ
beta/NN folate/NN intakes/NNS carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN
carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN cardiovascular/JJ
carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN
vitamin/NNP intake/NN quintiles/NNS 0/CD </VBG trend/NN P/NNP 1/CD type/NN medication/NN diabetes/NN
C/NNP intake/NN quintiles/NNS 0/CD </VBG trend/NN P/NNP 1/CD type/NN medication/NN diabetes/NN
vitamin/NNP intake/NN quintiles/NNS 0/CD </VBG trend/NN P/NNP 1/CD type/NN medication/NN duration/NN diabetes/NN
C/NNP intake/NN quintiles/NNS 0/CD </VBG trend/NN P/NNP 1/CD type/NN medication/NN duration/NN diabetes/NN
vitamin/NNP E/NNP folate/NN intakes/NNS medication/NN diabetes/NN
E/NNP folate/NN intakes/NNS medication/NN diabetes/NN
vitamin/NNP E/NNP folate/NN intakes/NNS medication/NN duration/NN diabetes/NN
E/NNP folate/NN intakes/NNS medication/NN duration/NN diabetes/NN
folate/NN intakes/NNS medication/NN diabetes/NN
folate/NN intakes/NNS medication/NN duration/NN diabetes/NN
beta/NN folate/NN intakes/NNS medication/NN diabetes/NN
carotene/NN intakes/NNS medication/NN diabetes/NN
beta/NN folate/NN intakes/NNS medication/NN duration/NN diabetes/NN
carotene/NN intakes/NNS medication/NN duration/NN diabetes/NN
folate/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS cardiovascular/JJ
folate/NN intakes/NNS medication/NN type/NN 1/CD adjustment/NN factors/NNS disease/NN
folate/NN intakes/NNS carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN cardiovascular/JJ
folate/NN intakes/NNS carotene/NN mortality/NN adjusted/VBN risks/NNS disease/NN
vitamin/NNP intake/NN associated/VBN risk/NN mortality/NN women/NNS diabetes/NN
C/NNP intake/NN associated/VBN risk/NN mortality/NN women/NNS diabetes/NN
trihexyphenidyl/JJ hydrochloride/NN drug/NN treated/VBN patient/NN schizophrenic/JJ
hydrochloride/NN drug/NN treated/VBN patient/NN schizophrenic/JJ
heparin/NN therapy/NN receiving/VBG patients/NNS thromboembolism/NN
heparin/NN associated/VBN complication/NN thromboembolism/NN
heparin/NN therapy/NN complication/NN thromboembolism/NN
heparin/NN therapy/NN initiation/NN days/NNS occurring/VBG ischemia/NN
heparin/NN therapy/NN initiation/NN days/NNS occurring/VBG ischemia/NN thrombi/NNS
heparin/NN induced/VBN aggregation/NN platelet/JJ
heparin/NN induced/VBN aggregation/NN
heparin/NN factor/NN relating/VBG thromboembolism/NN
tachykinins/NNS involvement/NN E/NNP hyperactivity/NN bladder/NN
tachykinins/NNS involvement/NN E/NNP hyperactivity/NN
tachykinins/NNS release/NN contribute/VB hyperactivity/NN urge/NN bladder/NN
tachykinins/NNS release/NN contribute/VB hyperactivity/NN
Prostanoids/NNS contribute/VB hyperactivity/NN urge/NN bladder/NN
Prostanoids/NNS contribute/VB hyperactivity/NN
flumazenil/JJ group/NN nausea/NN pain/NN
azathioprine/JJ therapy/NN initiation/NN developed/VBD patient/NN polymyositis/NNS
azathioprine/JJ therapy/NN initiation/NN developed/VBD patient/NN patient/NN' evidence/NN disease/NN liver/NN
azathioprine/JJ therapy/NN initiation/NN developed/VBD patient/NN patient/NN' evidence/NN disease/NN
cephalosporins/NNS associated/VBN anemia/NN hemolytic/JJ
cephalosporins/NNS associated/VBN anemia/NN
deferoxamine/NN tocopherol/NN Effect/NN induced/VBN neurotoxicity/RB
methamphetamine/NN tocopherol/NN Effect/NN induced/VBN neurotoxicity/RB
alpha/NNP Effect/NN induced/VBN neurotoxicity/RB
tocopherol/NN Effect/NN induced/VBN neurotoxicity/RB
Methamphetamine/NNP neurotoxicity/NN
MA/NNP Methamphetamine/NNP neurotoxicity/NN
iron/NN chelator/NN scavenger/NN tocopherol/NN induced/VBN neurotoxicity/RB
oxygen/NN species/NNS scavenger/NN tocopherol/NN induced/VBN neurotoxicity/RB
deferoxamine/NN species/NNS scavenger/NN tocopherol/NN induced/VBN neurotoxicity/RB
DFO/NNP species/NNS scavenger/NN tocopherol/NN induced/VBN neurotoxicity/RB
MA/NNP scavenger/NN tocopherol/NN induced/VBN neurotoxicity/RB
alpha/NNP effect/NN examined/VBD induced/VBN neurotoxicity/RB
tocopherol/NN induced/VBN neurotoxicity/RB
alpha/NNP tocopherol/NN induced/VBN neurotoxicity/RB
TC/NNP alpha/NNP tocopherol/NN induced/VBN neurotoxicity/RB
alpha/NN TC/NNP attenuated/VBN induced/VBN hyperthermia/NN
TC/NNP attenuated/VBN induced/VBN hyperthermia/NN
DFO/NNP TC/NNP attenuated/VBN induced/VBN hyperthermia/NN
DFO/NNP TC/NNP ameliorate/VBP induced/VBN damage/NN neuronal/JJ
DFO/NNP TC/NNP ameliorate/VBP induced/VBN damage/NN
alpha/NN induced/VBN damage/NN neuronal/JJ
alpha/NN induced/VBN damage/NN
TC/NNP ameliorate/VBP induced/VBN damage/NN neuronal/JJ
TC/NNP ameliorate/VBP induced/VBN damage/NN
METH/VB secondary/JJ induced/VBN hyperactivity/RB
Chloroquine/JJ block/NN heart/NN
Chloroquine/JJ block/NN
chloroquine/NN ingestion/NN presented/VBN deterioration/NN
chloroquine/NN ingestion/NN presented/VBN deterioration/NN vision/NN of/IN
chloroquine/NN ingestion/NN presented/VBN deterioration/NN vision/NN
chloroquine/JJ retinopathy/NN features/NNS revealed/VBD revealed/VBD features/NNS failure/NN block/NN heart/NN
chloroquine/JJ retinopathy/NN features/NNS revealed/VBD revealed/VBD features/NNS failure/NN block/NN
chloroquine/JJ discontinuation/NN resolved/VBN failure/NN insertion/NN treated/VBN block/NN heart/NN
chloroquine/JJ discontinuation/NN resolved/VBN failure/NN insertion/NN treated/VBN block/NN
iohexol/JJ iopromide/JJ incidence/NN determined/VBD compared/VBD type/NN presence/NN cyanosis/NNS
contrast/NN media/NNS CIN/NNP incidence/NN determined/VBD compared/VBD type/NN presence/NN cyanosis/NNS
media/NNS CIN/NNP incidence/NN determined/VBD compared/VBD type/NN presence/NN cyanosis/NNS
CM/NNP media/NNS CIN/NNP incidence/NN determined/VBD compared/VBD type/NN presence/NN cyanosis/NNS
CM/NNP type/NN presence/NN cyanosis/NNS
iopromide/JJ incidence/NN determined/VBD compared/VBD type/NN presence/NN cyanosis/NNS
CM/NN type/NN depends/VBZ' depends/VBZ presence/NN cyanosis/NNS
hepatitis/NNP antigen/NN born/VBN infants/NNS done/VBN following/NN screening/NN B/NNP rubella/NN
B/NNP antigen/NN born/VBN infants/NNS done/VBN following/NN screening/NN B/NNP rubella/NN
surface/NN antigen/NN born/VBN infants/NNS done/VBN following/NN screening/NN B/NNP rubella/NN
antigen/NN born/VBN infants/NNS done/VBN following/NN screening/NN B/NNP rubella/NN
hepatitis/NNP antigen/NN immunity/NN rubella/NN
B/NNP antigen/NN immunity/NN rubella/NN
surface/NN antigen/NN immunity/NN rubella/NN
antigen/NN immunity/NN rubella/NN
hepatitis/NNP antigen/NN administration/NN vaccine/NN rubella/NN
B/NNP antigen/NN administration/NN vaccine/NN rubella/NN
surface/NN antigen/NN administration/NN vaccine/NN rubella/NN
antigen/NN administration/NN vaccine/NN rubella/NN
hepatitis/NNP antigen/NN born/VBN women/NNS rubella/NN
B/NNP antigen/NN born/VBN women/NNS rubella/NN
surface/NN antigen/NN born/VBN women/NNS rubella/NN
antigen/NN born/VBN women/NNS rubella/NN
Doxorubicin/NNP anti/NN agent/NN tumor/NN
Disulfiram/NNP induced/VBN optic/NN
Disulfiram/NNP induced/VBN optic/NN and/CC
Disulfiram/NNP induced/VBN optic/NN neuropathy/NN peripheral/JJ
Disulfiram/NNP induced/VBN optic/NN neuropathy/NN
disulfiram/NN use/NN report/VB management/NN alcohol/NN
disulfiram/NN use/NN report/VB management/NN dependence/NN
disulfiram/NN use/NN report/VB case/NN neuropathy/NN optic/JJ
disulfiram/NN use/NN report/VB case/NN neuropathy/NN optic/JJ and/CC
disulfiram/NN use/NN report/VB case/NN neuropathy/NN optic/JJ peripheral/JJ
disulfiram/NN use/NN report/VB case/NN neuropathy/NN
disulfiram/NN taking/VBG dependence/NN alcohol/NN
disulfiram/NN taking/VBG dependence/NN
trifluoroacetyl/JJ adduct/NN protein/NN response/NN detected/VBN patients/NNS hepatitis/NN
enflurane/NN reactivity/NN cross/NN determine/VB hypersensitivity/NN
halothane/NN induced/VBN hypersensitivity/NN
isoflurane/NN enflurane/NN reactivity/NN cross/NN determine/VB hypersensitivity/NN
enflurane/NN produce/VB condition/NN hypersensitivity/JJ
halothane/JJ hepatitis/NN that/DT similar/JJ produce/VB condition/NN hypersensitivity/JJ
halothane/JJ administration/NN subsequent/JJ produce/VB condition/NN hypersensitivity/JJ
isoflurane/NN //NN enflurane/NN produce/VB condition/NN hypersensitivity/JJ
cyclophosphamide/NN doxorubicin/NN encapsulated/VBN efficacy/NN preserved/VBD cardiotoxicity/NN
cyclophosphamide/JJ encapsulated/VBN efficacy/NN preserved/VBD cardiotoxicity/NN
doxorubicin/NN encapsulated/VBN efficacy/NN preserved/VBD cardiotoxicity/NN
doxorubicin/NN encapsulated/VBN efficacy/NN preserved/VBD cardiotoxicity/NN
cyclophosphamide/NN doxorubicin/NN encapsulated/VBN cyclophosphamide/JJ trial/NN cancer/NN breast/NN
cyclophosphamide/NN doxorubicin/NN encapsulated/VBN cyclophosphamide/JJ trial/NN cancer/NN
cyclophosphamide/JJ trial/NN cancer/NN breast/NN
cyclophosphamide/JJ trial/NN cancer/NN
doxorubicin/NN encapsulated/VBN cyclophosphamide/JJ trial/NN cancer/NN breast/NN
doxorubicin/NN encapsulated/VBN cyclophosphamide/JJ trial/NN cancer/NN
doxorubicin/NN encapsulated/VBN cyclophosphamide/JJ trial/NN cancer/NN breast/NN
doxorubicin/NN encapsulated/VBN cyclophosphamide/JJ trial/NN cancer/NN
cyclophosphamide/NN combination/NN Myocet/NNP reduces/VBZ cardiotoxicity/NN
Myocet/NNP reduces/VBZ cardiotoxicity/NN
doxorubicin/NN Myocet/NNP reduces/VBZ cardiotoxicity/NN
doxorubicin/NN cardiotoxicity/NN
cyclophosphamide/NN combination/NN Myocet/NNP reduces/VBZ determine/VB treatment/NN cancer/NN breast/NN
cyclophosphamide/NN combination/NN Myocet/NNP reduces/VBZ determine/VB treatment/NN cancer/NN
cyclophosphamide/NN combination/NN Myocet/NNP reduces/VBZ determine/VB treatment/NN cancer/NN MBC/NNP
Myocet/NNP reduces/VBZ determine/VB treatment/NN cancer/NN breast/NN
Myocet/NNP reduces/VBZ determine/VB treatment/NN cancer/NN
Myocet/NNP reduces/VBZ determine/VB treatment/NN cancer/NN MBC/NNP
doxorubicin/NN Myocet/NNP reduces/VBZ determine/VB treatment/NN cancer/NN breast/NN
doxorubicin/NN Myocet/NNP reduces/VBZ determine/VB treatment/NN cancer/NN
doxorubicin/NN Myocet/NNP reduces/VBZ determine/VB treatment/NN cancer/NN MBC/NNP
doxorubicin/NN cardiotoxicity/NN reduces/VBZ determine/VB treatment/NN cancer/NN breast/NN
doxorubicin/NN cardiotoxicity/NN reduces/VBZ determine/VB treatment/NN cancer/NN
doxorubicin/NN cardiotoxicity/NN reduces/VBZ determine/VB treatment/NN cancer/NN MBC/NNP
Myocet/NNP m/NN mg/NN m/NN cyclophosphamide/NN toxicity/NN
doxorubicin/NN Myocet/NNP m/NN mg/NN m/NN cyclophosphamide/NN toxicity/NN
cyclophosphamide/NN toxicity/NN
cyclophosphamide/NN m/NN receive/VB randomized/VBN Two/CD patients/NNS MBC/NNP
Myocet/NNP m/NN mg/NN m/NN receive/VB randomized/VBN Two/CD patients/NNS MBC/NNP
doxorubicin/NN Myocet/NNP m/NN mg/NN m/NN receive/VB randomized/VBN Two/CD patients/NNS MBC/NNP
cyclophosphamide/NN used/VBN provides/VBZ improves/VBZ index/NN doxorubicin/NN reducing/VBG neutropenia/NN cardiotoxicity/JJ
Myocet/NNP improves/VBZ index/NN doxorubicin/NN reducing/VBG neutropenia/NN cardiotoxicity/JJ
doxorubicin/NN reducing/VBG neutropenia/NN cardiotoxicity/JJ
cyclophosphamide/NN used/VBN first/JJ therapy/NN MBC/NNP
Myocet/NNP improves/VBZ provides/VBZ used/VBN first/JJ therapy/NN MBC/NNP
doxorubicin/NN index/NN improves/VBZ provides/VBZ used/VBN first/JJ therapy/NN MBC/NNP
puromycin/NN aminonucleoside/NN rats/NNS nephrosis/NNS model/NN syndrome/NN nephrotic/JJ
puromycin/NN aminonucleoside/NN rats/NNS nephrosis/NNS model/NN syndrome/NN
aminonucleoside/NN rats/NNS nephrosis/NNS model/NN syndrome/NN nephrotic/JJ
aminonucleoside/NN rats/NNS nephrosis/NNS model/NN syndrome/NN
puromycin/NN aminonucleoside/NN induced/VBN abnormalities/NNS hematological/JJ
puromycin/NN aminonucleoside/NN induced/VBN abnormalities/NNS
aminonucleoside/NN induced/VBN abnormalities/NNS hematological/JJ
aminonucleoside/NN induced/VBN abnormalities/NNS
Puromycin/NN aminonucleoside/NN induced/VBN dysfunction/NN hyperlipidemia/NN
aminonucleoside/NN induced/VBN dysfunction/NN hyperlipidemia/NN
Puromycin/NN aminonucleoside/NN induced/VBN dysfunction/NN renal/JJ
Puromycin/NN aminonucleoside/NN induced/VBN dysfunction/NN
aminonucleoside/NN induced/VBN dysfunction/NN renal/JJ
aminonucleoside/NN induced/VBN dysfunction/NN
puromycin/NN aminonucleoside/NN induced/VBN syndrome/NN nephrotic/JJ
puromycin/NN aminonucleoside/NN induced/VBN syndrome/NN
aminonucleoside/NN induced/VBN syndrome/NN nephrotic/JJ
aminonucleoside/NN induced/VBN syndrome/NN
LSD/NNP abuse/NN history/NN patients/NNS schizophrenic/JJ
LSD/NNP abuse/NN history/NN patients/NNS disturbances/NNS visual/JJ
LSD/NNP abuse/NN history/NN patients/NNS disturbances/NNS
Risperidone/NNP disturbances/NNS patients/NNS schizophrenic/JJ
risperidone/NN treated/VBN patients/NNS had/VBD developed/VBN EPS/NNP
LSD/NNP abuse/NN history/NN had/VBD patients/NNS schizophrenic/JJ
LSD/NNP abuse/NN history/NN had/VBD developed/VBN EPS/NNP
risperidone/NN treated/VBN patients/NNS schizophrenic/JJ
LSD/NNP consumption/NN related/VBN flashbacks/NNS experienced/JJ disturbances/NNS visual/JJ
LSD/NNP consumption/NN related/VBN flashbacks/NNS experienced/JJ disturbances/NNS
lometrexol/NN has/VBZ activity/NN tumours/NNS
methotrexate/NN drugs/NNS refractory/JJ tumours/NNS
lometrexol/NN development/NN curtailed/VBN toxicities/NNS
folic/JJ administration/NN prevented/VBN toxicity/NN
acid/NN administration/NN prevented/VBN toxicity/NN
lometrexol/NN toxicity/NN
folic/JJ supplementation/NN confirmed/VBN reduced/JJ toxicity/NN
acid/JJ supplementation/NN confirmed/VBN reduced/JJ toxicity/NN
folic/JJ supplementation/NN reduced/JJ toxicity/NN
acid/JJ supplementation/NN reduced/JJ toxicity/NN
lometrexol/NN study/NN prompted/VBD supplementation/NN confirmed/VBN reduced/JJ toxicity/NN
lometrexol/NN toxicity/NN
folate/NN elevation/NN extent/NN relationship/NN toxicity/NN
folic/JJ administration/NN altered/VBN indicating/VBG unlikely/JJ reduce/VB toxicity/NN
acid/JJ administration/NN altered/VBN indicating/VBG unlikely/JJ reduce/VB toxicity/NN
lometrexol/JJ pharmacokinetics/NNS altered/VBN indicating/VBG unlikely/JJ reduce/VB toxicity/NN
lometrexol/JJ clearance/NN enhancing/VBG reduce/VB toxicity/NN
calcium/NN resuscitation/NN arrest/NN asystolic/JJ
calcium/NN resuscitation/NN arrest/NN cardiac/JJ
calcium/NN resuscitation/NN arrest/NN
calcium/NN resuscitation/NN arrest/NN overdose/NN
aspirin/NN nitrate/NN g/NN 8/CD overdose/NN
paracetamol/NN nitrate/NN g/NN 8/CD overdose/NN
nitrate/NN g/NN 8/CD overdose/NN
alcohol/NN overdose/NN
isosorbide/NN nitrate/NN g/NN 8/CD overdose/NN
calcium/NN therapy/NN overdose/VBP onset/NN asystole/NN
calcium/NN therapy/NN overdose/VBP
Ca/JJ L/NNP decreases/VBZ promotes/VBZ occurrence/NN fibrillation/NN atrial/JJ
Ca/JJ L/NNP decreases/VBZ promotes/VBZ occurrence/NN fibrillation/NN
Ca/JJ L/NNP decreases/VBZ promotes/VBZ occurrence/NN fibrillation/NN AF/NNP
Ca/JJ L/NNP decreases/VBZ promotes/VBZ BACKGROUND/NNP tachycardia/NNP Atrial/NNP
Ca/JJ L/NNP decreases/VBZ promotes/VBZ BACKGROUND/NNP tachycardia/NNP
Ca/MD channel/VB promote/VB AF/NNP
Ca/MD channel/VB promote/VB AF/NNP consistent/JJ AF/NNP
Ca/JJ inhibition/NN effect/NN promoting/VBG AF/NNP
Ca/JJ inhibition/NN effect/NN promoting/VBG AF/NNP consistent/JJ AF/NNP
chloralose/JJ dogs/NNS morphine/VB verapamil/JJ administered/VBZ evaluate/VB mechanisms/NNS promotion/NN AF/NNP
Ca/JJ blockers/NNS evaluate/VB mechanisms/NNS promotion/NN AF/NNP
morphine/VB verapamil/JJ administered/VBZ evaluate/VB mechanisms/NNS promotion/NN AF/NNP
Diltiazem/NNP affect/VB ERP/NNP length/NN AF/NNP
Diltiazem/NNP affect/VB ERP/NNP duration/NNP AF/NNP
diltiazem/NN shared/VBN promoting/VBG dogs/NNS AF/NNP
UMB/NNP pretreatment/VB -/VB SM/NNP convulsions/NNS
24/CD UMB/NNP pretreatment/VB -/VB SM/NNP convulsions/NNS
SM/NNP convulsions/NNS
21/CD SM/NNP convulsions/NNS
13/CD trial/NN cis/NN acid/NN children/NNS neuroblastoma/NN
cis/NN acid/NN children/NNS neuroblastoma/NN
retinoic/JJ acid/NN children/NNS neuroblastoma/NN
acid/NN children/NNS neuroblastoma/NN
13/CD lines/NNS neuroblastoma/NN
cis/NN PURPOSE/NNP Treatment/NNP lines/NNS neuroblastoma/NN
retinoic/JJ acid/NN cause/VB PURPOSE/NNP Treatment/NNP lines/NNS neuroblastoma/NN
acid/NN cause/VB PURPOSE/NNP Treatment/NNP lines/NNS neuroblastoma/NN
cis/NN acid/NN cause/VB PURPOSE/NNP Treatment/NNP lines/NNS neuroblastoma/NN
RA/NNP cis/NN acid/NN cause/VB PURPOSE/NNP Treatment/NNP lines/NNS neuroblastoma/NN
cis/NN effective/JJ demonstrated/VBN patients/NNS neuroblastoma/NN
RA/NNP demonstrated/VBN patients/NNS neuroblastoma/NN
cis/NN pharmacokinetics/NNS maximal/NN toxicities/NNS
RA/NNP pharmacokinetics/NNS maximal/NN toxicities/NNS
cis/NN pharmacokinetics/NNS RA/NNP administered/VBN neuroblastoma/NN
RA/NNP administered/VBN neuroblastoma/NN
cis/NN resolved/VBN toxicities/NNS
RA/NNP discontinued/VBN resolved/VBN toxicities/NNS
mitomycin/JJ treatment/NN associated/VBN failure/NN anemia/NN hemolytic/JJ
mitomycin/JJ treatment/NN associated/VBN failure/NN anemia/NN
C/NNP treatment/NN associated/VBN failure/NN anemia/NN hemolytic/JJ
C/NNP treatment/NN associated/VBN failure/NN anemia/NN
mitomycin/JJ treatment/NN associated/VBN failure/NN anemia/NN thrombocytopenia/NN
C/NNP treatment/NN associated/VBN failure/NN anemia/NN thrombocytopenia/NN
mitomycin/JJ treatment/NN start/NN mth/NN 8/CD develops/VBZ %/NN failure/NN edema/NN pulmonary/JJ
mitomycin/JJ treatment/NN start/NN mth/NN 8/CD develops/VBZ %/NN failure/NN edema/NN
C/NNP treatment/NN start/NN mth/NN 8/CD develops/VBZ %/NN failure/NN edema/NN pulmonary/JJ
C/NNP treatment/NN start/NN mth/NN 8/CD develops/VBZ %/NN failure/NN edema/NN
mitomycin/NNP C/NNP developed/VBD died/VBD edema/NN pulmonary/JJ
mitomycin/NNP C/NNP developed/VBD died/VBD edema/NN
C/NNP developed/VBD died/VBD edema/NN pulmonary/JJ
C/NNP developed/VBD died/VBD edema/NN
mitomycin/NNP C/NNP developed/VBD failure/NN while/NN thrombocytopenia/NN
C/NNP developed/VBD failure/NN while/NN thrombocytopenia/NN
mitomycin/NNP C/NNP developed/VBD man/NN adenocarcinoma/NN gastric/JJ
mitomycin/NNP C/NNP developed/VBD man/NN adenocarcinoma/NN
C/NNP developed/VBD man/NN adenocarcinoma/NN gastric/JJ
C/NNP developed/VBD man/NN adenocarcinoma/NN
Ciprofloxacin/NNP induced/VBN patients/NNS cancer/NN
Ciprofloxacin/NNP induced/VBN nephrotoxicity/RB
ciprofloxacin/NN associated/VBN Nephrotoxicity/RB
ciprofloxacin/NN treatment/NN described/VBN followed/VBD failure/NN developed/VBD cancer/NN
echothiophate/JJ eye/NN instillation/NN resulting/VBG toxicity/NN
iodide/NN eye/NN instillation/NN resulting/VBG toxicity/NN
echothiophate/JJ drops/NNS use/NN developed/VBD given/VBN diagnosis/NN gravis/NNS myasthenia/NN
echothiophate/JJ drops/NNS use/NN developed/VBD given/VBN diagnosis/NN gravis/NNS
iodide/JJ drops/NNS use/NN developed/VBD given/VBN diagnosis/NN gravis/NNS myasthenia/NN
iodide/JJ drops/NNS use/NN developed/VBD given/VBN diagnosis/NN gravis/NNS
levodopa/JJ pallidotomy/JJ signs/NNS parkinsonian/NN
levodopa/NN responsiveness/NNS outcome/NN signs/NNS parkinsonian/NN
levodopa/NN responsiveness/NNS outcome/NN correlations/NNS volume/NN dyskinesias/NNS signs/NNS parkinsonian/NN
levodopa/NN responsiveness/NNS value/NN indicate/VBP responsible/JJ generation/NN signs/NNS parkinsonian/NN
ifosfamide/NN prevention/NN mesna/NN dexamethasone/NN Use/NN cystitis/NNS hemorrhagic/JJ
ifosfamide/NN prevention/NN mesna/NN dexamethasone/NN Use/NN cystitis/NNS
dexamethasone/NN Use/NN cystitis/NNS hemorrhagic/JJ
dexamethasone/NN Use/NN cystitis/NNS
mesna/NN dexamethasone/NN Use/NN cystitis/NNS hemorrhagic/JJ
mesna/NN dexamethasone/NN Use/NN cystitis/NNS
ifosfamide/NN chemotherapy/NN effect/NN AIM/NNP cystitis/NNS Hemorrhagic/JJ
ifosfamide/NN chemotherapy/NN effect/NN AIM/NNP cystitis/NNS
ifosfamide/NN chemotherapy/NN effect/NN AIM/NNP cystitis/NNS HC/NNP
IFS/NNP ifosfamide/NN chemotherapy/NN effect/NN AIM/NNP cystitis/NNS Hemorrhagic/JJ
IFS/NNP ifosfamide/NN chemotherapy/NN effect/NN AIM/NNP cystitis/NNS
IFS/NNP ifosfamide/NN chemotherapy/NN effect/NN AIM/NNP cystitis/NNS HC/NNP
IFS/NNP prevention/NN HC/NNP
dexamethasone/NN use/NN investigated/VBD mesna/NN prevention/NN HC/NNP
mesna/NN prevention/NN HC/NNP
IFS/NNP HC/NNP
Dexamethasone/NNP efficient/JJ blocking/VBG IFS/NNP HC/NNP
mesna/NN combination/NN Dexamethasone/NNP efficient/JJ blocking/VBG IFS/NNP HC/NNP
dexamethasone/NN doses/NNS all/DT mesna/NN replacement/NN prevent/VB HC/NNP
mesna/NN replacement/NN prevent/VB HC/NNP
mesna/NN doses/NNS all/DT mesna/NN replacement/NN prevent/VB HC/NNP
chloride/NN channels/NNS blocks/VBZ rats/NNS pretreatment/NN antagonized/VBN enhancement/NN adrenaline/NN induced/VBN bradycardia/NN
chloride/NN macromolecular/NN benzodiazepine/NN associated/VBN sites/NNS binding/JJ complex/NN blocks/VBZ rats/NNS pretreatment/NN antagonized/VBN enhancement/NN adrenaline/NN induced/VBN bradycardia/NN
benzodiazepine/NN associated/VBN sites/NNS binding/JJ complex/NN blocks/VBZ rats/NNS pretreatment/NN antagonized/VBN enhancement/NN adrenaline/NN induced/VBN bradycardia/NN
GABA/NNP benzodiazepine/NN associated/VBN sites/NNS binding/JJ complex/NN blocks/VBZ rats/NNS pretreatment/NN antagonized/VBN enhancement/NN adrenaline/NN induced/VBN bradycardia/NN
picrotoxin/NN dose/NN rats/NNS pretreatment/NN antagonized/VBN enhancement/NN adrenaline/NN induced/VBN bradycardia/NN
chloride/NN complex/NN acts/VBZ facilitate/VB bradycardia/NN
benzodiazepine/JJ chloride/NN complex/NN acts/VBZ facilitate/VB bradycardia/NN
GABA/NNP chloride/NN complex/NN acts/VBZ facilitate/VB bradycardia/NN
D/NNP penicillamine/NN treatment/NN scleroderma/NN localized/VBN
D/NNP penicillamine/NN treatment/NN scleroderma/NN
penicillamine/NN treatment/NN scleroderma/NN localized/VBN
penicillamine/NN treatment/NN scleroderma/NN
D/NNP treated/VBN reports/NNS patients/NNS scleroderma/NN localized/NNP
D/NNP treated/VBN reports/NNS patients/NNS scleroderma/NN
penicillamine/RB summarized/VBG reports/NNS patients/NNS scleroderma/NN localized/NNP
penicillamine/RB summarized/VBG reports/NNS patients/NNS scleroderma/NN
D/NNP caused/VBD developed/VBD insufficiency/NN renal/JJ
D/NNP caused/VBD developed/VBD insufficiency/NN
Penicillamine/NNP caused/VBD developed/VBD insufficiency/NN renal/JJ
Penicillamine/NNP caused/VBD developed/VBD insufficiency/NN
D/NNP effective/JJ cases/NNS scleroderma/NN localized/VBN
D/NNP effective/JJ cases/NNS scleroderma/NN
penicillamine/NN D/NNP effective/JJ cases/NNS scleroderma/NN localized/VBN
penicillamine/NN D/NNP effective/JJ cases/NNS scleroderma/NN
serotonin/NN inhibitor/NN hydrochloride/NN induced/VBN hyperprolactinemia/NN effects/NNS model/NN adenomyosis/NNS
serotonin/NN inhibitor/NN hydrochloride/NN induced/VBN induction/NN adenomyosis/JJ
serotonin/NN inhibitor/NN hydrochloride/NN induced/VBN hyperprolactinemia/NN
serotonin/JJ inhibitor/NN Fluoxetine/NNP given/VBN produce/VB hyperprolactinemia/NN
methimazole/NN had/VBD jaundice/NN
propranolol/NN methimazole/NN had/VBD treatment/NN hyperthyroidism/NN
propranolol/NN methimazole/NN had/VBD jaundice/NN
methimazole/NN had/VBD treatment/NN hyperthyroidism/NN
propranolol/NN methimazole/NN had/VBD jaundice/NN itching/NN
Methimazole/NNP diagnosed/VBN cholestasis/NNS
propranolol/JJ therapy/NN resumed/VBN diagnosed/VBN cholestasis/NNS
dipivalyl/JJ epinephrine/NN glaucoma/NN
epinephrine/NN glaucoma/NN
amphetamine/NN cocaine/NN screening/NN prevalence/NN determine/VB patients/NNS seizure/NN
cocaine/NN screening/NN prevalence/NN determine/VB patients/NNS seizure/NN
alcohol/NN drug/NN underlying/VBG history/NN time/NN seizure/NN
alcohol/NN drug/NN underlying/VBG history/NN time/NN seizure/NN
alcohol/NN drug/NN underlying/VBG history/NN history/NN abuse/NN cocaine/NN
alcohol/NN drug/NN underlying/VBG history/NN history/NN abuse/NN cocaine/NN or/CC
alcohol/NN drug/NN underlying/VBG history/NN history/NN abuse/NN cocaine/NN amphetamine/NN
alcohol/NN drug/NN underlying/VBG history/NN history/NN abuse/NN
amphetamines/NNS cocaine/NN screening/NN patients/NNS seizure/NN
cocaine/NN screening/NN patients/NNS seizure/NN
verapamil/NN therapy/NN hypotension/NN adrenergic/JJ failure/NN developed/VBD patients/NNS disease/NN ischaemic/JJ
verapamil/NN therapy/NN hypotension/NN adrenergic/JJ failure/NN developed/VBD patients/NNS disease/NN heart/NN
verapamil/NN therapy/NN hypotension/NN adrenergic/JJ failure/NN developed/VBD patients/NNS disease/NN
beta/NN verapamil/NN therapy/NN hypotension/NN adrenergic/JJ failure/NN developed/VBD patients/NNS disease/NN ischaemic/JJ
beta/NN verapamil/NN therapy/NN hypotension/NN adrenergic/JJ failure/NN developed/VBD patients/NNS disease/NN heart/NN
beta/NN verapamil/NN therapy/NN hypotension/NN adrenergic/JJ failure/NN developed/VBD patients/NNS disease/NN
adrenergic/JJ failure/NN developed/VBD patients/NNS disease/NN ischaemic/JJ
adrenergic/JJ failure/NN developed/VBD patients/NNS disease/NN heart/NN
adrenergic/JJ failure/NN developed/VBD patients/NNS disease/NN
blocking/VBG developed/VBD patients/NNS disease/NN ischaemic/JJ
blocking/VBG developed/VBD patients/NNS disease/NN heart/NN
blocking/VBG developed/VBD patients/NNS disease/NN
drugs/NNS blocking/VBG developed/VBD patients/NNS disease/NN ischaemic/JJ
drugs/NNS blocking/VBG developed/VBD patients/NNS disease/NN heart/NN
drugs/NNS blocking/VBG developed/VBD patients/NNS disease/NN
Thiazide/JJ diuretics/NNS hypokalemia/NN arrhythmias/NNS cardiac/JJ
Thiazide/JJ diuretics/NNS hypokalemia/NN arrhythmias/NNS
Thiazide/JJ diuretics/NNS hypokalemia/NN
thiazide/NN therapy/NN consequence/NN Hypokalemia/NNP
hydrochlorothiazide/NN treated/VBD patients/NNS hypertension/NN diastolic/JJ
hydrochlorothiazide/NN treated/VBD patients/NNS hypertension/NN
HCTC/NNP hydrochlorothiazide/NN treated/VBD patients/NNS hypertension/NN diastolic/JJ
HCTC/NNP hydrochlorothiazide/NN treated/VBD patients/NNS hypertension/NN
thiazide/JJ diuretics/NNS cause/VBP hypokalemia/NN
potassium/NN hypokalemia/NN
prazosin/NN blockade/NN 2/CD rats/NNS hypertensive/NN
prazosin/NN treatment/NN alters/VBZ function/NN control/NN pressure/NN rats/NNS hypertensive/JJ
rauwolscine/NN treated/VBN SHR/NNP treated/VBN' treated/VBN hypotension/NN orthostatic/JJ
rauwolscine/NN treated/VBN SHR/NNP treated/VBN' treated/VBN hypotension/NN
prazosin/NN pretreatment/NN determined/VBN responses/NNS bradycardia/NN
prazosin/NN abolished/VBN pressor/NN effects/NNS bradycardia/NN
prazosin/NN treatment/NN greater/JJR bradycardia/NN
prazosin/NN treatment/NN similar/JJ bradycardia/NN
methylprednisolone/NN Value/NNP syndrome/NN myalgia/NN
iron/NN dextran/NN infusion/NN associated/VBN syndrome/NN myalgia/NN
dextran/NN infusion/NN associated/VBN syndrome/NN myalgia/NN
methylprednisolone/NN prevention/NN arthralgia/NN
MP/NNP administration/NN demonstrate/VBP reduces/VBZ frequency/NN syndrome/NN myalgia/NN
MP/NNP administration/NN demonstrate/VBP reduces/VBZ frequency/NN syndrome/NN arthralgia/JJ
Levodopa/NNP alleviated/VBN dyskinesia/NN choreic/JJ dystonic/JJ
Levodopa/NNP alleviated/VBN dyskinesia/NN limbs/NNS cases/NNS Parkinsonism/NNP
levodopa/NN induced/VBN lesions/NNS course/NN treatment/NN Parkinsonism/NNP
levodopa/NN induced/VBN lesions/NNS thalamic/JJ
levodopa/NN induced/VBN lesions/NNS
bupivacaine/NN antagonist/NN effect/NN impairments/NNS cardiovascular/JJ
bupivacaine/NN antagonist/NN effect/NN impairments/NNS
BN/NNP antagonist/NN effect/NN impairments/NNS cardiovascular/JJ
BN/NNP antagonist/NN effect/NN impairments/NNS
52021/CD BN/NNP antagonist/NN effect/NN impairments/NNS cardiovascular/JJ
52021/CD BN/NNP antagonist/NN effect/NN impairments/NNS
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN of/IN
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN mean/JJ
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN arterial/JJ
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN blood/NN
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN MBP/NNP
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN and/CC
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN rate/NN heart/NN
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN rate/NN
bupivacaine/NN Administration/NNP elicited/VBD decrease/NN pressure/NN HR/NNP
bupivacaine/JJ administration/NN min/NN suppressed/VBD decrease/NN
bupivacaine/JJ administration/NN min/NN suppressed/VBD decrease/NN MBP/NNP of/IN
bupivacaine/JJ administration/NN min/NN suppressed/VBD decrease/NN MBP/NNP
bupivacaine/JJ administration/NN min/NN suppressed/VBD decrease/NN MBP/NNP and/CC
bupivacaine/JJ administration/NN min/NN suppressed/VBD decrease/NN MBP/NNP HR/NNP
BN/NNP 52021/NNP activating/VBG suppressed/VBD decrease/NN
BN/NNP 52021/NNP activating/VBG suppressed/VBD decrease/NN MBP/NNP of/IN
BN/NNP 52021/NNP activating/VBG suppressed/VBD decrease/NN MBP/NNP
BN/NNP 52021/NNP activating/VBG suppressed/VBD decrease/NN MBP/NNP and/CC
BN/NNP 52021/NNP activating/VBG suppressed/VBD decrease/NN MBP/NNP HR/NNP
52021/NNP activating/VBG suppressed/VBD decrease/NN
52021/NNP activating/VBG suppressed/VBD decrease/NN MBP/NNP of/IN
52021/NNP activating/VBG suppressed/VBD decrease/NN MBP/NNP
52021/NNP activating/VBG suppressed/VBD decrease/NN MBP/NNP and/CC
52021/NNP activating/VBG suppressed/VBD decrease/NN MBP/NNP HR/NNP
bupivacaine/NN injected/VBN observed/JJ reversion/NN decrease/NN
bupivacaine/NN injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP of/IN
bupivacaine/NN injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP
bupivacaine/NN injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP and/CC
bupivacaine/NN injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP HR/NNP
BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN
BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP of/IN
BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP
BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP and/CC
BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP HR/NNP
52021/CD BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN
52021/CD BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP of/IN
52021/CD BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP
52021/CD BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP and/CC
52021/CD BN/NNP injected/VBN observed/JJ reversion/NN decrease/NN MBP/NNP HR/NNP
bupivacaine/NN induced/VBN toxicity/NN cardiovascular/JJ
bupivacaine/NN induced/VBN toxicity/NN
BN/NNP administration/NN alter/VB demonstrate/VBP action/NN bupivacaine/NN induced/VBN toxicity/NN cardiovascular/JJ
BN/NNP administration/NN alter/VB demonstrate/VBP action/NN bupivacaine/NN induced/VBN toxicity/NN
52021/CD BN/NNP administration/NN alter/VB demonstrate/VBP action/NN bupivacaine/NN induced/VBN toxicity/NN cardiovascular/JJ
52021/CD BN/NNP administration/NN alter/VB demonstrate/VBP action/NN bupivacaine/NN induced/VBN toxicity/NN
BN/NNP action/NN bupivacaine/NN induced/VBN toxicity/NN cardiovascular/JJ
BN/NNP action/NN bupivacaine/NN induced/VBN toxicity/NN
52021/CD BN/NNP action/NN bupivacaine/NN induced/VBN toxicity/NN cardiovascular/JJ
52021/CD BN/NNP action/NN bupivacaine/NN induced/VBN toxicity/NN
bupivacaine/NN implicated/VBN appears/VBZ induced/VBN alterations/NNS cardiovascular/JJ
bupivacaine/NN implicated/VBN appears/VBZ induced/VBN alterations/NNS
benzodiazepine/JJ antagonist/NN used/VBN reverse/VB depression/NN sedation/NN respiratory/NN
benzodiazepine/JJ antagonist/NN used/VBN reverse/VB depression/NN
benzodiazepines/NNS induced/VBN depression/NN sedation/NN respiratory/NN
benzodiazepines/NNS induced/VBN depression/NN
Flumazenil/NNP antagonist/NN used/VBN reverse/VB depression/NN sedation/NN respiratory/NN
Flumazenil/NNP antagonist/NN used/VBN reverse/VB depression/NN
levodopa/NN improving/VBG seems/VBZ improves/VBZ bradykinesia/NN rigidity/NN
levodopa/NN improving/VBG seems/VBZ improves/VBZ bradykinesia/NN
propofol/JJ sedation/NN underwent/VBD dementia/NN
propofol/JJ sedation/NN underwent/VBD repair/NN hip/NN
propofol/JJ sedation/NN underwent/VBD repair/NN fracture/NN
propofol/JJ sedation/NN use/NN decreased/VBD prevalence/NN delirium/NN postoperative/JJ
propofol/JJ sedation/NN use/NN decreased/VBD prevalence/NN delirium/NN
aminoglycoside/NN commonly/RB used/VBN provide/VB gram/NN treatment/NN neutropenia/NN febrile/NN
aminoglycoside/NN commonly/RB used/VBN provide/VB gram/NN treatment/NN neutropenia/NN
Amikacin/NNP used/VBN provide/VB gram/NN treatment/NN neutropenia/NN febrile/NN
Amikacin/NNP used/VBN provide/VB gram/NN treatment/NN neutropenia/NN
aminoglycoside/NN commonly/RB used/VBN provide/VB gram/NN treatment/NN neutropenia/NN infections/NNS
Amikacin/NNP used/VBN provide/VB gram/NN treatment/NN neutropenia/NN infections/NNS
amikacin/NN conventional/JJ randomized/VBN patients/NNS diagnosis/NN consistent/JJ disorder/NN hematologic/JJ
amikacin/NN conventional/JJ randomized/VBN patients/NNS diagnosis/NN consistent/JJ disorder/NN //JJ
amikacin/NN conventional/JJ randomized/VBN patients/NNS diagnosis/NN consistent/JJ disorder/NN oncologic/JJ
amikacin/NN conventional/JJ randomized/VBN patients/NNS diagnosis/NN consistent/JJ disorder/NN
aminoglycoside/NN required/VBD disorder/NN hematologic/JJ
aminoglycoside/NN required/VBD disorder/NN //JJ
aminoglycoside/NN required/VBD disorder/NN oncologic/JJ
aminoglycoside/NN required/VBD disorder/NN
creatinine/NN increase/NN means/NNS nephrotoxicity/JJ
catecholamines/NNS severity/NN hyperkinesia/NN
catecholamines/NNS severity/NN relationship/NN levels/NNS psychosis/NNS
amphetamine/NN diagnosis/NN service/NN psychiatric/JJ
catecholamines/NNS relationship/NN patients/NNS service/NN psychiatric/JJ
catecholamine/NN levels/NNS drug/NN assays/NNS collected/VBN examine/VB relationship/NN patients/NNS service/NN psychiatric/JJ
cocaine/NN relationship/NN patients/NNS service/NN psychiatric/JJ
catecholamines/NNS symptoms/NNS psychotic/JJ
catecholamines/NNS symptoms/NNS
catecholamines/NNS relationship/NN examine/VB interviewed/VBN psychosis/NNS
catecholamine/NN levels/NNS drug/NN assays/NNS collected/VBN examine/VB relationship/NN catecholamines/NNS symptoms/NNS psychotic/JJ
catecholamine/NN levels/NNS drug/NN assays/NNS collected/VBN examine/VB relationship/NN catecholamines/NNS symptoms/NNS
catecholamine/NN levels/NNS drug/NN assays/NNS collected/VBN examine/VB interviewed/VBN psychosis/NNS
morphine/NN premedicated/VBN patients/NNS kg/VBP found/VBN lasted/VBD occurred/VBD apnoea/NN
nitrazepam/NN +/VBN morphine/NN premedicated/VBN patients/NNS kg/VBP found/VBN lasted/VBD occurred/VBD apnoea/NN
scopolamine/JJ morphine/NN premedicated/VBN patients/NNS kg/VBP found/VBN lasted/VBD occurred/VBD apnoea/NN
oxypurines/VBZ nucleosides/VBZ ischemia/NN cerebral/JJ
oxypurines/VBZ nucleosides/VBZ ischemia/NN
nucleosides/VBZ ischemia/NN cerebral/JJ
nucleosides/VBZ ischemia/NN
oxypurines/NNS time/NN observed/JJ ischemia/NN
nucleosides/NNS oxypurines/NNS time/NN observed/JJ ischemia/NN
malondialdehyde/NNP increased/VBD min/NN ischemia/NN
nitroprusside/NN mg/NN w/NNP ischemia/NN
nitroprusside/NN mg/NN receiving/VBG one/CD model/NN subjected/VBN animals/NNS groups/NNS recorded/VBN min/NN ischemia/NN
acetylsalicylate/NN intravenously/NN w/NNP mg/NN nitroprusside/NN hypotensive/JJ
malondialdehyde/NN recorded/VBN groups/NNS animals/NNS subjected/VBN model/NN one/CD receiving/VBG mg/NN nitroprusside/NN hypotensive/JJ
malondialdehyde/NN higher/JJR ischemia/NN min/NN recorded/VBN groups/NNS animals/NNS subjected/VBN model/NN one/CD receiving/VBG mg/NN nitroprusside/NN hypotensive/JJ
acetylsalicylate/NN intravenously/NN w/NNP ischemia/NN
acetylsalicylate/NN intravenously/NN w/NNP mg/NN receiving/VBG one/CD model/NN subjected/VBN animals/NNS groups/NNS recorded/VBN min/NN ischemia/NN
malondialdehyde/NN recorded/VBN groups/NNS animals/NNS subjected/VBN model/NN one/CD receiving/VBG mg/NN w/NNP ischemia/NN
malondialdehyde/NN recorded/VBN min/NN ischemia/NN
malondialdehyde/NN higher/JJR ischemia/NN min/NN recorded/VBN groups/NNS animals/NNS subjected/VBN model/NN one/CD receiving/VBG mg/NN w/NNP ischemia/NN
malondialdehyde/NN higher/JJR ischemia/NN
nitroprusside/NN hypotensive/JJ
oxypurines/NNS malondialdehyde/NN determination/NN used/VBN monitor/VB alterations/NNS tissues/NNS occurring/VBG phenomena/NNS ischemic/JJ
nucleosides/NNS malondialdehyde/NN determination/NN used/VBN monitor/VB alterations/NNS tissues/NNS occurring/VBG phenomena/NNS ischemic/JJ
malondialdehyde/NN determination/NN used/VBN monitor/VB alterations/NNS tissues/NNS occurring/VBG phenomena/NNS ischemic/JJ
corticosteroids/NNS agents/NNS blocking/VBG neuromuscular/VBP paralysis/NN
nondepolarizing/JJ paralysis/NN
neuromuscular/VBP paralysis/NN
blocking/VBG neuromuscular/VBP paralysis/NN
agents/NNS blocking/VBG neuromuscular/VBP paralysis/NN
ND/NNP discontinuation/NN weakness/NN developed/VBD insufficiency/NN respiratory/NN
ND/NNP discontinuation/NN weakness/NN developed/VBD insufficiency/NN
NMBAs/VBZ patients/NNS insufficiency/NN respiratory/NN
NMBAs/VBZ patients/NNS insufficiency/NN
corticosteroids/NNS due/JJ junction/NN pathology/VB due/JJ weakness/NN
corticosteroids/NNS due/JJ junction/NN pathology/VB
corticosteroids/NNS due/JJ junction/NN at/IN
corticosteroids/NNS due/JJ junction/NN both/PDT
corticosteroids/NNS due/JJ junction/NN the/DT
corticosteroids/NNS due/JJ junction/NN neuromuscular/NN
corticosteroids/NNS due/JJ junction/NN
doxorubicin/NN cycle/NN fibrillation/NN association/NN form/NN dystrophy/NN muscular/JJ
doxorubicin/NN cycle/NN fibrillation/NN association/NN form/NN dystrophy/NN
doxorubicin/NN cycle/NN fibrillation/NN association/NN lymphoma/NN gastric/JJ
doxorubicin/NN cycle/NN fibrillation/NN association/NN lymphoma/NN
doxorubicin/NN cycle/NN fibrillation/NN association/NN lymphoma/NN dystrophy/NN myotonic/JJ
doxorubicin/NN cycle/NN fibrillation/NN association/NN lymphoma/NN dystrophy/NN
ranitidine/NN replaced/VBN disappeared/VBD developed/VBD impotence/VBP
cimetidine/NN doses/NNS Treatment/NNP associated/VBN toxicity/NN hepatic/JJ
cimetidine/NN doses/NNS Treatment/NNP associated/VBN toxicity/NN hepatic/JJ or/CC
cimetidine/NN doses/NNS Treatment/NNP associated/VBN toxicity/NN hepatic/JJ hematologic/JJ
cimetidine/NN doses/NNS Treatment/NNP associated/VBN toxicity/NN
cimetidine/JJ therapy/NN seen/VBN level/NN associated/VBN associated/VBN toxicity/NN hepatic/JJ
cimetidine/JJ therapy/NN seen/VBN level/NN associated/VBN associated/VBN toxicity/NN hepatic/JJ or/CC
cimetidine/JJ therapy/NN seen/VBN level/NN associated/VBN associated/VBN toxicity/NN hepatic/JJ hematologic/JJ
cimetidine/JJ therapy/NN seen/VBN level/NN associated/VBN associated/VBN toxicity/NN
creatinine/NN level/NN associated/VBN associated/VBN toxicity/NN hepatic/JJ
creatinine/NN level/NN associated/VBN associated/VBN toxicity/NN hepatic/JJ or/CC
creatinine/NN level/NN associated/VBN associated/VBN toxicity/NN hepatic/JJ hematologic/JJ
creatinine/NN level/NN associated/VBN associated/VBN toxicity/NN
ranitidine/NN cimetidine/NN doses/NNS Treatment/NNP associated/VBN toxicity/NN hepatic/JJ
ranitidine/NN cimetidine/NN doses/NNS Treatment/NNP associated/VBN toxicity/NN hepatic/JJ or/CC
ranitidine/NN cimetidine/NN doses/NNS Treatment/NNP associated/VBN toxicity/NN hepatic/JJ hematologic/JJ
ranitidine/NN cimetidine/NN doses/NNS Treatment/NNP associated/VBN toxicity/NN
ranitidine/JJ therapy/NN associated/VBN associated/VBN toxicity/NN hepatic/JJ
ranitidine/JJ therapy/NN associated/VBN associated/VBN toxicity/NN hepatic/JJ or/CC
ranitidine/JJ therapy/NN associated/VBN associated/VBN toxicity/NN hepatic/JJ hematologic/JJ
ranitidine/JJ therapy/NN associated/VBN associated/VBN toxicity/NN
corticosteroids/NNS respond/VB %/NN cases/NNS uveitis/NNS
chloroquine/NN used/VBD found/VBD case/NN drugs/NNS attributable/JJ chorioretinopathy/RB
corticosteroids/NNS used/VBN found/VBN number/NN cataracts/NNS
cibenzoline/NN effects/NNS arrhythmias/NNS ventricular/NN
cibenzoline/NN effects/NNS arrhythmias/NNS
cibenzoline/NN +/NNP effects/NNS examined/VBN using/VBG models/NNS ventricular/NN
cibenzoline/NN +/NNP effects/NNS examined/VBN using/VBG models/NNS arrhythmia/NN
cibenzoline/RB examined/VBN using/VBG models/NNS ventricular/NN
cibenzoline/RB examined/VBN using/VBG models/NNS arrhythmia/NN
pentobarbital/NN ouabain/NN injection/NN intermittent/VBG induced/VBN arrhythmia/NN
Na/NNP blockers/NNS suppressed/VBN arrhythmia/NN
Digitalis/JJ arrhythmia/NN
Ca/JJ blockers/NNS suppressed/VBN arrhythmia/NN Adrenaline/JJ
Ca/JJ blockers/NNS suppressed/VBN arrhythmia/NN
halothane/NN infusion/NN induced/VBN arrhythmia/NN Adrenaline/JJ
halothane/NN infusion/NN induced/VBN arrhythmia/NN
cibenzoline/VBP arrhythmias/NNS
digitalis/JJ cibenzoline/VBP arrhythmias/NNS
cibenzoline/RB 1/CD arrhythmias/NNS
digitalis/JJ arrhythmias/NNS
cibenzoline/NN suppressed/VBN induced/VBN v/JJ arrhythmia/NN
cibenzoline/NN -/NNP dose/NN needed/VBN suppress/VB adrenaline/NN arrhythmias/NNS
digitalis/NN induced/VBN v/JJ arrhythmia/NN
digitalis/NN induced/VBN suppressed/VBN cibenzoline/NN -/NNP dose/NN needed/VBN suppress/VB adrenaline/NN arrhythmias/NNS
cibenzoline/RB 0/CD arrhythmia/NNP
digitalis/JJ arrhythmia/NNP
naloxone/JJ reversal/NN paralysis/NN respiratory/JJ
naloxone/JJ reversal/NN paralysis/NN
GABA/NNP involvement/NN reversal/NN paralysis/NN respiratory/JJ
GABA/NNP involvement/NN reversal/NN paralysis/NN
naloxone/NN reversed/VBD paralysis/NN respiratory/JJ
naloxone/NN reversed/VBD paralysis/NN
amino/JJ acids/NNS any/DT affecting/VBG stem/VBP produced/VBD arrest/NN respiratory/JJ
amino/JJ acids/NNS any/DT affecting/VBG stem/VBP produced/VBD arrest/NN
acids/NNS any/DT affecting/VBG stem/VBP produced/VBD arrest/NN respiratory/JJ
acids/NNS any/DT affecting/VBG stem/VBP produced/VBD arrest/NN
glutamate/NN decrease/NN stem/VBP produced/VBD arrest/NN respiratory/JJ
glutamate/NN decrease/NN stem/VBP produced/VBD arrest/NN
thiopental/NNP produced/VBD arrest/NN respiratory/JJ
thiopental/NNP produced/VBD arrest/NN
GABA/NNP produced/VBD arrest/NN respiratory/JJ
GABA/NNP produced/VBD arrest/NN
Naloxone/NNP reversed/VBD levels/NNS respiratory/JJ
Naloxone/NNP reversed/VBD levels/NNS paralysis/NN
glutamate/NN paralysis/NN levels/NNS respiratory/JJ
glutamate/NN paralysis/NN
GABA/NNP paralysis/NN levels/NNS respiratory/JJ
GABA/NNP paralysis/NN
naloxone/NN reverses/VBZ paralysis/NN respiratory/JJ
naloxone/NN reverses/VBZ paralysis/NN
GABA/NNP involves/VBZ reverses/VBZ paralysis/NN respiratory/JJ
GABA/NNP involves/VBZ reverses/VBZ paralysis/NN
DA/NNP receptors/NNS density/NN increases/NNS due/JJ concentration/NN nicotine/VB develop/VB hyperactivity/NN locomotor/NN
DA/NNP receptors/NNS density/NN increases/NNS due/JJ concentration/NN nicotine/VB develop/VB hyperactivity/NN
DA/NNP receptor/NN inducing/VBG followed/VBD nicotine/NN treated/VBD develop/VB hyperactivity/NN locomotor/NN
DA/NNP receptor/NN inducing/VBG followed/VBD nicotine/NN treated/VBD develop/VB hyperactivity/NN
prostaglandins/NNS responses/NNS pain/NN
acetic/JJ tests/NNS plate/NN using/VBG evaluated/VBN effects/NNS administration/NN prostaglandins/NNS responses/NNS pain/NN
acid/JJ tests/NNS plate/NN using/VBG evaluated/VBN effects/NNS administration/NN prostaglandins/NNS responses/NNS pain/NN
pg/NN doses/NNS showed/VBD effect/NN hyperalgesic/JJ
AH/NNP blocked/VBN' blocked/VBN effect/NN hyperalgesic/JJ
6809/CD AH/NNP blocked/VBN' blocked/VBN effect/NN hyperalgesic/JJ
AH/NNP blocked/VBN hyperalgesia/NN
6809/CD AH/NNP blocked/VBN hyperalgesia/NN
Prostaglandin/NNP F/NNP had/VBD effect/NN responses/NNS pain/NN
F/NNP had/VBD effect/NN responses/NNS pain/NN
2/CD alpha/NN F/NNP had/VBD effect/NN responses/NNS pain/NN
alpha/NN F/NNP had/VBD effect/NN responses/NNS pain/NN
heparin/NN products/NNS lots/NNS number/NN found/VBN contaminated/VBN derivative/NN elicit/VB response/NN hypotensive/JJ
heparin/NN products/NNS Using/VBG showed/VBD produces/VBZ dose/NN hypotension/NN
glutathione/NNP S/NNP alpha/NN transferase/NN levels/NNS evaluated/VBN toxicity/NNP Liver/NNP
glutathione/NNP S/NNP alpha/NN transferase/NN levels/NNS evaluated/VBN toxicity/NNP
15/CD levels/NNS measured/VBN results/NNS steatosis/VBZ
F/NN levels/NNS measured/VBN results/NNS steatosis/VBZ
2/CD t/CD F/NN levels/NNS measured/VBN results/NNS steatosis/VBZ
t/CD F/NN levels/NNS measured/VBN results/NNS steatosis/VBZ
IsoP/NNP measured/VBN results/NNS steatosis/VBZ
15/CD levels/NNS measured/VBN IsoP/NNP precedes/VBZ onset/NN necrosis/NNS
F/NN levels/NNS measured/VBN IsoP/NNP precedes/VBZ onset/NN necrosis/NNS
2/CD t/CD F/NN levels/NNS measured/VBN IsoP/NNP precedes/VBZ onset/NN necrosis/NNS
t/CD F/NN levels/NNS measured/VBN IsoP/NNP precedes/VBZ onset/NN necrosis/NNS
IsoP/NNP precedes/VBZ onset/NN necrosis/NNS
Topiramate/NNP medication/NN becoming/VBG more/JJR prescribed/VBN efficacy/NN treating/VBG seizures/NNS refractory/JJ
Topiramate/NNP medication/NN becoming/VBG more/JJR prescribed/VBN efficacy/NN treating/VBG seizures/NNS
calcium/NN nephrolithiasis/NNS
phosphate/NN nephrolithiasis/NNS
allopurinol/NN other/JJ given/VBN described/VBN case/NN anemia/NN aplastic/JJ
allopurinol/NN other/JJ given/VBN described/VBN case/NN anemia/NN
Loreclezole/NNP exerted/VBN reducing/VBG durations/NNS seizure/NN
Hibiscus/NNP sinensis/NNS extract/NNS Effect/NN studied/VBN reserpine/NN induced/VBN dyskinesia/NN
rosa/NN sinensis/NNS extract/NNS Effect/NN studied/VBN reserpine/NN induced/VBN dyskinesia/NN
sinensis/NNS extract/NNS Effect/NN studied/VBN reserpine/NN induced/VBN dyskinesia/NN
Hibiscus/NNP sinensis/NNS had/VBD role/NN dyskinesia/NN
rosa/NN sinensis/NNS had/VBD role/NN dyskinesia/NN
sinensis/NNS had/VBD role/NN dyskinesia/NN
Ketanserin/NN alfentanil/NNS induced/VBN rigidity/NN muscle/NN
Ketanserin/NN alfentanil/NNS induced/VBN rigidity/NN
serotonin/NN antagonist/NN type/NN attenuated/VBD produced/VBD rigidity/NN muscle/NN
serotonin/NN antagonist/NN type/NN attenuated/VBD produced/VBD rigidity/NN
ketanserin/NN pretreatment/NN attenuated/VBD produced/VBD rigidity/NN muscle/NN
ketanserin/NN pretreatment/NN attenuated/VBD produced/VBD rigidity/NN
Chlordiazepoxide/NNP failed/VBD influence/VB rigidity/NN
ketanserin/NN received/VBD animals/NNS motionless/JJ absence/NN rigidity/NN
serotonin/JJ antagonists/NNS useful/JJ Pretreatment/NNP induced/VBN rigidity/NN
serotonin/JJ antagonists/NNS useful/JJ Pretreatment/NNP induced/VBN necessary/JJ assess/VB interaction/NN CNS/NN cardiovascular/JJ
serotonin/JJ antagonists/NNS useful/JJ Pretreatment/NNP induced/VBN necessary/JJ assess/VB interaction/NN CNS/NN and/CC
serotonin/JJ antagonists/NNS useful/JJ Pretreatment/NNP induced/VBN necessary/JJ assess/VB interaction/NN CNS/NN depression/NN respiratory/JJ
serotonin/JJ antagonists/NNS useful/JJ Pretreatment/NNP induced/VBN necessary/JJ assess/VB interaction/NN CNS/NN depression/NN
epinephrine/NN induced/VBN ischemia/NN Mechanisms/NNPS induced/NNP ischemia/NN
epinephrine/NN role/NN examined/VBN patients/NNS disease/NN coronary/JJ
epinephrine/NN role/NN examined/VBN patients/NNS disease/NN artery/NN
epinephrine/NN role/NN examined/VBN patients/NNS disease/NN
epinephrine/JJ infusion/NN compared/VBN signs/NNS ischemia/NN
oxygen/NN consumption/NN increasing/VBG signs/NNS ischemia/NN
epinephrine/NN produced/VBD depression/NN angina/NN
epinephrine/NN produced/VBD depression/NN
epinephrine/NN volume/NN product/NN rate/NN induced/VBN characterized/VBN ischemia/NN
epinephrine/NN produced/VBN ischemia/NN
caffeine/NNP lead/VB stroke/NN
pindolol/JJ propranolol/JJ inhibiting/VBG arrhythmia/NN
propranolol/JJ inhibiting/VBG arrhythmia/NN
deoxycholic/JJ acid/NN hydroxylation/NN sulfation/NN cholestasis/NNS
acid/NN hydroxylation/NN sulfation/NN cholestasis/NNS
potassium/NN Diuretics/NNS disease/NN hypertensive/JJ
potassium/NN Diuretics/NNS arrhythmias/NNS
potassium/NN Diuretics/NNS disease/NN coronary/JJ
potassium/NN Diuretics/NNS disease/NN
potassium/NN changes/NNS alter/VB tendency/NN arrhythmias/NNS cardiac/JJ
potassium/NN changes/NNS alter/VB tendency/NN arrhythmias/NNS
potassium/NN known/VBN hypertension/NN
potassium/NN conserving/VBG known/VBN hypertension/NN
amiloride/NN conserving/VBG known/VBN hypertension/NN
potassium/NN known/VBN disease/NN coronary/JJ
potassium/NN known/VBN disease/NN artery/NN
potassium/NN known/VBN disease/NN
potassium/NN conserving/VBG known/VBN disease/NN coronary/JJ
potassium/NN conserving/VBG known/VBN disease/NN artery/NN
potassium/NN conserving/VBG known/VBN disease/NN
chlorthalidone/NN losing/VBG known/VBN disease/NN coronary/JJ
chlorthalidone/NN losing/VBG known/VBN disease/NN artery/NN
chlorthalidone/NN losing/VBG known/VBN disease/NN
amiloride/NN conserving/VBG known/VBN disease/NN coronary/JJ
amiloride/NN conserving/VBG known/VBN disease/NN artery/NN
amiloride/NN conserving/VBG known/VBN disease/NN
chlorthalidone/NN losing/VBG known/VBN hypertension/NN
amiloride/JJ treatment/NN associated/VBN frequency/NN beats/NNS ventricular/JJ
amiloride/JJ treatment/NN associated/VBN frequency/NN beats/NNS ectopic/JJ
amiloride/JJ treatment/NN associated/VBN frequency/NN beats/NNS
potassium/NN increase/VB patients/NNS disease/NN ischaemic/JJ
potassium/NN increase/VB patients/NNS disease/NN heart/NN
potassium/NN increase/VB patients/NNS disease/NN
potassium/NN concentrations/NNS avoided/VBN falls/VBZ increase/VB patients/NNS disease/NN ischaemic/JJ
potassium/NN concentrations/NNS avoided/VBN falls/VBZ increase/VB patients/NNS disease/NN heart/NN
potassium/NN concentrations/NNS avoided/VBN falls/VBZ increase/VB patients/NNS disease/NN
N/NNP safety/NN butyl/NN deoxynojirimycin/NN zidovudine/NN patients/NNS HIV/NNP
N/NNP safety/NN butyl/NN deoxynojirimycin/NN infection/NN 1/CD
N/NNP safety/NN butyl/NN deoxynojirimycin/NN infection/NN
butyl/NN deoxynojirimycin/NN zidovudine/NN patients/NNS HIV/NNP
butyl/NN deoxynojirimycin/NN infection/NN 1/CD
butyl/NN deoxynojirimycin/NN infection/NN
deoxynojirimycin/NN zidovudine/NN patients/NNS HIV/NNP
deoxynojirimycin/NN infection/NN 1/CD
deoxynojirimycin/NN infection/NN
SC/NNP deoxynojirimycin/NN zidovudine/NN patients/NNS HIV/NNP
SC/NNP deoxynojirimycin/NN infection/NN 1/CD
SC/NNP deoxynojirimycin/NN infection/NN
48334/CD SC/NNP deoxynojirimycin/NN zidovudine/NN patients/NNS HIV/NNP
48334/CD SC/NNP deoxynojirimycin/NN infection/NN 1/CD
48334/CD SC/NNP deoxynojirimycin/NN infection/NN
zidovudine/NN patients/NNS HIV/NNP
zidovudine/NN deoxynojirimycin/NN infection/NN 1/CD
zidovudine/NN deoxynojirimycin/NN infection/NN
SC/NN level/NN concentration/NN virus/NN immunodeficiency/NN
48334/CD steady/JJ SC/NN level/NN concentration/NN virus/NN immunodeficiency/NN
creatine/NN levels/NNS lupus/NNS systemic/JJ
creatine/NN levels/NNS lupus/NNS
creatine/NN levels/NNS diagnosis/NN erythematosus/VBZ
chloroquine/NN woman/NN year/NN induced/VBN myopathy/RB
cyclophosphamide/NN azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS involvement/NN renal/JJ
cyclophosphamide/NN azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS involvement/NN
azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS systemic/JJ
azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS lupus/NNS
azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS
azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS SLE/NNP
azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS involvement/NN renal/JJ
azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS involvement/NN
cyclophosphamide/NN azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS systemic/JJ
cyclophosphamide/NN azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS lupus/NNS
cyclophosphamide/NN azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS
cyclophosphamide/NN azathioprine/NN undergone/VBN suffering/VBG erythematosus/NNS SLE/NNP
chloroquine/NN therapy/NN started/VBN arthralgia/NN
CQ/NNP therapy/NN started/VBN arthralgia/NN
steroids/NNS treated/VBN suspected/VBN Myositis/NNS
chloroquine/NN induced/VBN myopathy/RB
aniracetam/NN learning/NN impaired/VBN
aniracetam/NN learning/NN
aniracetam/NN learning/NN and/CC
aniracetam/NN learning/NN memory/NN
Ro/NNP aniracetam/NN learning/NN impaired/VBN
Ro/NNP aniracetam/NN learning/NN
Ro/NNP aniracetam/NN learning/NN and/CC
Ro/NNP aniracetam/NN learning/NN memory/NN
13/CD Ro/NNP aniracetam/NN learning/NN impaired/VBN
13/CD Ro/NNP aniracetam/NN learning/NN
13/CD Ro/NNP aniracetam/NN learning/NN and/CC
13/CD Ro/NNP aniracetam/NN learning/NN memory/NN
5057/CD Ro/NNP aniracetam/NN learning/NN impaired/VBN
5057/CD Ro/NNP aniracetam/NN learning/NN
5057/CD Ro/NNP aniracetam/NN learning/NN and/CC
5057/CD Ro/NNP aniracetam/NN learning/NN memory/NN
aniracetam/NN effect/NN studied/VBN forms/NNS functions/NNS impaired/VBN
aniracetam/NN effect/NN studied/VBN forms/NNS functions/NNS cognitive/NN
aniracetam/NN effect/NN studied/VBN forms/NNS functions/NNS
Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS impaired/VBN
Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS cognitive/NN
Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS
13/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS impaired/VBN
13/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS cognitive/NN
13/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS
5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS impaired/VBN
5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS cognitive/NN
5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS
1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS impaired/VBN
1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS cognitive/NN
1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS
anisoyl/JJ pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS impaired/VBN
anisoyl/JJ pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS cognitive/NN
anisoyl/JJ pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS
2/CD pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS impaired/VBN
2/CD pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS cognitive/NN
2/CD pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS
pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS impaired/VBN
pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS cognitive/NN
pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN forms/NNS functions/NNS
chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN learn/VB incapacity/JJ reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS impaired/VBN
chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN learn/VB incapacity/JJ reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS cognitive/NN
chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN learn/VB incapacity/JJ reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS
cycloheximide/NN chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
cycloheximide/NN chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN protection/NN amnesia/NN
cycloheximide/NN induced/VBN task/NN deficit/NN h/NN late/JJ administered/VBN prevention/NN applied/VBD reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
cycloheximide/NN induced/VBN task/NN deficit/NN h/NN late/JJ administered/VBN prevention/NN applied/VBD reversal/NN incapacity/JJ learn/VB response/NN protection/NN amnesia/NN
chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN learn/VB incapacity/JJ reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
scopolamine/NN prevention/NN rats/NNS sublethal/VB exposed/VBN rats/NNS response/NN learn/VB incapacity/JJ reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS impaired/VBN
scopolamine/NN prevention/NN rats/NNS sublethal/VB exposed/VBN rats/NNS response/NN learn/VB incapacity/JJ reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS cognitive/NN
scopolamine/NN prevention/NN rats/NNS sublethal/VB exposed/VBN rats/NNS response/NN learn/VB incapacity/JJ reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS
aniracetam/NN effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
aniracetam/NN effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN protection/NN amnesia/NN
Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
13/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN protection/NN amnesia/NN
13/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN protection/NN amnesia/NN
5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN protection/NN amnesia/NN
1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
anisoyl/JJ pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
2/CD pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN protection/NN amnesia/NN
anisoyl/JJ pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN protection/NN amnesia/NN
2/CD pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN protection/NN amnesia/NN
pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN protection/NN amnesia/NN
aniracetam/NN effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
aniracetam/NN effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
13/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
13/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
anisoyl/JJ pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
2/CD pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
anisoyl/JJ pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
2/CD pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
pyrrolidinone/NN 1/CD 5057/CD Ro/NNP effect/NN studied/VBN produced/VBN effects/NNS prevention/NN reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
cycloheximide/NN chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN learn/VB incapacity/JJ reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS impaired/VBN
cycloheximide/NN chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN learn/VB incapacity/JJ reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS cognitive/NN
cycloheximide/NN chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN learn/VB incapacity/JJ reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS
cycloheximide/NN induced/VBN task/NN deficit/NN h/NN late/JJ administered/VBN prevention/NN applied/VBD reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS impaired/VBN
cycloheximide/NN induced/VBN task/NN deficit/NN h/NN late/JJ administered/VBN prevention/NN applied/VBD reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS cognitive/NN
cycloheximide/NN induced/VBN task/NN deficit/NN h/NN late/JJ administered/VBN prevention/NN applied/VBD reversal/NN prevention/NN effects/NNS produced/VBN studied/VBN forms/NNS functions/NNS
cycloheximide/NN chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
cycloheximide/NN chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN learn/VB incapacity/JJ reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
cycloheximide/NN induced/VBN task/NN deficit/NN h/NN late/JJ administered/VBN prevention/NN applied/VBD reversal/NN incapacity/JJ learn/VB response/NN rats/NNS exposed/VBN sublethal/VB hypercapnia/NN
cycloheximide/NN induced/VBN task/NN deficit/NN h/NN late/JJ administered/VBN prevention/NN induced/VBN electroshock/NN hypercapnia/NN
scopolamine/NN prevention/NN rats/NNS sublethal/VB hypercapnia/NN
scopolamine/NN prevention/NN rats/NNS sublethal/VB exposed/VBN rats/NNS response/NN learn/VB incapacity/JJ reversal/NN applied/VBD prevention/NN induced/VBN electroshock/NN hypercapnia/NN
chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN rats/NNS exposed/VBN sublethal/VB short/JJ amnesia/NN
chloramphenicol/NN induced/VBN task/NN deficit/NN retrieval/NN response/NN protection/NN amnesia/NN
aniracetam/NN doses/NNS seen/VBN improvements/NNS functions/NNS impaired/VBN
aniracetam/NN doses/NNS seen/VBN improvements/NNS functions/NNS cognitive/NN
aniracetam/NN doses/NNS seen/VBN improvements/NNS functions/NNS
fluconazole/NN had/VBD cardiomyopathy/RB
fluconazole/NNP initiation/NN association/NN was/VBD abnormalities/NNS woman/NN glabrata/NNP isolated/VBN abscess/NNS developed/VBN days/NNS commencing/VBG fluconazole/NN had/VBD cardiomyopathy/RB
fluconazole/NN had/VBD disease/NN coronary/JJ
fluconazole/NN had/VBD disease/NN artery/NN
fluconazole/NN had/VBD disease/NN
fluconazole/NNP initiation/NN association/NN was/VBD abnormalities/NNS woman/NN glabrata/NNP isolated/VBN abscess/NNS developed/VBN days/NNS commencing/VBG fluconazole/NN had/VBD disease/NN coronary/JJ
fluconazole/NNP initiation/NN association/NN was/VBD abnormalities/NNS woman/NN glabrata/NNP isolated/VBN abscess/NNS developed/VBN days/NNS commencing/VBG fluconazole/NN had/VBD disease/NN artery/NN
fluconazole/NNP initiation/NN association/NN was/VBD abnormalities/NNS woman/NN glabrata/NNP isolated/VBN abscess/NNS developed/VBN days/NNS commencing/VBG fluconazole/NN had/VBD disease/NN
fluconazole/NN commencing/VBG days/NNS developed/VBN abscess/NNS isolated/VBN glabrata/NNP woman/NN failure/NN congestive/JJ
fluconazole/NN commencing/VBG days/NNS developed/VBN abscess/NNS isolated/VBN glabrata/NNP woman/NN failure/NN heart/NN
fluconazole/NN commencing/VBG days/NNS developed/VBN abscess/NNS isolated/VBN glabrata/NNP woman/NN failure/NN
fluconazole/NNP initiation/NN association/NN was/VBD abnormalities/NNS woman/NN failure/NN congestive/JJ
fluconazole/NNP initiation/NN association/NN was/VBD abnormalities/NNS woman/NN failure/NN heart/NN
fluconazole/NNP initiation/NN association/NN was/VBD abnormalities/NNS woman/NN failure/NN
fluconazole/NN discontinued/VBN resolved/VBD continued/VBD nonsustained/VBD tachycardia/NN ventricular/NN
fluconazole/NN discontinued/VBN resolved/VBD continued/VBD nonsustained/VBD tachycardia/NN
fluconazole/NN discontinued/VBN resolved/VBD continued/VBD nonsustained/VBD tachycardia/NN NSVT/NNP
fluconazole/NN use/NN relationship/NN indicates/VBZ resolved/VBD continued/VBD nonsustained/VBD tachycardia/NN ventricular/NN
fluconazole/NN use/NN relationship/NN indicates/VBZ resolved/VBD continued/VBD nonsustained/VBD tachycardia/NN
fluconazole/NN use/NN relationship/NN indicates/VBZ resolved/VBD continued/VBD nonsustained/VBD tachycardia/NN NSVT/NNP
fluconazole/NN discontinued/VBN resolved/VBD continued/VBD have/VB contractions/NNS premature/JJ
fluconazole/NN discontinued/VBN resolved/VBD continued/VBD have/VB contractions/NNS ventricular/NN
fluconazole/NN discontinued/VBN resolved/VBD continued/VBD have/VB contractions/NNS
fluconazole/NN use/NN relationship/NN indicates/VBZ resolved/VBD continued/VBD have/VB contractions/NNS premature/JJ
fluconazole/NN use/NN relationship/NN indicates/VBZ resolved/VBD continued/VBD have/VB contractions/NNS ventricular/NN
fluconazole/NN use/NN relationship/NN indicates/VBZ resolved/VBD continued/VBD have/VB contractions/NNS
potassium/NN currents/NNS activating/VBG depression/NN
fluconazole/JJ suggests/VBZ was/VBD etiology/NN explain/VB TDP/VB disappearance/NN NSVT/NNP
fluconazole/JJ suggests/VBZ contractions/NNS premature/JJ
fluconazole/JJ suggests/VBZ contractions/NNS ventricular/NN
fluconazole/JJ suggests/VBZ contractions/NNS
fluconazole/JJ suggests/VBZ was/VBD etiology/NN explain/VB prolongation/NN QT/NNP
fluconazole/JJ suggests/VBZ was/VBD etiology/NN explain/VB prolongation/NN
fluconazole/NN cause/VB prolongation/NN
fluconazole/NN cause/VB prolongation/NN interval/NN of/IN
fluconazole/NN cause/VB prolongation/NN interval/NN the/DT
fluconazole/NN cause/VB prolongation/NN interval/NN QT/NNP
fluconazole/NN cause/VB prolongation/NN interval/NN
fluconazole/NN administered/VBN patients/NNS risk/NN arrhythmias/NNS ventricular/NN
fluconazole/NN administered/VBN patients/NNS risk/NN arrhythmias/NNS
olanzapine/JJ treatment/NN introduction/NN developed/VBD disorder/NN psychotic/JJ
olanzapine/JJ treatment/NN introduction/NN developed/VBD disorder/NN
lindane/NN Effect/NN s/VBZ influence/VBP lindane/NN induced/VBN neurotoxicity/RB
lindane/NN induced/VBN neurotoxicity/RB
phenobarbital/NN increased/VBD pretreatment/VB produce/VB incidence/NN convulsions/NNS
phenobarbital/NN increased/VBD incidence/NN convulsions/NNS
3/CD methylcholanthrene/CD pretreatment/NN produce/VB incidence/NN convulsions/NNS
methylcholanthrene/CD pretreatment/NN produce/VB incidence/NN convulsions/NNS
3/CD methylcholanthrene/CD pretreatment/NN produce/VB pretreatment/VB increased/VBD incidence/NN convulsions/NNS
methylcholanthrene/CD pretreatment/NN produce/VB pretreatment/VB increased/VBD incidence/NN convulsions/NNS
MC/NNP methylcholanthrene/CD pretreatment/NN produce/VB incidence/NN convulsions/NNS
MC/NNP methylcholanthrene/CD pretreatment/NN produce/VB pretreatment/VB increased/VBD incidence/NN convulsions/NNS
ethanol/NN B/NNP P/NNP inducer/NN phenobarbital/NN increased/VBD pretreatment/VB produce/VB incidence/NN convulsions/NNS
ethanol/NN B/NNP P/NNP inducer/NN phenobarbital/NN increased/VBD incidence/NN convulsions/NNS
cobalt/JJ incidence/NN convulsions/NNS
chloride/NN incidence/NN convulsions/NNS
cobalt/JJ incidence/NN blocked/VBN lindane/NN metabolism/NN P/NNP increased/VBN involved/VBN toxicity/NN
chloride/NN incidence/NN blocked/VBN lindane/NN metabolism/NN P/NNP increased/VBN involved/VBN toxicity/NN
lindane/NN metabolism/NN P/NNP increased/VBN involved/VBN toxicity/NN
lindane/NN treated/VBN animals/NNS increased/VBN involved/VBN toxicity/NN
lindane/NN se/FW indicating/VBG lindane/NN treated/VBN animals/NNS increased/VBN involved/VBN toxicity/NN
ethanol/NN PB/NNP P/NNP formed/VBN metabolites/NNS lindane/NN treated/VBN animals/NNS increased/VBN P/NNP metabolism/NN lindane/NN blocked/VBN incidence/NN convulsions/NNS
ethanol/NN PB/NNP P/NNP formed/VBN metabolites/NNS lindane/NN treated/VBN animals/NNS increased/VBN involved/VBN toxicity/NN
PTU/NNP associated/VBN Syndrome/NNP Turner/NNP
PTU/NNP associated/VBN Syndrome/NNP
PTU/NNP associated/VBN Syndrome/NNP disease/NN Graves/NNP
PTU/NNP associated/VBN Syndrome/NNP disease/NN Graves/NNP '/POS
PTU/NNP associated/VBN Syndrome/NNP disease/NN
carbamazepine/NN inhibits/VBZ development/NN seizures/NNS
carbamazepine/JJ treatment/NN seizures/NNS
CBZ/NNP treatment/NN seizures/NNS
CBZ/NNP administration/NN methods/NNS evaluated/VBN' evaluated/VBN effects/NNS treatment/NN seizures/NNS
CBZ/NNP inhibited/VBD development/NN seizures/NNS
CBZ/NNP inhibited/VBD had/VBD effect/NN seizures/NNS
CBZ/NNP decreased/VBD injected/VBD incidence/NN seizure/NN
CBZ/NNP had/VBD effect/NN lidocaine/NN induced/VBN seizures/NNS
CBZ/NNP injection/NN i/NNP effect/NN development/NN seizures/NNS
CBZ/NNP effects/NNS suggest/VBP stage/NN development/NN seizure/NN
CBZ/NNP effects/NNS suggest/VBP underlie/VB development/NN seizures/NNS
sevoflurane/JJ induction/NN undergoing/VBG arrest/VB child/NN palsy/NN cerebral/JJ
sevoflurane/JJ induction/NN undergoing/VBG arrest/VB child/NN palsy/NN
clonidine/NN undergoing/VBG arrest/VB child/NN palsy/NN cerebral/JJ
clonidine/NN undergoing/VBG arrest/VB child/NN palsy/NN
sevoflurane/JJ induction/NN undergoing/VBG arrest/VB Cardiac/NNP
sevoflurane/JJ induction/NN undergoing/VBG arrest/VB
baclofen/NN pump/NN placement/NN presented/VBN restlessness/NNS receiving/VBG present/VBP case/NN 5/CD child/NN palsy/NN disorder/NN seizure/NN
baclofen/NN pump/NN placement/NN presented/VBN restlessness/NNS receiving/VBG present/VBP case/NN 5/CD child/NN palsy/NN disorder/NN
clonidine/NN receiving/VBG restlessness/NNS
baclofen/NN pump/NN placement/NN presented/VBN restlessness/NNS receiving/VBG present/VBP case/NN 5/CD child/NN palsy/NN cerebral/JJ
baclofen/NN pump/NN placement/NN presented/VBN restlessness/NNS receiving/VBG present/VBP case/NN 5/CD child/NN palsy/NN
baclofen/NN pump/NN placement/NN presented/VBN restlessness/NNS
clonidine/NN receiving/VBG present/VBP case/NN 5/CD child/NN palsy/NN cerebral/JJ
clonidine/NN receiving/VBG present/VBP case/NN 5/CD child/NN palsy/NN
clonidine/NN receiving/VBG present/VBP case/NN 5/CD child/NN palsy/NN disorder/NN seizure/NN
clonidine/NN receiving/VBG present/VBP case/NN 5/CD child/NN palsy/NN disorder/NN
clonidine/NN doses/NNS administered/VBN reduce/VB anxiety/NN
Heparin/NNP BACKGROUND/NNP presents/VBZ thromboemboli/NNS arterial/JJ
Heparin/NNP BACKGROUND/NNP presents/VBZ thromboemboli/NNS arterial/JJ or/CC
Heparin/NNP BACKGROUND/NNP presents/VBZ thromboemboli/NNS arterial/JJ venous/JJ
Heparin/NNP BACKGROUND/NNP presents/VBZ thromboemboli/NNS
heparin/NN exposure/NN presents/VBZ thromboemboli/NNS arterial/JJ
heparin/NN exposure/NN presents/VBZ thromboemboli/NNS arterial/JJ or/CC
heparin/NN exposure/NN presents/VBZ thromboemboli/NNS arterial/JJ venous/JJ
heparin/NN exposure/NN presents/VBZ thromboemboli/NNS
heparin/NN became/VBD complications/NNS thromboembolic/JJ
heparin/NN results/NNS Platelet/NNP onset/NN thromboembolism/NN
heparin/NN exposure/NN included/VBN return/VB complications/NNS thromboembolic/JJ
heparin/NN thrombocytopenia/NN initiated/VBN returns/NNS thromboembolism/NN
heparin/JJ returns/NNS thromboembolism/NN
amlodipine/NN pill/NN started/VBN report/NN female/NN hypertension/NN
benazapril/VB report/NN female/NN hypertension/NN
angiotensin/NN converting/VBG enzyme/NN angioedema/NN intestinal/JJ
angiotensin/NN converting/VBG enzyme/NN angioedema/NN
angiotensin/NN blocker/NN enzyme/NN angioedema/NN intestinal/JJ
angiotensin/NN blocker/NN enzyme/NN angioedema/NN
prednisone/NN exposure/NN developed/VBD lethargy/NN
prednisone/NN exposure/NN developed/VBD lethargy/NN polydipsia/NN
prednisone/NN exposure/NN developed/VBD lethargy/NN somnolence/NN
prednisone/NN exposure/NN developed/VBD lethargy/NN polyuria/NN
prednisone/NN exposure/NN developed/VBD lethargy/NN polyphagia/NN
lactate/NN level/NN ketosis/NNS
lactate/NN level/NN ketosis/NNS present/JJ present/JJ acidosis/NNS lactic/JJ
lactate/NN level/NN ketosis/NNS present/JJ present/JJ acidosis/NNS
bupropion/NN use/NN associated/VBN failure/NN liver/NN
bupropion/NN use/NN associated/VBN failure/NN
carbimazole/NN bupropion/NN use/NN associated/VBN failure/NN liver/NN
carbimazole/NN bupropion/NN use/NN associated/VBN failure/NN
propranolol/NN carbimazole/NN treated/VBN man/NN history/NN hyperthyroidism/NN
carbimazole/NN treated/VBN man/NN history/NN hyperthyroidism/NN
azelastine/NN treatment/NN rhinitis/NNS spring/NN
azelastine/NN treatment/NN rhinitis/NNS allergic/JJ
azelastine/NN treatment/NN rhinitis/NNS
chlorpheniramine/NN azelastine/NN treatment/NN rhinitis/NNS spring/NN
chlorpheniramine/NN azelastine/NN treatment/NN rhinitis/NNS allergic/JJ
chlorpheniramine/NN azelastine/NN treatment/NN rhinitis/NNS
Azelastine/NNP compared/VBN study/NN efficacy/JJ safety/NN treatment/NN rhinitis/NNS spring/NN
Azelastine/NNP compared/VBN study/NN efficacy/JJ safety/NN treatment/NN rhinitis/NNS allergic/JJ
Azelastine/NNP compared/VBN study/NN efficacy/JJ safety/NN treatment/NN rhinitis/NNS
chlorpheniramine/JJ maleate/NN compared/VBN study/NN efficacy/JJ safety/NN treatment/NN rhinitis/NNS spring/NN
chlorpheniramine/JJ maleate/NN compared/VBN study/NN efficacy/JJ safety/NN treatment/NN rhinitis/NNS allergic/JJ
chlorpheniramine/JJ maleate/NN compared/VBN study/NN efficacy/JJ safety/NN treatment/NN rhinitis/NNS
maleate/NN compared/VBN study/NN efficacy/JJ safety/NN treatment/NN rhinitis/NNS spring/NN
maleate/NN compared/VBN study/NN efficacy/JJ safety/NN treatment/NN rhinitis/NNS allergic/JJ
maleate/NN compared/VBN study/NN efficacy/JJ safety/NN treatment/NN rhinitis/NNS
Azelastine/NNP appears/VBZ medication/NN rhinitis/NNS seasonal/JJ
Azelastine/NNP appears/VBZ medication/NN rhinitis/NNS allergic/JJ
Azelastine/NNP appears/VBZ medication/NN rhinitis/NNS
Dopamine/NNP plays/VBZ role/NN control/NN seizures/NNS epileptic/JJ
Dopamine/NNP plays/VBZ role/NN control/NN seizures/NNS
DA/NNP Dopamine/NNP plays/VBZ role/NN control/NN seizures/NNS epileptic/JJ
DA/NNP Dopamine/NNP plays/VBZ role/NN control/NN seizures/NNS
DA/NNP receptors/NNS role/NN known/VBN occurrence/NN epilepsy/NN
pilocarpine/NN treated/VBN analyze/VBP occurrence/NN seizures/NNS neurotoxicity/NN
acetylcholine/NN glutamate/NN induced/VBN seizures/NNS
glutamate/NN induced/VBN seizures/NNS
morphine/NN treated/VBN Hyperalgesia/NNS patients/NNS cancer/NN
morphine/NN doses/NNS treated/VBN disease/NN stages/NNS patients/NNS cancer/NN
potassium/NN loss/NN administration/NN patients/NNS hypertension/NN
potassium/NN loss/NN hypokalaemia/NN
sodium/NN restriction/NN influence/NN loss/NN administration/NN patients/NNS hypertension/NN
sodium/NN restriction/NN influence/NN loss/NN hypokalaemia/NN
chlorthalidone/JJ administration/NN patients/NNS hypertension/NN
potassium/NN loss/NN investigate/VB performed/VBN hypertension/NN
potassium/NN loss/NN hypokalaemia/NN
potassium/NN loss/NN investigate/VB performed/VBN hypertension/NN shown/VBN hypokalaemia/NN
D/NNP Tiopronin/NNP due/JJ nephritis/NNS
Penicillamine/NNP D/NNP Tiopronin/NNP due/JJ nephritis/NNS
D/NNP Tiopronin/NNP due/JJ nephritis/NNS dermatitis/NNS
Penicillamine/NNP D/NNP Tiopronin/NNP due/JJ nephritis/NNS dermatitis/NNS
D/NNP Tiopronin/NNP due/JJ due/JJ' dermatitis/NNS
Penicillamine/NNP D/NNP Tiopronin/NNP due/JJ due/JJ' dermatitis/NNS
gold/JJ thiosulphate/NN due/JJ dermatitis/NNS due/JJ' due/JJ nephritis/NNS
thiosulphate/NN due/JJ dermatitis/NNS due/JJ' due/JJ nephritis/NNS
thiosulphate/NN due/JJ dermatitis/NNS due/JJ' due/JJ nephritis/NNS dermatitis/NNS
thiosulphate/NN due/JJ dermatitis/NNS
Tiopronin/NNP group/NN observed/VBD patients/NNS RA/NNP
N/NNP effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
nitro/NN effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
L/NNP nitro/NN effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
arginine/NN nitro/NN effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
methyl/NN ester/NN effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
ester/NN effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
L/NNP ester/NN effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
NAME/NNP L/NNP ester/NN effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
nitric/JJ oxide/NN ester/NN effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
oxide/NN ester/NN effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
NO/RB effects/NNS synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
NO/JJ precursor/NN arginine/NN investigated/VBN lidocaine/NN convulsions/NNS
L/NNP inhibitor/NN synthase/VBP investigated/VBN lidocaine/NN convulsions/NNS
arginine/NN investigated/VBN lidocaine/NN convulsions/NNS
L/NNP decreased/VBD incidence/NN lidocaine/NN convulsions/NNS
NAME/NNP decreased/VBD incidence/NN lidocaine/NN convulsions/NNS
diazepam/NN NAME/NNP decreased/VBD incidence/NN lidocaine/NN convulsions/NNS
L/NNP induced/VBZ convulsions/NNS
arginine/JJ treatment/NN L/NNP induced/VBZ convulsions/NNS
NO/NNP mediator/NN convulsions/NNS
tamoxifen/NN cancer/NN breast/NN
tamoxifen/NN cancer/NN
Tamoxifen/NNP agent/NN cancer/NN breast/NN
Tamoxifen/NNP agent/NN cancer/NN
Tamoxifen/NNP agent/NN associated/VBN development/NN cancer/NN endometrial/JJ
Tamoxifen/NNP agent/NN associated/VBN development/NN cancer/NN
tamoxifen/NN trial/NN randomised/VBD have/VB cancer/NN breast/NN
tamoxifen/NN trial/NN randomised/VBD have/VB cancer/NN
tamoxifen/NN placebo/NN frequency/NN breast/JJ
tamoxifen/NN placebo/NN frequency/NN cancer/NN
tamoxifen/NN receiving/VBG women/NNS cancer/NN breast/NN
tamoxifen/NN receiving/VBG women/NNS cancer/NN
tamoxifen/NN receiving/VBG women/NNS cancer/NN reduction/NN is/VBZ found/VBD cases/NNS cancer/NN breast/NN
tamoxifen/NN receiving/VBG women/NNS cancer/NN reduction/NN is/VBZ found/VBD cases/NNS cancer/NN
tamoxifen/NN allocated/VBN women/NNS case/NN found/VBD is/VBZ reduction/NN cancer/NN breast/NN
tamoxifen/NN allocated/VBN women/NNS case/NN found/VBD is/VBZ reduction/NN cancer/NN
tamoxifen/NN allocated/VBN women/NNS case/NN found/VBD cases/NNS cancer/NN breast/NN
tamoxifen/NN allocated/VBN women/NNS case/NN found/VBD cases/NNS cancer/NN
tamoxifen/NN effects/NNS apparent/JJ has/VBZ cohort/NN women/NNS risk/NN cancer/NN breast/NN
tamoxifen/NN effects/NNS apparent/JJ has/VBZ cohort/NN women/NNS risk/NN cancer/NN
L/NNP patients/NNS parkinsonian/NN
dopa/NN overactivation/NN patients/NNS parkinsonian/NN
L/NNP patients/NNS parkinsonian/NN
dopa/NN medication/NN execution/NN task/NN supplementary/NN groups/NNS patients/NNS parkinsonian/NN
L/NNP one/NN medication/NN execution/NN task/NN supplementary/NN groups/NNS patients/NNS parkinsonian/NN
dopa/NN execution/NN task/NN supplementary/NN groups/NNS patients/NNS parkinsonian/NN
L/NNP movement/NN hyperkinetic/JJ
dopa/NNP L/NNP movement/NN hyperkinetic/JJ
thiamine/NN transketolase/JJ studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ Wernicke/NNP
thiamine/NN transketolase/JJ studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ Wernicke/NNP '/POS
thiamine/NN transketolase/JJ studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ s/VBZ
thiamine/NN transketolase/JJ studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ
thiamine/NN transketolase/JJ studied/VBD fibroblasts/NNS patient/NN diabetic/JJ
tolazamide/NN treated/VBN encephalopathy/JJ developed/VBD patient/NN fibroblasts/NNS studied/VBD delineate/VB transketolase/VBN syndrome/NN Km/JJ reported/JJ Wernicke/NNP
tolazamide/NN treated/VBN encephalopathy/JJ developed/VBD patient/NN fibroblasts/NNS studied/VBD delineate/VB transketolase/VBN syndrome/NN Korsakoff/NNP
tolazamide/NN treated/VBN encephalopathy/JJ developed/VBD patient/NN fibroblasts/NNS studied/VBD delineate/VB transketolase/VBN syndrome/NN
thiamine/JJ pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN diabetic/JJ
pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN diabetic/JJ
TPP/NNP -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN diabetic/JJ
tolazamide/NN treated/VBN encephalopathy/JJ developed/VBD patient/NN diabetic/JJ
thiamine/NN transketolase/JJ studied/VBD delineate/VB transketolase/VBN syndrome/NN Km/JJ reported/JJ Wernicke/NNP
thiamine/NN transketolase/JJ studied/VBD delineate/VB transketolase/VBN syndrome/NN Korsakoff/NNP
thiamine/NN transketolase/JJ studied/VBD delineate/VB transketolase/VBN syndrome/NN
thiamine/JJ pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ Wernicke/NNP
thiamine/JJ pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ Wernicke/NNP '/POS
thiamine/JJ pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ s/VBZ
thiamine/JJ pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ
pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ Wernicke/NNP
pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ Wernicke/NNP '/POS
pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ s/VBZ
pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ
TPP/NNP -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ Wernicke/NNP
TPP/NNP -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ Wernicke/NNP '/POS
TPP/NNP -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ s/VBZ
TPP/NNP -RSB-/NNS Km/JJ syndrome/NN transketolase/VBN delineate/VB studied/VBD fibroblasts/NNS patient/NN developed/VBD encephalopathy/JJ
thiamine/JJ pyrophosphate/JJ -RSB-/NNS Km/JJ reported/JJ Wernicke/NNP
thiamine/JJ pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN Korsakoff/NNP
thiamine/JJ pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN
pyrophosphate/JJ -RSB-/NNS Km/JJ reported/JJ Wernicke/NNP
pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN Korsakoff/NNP
pyrophosphate/JJ -RSB-/NNS Km/JJ syndrome/NN
TPP/NNP -RSB-/NNS Km/JJ reported/JJ Wernicke/NNP
TPP/NNP -RSB-/NNS Km/JJ syndrome/NN Korsakoff/NNP
TPP/NNP -RSB-/NNS Km/JJ syndrome/NN
TPP/NNP Km/NN determined/VBN mentioned/VBN patient/NN kindreds/NNS diabetic/JJ
TPP/NNP Km/NN determined/VBN mentioned/VBN history/NN encephalopathy/NN Wernicke/NNP
TPP/NNP Km/NN determined/VBN mentioned/VBN history/NN encephalopathy/NN Wernicke/NNP '/POS
TPP/NNP Km/NN determined/VBN mentioned/VBN history/NN encephalopathy/NN s/JJ
TPP/NNP Km/NN determined/VBN mentioned/VBN history/NN encephalopathy/NN
tolazamide/NN patient/NN syndrome/NN similarity/NN Wernicke/NNP
tolazamide/NN patient/NN syndrome/NN Korsakoff/NN
tolazamide/NN patient/NN syndrome/NN
cocaine/NN exposed/VBN prenatally/NN dysgenesis/VBZ Brainstem/NNP
cocaine/NN exposed/VBN prenatally/NN dysgenesis/VBZ
serotonin/NN nerves/NNS involved/VBN effect/NN hypotensive/JJ
serotonin/NN cells/NNS methyldopa/JJ neurons/NNS microinjection/NN elicits/VBZ response/NN hypotensive/JJ
methyldopa/NN microinjection/NN caused/VBD hypertensive/NN
serotonin/NN group/NN area/NN caused/VBD hypotension/NN
serotonin/NN abolished/VBN caused/VBD hypotension/NN
5/CD neurotoxin/NNP serotonin/NN abolished/VBN caused/VBD hypotension/NN
7/CD neurotoxin/NNP serotonin/NN abolished/VBN caused/VBD hypotension/NN
dihydroxytryptamine/NN injected/VBD caused/VBD hypotension/NN
5/CD dihydroxytryptamine/NN injected/VBD caused/VBD hypotension/NN
7/CD 5/CD dihydroxytryptamine/NN injected/VBD caused/VBD hypotension/NN
DHT/NNP 5/CD dihydroxytryptamine/NN injected/VBD caused/VBD hypotension/NN
5/CD neurotoxin/NNP serotonin/NN abolished/VBN caused/VBD hypertensive/NN stroke/NN
7/CD neurotoxin/NNP serotonin/NN abolished/VBN caused/VBD hypertensive/NN stroke/NN
dihydroxytryptamine/NN injected/VBD caused/VBD hypertensive/NN stroke/NN
5/CD dihydroxytryptamine/NN injected/VBD caused/VBD hypertensive/NN stroke/NN
7/CD 5/CD dihydroxytryptamine/NN injected/VBD caused/VBD hypertensive/NN stroke/NN
DHT/NNP 5/CD dihydroxytryptamine/NN injected/VBD caused/VBD hypertensive/NN stroke/NN
serotonin/NN group/NN area/NN caused/VBD hypertensive/NN
serotonin/NN abolished/VBN caused/VBD hypertensive/NN
5/CD neurotoxin/NNP serotonin/NN abolished/VBN caused/VBD hypertensive/NN
7/CD neurotoxin/NNP serotonin/NN abolished/VBN caused/VBD hypertensive/NN
dihydroxytryptamine/NN injected/VBD caused/VBD hypertensive/NN
5/CD dihydroxytryptamine/NN injected/VBD caused/VBD hypertensive/NN
7/CD 5/CD dihydroxytryptamine/NN injected/VBD caused/VBD hypertensive/NN
DHT/NNP 5/CD dihydroxytryptamine/NN injected/VBD caused/VBD hypertensive/NN
serotonin/NN group/NN area/NN caused/VBD hypertensive/NN stroke/NN
serotonin/NN abolished/VBN caused/VBD hypertensive/NN stroke/NN
methyldopa/NN microinjection/NN caused/VBD hypertensive/NN stroke/NN
serotonin/NN projections/NNS lesion/NN produce/VB 5/CD injection/NN affect/VB hypotension/NN
5/CD injection/NN affect/VB hypotension/NN
7/CD 5/CD injection/NN affect/VB hypotension/NN
DHT/RB produce/VB 5/CD injection/NN affect/VB hypotension/NN
serotonin/NN contribute/VBP cells/NNS mediate/VB hypotension/NN
serotonin/NN contribute/VBP action/NN hypotensive/JJ
Lamotrigine/NNP associated/VBN myoclonus/NNS epilepsies/NNS idiopathic/JJ
Lamotrigine/NNP associated/VBN myoclonus/NNS epilepsies/NNS generalized/JJ
Lamotrigine/NNP associated/VBN myoclonus/NNS epilepsies/NNS
lamotrigine/JJ exacerbation/NN treated/VBN patients/NNS epilepsies/NNS idiopathic/JJ
lamotrigine/JJ exacerbation/NN treated/VBN patients/NNS epilepsies/NNS generalized/JJ
lamotrigine/JJ exacerbation/NN treated/VBN patients/NNS epilepsies/NNS
lamotrigine/JJ exacerbation/NN treated/VBN patients/NNS IGE/NNP
LTG/NNP exacerbation/NN treated/VBN patients/NNS epilepsies/NNS idiopathic/JJ
LTG/NNP exacerbation/NN treated/VBN patients/NNS epilepsies/NNS generalized/JJ
LTG/NNP exacerbation/NN treated/VBN patients/NNS epilepsies/NNS
LTG/NNP exacerbation/NN treated/VBN patients/NNS IGE/NNP
Coenzyme/NNP treatment/NN ameliorates/VBZ nephrotoxicity/NN
Q/NNP treatment/NN ameliorates/VBZ nephrotoxicity/NN
10/CD treatment/NN ameliorates/VBZ nephrotoxicity/NN
cisplatin/NN nephrotoxicity/NN
coenzyme/JJ Q/NNP effect/NN investigated/VBN injury/NN acute/JJ
coenzyme/JJ Q/NNP effect/NN investigated/VBN injury/NN renal/JJ
coenzyme/JJ Q/NNP effect/NN investigated/VBN injury/NN
Q/NNP effect/NN investigated/VBN injury/NN acute/JJ
Q/NNP effect/NN investigated/VBN injury/NN renal/JJ
Q/NNP effect/NN investigated/VBN injury/NN
10/CD Q/NNP effect/NN investigated/VBN injury/NN acute/JJ
10/CD Q/NNP effect/NN investigated/VBN injury/NN renal/JJ
10/CD Q/NNP effect/NN investigated/VBN injury/NN
nitric/JJ oxide/NN alpha/NN elevations/NNS factor/NN necrosis/NNS
oxide/NN alpha/NN elevations/NNS factor/NN necrosis/NNS
superoxide/JJ activity/NN level/NN mechanisms/NNS deficits/NNS decreased/VBD elevations/NNS factor/NN tumor/NN
Coenzyme/NNP deficits/NNS decreased/VBD elevations/NNS factor/NN necrosis/NNS
Q/NNP deficits/NNS decreased/VBD elevations/NNS factor/NN necrosis/NNS
10/CD deficits/NNS decreased/VBD elevations/NNS factor/NN necrosis/NNS
cisplatin/NN administration/NN resulted/VBN tissue/NN attenuated/VBN alpha/NN elevations/NNS factor/NN necrosis/NNS
reduced/JJ level/NN mechanisms/NNS deficits/NNS decreased/VBD elevations/NNS factor/NN tumor/NN
glutathione/NN level/NN mechanisms/NNS deficits/NNS decreased/VBD elevations/NNS factor/NN tumor/NN
platinum/NN concentration/NN oxide/NN alpha/NN elevations/NNS factor/NN necrosis/NNS
selenium/NN ions/NNS reductions/NNS attenuated/VBN alpha/NN elevations/NNS factor/NN necrosis/NNS
zinc/NN selenium/NN ions/NNS reductions/NNS attenuated/VBN alpha/NN elevations/NNS factor/NN necrosis/NNS
nitric/JJ oxide/NN alpha/NN elevations/NNS factor/NN tumor/NN
oxide/NN alpha/NN elevations/NNS factor/NN tumor/NN
superoxide/JJ activity/NN level/NN mechanisms/NNS deficits/NNS decreased/VBD elevations/NNS factor/NN necrosis/NNS
Coenzyme/NNP deficits/NNS decreased/VBD elevations/NNS factor/NN tumor/NN
Q/NNP deficits/NNS decreased/VBD elevations/NNS factor/NN tumor/NN
10/CD deficits/NNS decreased/VBD elevations/NNS factor/NN tumor/NN
cisplatin/NN administration/NN resulted/VBN tissue/NN attenuated/VBN alpha/NN elevations/NNS factor/NN tumor/NN
reduced/JJ level/NN mechanisms/NNS deficits/NNS decreased/VBD elevations/NNS factor/NN necrosis/NNS
glutathione/NN level/NN mechanisms/NNS deficits/NNS decreased/VBD elevations/NNS factor/NN necrosis/NNS
platinum/NN concentration/NN oxide/NN alpha/NN elevations/NNS factor/NN tumor/NN
selenium/NN ions/NNS reductions/NNS attenuated/VBN alpha/NN elevations/NNS factor/NN tumor/NN
zinc/NN selenium/NN ions/NNS reductions/NNS attenuated/VBN alpha/NN elevations/NNS factor/NN tumor/NN
coenzyme/JJ treatment/NN ameliorated/VBN damage/NN renal/JJ
coenzyme/JJ treatment/NN ameliorated/VBN damage/NN tissue/NN
coenzyme/JJ treatment/NN ameliorated/VBN damage/NN
Q/NN treatment/NN ameliorated/VBN damage/NN renal/JJ
Q/NN treatment/NN ameliorated/VBN damage/NN tissue/NN
Q/NN treatment/NN ameliorated/VBN damage/NN
10/CD treatment/NN ameliorated/VBN damage/NN renal/JJ
10/CD treatment/NN ameliorated/VBN damage/NN tissue/NN
10/CD treatment/NN ameliorated/VBN damage/NN
cisplatin/NN mediated/VBN damage/NN renal/JJ
cisplatin/NN mediated/VBN damage/NN tissue/NN
cisplatin/NN mediated/VBN damage/NN
coenzyme/NNP Q/NNP represents/VBZ protect/VB nephrotoxicity/NN
Q/NNP represents/VBZ protect/VB nephrotoxicity/NN
10/CD Q/NNP represents/VBZ protect/VB nephrotoxicity/NN
cisplatin/NN nephrotoxicity/NN
paracetamol/NNP Induction/NNP tumours/NNS bladder/NN
paracetamol/NNP Induction/NNP tumours/NNS bladder/NN and/CC
paracetamol/NNP Induction/NNP tumours/NNS bladder/NN liver/NN
paracetamol/NNP Induction/NNP tumours/NNS
paracetamol/NNP developed/VBN bladder/NN epithelium/NN Papillomas/NNS
paracetamol/NNP %/NN treated/VBD developed/VBD hyperplasia/NN epithelium/NN coincident/VBN presence/NN calculi/NNS bladder/NN
paracetamol/NNP %/NN treated/VBD developed/VBD hyperplasia/NN epithelium/NN coincident/VBN presence/NN calculi/NNS
paracetamol/NNP feeding/NN arose/VBD yield/NN tumours/NNS
kainate/JJ receptor/NN prodrugs/NNS antagonists/VBD models/NNS pain/NN
formalin/NN reversal/NN models/NNS pain/NN
formalin/NN reversal/NN models/NNS induced/VBN hyperalgesia/NN thermal/JJ
formalin/NN reversal/NN models/NNS induced/VBN hyperalgesia/NN
formalin/NN reversal/NN models/NNS induced/VBN hyperalgesia/NN mechanical/JJ
formalin/NN reversal/NN models/NNS induced/VBN hyperalgesia/NN
carrageenan/NN licking/NNP models/NNS pain/NN
capsaicin/NN hyperalgesia/NN induced/VBN models/NNS pain/NN
carboplatin/NN paclitaxel/NN chemotherapy/NN glioblastoma/NN
paclitaxel/NN chemotherapy/NN glioblastoma/NN
carboplatin/NN paclitaxel/NN application/NN effects/NNS feasibility/NN examined/VBN recurrences/NNS glioblastoma/NN
paclitaxel/NN application/NN effects/NNS feasibility/NN examined/VBN recurrences/NNS glioblastoma/NN
carboplatin/JJ paclitaxel/JJ phases/NNS application/NN resection/VBN re/NN underwent/VBD total/NN patients/NNS recurrence/NN multiforme/NN glioblastoma/NN
paclitaxel/JJ phases/NNS application/NN resection/VBN re/NN underwent/VBD total/NN patients/NNS recurrence/NN multiforme/NN glioblastoma/NN
tolterodine/JJ treatment/NN changes/VBZ women/NNS bladder/NN overactive/JJ
tolterodine/JJ treatment/NN changes/VBZ women/NNS bladder/NN
tolterodine/JJ treatment/NN study/VB bladder/NN overactive/JJ
tolterodine/JJ treatment/NN study/VB bladder/NN
tolterodine/JJ treatment/NN study/VB bladder/NN OAB/NNP
Tolterodine/NNP tolerated/JJ improved/VBD OAB/NNP
ISO/NNP response/NN shows/VBZ phase/NN hypertrophic/JJ
serotonin/NN stimulation/NN HT/VBP 1/CD causes/VBZ syndrome/NN consists/VBZ shivering/VBG muscle/VBG
serotonin/NN stimulation/NN HT/VBP 1/CD causes/VBZ syndrome/NN consists/VBZ shivering/VBG rigidity/NN
serotonin/NN excess/NN syndrome/NN consists/VBZ shivering/VBG muscle/VBG
serotonin/NN excess/NN syndrome/NN consists/VBZ shivering/VBG rigidity/NN
serotonin/NN stimulation/NN HT/VBP 1/CD causes/VBZ syndrome/NN consists/VBZ shivering/VBG rigidity/NN confusion/NN
serotonin/NN excess/NN syndrome/NN consists/VBZ shivering/VBG rigidity/NN confusion/NN
serotonin/NN stimulation/NN HT/VBP 1/CD causes/VBZ syndrome/NN consists/VBZ shivering/VBG rigidity/NN salivation/NN
serotonin/NN excess/NN syndrome/NN consists/VBZ shivering/VBG rigidity/NN salivation/NN
serotonin/NN stimulation/NN HT/VBP 1/CD causes/VBZ syndrome/NN consists/VBZ shivering/VBG rigidity/NN hyperthermia/NN
serotonin/NN excess/NN syndrome/NN consists/VBZ shivering/VBG rigidity/NN hyperthermia/NN
serotonin/NN stimulation/NN HT/VBP 1/CD causes/VBZ syndrome/NN consists/VBZ shivering/VBG rigidity/NN agitation/NN
serotonin/NN excess/NN syndrome/NN consists/VBZ shivering/VBG rigidity/NN agitation/NN
tranylcypromine/NN depression/NN
venlafaxine/NN y/NN male/NN taking/VBG tranylcypromine/NN depression/NN
diazepam/FW i/FW mg/NN F/NN 120/CD pressure/NN v/VBP were/VBD remained/VBD rigidity/NN muscle/NN
diazepam/FW i/FW mg/NN F/NN 120/CD pressure/NN v/VBP were/VBD remained/VBD rigidity/NN
22/CD suppresses/VBZ inducing/VBG dogs/NNS failure/NN renal/JJ
22/CD suppresses/VBZ inducing/VBG dogs/NNS failure/NN
oxacalcitriol/NN suppresses/VBZ inducing/VBG dogs/NNS failure/NN renal/JJ
oxacalcitriol/NN suppresses/VBZ inducing/VBG dogs/NNS failure/NN
22/CD suppresses/VBZ inducing/VBG turnover/NN low/JJ
22/CD suppresses/VBZ inducing/VBG turnover/NN bone/NN
22/CD suppresses/VBZ inducing/VBG turnover/NN
oxacalcitriol/NN suppresses/VBZ inducing/VBG turnover/NN low/JJ
oxacalcitriol/NN suppresses/VBZ inducing/VBG turnover/NN bone/NN
oxacalcitriol/NN suppresses/VBZ inducing/VBG turnover/NN
22/CD suppresses/VBZ hyperparathyroidism/NN secondary/JJ
22/CD suppresses/VBZ hyperparathyroidism/NN
oxacalcitriol/NN suppresses/VBZ hyperparathyroidism/NN secondary/JJ
oxacalcitriol/NN suppresses/VBZ hyperparathyroidism/NN
Calcitriol/NNP therapy/NN suppresses/VBZ patients/NNS failure/NN renal/JJ
Calcitriol/NNP therapy/NN suppresses/VBZ patients/NNS failure/NN
OCT/NNP effects/NNS determine/VB states/NNS function/NN normal/JJ impaired/JJ
OCT/NNP effects/NNS determine/VB states/NNS function/NN renal/JJ
OCT/NNP effects/NNS determine/VB states/NNS function/NN
OCT/NNP decreased/VBD induction/NN insufficiency/NN renal/JJ
OCT/NNP decreased/VBD induction/NN insufficiency/NN
OCT/NNP stabilized/VBD long/JJ standing/VBG hyperparathyroidism/NN secondary/JJ
OCT/NNP stabilized/VBD long/JJ standing/VBG hyperparathyroidism/NN
OCT/NNP reversed/VBD formation/NN osteoid/NN woven/JJ
OCT/NNP reversed/VBD formation/NN osteoid/NN
OCT/NNP reversed/VBD formation/NN osteoid/NN fibrosis/NN
OCT/NNP prevent/VB insufficiency/NN renal/JJ
OCT/NNP prevent/VB insufficiency/NN
OCT/NNP prevent/VB use/NN induce/VB turnover/NN low/JJ
OCT/NNP prevent/VB use/NN induce/VB turnover/NN bone/NN
OCT/NNP prevent/VB use/NN induce/VB turnover/NN
OCT/NNP prevent/VB use/NN induce/VB increase/VB risk/NN disease/NN adynamic/JJ
OCT/NNP prevent/VB use/NN induce/VB increase/VB risk/NN disease/NN bone/NN
OCT/NNP prevent/VB use/NN induce/VB increase/VB risk/NN disease/NN
OCT/NNP prevent/VB use/NN management/NN hyperparathyroidism/NN secondary/JJ
OCT/NNP prevent/VB use/NN management/NN hyperparathyroidism/NN
Ciprofloxacin/NNP induced/VBN nephritis/NNS anemia/NN autoimmune/JJ
Ciprofloxacin/NNP induced/VBN nephritis/NNS anemia/NN hemolytic/JJ
Ciprofloxacin/NNP induced/VBN nephritis/NNS anemia/NN
ciprofloxacin/NN case/NN nephritis/NNS anemia/NN autoimmune/JJ
ciprofloxacin/NN case/NN nephritis/NNS anemia/NN hemolytic/JJ
ciprofloxacin/NN case/NN nephritis/NNS anemia/NN
steroid/JJ therapy/NN drug/NN stopping/VBG improved/VBD anemia/NNP Hemolytic/NNP
steroid/JJ therapy/NN drug/NN stopping/VBG improved/VBD anemia/NNP
trihexyphenidyl/NN relationship/NN examine/VB measures/NNS reflecting/VBG sedation/NN confusion/NN
trihexyphenidyl/NN relationship/NN investigate/VB examine/VB measures/NNS reflecting/VBG sedation/NN confusion/NN
cholesteryl/JJ esters/NNS that/DT remained/VBD decreased/VBD pre/NN stage/NN nephrotic/JJ
esters/NNS that/DT remained/VBD decreased/VBD pre/NN stage/NN nephrotic/JJ
fatty/JJ acids/NNS level/NN stage/NN nephrotic/JJ
acids/NNS level/NN stage/NN nephrotic/JJ
triacylglycerol/NNP decreased/VBD pre/NN stage/NN nephrotic/JJ
oral/JJ therapy/NN complications/NNS Thromboembolic/JJ
contraceptive/JJ therapy/NN complications/NNS Thromboembolic/JJ
Cisapride/NNP prescribed/VBN treatment/NN disorders/NNS gastrointestinal/JJ
Cisapride/NNP prescribed/VBN treatment/NN disorders/NNS motility/NN
Cisapride/NNP prescribed/VBN treatment/NN disorders/NNS
diltiazem/NN agent/NN has/VBZ hypertension/NN
cisapride/NN taking/VBG woman/NN year/NN diltiazem/NN agent/NN has/VBZ hypertension/NN
diltiazem/NN year/NN woman/NN taking/VBG cisapride/NN disorder/NN gastroesophageal/JJ
diltiazem/NN year/NN woman/NN taking/VBG cisapride/NN disorder/NN reflux/NN
diltiazem/NN year/NN woman/NN taking/VBG cisapride/NN disorder/NN
cisapride/NN disorder/NN gastroesophageal/JJ
cisapride/NN disorder/NN reflux/NN
cisapride/NN disorder/NN
mitomycin/NNP C/NNP induced/VBN study/NN dependency/NN cardiotoxicity/NN
C/NNP induced/VBN study/NN dependency/NN cardiotoxicity/NN
mitomycin/NN suggested/VBN cardiotoxic/JJ
C/NNP suggested/VBN cardiotoxic/JJ
MMC/NNP C/NNP suggested/VBN cardiotoxic/JJ
doxorubicin/NN given/VBN combined/VBN cardiotoxic/JJ
MMC/NNP dose/VBG cardiotoxicity/RB
doxorubicin/NN treated/VBN patients/NNS 2/CD dose/VBG cardiotoxicity/RB
lithium/NN treatment/NN hypothyroidism/VB important/JJ development/NN insipidus/NNS nephrogenic/JJ
lithium/NN treatment/NN hypothyroidism/VB important/JJ development/NN insipidus/NNS diabetes/NN
lithium/NN treatment/NN hypothyroidism/VB important/JJ development/NN insipidus/NNS
gentamicin/NN nephrotoxicity/NN prevent/VB glycosuria/NNP
Phlorizin/NNP prevent/VB glycosuria/NNP
Phlorizin/NNP prevent/VB nephrotoxicity/NN
gentamicin/NN nephrotoxicity/NN
streptozotocin/NN rats/NNS have/VBP diuresis/NNS glycosuria/NN
gentamicin/VB resistance/NN responsible/JJ suggested/VBN have/VBP diuresis/NNS glycosuria/NN
gentamicin/VB resistance/NN responsible/JJ suggested/VBN have/VBP rats/NNS streptozotocin/NN mellitus/NNS diabetes/NN
gentamicin/VB resistance/NN responsible/JJ suggested/VBN have/VBP rats/NNS streptozotocin/NN mellitus/NNS
gentamicin/VB resistance/NN responsible/JJ suggested/VBN have/VBP rats/NNS streptozotocin/NN DM/NNP
streptozotocin/NN rats/NNS have/VBP suggested/VBN failure/NN acute/JJ
streptozotocin/NN rats/NNS have/VBP suggested/VBN failure/NN renal/JJ
streptozotocin/NN rats/NNS have/VBP suggested/VBN failure/NN
streptozotocin/NN rats/NNS have/VBP suggested/VBN failure/NN ARF/NNP
glucose/NN reabsorption/NN blockage/NN induced/VBN studied/VBN protection/NN nephrotoxicity/NN
glucose/NN reabsorption/NN blockage/NN induced/VBN rats/NNS diabetic/JJ
phlorizin/NN reabsorption/NN blockage/NN induced/VBN rats/NNS diabetic/JJ
P/NNP phlorizin/NN reabsorption/NN blockage/NN induced/VBN rats/NNS diabetic/JJ
phlorizin/NN reabsorption/NN blockage/NN induced/VBN studied/VBN protection/NN nephrotoxicity/NN
P/NNP phlorizin/NN reabsorption/NN blockage/NN induced/VBN studied/VBN protection/NN nephrotoxicity/NN
gentamicin/NN nephrotoxicity/NN
gentamicin/NN nephrotoxicity/NN protection/NN studied/VBN induced/VBN rats/NNS diabetic/JJ
P/NNP animals/NNS that/DT similar/JJ rats/NNS glycosuria/NN
P/NNP animals/NNS that/DT similar/JJ rats/NNS DM/NNP
P/NNP alone/RB Group/NNP received/VBD P/NNP IV/NNP gentamicin/NNP DM/NNP
P/NNP IV/NNP gentamicin/NNP DM/NNP
P/NNP +/NNP P/NNP IV/NNP gentamicin/NNP DM/NNP
gentamicin/VBN +/NNP P/NNP IV/NNP gentamicin/NNP DM/NNP
gentamicin/VBN III/NNP P/NNP IV/NNP gentamicin/NNP DM/NNP
gentamicin/NNP DM/NNP
gentamicin/NN doses/NNS Nephrotoxic/JJ
P/NNP induced/VBN glycosuria/NN evidence/NN dysfunction/NN -RSB-/NN tubular/JJ
P/NNP induced/VBN glycosuria/NN evidence/NN dysfunction/NN -RSB-/NN necrosis/NN
P/NNP induced/VBN glycosuria/NN
P/NNP induced/VBN glycosuria/NN evidence/NN dysfunction/NN renal/JJ
P/NNP induced/VBN glycosuria/NN evidence/NN dysfunction/NN
P/NNP prevent/VB gentamicin/NN ARF/NNP 1/CD 0/CD 001/CD necrosis/NNS tubular/JJ
P/NNP prevent/VB gentamicin/NN ARF/NNP 1/CD 0/CD 001/CD necrosis/NNS
P/NNP less/RBR 9/CD 001/CD necrosis/NNS tubular/JJ
P/NNP less/RBR 9/CD 001/CD necrosis/NNS
P/NNP prevent/VB gentamicin/NN ARF/NNP
P/NNP less/RBR 9/CD 001/CD 0/CD 1/CD ARF/NNP
gentamicin/NN ARF/NNP 1/CD 0/CD 001/CD necrosis/NNS tubular/JJ
gentamicin/NN ARF/NNP 1/CD 0/CD 001/CD necrosis/NNS
P/NNP %/NN decrease/NN those/DT different/JJ ABSTRACT/VBP +/CD 701/CD day/NN necrosis/NNS tubular/JJ
P/NNP %/NN decrease/NN those/DT different/JJ ABSTRACT/VBP +/CD 701/CD day/NN necrosis/NNS
ethambutol/JJ toxicity/NN
Pemoline/JJ choreoathetosis/NNS
amphetamines/NNS different/JJ used/VBN treatment/NN disorder/NN attention/NN
amphetamines/NNS different/JJ used/VBN treatment/NN disorder/NN deficit/NN
amphetamines/NNS different/JJ used/VBN treatment/NN disorder/NN
oxazolidine/JJ derivative/NN different/JJ used/VBN treatment/NN disorder/NN attention/NN
oxazolidine/JJ derivative/NN different/JJ used/VBN treatment/NN disorder/NN deficit/NN
oxazolidine/JJ derivative/NN different/JJ used/VBN treatment/NN disorder/NN
Pemoline/NNP derivative/NN different/JJ used/VBN treatment/NN disorder/NN attention/NN
Pemoline/NNP derivative/NN different/JJ used/VBN treatment/NN disorder/NN deficit/NN
Pemoline/NNP derivative/NN different/JJ used/VBN treatment/NN disorder/NN
Pemoline/NNP associated/VBN literature/NN cause/NN disorders/NNS movement/NN
Pemoline/NNP associated/VBN literature/NN cause/NN disorders/NNS
pemoline/NN experienced/VBD choreoathetosis/NNS
methylphenidate/NN treated/VBN disorder/NN attention/NN
methylphenidate/NN treated/VBN disorder/NN deficit/NN
methylphenidate/NN treated/VBN disorder/NN
benzodiazepines/NNS decontamination/NN received/VBD attempt/NN control/VB movements/NNS choreoathetoid/JJ
Pemoline/NNP associated/VBN reported/VBN disorder/NN movement/NN
Pemoline/NNP associated/VBN reported/VBN disorder/NN
pemoline/JJ overdose/NN presenting/VBG patients/NNS considered/VBN possibility/NN movements/NNS choreoathetoid/JJ
vasopressin/NN secretion/NN thirst/NN have/VB showed/VBD remained/VBD thirsty/JJ polyuric/JJ
vasopressin/NN secretion/NN thirst/NN have/VB showed/VBD evidence/NN insipidus/NNS nephrogenic/JJ
vasopressin/NN secretion/NN thirst/NN have/VB showed/VBD evidence/NN insipidus/NNS diabetes/NN
vasopressin/NN secretion/NN thirst/NN have/VB showed/VBD evidence/NN insipidus/NNS
rifampin/NN proteinuria/NN treated/VBD tuberculosis/NNP
rifampin/NN treated/VBN patients/NNS tuberculosis/NNP
sodium/NN retention/NN edema/NN
sodium/NN retention/NN accompanied/VBN syndrome/NN Nephrotic/JJ
sodium/NN retention/NN accompanied/VBN syndrome/NN
sodium/NN excretion/NN proteinuria/NN ascites/NNS
sodium/NN excretion/NN proteinuria/NN hypoalbuminemia/NN
sodium/NN excretion/NN proteinuria/NN
sodium/NN retention/NN associated/VBN syndrome/NN nephrotic/JJ
sodium/NN retention/NN associated/VBN syndrome/NN
sulphasalazine/JJ treatment/NN restarting/VBG glomerulonephritis/VBZ
sulphasalazine/JJ treatment/NN restarting/VBG developed/VBD eyes/NNS abnormalities/NNS urinary/JJ
sulphasalazine/JJ treatment/NN restarting/VBG developed/VBD eyes/NNS abnormalities/NNS
sulphasalazine/JJ treatment/NN restarting/VBG developed/VBD woman/NN colitis/NNS ulcerative/JJ
sulphasalazine/JJ treatment/NN restarting/VBG developed/VBD woman/NN colitis/NNS
sulphasalazine/JJ treatment/NN restarting/VBG developed/VBD eyes/NNS eosinophilia/NN
sulphasalazine/JJ treatment/NN restarting/VBG developed/VBD eyes/NNS red/JJ
sulphasalazine/JJ treatment/NN restarting/VBG developed/VBD eyes/NNS
steroid/JJ therapy/NN rose/VBD increased/VBD initiated/VBD resulted/VBD fever/NN pain/NN chest/NN
steroid/JJ therapy/NN rose/VBD increased/VBD initiated/VBD resulted/VBD fever/NN pain/NN
steroid/JJ therapy/NN rose/VBD increased/VBD initiated/VBD resulted/VBD fever/NN
steroid/JJ therapy/NN rose/VBD increased/VBD initiated/VBD resulted/VBD fever/NN eyes/NNS red/JJ
steroid/JJ therapy/NN rose/VBD increased/VBD initiated/VBD resulted/VBD fever/NN eyes/NNS
steroid/JJ therapy/NN rose/VBD increased/VBD initiated/VBD resulted/VBD fever/NN effusions/NNS pleural/JJ
steroid/JJ therapy/NN rose/VBD increased/VBD initiated/VBD resulted/VBD fever/NN effusions/NNS
steroid/JJ therapy/NN rose/VBD increased/VBD initiated/VBD remained/VBD effusion/NN pleural/JJ
steroid/JJ therapy/NN rose/VBD increased/VBD initiated/VBD remained/VBD effusion/NN
sulphasalazine/JJ treatment/NN cessation/NN resulted/VBD fever/NN pain/NN chest/NN
sulphasalazine/JJ treatment/NN cessation/NN resulted/VBD fever/NN pain/NN
sulphasalazine/JJ treatment/NN cessation/NN resulted/VBD fever/NN eyes/NNS red/JJ
sulphasalazine/JJ treatment/NN cessation/NN resulted/VBD fever/NN eyes/NNS
steroid/JJ therapy/NN disappeared/VBD effusion/NN pleural/JJ
steroid/JJ therapy/NN disappeared/VBD effusion/NN
sulphasalazine/NN induce/VB PR/NNP ANCA/NNP glomerulonephritis/NNS
prostaglandins/NNS factor/NN urine/NN patients/NNS bladder/NN overactive/JJ
prostaglandins/NNS factor/NN urine/NN patients/NNS bladder/NN
PGs/NNP NGF/NNP investigated/VBD women/NNS OAB/NNP
PG/NNP NGF/NNP correlations/NNS parameters/NNS patients/NNS OAB/NNP
PGI/NNP different/JJ OAB/NNP
2/CD PGI/NNP different/JJ OAB/NNP
PGI/NNP alpha/NNP correlate/VB parameters/NNS patients/NNS OAB/NNP
2/CD PGI/NNP alpha/NNP correlate/VB parameters/NNS patients/NNS OAB/NNP
PGs/NNP NGF/NNP have/VBP roles/NNS development/NN symptoms/NNS OAB/NNP
cyclophosphamide/VB secondary/JJ myocarditis/VBZ haemorrhagic/NN
cyclophosphamide/VB secondary/JJ myocarditis/VBZ
cyclophosphamide/JJ therapy/NN complication/NN myocarditis/NNS Haemorrhagic/JJ
cyclophosphamide/JJ therapy/NN complication/NN myocarditis/NNS
Iron/NNP accumulation/NNP considered/VBN involved/VBN pathogenesis/NNS disease/NN Parkinson/NNP
Iron/NNP accumulation/NNP considered/VBN involved/VBN pathogenesis/NNS disease/NN Parkinson/NNP '/POS
Iron/NNP accumulation/NNP considered/VBN involved/VBN pathogenesis/NNS disease/NN s/JJ
Iron/NNP accumulation/NNP considered/VBN involved/VBN pathogenesis/NNS disease/NN
tyrosine/JJ immunohistochemistry/NN used/VBD study/NN demonstrate/VB detection/NN study/VB degeneration/NN
tyrosine/JJ immunohistochemistry/NN used/VBD study/NN demonstrate/VB detection/NN study/VB degeneration/NN neurons/NNS of/IN
tyrosine/JJ immunohistochemistry/NN used/VBD study/NN demonstrate/VB detection/NN study/VB degeneration/NN neurons/NNS dopaminergic/JJ
tyrosine/JJ immunohistochemistry/NN used/VBD study/NN demonstrate/VB detection/NN study/VB degeneration/NN neurons/NNS
iron/NN overload/NN relationship/NN demonstrate/VB detection/NN study/VB degeneration/NN
iron/NN overload/NN relationship/NN demonstrate/VB detection/NN study/VB degeneration/NN neurons/NNS of/IN
iron/NN overload/NN relationship/NN demonstrate/VB detection/NN study/VB degeneration/NN neurons/NNS dopaminergic/JJ
iron/NN overload/NN relationship/NN demonstrate/VB detection/NN study/VB degeneration/NN neurons/NNS
iron/NN staining/NN immunohistochemistry/NN used/VBD study/NN demonstrate/VB detection/NN study/VB degeneration/NN
iron/NN staining/NN immunohistochemistry/NN used/VBD study/NN demonstrate/VB detection/NN study/VB degeneration/NN neurons/NNS of/IN
iron/NN staining/NN immunohistochemistry/NN used/VBD study/NN demonstrate/VB detection/NN study/VB degeneration/NN neurons/NNS dopaminergic/JJ
iron/NN staining/NN immunohistochemistry/NN used/VBD study/NN demonstrate/VB detection/NN study/VB degeneration/NN neurons/NNS
iron/NN content/NN detection/NN study/VB degeneration/NN
iron/NN content/NN detection/NN study/VB degeneration/NN neurons/NNS of/IN
iron/NN content/NN detection/NN study/VB degeneration/NN neurons/NNS dopaminergic/JJ
iron/NN content/NN detection/NN study/VB degeneration/NN neurons/NNS
iron/NN level/NN increase/VB SN/NNP causes/VBZ degeneration/NN
iron/NN level/NN increase/VB SN/NNP causes/VBZ degeneration/NN neurons/NNS of/IN
iron/NN level/NN increase/VB SN/NNP causes/VBZ degeneration/NN neurons/NNS dopaminergic/JJ
iron/NN level/NN increase/VB SN/NNP causes/VBZ degeneration/NN neurons/NNS
iron/NN causes/VBZ degeneration/NN
iron/NN causes/VBZ degeneration/NN neurons/NNS of/IN
iron/NN causes/VBZ degeneration/NN neurons/NNS dopaminergic/JJ
iron/NN causes/VBZ degeneration/NN neurons/NNS
methylphenidate/NN started/VBN depression/NN year/NN man/NN treatment/NN
methylphenidate/NN started/VBN depression/NN year/NN resistant/JJ
methylphenidate/NN started/VBN depression/NN
methylphenidate/NN started/VBN depression/NN disease/NN Alzheimer/NNP
methylphenidate/NN started/VBN depression/NN disease/NN Alzheimer/NNP '/POS
methylphenidate/NN started/VBN depression/NN disease/NN s/JJ
methylphenidate/NN started/VBN depression/NN disease/NN
fluvoxamine/NN replaced/VBN diminished/VBN ensued/VBD obsessive/NN
fluvoxamine/NN replaced/VBN diminished/VBN ensued/VBD behavior/NN compulsive/JJ
fluvoxamine/NN replaced/VBN diminished/VBN ensued/VBD behavior/NN
lithium/NN resistant/JJ polyuria/JJ
lithium/NN development/NN required/VBN Cyclooxygenase/NNP induced/VBN polyuria/NN
lithium/NN induced/VBN polyuria/NN
prostaglandin/NN synthase/NN induced/VBN polyuria/NN
E/NN synthase/NN induced/VBN polyuria/NN
lithium/NN resistant/JJ //VBG induced/VBN concentrating/VBG polyuria/NN
PGE/VB mPGES/NNS 1/CD //VBG induced/VBN concentrating/VBG polyuria/NN
2/CD PGE/VB mPGES/NNS 1/CD //VBG induced/VBN concentrating/VBG polyuria/NN
lithium/NN PGE/NNP 1/CD mPGES/NNS induced/VBN expression/NN polyuria/JJ
PGE/NNP 1/CD mPGES/NNS induced/VBN expression/NN polyuria/JJ
2/CD PGE/NNP 1/CD mPGES/NNS induced/VBN expression/NN polyuria/JJ
everolimus/NNS prophylaxis/NNS Graft/NNP
everolimus/NNS prophylaxis/NNS versus/IN
everolimus/NNS prophylaxis/NNS host/NN
everolimus/NNS prophylaxis/NNS disease/NN
tacrolimus/NNS everolimus/NNS prophylaxis/NNS Graft/NNP
tacrolimus/NNS everolimus/NNS prophylaxis/NNS versus/IN
tacrolimus/NNS everolimus/NNS prophylaxis/NNS host/NN
tacrolimus/NNS everolimus/NNS prophylaxis/NNS disease/NN
methotrexate/NN inhibitor/NN prophylaxis/NNS graft/NN
methotrexate/NN inhibitor/NN prophylaxis/NNS disease/NN versus/IN
methotrexate/NN inhibitor/NN prophylaxis/NNS disease/NN host/NN
methotrexate/NN inhibitor/NN prophylaxis/NNS disease/NN
methotrexate/NN inhibitor/NN prophylaxis/NNS disease/NN GVHD/NNP
everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN leukemia/NN acute/JJ
everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN leukemia/NN myeloid/JJ
everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN leukemia/NN
everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN AML/NNP
tacrolimus/NNS everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN myelodysplastic/JJ
tacrolimus/NNS everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN
tacrolimus/NNS everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN MDS/NNP
tacrolimus/NNS everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN leukemia/NN acute/JJ
tacrolimus/NNS everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN leukemia/NN myeloid/JJ
tacrolimus/NNS everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN leukemia/NN
tacrolimus/NNS everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN AML/NNP
everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN myelodysplastic/JJ
everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN
everolimus/NNS combination/NN report/VBP undergoing/VBG patients/NNS syndrome/NN MDS/NNP
Pravastatin/NNP associated/VBN myopathy/RB
pravastatin/NN hypercholesterolemia/NN
pravastatin/NN discontinuation/NN resolved/VBN myopathy/NN
simvastatin/NN lovastatin/NN associated/VBN myopathy/NN
simvastatin/NN lovastatin/NN associated/VBN represent/VB pravastatin/NN myopathy/NN
lovastatin/NN associated/VBN myopathy/NN
lovastatin/NN associated/VBN represent/VB pravastatin/NN myopathy/NN
pravastatin/NN represent/VB associated/VBN myopathy/NN
pravastatin/NN myopathy/NN
PCPA/NNP exposure/NN decreased/VBD activity/NN irritability/NN
PCPA/NNP exposure/NN decreased/VBD had/VBD effect/NN behavior/NN aggression/NN
5/CD central/JJ speculated/VBN prone/JJ exhibit/VB behavior/NN aggressive/JJ
5/CD central/JJ speculated/VBN prone/JJ exhibit/VB behavior/NN
HT/NNP prone/JJ exhibit/VB behavior/NN aggressive/JJ
HT/NNP prone/JJ exhibit/VB behavior/NN
angiotensin/NN failure/NN heart/NN
angiotensin/NN failure/NN
angiotensin/NN failure/NN patients/NNS function/NN decreased/VBN
angiotensin/NN failure/NN patients/NNS function/NN renal/JJ
angiotensin/NN failure/NN patients/NNS function/NN
angiotensin/NN failure/NN patients/NNS function/NN converting/VBG therapy/NN results/NNS studies/NNS dysfunction/NN left/JJ
angiotensin/NN failure/NN patients/NNS function/NN converting/VBG therapy/NN results/NNS studies/NNS dysfunction/NN ventricular/NN
angiotensin/NN failure/NN patients/NNS function/NN converting/VBG therapy/NN results/NNS studies/NNS dysfunction/NN
angiotensin/VBG reduces/VBZ patients/NNS failure/NN congestive/JJ
angiotensin/VBG reduces/VBZ patients/NNS failure/NN heart/NN
angiotensin/VBG reduces/VBZ patients/NNS failure/NN
angiotensin/VBG reduces/VBZ patients/NNS failure/NN CHF/NNP
angiotensin/VBG reduces/VBZ cause/VB function/NN decreased/JJ
angiotensin/VBG reduces/VBZ cause/VB function/NN renal/JJ
angiotensin/VBG reduces/VBZ cause/VB function/NN
angiotensin/NN prescribed/VBN function/NN patients/NNS CHF/NNP
angiotensin/NN prescribed/VBN function/NN quantify/VB predictors/NNS reduction/NN
angiotensin/NN prescribed/VBN function/NN in/IN
angiotensin/NN prescribed/VBN function/NN renal/JJ
angiotensin/NN prescribed/VBN function/NN
enalapril/NN trial/NN controlled/VBD data/NNS Studies/NNPS Dysfunction/NNP Left/NNP
enalapril/NN trial/NN controlled/VBD data/NNS Studies/NNPS Dysfunction/NNP Ventricular/NNP
enalapril/NN trial/NN controlled/VBD data/NNS Studies/NNPS Dysfunction/NNP
enalapril/NN trial/NN controlled/VBD treatment/NN CHF/NNP
creatinine/NN >/NNS rise/NN defined/VBN function/NN Decreased/JJ
creatinine/NN >/NNS rise/NN defined/VBN function/NN renal/JJ
creatinine/NN >/NNS rise/NN defined/VBN function/NN
diuretic/NN antiplatelet/NN hypertension/NN diabetes/NN
diuretic/NN antiplatelet/NN hypertension/NN
creatinine/NN age/NN pressure/NN history/NN hypertension/NN diabetes/NN
creatinine/NN age/NN pressure/NN history/NN hypertension/NN
diuretic/JJ therapy/NN age/NN diabetes/NN
enalapril/JJ groups/NNS placebo/NN associated/VBN age/NN diabetes/NN
enalapril/NN had/VBD placebo/NN patients/NNS diabetes/NN
Enalapril/JJ use/NN caused/VBN risk/NN function/NN patients/NNS CHF/NNP
enalapril/JJ group/NN reduced/VBN associated/VBN Diabetes/NNP
enalapril/JJ group/NN reduced/VBN associated/VBN risk/NN impairment/NN patients/NNS CHF/NNP
NIK/NNP 247/NNP drug/NN treatment/NN disease/NN Alzheimer/NNP
NIK/NNP 247/NNP drug/NN treatment/NN disease/NN Alzheimer/NNP '/POS
NIK/NNP 247/NNP drug/NN treatment/NN disease/NN s/JJ
NIK/NNP 247/NNP drug/NN treatment/NN disease/NN
-/NNP 247/NNP drug/NN treatment/NN disease/NN Alzheimer/NNP
-/NNP 247/NNP drug/NN treatment/NN disease/NN Alzheimer/NNP '/POS
-/NNP 247/NNP drug/NN treatment/NN disease/NN s/JJ
-/NNP 247/NNP drug/NN treatment/NN disease/NN
247/NNP drug/NN treatment/NN disease/NN Alzheimer/NNP
247/NNP drug/NN treatment/NN disease/NN Alzheimer/NNP '/POS
247/NNP drug/NN treatment/NN disease/NN s/JJ
247/NNP drug/NN treatment/NN disease/NN
adenosine/NN studies/NNS suggest/VBP suggests/VBZ effective/JJ states/NNS hypersensitivity/JJ
adenosine/NN formulation/NN volunteers/NNS studies/NNS suggests/VBZ effective/JJ states/NNS hypersensitivity/JJ
adenosine/NN studies/NNS suggest/VBP effective/JJ treatment/NN pain/NN acute/JJ
adenosine/NN studies/NNS suggest/VBP effective/JJ treatment/NN pain/NN acute/JJ and/CC
adenosine/NN studies/NNS suggest/VBP effective/JJ treatment/NN pain/NN acute/JJ chronic/JJ
adenosine/NN studies/NNS suggest/VBP effective/JJ treatment/NN pain/NN
adenosine/NN formulation/NN volunteers/NNS studies/NNS suggests/VBZ suggest/VBP effective/JJ treatment/NN pain/NN acute/JJ
adenosine/NN formulation/NN volunteers/NNS studies/NNS suggests/VBZ suggest/VBP effective/JJ treatment/NN pain/NN acute/JJ and/CC
adenosine/NN formulation/NN volunteers/NNS studies/NNS suggests/VBZ suggest/VBP effective/JJ treatment/NN pain/NN acute/JJ chronic/JJ
adenosine/NN formulation/NN volunteers/NNS studies/NNS suggests/VBZ suggest/VBP effective/JJ treatment/NN pain/NN
adenosine/NN formulation/NN efficacy/NN screen/VB using/VBG stimulation/NN hypersensitivity/NN
capsaicin/NN stimulation/NN hypersensitivity/NN
adenosine/NN trial/NN doses/NNS 25/CD 2/CD mg/NN blind/JJ studied/VBN obtained/VBN analysis/NN ratings/NNS pain/NN
adenosine/NN trial/NN placebo/NN blind/JJ studied/VBN obtained/VBN analysis/NN ratings/NNS pain/NN
adenosine/NN trial/NN doses/NNS 25/CD 2/CD mg/NN blind/JJ studied/VBN obtained/VBN stimuli/NNS hyperalgesia/NN mechanical/JJ
adenosine/NN trial/NN doses/NNS 25/CD 2/CD mg/NN blind/JJ studied/VBN obtained/VBN stimuli/NNS hyperalgesia/NN
adenosine/NN trial/NN doses/NNS 25/CD 2/CD mg/NN blind/JJ studied/VBN obtained/VBN stimuli/NNS hyperalgesia/NN allodynia/NN
adenosine/NN trial/NN placebo/NN blind/JJ studied/VBN obtained/VBN stimuli/NNS hyperalgesia/NN mechanical/JJ
adenosine/NN trial/NN placebo/NN blind/JJ studied/VBN obtained/VBN stimuli/NNS hyperalgesia/NN
adenosine/NN trial/NN placebo/NN blind/JJ studied/VBN obtained/VBN stimuli/NNS hyperalgesia/NN allodynia/NN
capsaicin/NN injection/NN determined/VBN obtained/VBN analysis/NN ratings/NNS pain/NN
Adenosine/NNP produced/VBD report/NN pain/NN
Adenosine/NNP produced/VBD reduced/VBD hyperalgesia/NN mechanical/JJ
Adenosine/NNP produced/VBD reduced/VBD hyperalgesia/NN
Adenosine/NNP produced/VBD reduced/VBD hyperalgesia/NN allodynia/NN
capsaicin/NN injection/NN reduced/VBD produced/VBD report/NN pain/NN
adenosine/NN hypersensitivity/NN
capsaicin/NN injection/NN reflect/VB presumed/VBN adenosine/NN hypersensitivity/NN
adenosine/NN residence/NN due/JJ observed/VBD pain/NN neuropathic/JJ
adenosine/NN residence/NN due/JJ observed/VBD pain/NN
penicillin/NN discharges/NNS epileptic/JJ
penicillin/NN discharges/NNS stimulation/NN Effects/NNPS model/NN epilepsy/NN
penicillin/NN activity/NN epileptic/JJ
penicillin/NN activity/NN model/NN epilepsy/NN
penicillin/NN suppressed/VBN DBS/NNP RESULTS/NNS induced/VBN independent/JJ activity/NN epileptic/JJ
doxorubicin/NN both/DT T/NNP survivors/NNS tumors/NNS bone/NN
doxorubicin/NN both/DT T/NNP survivors/NNS tumors/NNS
Rosen/NNP treated/VBN tumors/NNS bone/NN
Rosen/NNP treated/VBN tumors/NNS
'/POS Rosen/NNP treated/VBN tumors/NNS bone/NN
'/POS Rosen/NNP treated/VBN tumors/NNS
s/VBZ T/NNP survivors/NNS tumors/NNS bone/NN
s/VBZ T/NNP survivors/NNS tumors/NNS
T/NNP survivors/NNS tumors/NNS bone/NN
T/NNP survivors/NNS tumors/NNS
5/CD T/NNP survivors/NNS tumors/NNS bone/NN
5/CD T/NNP survivors/NNS tumors/NNS
or/CC T/NNP survivors/NNS tumors/NNS bone/NN
or/CC T/NNP survivors/NNS tumors/NNS
T/NNP protocol/NN T/NNP survivors/NNS tumors/NNS bone/NN
T/NNP protocol/NN T/NNP survivors/NNS tumors/NNS
10/CD protocol/NN T/NNP survivors/NNS tumors/NNS bone/NN
10/CD protocol/NN T/NNP survivors/NNS tumors/NNS
protocol/NN T/NNP survivors/NNS tumors/NNS bone/NN
protocol/NN T/NNP survivors/NNS tumors/NNS
doxorubicin/NN induced/VBN cardiotoxicity/RB
methotrexate/NN accident/NN cerebrovascular/NN
methotrexate/NN accident/NN
methotrexate/NN accident/NN leukaemia/NN
pilocarpine/NN tropicamide/NN administration/NN points/NNS size/NN MEASURES/NNP impairment/NN
pilocarpine/NN tropicamide/NN administration/NN points/NNS size/NN MEASURES/NNP impairment/NN recall/NN in/IN
pilocarpine/NN tropicamide/NN administration/NN points/NNS size/NN MEASURES/NNP impairment/NN recall/NN word/NN
pilocarpine/NN tropicamide/NN administration/NN points/NNS size/NN MEASURES/NNP impairment/NN recall/NN
tropicamide/NN administration/NN points/NNS size/NN MEASURES/NNP impairment/NN
tropicamide/NN administration/NN points/NNS size/NN MEASURES/NNP impairment/NN recall/NN in/IN
tropicamide/NN administration/NN points/NNS size/NN MEASURES/NNP impairment/NN recall/NN word/NN
tropicamide/NN administration/NN points/NNS size/NN MEASURES/NNP impairment/NN recall/NN
amiodarone/NN therapy/NN tachycardia/NN fibrillation/NNS ventricular/NN
amiodarone/NN therapy/NN tachycardia/NN fibrillation/NNS
amiodarone/NN therapy/NN Long/NNP efficacy/NN toxicity/NN
amiodarone/NN therapy/NN tachycardia/NN ventricular/NN
amiodarone/NN therapy/NN tachycardia/NN
Amiodarone/NNP administered/VBN sustained/VBN tachycardia/NN ventricular/NN
Amiodarone/NNP administered/VBN sustained/VBN tachycardia/NN
Amiodarone/NNP administered/VBN sustained/VBN tachycardia/NN VT/NNP
Amiodarone/NNP administered/VBN sustained/VBN tachycardia/NN arrest/NN cardiac/JJ
Amiodarone/NNP administered/VBN sustained/VBN tachycardia/NN arrest/NN
amiodarone/NN continued/VBD had/VBD recurrence/NN VT/NN fibrillation/NN ventricular/NN
amiodarone/NN continued/VBD had/VBD recurrence/NN VT/NN fibrillation/NN
amiodarone/NN continued/VBD had/VBD recurrence/NN VT/NN VF/NNP
amiodarone/NN continued/VBD had/VBD recurrence/NN VT/NN
amiodarone/NN managed/VBN had/VBD recurrence/NN VT/NNP
amiodarone/NN large/JJ effective/JJ VT/NNP VF/NNP
amiodarone/NN large/JJ effective/JJ causes/VBZ toxicity/NN
amiodarone/NN large/JJ effective/JJ VT/NNP
amiodarone/NN managed/VBN %/NN patients/NNS VT/NNP VF/NNP
amiodarone/NN managed/VBN %/NN patients/NNS VT/NNP
Calcium/JJ toxicity/NN
carbonate/NN toxicity/NN
calcium/NN corrected/VBN hypercalcemia/NN
calcium/NN corrected/VBN hypercalcemia/NN presented/VBN patients/NNS report/VB review/VB literature/NN milk/NN
calcium/NN corrected/VBN hypercalcemia/NN presented/VBN patients/NNS report/VB review/VB literature/NN syndrome/NN alkali/JJ
calcium/NN corrected/VBN hypercalcemia/NN presented/VBN patients/NNS report/VB review/VB literature/NN syndrome/NN
1/CD peptide/NN RESULTS/NNS patients/NNS had/VBN insufficiency/NN alkalosis/NNS metabolic/JJ
1/CD peptide/NN RESULTS/NNS patients/NNS had/VBN insufficiency/NN alkalosis/NNS
25/CD RESULTS/NNS patients/NNS had/VBN insufficiency/NN alkalosis/NNS metabolic/JJ
25/CD RESULTS/NNS patients/NNS had/VBN insufficiency/NN alkalosis/NNS
dihydroxyvitamin/NNP D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN alkalosis/NNS metabolic/JJ
dihydroxyvitamin/NNP D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN alkalosis/NNS
D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN alkalosis/NNS metabolic/JJ
D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN alkalosis/NNS
1/CD peptide/NN RESULTS/NNS patients/NNS had/VBN insufficiency/NN acute/JJ
1/CD peptide/NN RESULTS/NNS patients/NNS had/VBN insufficiency/NN renal/JJ
1/CD peptide/NN RESULTS/NNS patients/NNS had/VBN insufficiency/NN
25/CD RESULTS/NNS patients/NNS had/VBN insufficiency/NN acute/JJ
25/CD RESULTS/NNS patients/NNS had/VBN insufficiency/NN renal/JJ
25/CD RESULTS/NNS patients/NNS had/VBN insufficiency/NN
dihydroxyvitamin/NNP D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN acute/JJ
dihydroxyvitamin/NNP D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN renal/JJ
dihydroxyvitamin/NNP D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN
D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN acute/JJ
D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN renal/JJ
D/NNP RESULTS/NNS patients/NNS had/VBN insufficiency/NN
calcium/NN concentrations/NNS patients/NNS received/VBD intravenously/NN caused/VBD hypocalcemia/NN
Pamidronate/JJ treatment/NN associated/VBN cases/NNS hypercalcemia/NN
sirolimus/NNS administration/NN psoriasis/NNS
rapamycin/NN sirolimus/NNS administration/NN psoriasis/NNS
sirolimus/NNS administration/NN toxicity/NN
rapamycin/NN sirolimus/NNS administration/NN toxicity/NN
sirolimus/NNS treatment/NN syndrome/NN developed/VBN psoriasis/NNS
sirolimus/NNS specimen/NN OBSERVATIONS/NNP induced/VBN leak/NN syndrome/NN 3/CD fold/VB sirolimus/NNS treated/VBN psoriasis/NNS
sirolimus/NNS treated/VBN psoriasis/NNS
dexamethasone/NN spontaneous/NNS exhibit/VB tended/VBN psoriasis/NNS
sirolimus/NNS presence/NN apoptosis/NNS Activated/VBN patients/NNS psoriasis/NNS
sirolimus/NNS effects/NNS include/VBP fever/NN
sirolimus/NNS effects/NNS include/VBP fever/NN anemia/NN
midazolam/NN group/NN %/NN occurred/VBD Pain/NNP
diazepam/NN group/NN patients/NNS %/NN occurred/VBD Pain/NNP
alcohol/NN use/NN needle/NN time/NN Smoking/NN had/VBD effect/NN incidence/NN complications/NNS venous/JJ
alcohol/NN use/NN needle/NN time/NN Smoking/NN had/VBD effect/NN incidence/NN complications/NNS
alcohol/NN use/NN needle/NN time/NN Smoking/NN pain/NN
nitric/JJ oxide/NN type/NN study/NN 1/CD arteritis/NNS
oxide/NN type/NN study/NN 1/CD arteritis/NNS
theophylline/NN fenoldopam/NN induced/VBN arteritis/NNS 1/CD study/NN type/NN oxide/NN factor/NN tumor/NN
nitric/JJ oxide/NN factor/NN tumor/NN
oxide/NN factor/NN tumor/NN
fenoldopam/NN induced/VBN arteritis/NNS 1/CD study/NN type/NN oxide/NN factor/NN tumor/NN
nitric/JJ synthase/NN type/NN expressions/NNS examined/VBN Arteritis/NNS
oxide/NN synthase/NN type/NN expressions/NNS examined/VBN Arteritis/NNS
theophylline/NN vasodilators/NNS induced/VBN Arteritis/NNS examined/VBN expressions/NNS type/NN synthase/NN factor/NN tumor/NN
nitric/JJ synthase/NN factor/NN tumor/NN
oxide/NN synthase/NN factor/NN tumor/NN
fenoldopam/NN vasodilators/NNS induced/VBN Arteritis/NNS examined/VBN expressions/NNS type/NN synthase/NN factor/NN tumor/NN
oxygen/NN species/NNS production/NN accompanied/VBN failure/NN renal/JJ
oxygen/NN species/NNS production/NN accompanied/VBN failure/NN
oxygen/NN species/NNS production/NN accompanied/VBN failure/NN causes/NNS one/CD Diabetic/NNP
oxygen/NN species/NNS production/NN accompanied/VBN failure/NN causes/NNS one/CD nephropathy/RB
streptozotocin/NN induced/VBN damage/NN renal/JJ
streptozotocin/NN induced/VBN damage/NN
crocin/NN L/NNP constituents/NNS Effects/NNPS model/NN disease/NN Alzheimer/NNP
crocin/NN L/NNP constituents/NNS Effects/NNPS model/NN disease/NN Alzheimer/NNP '/POS
crocin/NN L/NNP constituents/NNS Effects/NNPS model/NN disease/NN s/JJ
crocin/NN L/NNP constituents/NNS Effects/NNPS model/NN disease/NN
crocins/NNS disease/NN Alzheimer/NNP
crocins/NNS disease/NN Alzheimer/NNP '/POS
crocins/NNS disease/NN s/JJ
crocins/NNS disease/NN
crocin/NN attenuated/VB impairment/NN learning/NN
crocin/NN attenuated/VB impairment/NN learning/NN and/CC
crocin/NN attenuated/VB impairment/NN learning/NN memory/NN
crocin/NN attenuated/VB impairment/NN
STZ/NNP attenuated/VB impairment/NN learning/NN
STZ/NNP attenuated/VB impairment/NN learning/NN and/CC
STZ/NNP attenuated/VB impairment/NN learning/NN memory/NN
STZ/NNP attenuated/VB impairment/NN
crocin/NN effectiveness/NN demonstrate/VBP antagonizing/VBG deficits/NNS cognitive/JJ
crocin/NN effectiveness/NN demonstrate/VBP antagonizing/VBG deficits/NNS
crocin/NN effectiveness/NN demonstrate/VBP disease/NN potential/NN treatment/NN diseases/NNS neurodegenerative/JJ
crocin/NN effectiveness/NN demonstrate/VBP disease/NN potential/NN treatment/NN diseases/NNS
STZ/NNP caused/VBN deficits/NNS antagonizing/VBG demonstrate/VBP disease/NN potential/NN treatment/NN diseases/NNS neurodegenerative/JJ
STZ/NNP caused/VBN deficits/NNS antagonizing/VBG demonstrate/VBP disease/NN potential/NN treatment/NN diseases/NNS
crocin/NN effectiveness/NN demonstrate/VBP disease/NN potential/NN treatment/NN diseases/NNS Alzheimer/NNP
crocin/NN effectiveness/NN demonstrate/VBP disease/NN potential/NN treatment/NN diseases/NNS Alzheimer/NNP '/POS
crocin/NN effectiveness/NN demonstrate/VBP disease/NN s/VBZ
crocin/NN effectiveness/NN demonstrate/VBP disease/NN
bethanechol/NN stimulation/NN prevented/VBD rats/NNS diabetic/JJ
ATP/NNP stimulation/NN prevented/VBD rats/NNS diabetic/JJ
bethanechol/NN stimulation/NN reversed/VBD rats/NNS diabetic/JJ
ATP/NNP stimulation/NN reversed/VBD rats/NNS diabetic/JJ
cocaine/NN use/NN Fatal/VB provide/VB mechanisms/NNS toxicity/NN
cocaine/NN toxicity/NN
cocaine/NN registry/NN compared/VBN victims/NNS overdose/NN
cocaine/NN overdose/NN
benzoylecgonine/NN cocaine/NN concentrations/NNS had/VBD EDDs/NNS
cocaine/NN use/NN disrupts/VBZ precipitate/VB agitation/NN
cocaine/NN use/NN coupled/VBN disrupts/VBZ precipitate/VB agitation/NN
epsilon/NN associated/VBN thrombosis/VBZ sinus/NNS sagittal/JJ
epsilon/NN associated/VBN thrombosis/VBZ sinus/NNS sagittal/JJ and/CC
epsilon/NN associated/VBN thrombosis/VBZ sinus/NNS sagittal/JJ left/JJ
epsilon/NN associated/VBN thrombosis/VBZ sinus/NNS transverse/NN
epsilon/NN associated/VBN thrombosis/VBZ sinus/NNS
epsilon/NN associated/VBN thrombosis/VBZ
aminocaproic/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS sagittal/JJ
aminocaproic/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS sagittal/JJ and/CC
aminocaproic/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS sagittal/JJ left/JJ
aminocaproic/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS transverse/NN
aminocaproic/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS
aminocaproic/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ
acid/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS sagittal/JJ
acid/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS sagittal/JJ and/CC
acid/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS sagittal/JJ left/JJ
acid/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS transverse/NN
acid/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ sinus/NNS
acid/JJ therapy/NN year/NN woman/NN developed/VBD thrombosis/VBZ
epsilon/NN associated/VBN thrombosis/VBZ developed/VBD woman/NN year/NN therapy/NN menorrhagia/NN
aminocaproic/JJ therapy/NN menorrhagia/NN
acid/JJ therapy/NN menorrhagia/NN
epsilon/NN treatment/NN reported/VBN described/VBN thrombosis/NNS cerebral/JJ
epsilon/NN treatment/NN reported/VBN described/VBN thrombosis/NNS sinus/NNS
epsilon/NN treatment/NN reported/VBN described/VBN thrombosis/NNS
aminocaproic/JJ acid/NN treatment/NN reported/VBN described/VBN thrombosis/NNS cerebral/JJ
aminocaproic/JJ acid/NN treatment/NN reported/VBN described/VBN thrombosis/NNS sinus/NNS
aminocaproic/JJ acid/NN treatment/NN reported/VBN described/VBN thrombosis/NNS
acid/NN treatment/NN reported/VBN described/VBN thrombosis/NNS cerebral/JJ
acid/NN treatment/NN reported/VBN described/VBN thrombosis/NNS sinus/NNS
acid/NN treatment/NN reported/VBN described/VBN thrombosis/NNS
epsilon/NN treatment/NN reported/VBN risk/NN disease/NN thromboembolic/JJ
epsilon/NN treatment/NN reported/VBN risk/NN disease/NN
aminocaproic/JJ acid/NN treatment/NN reported/VBN risk/NN disease/NN thromboembolic/JJ
aminocaproic/JJ acid/NN treatment/NN reported/VBN risk/NN disease/NN
acid/NN treatment/NN reported/VBN risk/NN disease/NN thromboembolic/JJ
acid/NN treatment/NN reported/VBN risk/NN disease/NN
desipramine/NN administration/NN induced/VBN linking/VBG alteration/NN sensitivity/NN convulsions/NNS
norepinephrine/JJ function/NN induced/VBN linking/VBG alteration/NN sensitivity/NN convulsions/NNS
norepinephrine/JJ transporter/NN Alterations/NNS function/VBP sensitization/VB seizures/NNS
desipramine/NN administration/NN increased/VBD incidence/NN appearance/NN induced/VBN convulsions/NNS
desipramine/NN administration/NN increased/VBD incidence/NN appearance/NN induced/VBN convulsions/NNS
desipramine/NN lidocaine/NN administration/NN reversed/VBD changes/NNS activity/NN convulsive/JJ
desipramine/NN administration/NN induced/VBN activity/NN convulsive/JJ
desipramine/NN administration/NN induced/VBN NET/NNP regulation/NN relevant/JJ sensitization/NN convulsions/NNS
desipramine/VB relevant/JJ sensitization/NN convulsions/NNS
Desipramine/NNP have/VB sensitization/NN seizures/NNS
ACTH/NNP N/NNP stimulated/VBN axons/VBZ cause/VB long/JJ depression/NN
ACTH/NNP N/NNP stimulated/VBN axons/VBZ cause/VB long/JJ depression/NN synapses/NNS resulted/VBD duration/NN disorder/NN movement/NN
ACTH/NNP N/NNP stimulated/VBN axons/VBZ cause/VB long/JJ depression/NN synapses/NNS resulted/VBD duration/NN disorder/NN
lidocaine/NN reduce/VB succinylcholine/NN induced/VBN myalgia/NN postoperative/JJ
lidocaine/NN reduce/VB succinylcholine/NN induced/VBN myalgia/NN
lidocaine/JJ pretreatment/NN effect/NN determine/VB undertaken/VBN undergoing/VBG myalgia/NN
succinylcholine/NN reduction/NN determine/VB undertaken/VBN undergoing/VBG myalgia/NN
lidocaine/NN proven/VBN agent/NN reduction/NN myalgia/NN postoperative/JJ
lidocaine/NN proven/VBN agent/NN reduction/NN myalgia/NN
steroid/JJ developed/VBD discontinued/VBN induced/VBN pressure/NN elevated/JJ
steroid/JJ developed/VBD discontinued/VBN induced/VBN pressure/NN intraocular/JJ
steroid/JJ developed/VBD discontinued/VBN induced/VBN pressure/NN
steroid/NN induced/VBN seem/VB rise/NN IOP/NNP
steroid/NN induced/VBN seem/VB rise/NN
L/NNP rats/NNS Reversal/NNP coma/NN
dopa/NN Reversal/NNP coma/NN
ammonia/NN coma/NN
Ammonia/NNP coma/NNP
L/NNP dopa/NNS prevented/VBN coma/NN
-/NNP dopa/NNS prevented/VBN coma/NN
dopa/NNS prevented/VBN coma/NN
ammonium/NN injection/NN prevented/VBN coma/NN
salt/NN injection/NN prevented/VBN coma/NN
dopamine/NN infusion/NN prevent/VB coma/NN
dopamine/NN raise/VB sufficient/JJ dopamine/NN infusion/NN prevent/VB coma/NN
ammonia/NN coma/NN
ammonia/NN concentrations/NNS blood/NN affect/VBP prevent/VB coma/NN
L/NNP effect/NN eliminated/VBD prevented/VBN dopa/NN ammonia/NN coma/NN
dopa/NN ammonia/NN coma/NN
ammonia/NN coma/NN
ammonia/NN coma/NN
L/NNP coma/NN
dopa/NN reduction/NN prevention/NN coma/NN
dopamine/NN effect/NN accounted/VBN reduction/NN prevention/NN coma/NN
ammonia/NN reduction/NN prevention/NN coma/NN
ammonia/NN coma/NN
L/NNP receiving/VBG patients/NNS encephalopathic/JJ
dopa/NN L/NNP receiving/VBG patients/NNS encephalopathic/JJ
lignocaine/NN dose/NN ranged/VBD mg/NNP caused/VBN neurotoxicity/NN
lignocaine/NN neurotoxicity/NN
cyclophosphamide/JJ cytotoxicity/NN restores/VBZ reduction/NN anemia/NN
cyclophosphamide/JJ cytotoxicity/NN
cyclophosphamide/JJ cytotoxicity/NN tumors/NNS
cyclophosphamide/NN cytotoxicity/NN treatment/NN examine/VB impact/NN prevention/NN anemia/NN
cyclophosphamide/NN cytotoxicity/NN
cyclophosphamide/NN cytotoxicity/NN treatment/NN examine/VB tumors/NNS
carboplatin/NN treatment/NN days/NNS implanted/VBN tumors/NNS
carboplatin/NN treatment/NN days/NNS implanted/VBN tumors/NNS DS/NNP sarcoma/NN
carboplatin/NN influenced/VBD rate/NN tumor/NN
cyclophosphamide/NN dose/NN treated/VBN tumors/NNS
cyclophosphamide/NN dose/NN treated/VBN observed/JJ delay/NN regrowth/NN tumors/NNS
oxygen/NN supply/NN result/NN increases/VBZ reduces/VBZ anemia/NNP
oxygen/NN supply/NN result/NN increases/VBZ correction/NN anemia/NN
cyclophosphamide/NN cytotoxicity/NN reduces/VBZ anemia/NNP
cyclophosphamide/NN cytotoxicity/NN reduces/VBZ increases/VBZ correction/NN anemia/NN
cyclophosphamide/NN cytotoxicity/NN
cyclophosphamide/NN tumors/NNS
cyclophosphamide/NN cytotoxicity/NN reduces/VBZ increases/VBZ result/NN supply/NN tissue/NN tumor/NN
oxygen/NN supply/NN result/NN increases/VBZ reduces/VBZ cytotoxicity/NN cyclophosphamide/NN tumors/NNS
oxygen/NN supply/NN tissue/NN tumor/NN
oxygen/NN supply/NN result/NN increases/VBZ reduces/VBZ cytotoxicity/NN
ribavirin/VBD disease/NN adenovirus/NNS
ribavirin/VBD disease/NN
Ribavirin/NNP licensed/VBN form/NN treatment/NN infection/NN syncytial/JJ respiratory/RB
Ribavirin/NNP licensed/VBN form/NN treatment/NN infection/NN syncytial/JJ
Ribavirin/NNP licensed/VBN form/NN treatment/NN infection/NN virus/NN
Ribavirin/NNP licensed/VBN form/NN treatment/NN infection/NN
Ribavirin/NNP licensed/VBN treat/VB C/NNP hepatitis/NNP
Ribavirin/NNP licensed/VBN treat/VB C/NNP
ribavirin/NNP treatment/NN choice/NN infection/NN
ribavirin/NNP treatment/NN choice/NN infection/NN viruses/NNS with/IN
ribavirin/NNP treatment/NN choice/NN infection/NN viruses/NNS hemorrhagic/JJ
ribavirin/NNP treatment/NN choice/NN infection/NN viruses/NNS fever/NN
ribavirin/NNP treatment/NN choice/NN infection/NN viruses/NNS
ribavirin/NNP effect/NN anemia/NN
cidofovir/NN use/NN limited/VBN effects/NNS nephrotoxicity/JJ
cidofovir/NN infection/NN adenovirus/NNS
cidofovir/NN infection/NN
ribavirin/JJ therapy/NN disease/NN adenovirus/NNS
ribavirin/JJ therapy/NN disease/NN
ribavirin/NNP disease/NN adenovirus/NN
ribavirin/NNP disease/NN
ribavirin/NNP effective/JJ unlikely/JJ benefit/NN begun/VBN course/NN infection/NN
ribavirin/NNP effective/JJ disease/NN adenovirus/NNS
ribavirin/NNP effective/JJ disease/NN
ribavirin/NNP treated/VBN disease/NN adenovirus/NNS
ribavirin/NNP treated/VBN disease/NN
ribavirin/NNP trial/NN children/NNS required/VBN seriousness/NN prevalence/NN disease/NN adenovirus/JJ
ribavirin/NNP trial/NN children/NNS required/VBN seriousness/NN prevalence/NN disease/NN
hexamethonium/NN atropine/NN administration/NN reduced/VBD induced/NNS catalepsy/JJ
atropine/NN administration/NN reduced/VBD induced/NNS catalepsy/JJ
mecamylamine/NN atropine/NN administration/NN reduced/VBD induced/NNS catalepsy/JJ
naloxone/NN atropine/NN administration/NN reduced/VBD induced/NNS catalepsy/JJ
hexamethonium/NN atropine/NN injection/NN induced/VBN catalepsy/RB
atropine/NN injection/NN induced/VBN catalepsy/RB
naloxone/NN atropine/NN injection/NN induced/VBN catalepsy/RB
testosterone/NN rats/NNS Production/NN cancer/NN prostate/NN
testosterone/NN rats/NNS Production/NN cancer/NN
N/NNP treatments/NNS most/JJS tumor/NN
nitroso/NN treatments/NNS most/JJS tumor/NN
N/NNP treatments/NNS most/JJS tumor/NN
methylurea/NN treatments/NNS most/JJS tumor/NN
testosterone/NN methylurea/NN treatments/NNS most/JJS tumor/NN
propionate/NNP CAS/NNP testosterone/NN methylurea/NN treatments/NNS most/JJS tumor/NN
TP/NNP CAS/NNP testosterone/NN methylurea/NN treatments/NNS most/JJS tumor/NN
TP/NNP acted/VBD agent/NN tumor/NN
Dexmedetomidine/NNP prevents/VBZ opiate/NN rigidity/NN muscle/NN
Dexmedetomidine/NNP prevents/VBZ opiate/NN rigidity/NN
dexmedetomidine/NN highly/RB capable/JJ inducing/VBG flaccidity/NN muscle/NN
dexmedetomidine/NN highly/RB capable/JJ inducing/VBG flaccidity/NN
D/NNP highly/RB capable/JJ inducing/VBG flaccidity/NN muscle/NN
D/NNP highly/RB capable/JJ inducing/VBG flaccidity/NN
MED/NNP D/NNP highly/RB capable/JJ inducing/VBG flaccidity/NN muscle/NN
MED/NNP D/NNP highly/RB capable/JJ inducing/VBG flaccidity/NN
D/NNP MED/NNP treatment/NN prevents/VBZ rigidity/NN muscle/NN
D/NNP MED/NNP treatment/NN prevents/VBZ rigidity/NN
-/NNP MED/NNP treatment/NN prevents/VBZ rigidity/NN muscle/NN
-/NNP MED/NNP treatment/NN prevents/VBZ rigidity/NN
MED/NNP treatment/NN prevents/VBZ rigidity/NN muscle/NN
MED/NNP treatment/NN prevents/VBZ rigidity/NN
D/NNP induced/VBN rigidity/NN muscle/NN
D/NNP induced/VBN rigidity/NN
MED/NNP D/NNP induced/VBN rigidity/NN muscle/NN
MED/NNP D/NNP induced/VBN rigidity/NN
D/NNP akinetic/JJ
MED/NNP animals/NNS akinetic/JJ
D/NNP akinetic/JJ lacked/VBD response/NN startle/JJ
MED/NNP animals/NNS akinetic/JJ lacked/VBD response/NN startle/JJ
Apomorphine/NNP therapy/NN disease/NN Parkinson/NNP
Apomorphine/NNP therapy/NN disease/NN Parkinson/NNP '/POS
Apomorphine/NNP therapy/NN disease/NN s/JJ
Apomorphine/NNP therapy/NN disease/NN
Apomorphine/NNP used/VBN treat/VB symptoms/NNS disease/NN Parkinson/NNP
Apomorphine/NNP used/VBN treat/VB symptoms/NNS disease/NN Parkinson/NNP '/POS
Apomorphine/NNP used/VBN treat/VB symptoms/NNS disease/NN s/JJ
Apomorphine/NNP used/VBN treat/VB symptoms/NNS disease/NN
apomorphine/NN administration/NN fluctuating/VBG disease/NN Parkinson/NNP
apomorphine/NN administration/NN fluctuating/VBG disease/NN Parkinson/NNP '/POS
apomorphine/NN administration/NN fluctuating/VBG disease/NN s/JJ
apomorphine/NN administration/NN fluctuating/VBG disease/NN
apomorphine/NN infusions/NNS associated/VBN reductions/NNS preexisting/VBG levodopa/NN dyskinesias/NNS
apomorphine/NN treatment/NN effects/NNS related/VBN play/VBP complications/NNS sedation/JJ psychiatric/JJ
apomorphine/NN treatment/NN fluctuating/VBG disease/NN Parkinson/NNP
apomorphine/NN treatment/NN fluctuating/VBG disease/NN Parkinson/NNP '/POS
apomorphine/NN treatment/NN fluctuating/VBG disease/NN s/JJ
apomorphine/NN treatment/NN fluctuating/VBG disease/NN
etoposide/NN containing/VBG man/NN factors/NNS disease/NN coronary/JJ
etoposide/NN containing/VBG man/NN factors/NNS disease/NN heart/NN
etoposide/NN containing/VBG man/NN factors/NNS disease/NN
tobramycin/NN netilmicin/NN efficacy/NN toxicity/NN
netilmicin/NN efficacy/NN toxicity/NN
tobramycin/NN sulfate/NN sulfate/NN efficacy/NN compared/VBD sodium/NN patients/NNS infections/NNS
sulfate/NN sulfate/NN efficacy/NN compared/VBD sodium/NN patients/NNS infections/NNS
netilmicin/NN sulfate/NN efficacy/NN compared/VBD sodium/NN patients/NNS infections/NNS
sulfate/NN efficacy/NN compared/VBD sodium/NN patients/NNS infections/NNS
piperacillin/NN sodium/NN patients/NNS infections/NNS
sodium/NN patients/NNS infections/NNS
aminoglycoside/VB severe/JJ ototoxicity/RB
sodium/NN nitroprusside/NN cent/NN 8/CD flow/NN increased/VBN fenoldopam/NN induced/VBN +/NNS hypotension/JJ
sodium/NN nitroprusside/NN cent/NN 8/CD flow/NN hypotension/NN
dopamine/NN agonist/NN causes/VBZ preserves/VBZ kidney/NN hypotension/NN
N/NNP C/NNP markers/NNS toxicity/NN cardiovascular/JJ
N/NNP C/NNP markers/NNS toxicity/NN
terminal/NN brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN cardiovascular/JJ
terminal/NN brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN
pro/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN cardiovascular/JJ
pro/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN
brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN cardiovascular/JJ
brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN
natriuretic/JJ peptide/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN cardiovascular/JJ
natriuretic/JJ peptide/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN
peptide/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN cardiovascular/JJ
peptide/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN
NT/NNP peptide/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN cardiovascular/JJ
NT/NNP peptide/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN
proBNP/NN NT/NNP peptide/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN cardiovascular/JJ
proBNP/NN NT/NNP peptide/JJ brain/NN sensitive/JJ C/NNP markers/NNS toxicity/NN
glutamate/JJ mRNA/NN Loss/NN containing/VBG induced/VBN seizures/NNS
glutamic/JJ mRNA/NN determine/VB used/VBN vulnerable/JJ seizure/NN
acid/JJ mRNA/NN determine/VB used/VBN vulnerable/JJ seizure/NN
glutamic/JJ mRNA/NN determine/VB used/VBN vulnerable/JJ seizure/NN induced/VBN model/NN seizures/NNS
acid/JJ mRNA/NN determine/VB used/VBN vulnerable/JJ seizure/NN induced/VBN model/NN seizures/NNS
cresyl/JJ staining/NN methods/NNS neuronal/JJ
cresyl/JJ staining/NN methods/NNS degeneration/NN
violet/NN staining/NN methods/NNS neuronal/JJ
violet/NN staining/NN methods/NNS degeneration/NN
cresyl/JJ staining/NN studies/NNS suggested/VBD related/VBN loss/NN neuronal/JJ
cresyl/JJ staining/NN studies/NNS suggested/VBD related/VBN loss/NN
violet/NN staining/NN studies/NNS suggested/VBD related/VBN loss/NN neuronal/JJ
violet/NN staining/NN studies/NNS suggested/VBD related/VBN loss/NN
cibenzoline/NN concentrations/NNS arrhythmias/NNS ventricular/NN
cibenzoline/NN concentrations/NNS arrhythmias/NNS
cibenzoline/NN effects/NNS examined/VBN Using/VBG two/CD induced/VBN arrhythmias/NNS ventricular/NN
cibenzoline/NN effects/NNS examined/VBN Using/VBG two/CD induced/VBN arrhythmias/NNS
cibenzoline/NN effects/NNS examined/VBN determined/VBN concentration/NN model/NN arrhythmia/NN
Cibenzoline/RB suppressed/VBD arrhythmias/NNS
Cibenzoline/RB suppressed/VBD arrhythmias/NNS concentrations/NNS arrhythmias/NNS
cibenzoline/NN had/VBD found/VBN active/JJ given/VBN dogs/NNS arrhythmia/NN
cibenzoline/NN had/VBD hypotensive/NN
cibenzoline/NN had/VBD hypotensive/NN effects/NNS depressive/NN
estrogen/NN development/NN receptor/NN factor/NN induced/VBN mediate/VB tumors/NNS pituitary/NN
estrogen/NN development/NN receptor/NN factor/NN induced/VBN mediate/VB tumors/NNS
estrogen/NN mediate/VB tumors/NNS pituitary/NN
estrogen/NN mediate/VB tumors/NNS
estrogen/NN development/NN receptor/NN factor/NN initiated/VBD angiogenesis/NNS tumor/NN
estrogen/NN mediate/VB induced/VBN factor/NN initiated/VBD angiogenesis/NNS tumor/NN
Estrogens/NNS associated/VBN types/NNS cancers/NNS
Estrogens/NNS induce/VB angiogenesis/NNS tumor/NN
estrogen/NN carcinogenesis/NNS
estrogen/NN carcinogenesis/NNS unknown/JJ details/NNS induction/NN tumor/NN
estrogen/NN role/NN elucidate/VB regulation/NN angiogenesis/NNS tumor/NN
E/NN pituitary/NN expression/NN associated/VBN potential/NN tumor/NN
2/CD pituitary/NN expression/NN associated/VBN potential/NN tumor/NN
estrogen/NN induced/VBN angiogenesis/NNS tumor/NN
pregnenolone/JJ sulphate/NN effects/NNS amnesic/JJ
sulphate/NN effects/NNS amnesic/JJ
Steroid/JJ structure/NN determine/VBP anti/NN effects/NNS amnesic/JJ
PREGS/NNS able/JJ reverse/VB ligands/NNS amnesic/JJ
GABA/NNP NMDAR/NNP effects/NNS amnesic/JJ
PREGS/NNP effects/NNS enhancing/VBG tested/VBN task/NN using/VBG model/NN amnesia/NN
PREGS/NNS ability/NN demonstrated/VBN scopolamine/NN amnesia/NN
levodopa/JJ disability/NN reduces/VBZ stage/VBP disease/NN Parkinson/NNP
levodopa/JJ disability/NN reduces/VBZ stage/VBP disease/NN Parkinson/NNP '/POS
levodopa/JJ disability/NN reduces/VBZ stage/VBP disease/NN s/JJ
levodopa/JJ disability/NN reduces/VBZ stage/VBP disease/NN
mannitol/JJ gliomas/NNS
mannitol/JJ lower/JJR elevated/VBD ICP/NNP tumor/NN brain/NN
mannitol/JJ lower/JJR elevated/VBD ICP/NNP tumor/NN
mannitol/JJ reduce/VB edema/NN brain/NN
mannitol/JJ reduce/VB edema/NN
mannitol/NN passage/NN research/VB patients/NNS brain/NN
mannitol/NN passage/NN research/VB patients/NNS tumor/NN
Mannitol/NNP administered/VBN had/VBD glioma/NN malignant/JJ
Mannitol/NNP administered/VBN had/VBD glioma/NN
Mannitol/NNP administered/VBN had/VBD glioma/NN metastases/NNS
Mannitol/NNP administered/VBN had/VBD glioma/NN meningioma/NN
mannitol/JJ concentrations/NNS higher/JJR patients/NNS glioma/NN
mannitol/NN concentrations/NNS higher/RBR patients/NNS meningioma/NN metastases/NN
mannitol/NN concentrations/NNS higher/RBR patients/NNS meningioma/NN
mannitol/NN leak/VB BBB/NN gliomas/NNS
mannitol/NN leak/VB reversing/VBG edema/NN
corticosteroids/NNS doses/NNS treated/VBN patients/NNS occur/VB myopathy/NN
steroid/NN showed/VBD reduction/NN
steroid/NN showed/VBD reduction/NN intake/NN of/IN
steroid/NN showed/VBD reduction/NN intake/NN food/NN
steroid/NN showed/VBD reduction/NN intake/NN
M/NNP longer/RB was/VBD similar/JJ tensions/NNS tetanic/JJ
steroid/JJ groups/NNS prolonged/JJ was/VBD similar/JJ tensions/NNS tetanic/JJ
steroid/JJ groups/NNS IIa/NNS showed/VBD revealed/VBD absence/NN necrosis/NNS
steroid/JJ groups/NNS IIa/NNS atrophy/JJ
steroid/JJ groups/NNS IIa/NNS atrophy/RB
T/NNP showed/VBD revealed/VBD absence/NN necrosis/NNS
steroids/NNS induced/VBN respiratory/NN types/NNS steroids/NNS induced/VBN atrophy/JJ
steroids/NNS induced/VBN atrophy/JJ
steroid/NN caused/VBD conclude/VBP contractile/VBP treatment/NN doses/NNS steroids/NNS induced/VBN respiratory/NN types/NNS steroids/NNS induced/VBN atrophy/JJ
steroids/NNS doses/NNS treatment/NN contractile/VBP conclude/VBP caused/VBD necrosis/NNS
steroids/NNS types/NNS respiratory/NN induced/VBN steroids/NNS doses/NNS treatment/NN contractile/VBP conclude/VBP caused/VBD necrosis/NNS
steroid/NN caused/VBD necrosis/NNS
steroids/NNS doses/NNS treatment/NN contractile/VBP conclude/VBP caused/VBN atrophy/NN
steroids/NNS types/NNS respiratory/NN induced/VBN steroids/NNS doses/NNS treatment/NN contractile/VBP conclude/VBP caused/VBN atrophy/NN
steroid/NN caused/VBD conclude/VBP caused/VBN atrophy/NN
NMDA/NNP receptors/NNS mediated/VBN neurotransmission/NN modulate/VB haloperidol/NN induced/VBN catalepsy/RB
amino/JJ acid/NN influence/NN mechanisms/NNS IC/NNP catalepsy/NN
acid/NN influence/NN mechanisms/NNS IC/NNP catalepsy/NN
dopamine/JJ haloperidol/NN induced/VBN catalepsy/NN
glutamate/JJ antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
801/CD MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
NMDA/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
NMDA/NNP N/NNP 0/CD mmol/JJ 0/NNP 15/CD 801/CD MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
N/NNP 0/CD mmol/JJ 0/NNP 15/CD 801/CD MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
methyl/NNP 0/NNP 15/CD 801/CD MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
d/SYM 0/NNP 15/CD 801/CD MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
aspartate/NNP NMDA/NNP d/SYM 0/NNP 15/CD 801/CD MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
NMDA/NNP d/SYM 0/NNP 15/CD 801/CD MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
AP/NNP 0/CD mmol/JJ 0/NNP 15/CD 801/CD MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
7/CD AP/NNP 0/CD mmol/JJ 0/NNP 15/CD 801/CD MK/NNP antagonists/NNS microinjections/NNS challenged/VBN catalepsy/RB
MK/NNP microinjection/NN showed/VBD attenuated/VBD catalepsy/NN
801/CD previous/JJ attenuated/VBD catalepsy/NN
AP/CD 7/CD 801/CD previous/JJ attenuated/VBD catalepsy/NN
7/CD 801/CD previous/JJ attenuated/VBD catalepsy/NN
glutamate/NN induced/VBN catalepsy/RB
acetazolamide/NN induced/VBN confusion/NN reaction/NN patients/NNS impairment/NN renal/JJ
acetazolamide/NN induced/VBN confusion/NN reaction/NN patients/NNS impairment/NN
acetazolamide/NN induced/VBN confusion/NN
azithromycin/NN beginning/VBG treatment/NN pharyngitis/NNS
methylprednisolone/JJ dexamethasone/JJ Corticosteroids/NNS agents/NNS mentioned/VBN associated/VBN development/NN hiccups/NNS
dexamethasone/JJ Corticosteroids/NNS agents/NNS mentioned/VBN associated/VBN development/NN hiccups/NNS
midazolam/NNP benzodiazepines/NNS Corticosteroids/NNS agents/NNS mentioned/VBN associated/VBN development/NN hiccups/NNS
benzodiazepines/NNS Corticosteroids/NNS agents/NNS mentioned/VBN associated/VBN development/NN hiccups/NNS
macrolide/JJ antimicrobials/NNS related/VBN reported/VBN hiccups/NNS
macrolides/NNS reaction/NN reports/NNS possible/JJ absence/NN explanation/NN hiccups/NNS
macrolide/JJ antimicrobials/NNS reported/VBN associated/VBN hiccups/NNS
S/NNP correlates/NNS psychosis/NNS
ketamine/JJ psychosis/NNS
N/NNP D/NNP aspartate/NN implicated/VBN pathophysiology/NN schizophrenia/NN
methyl/NN D/NNP aspartate/NN implicated/VBN pathophysiology/NN schizophrenia/NN
D/NNP aspartate/NN implicated/VBN pathophysiology/NN schizophrenia/NN
aspartate/NN implicated/VBN pathophysiology/NN schizophrenia/NN
NMDA/NNP aspartate/NN implicated/VBN pathophysiology/NN schizophrenia/NN
NMDA/NN ketamine/NN non/NN dose/NN leads/VBZ psychopathological/VB similar/JJ those/DT observed/VBN schizophrenia/NN
ketamine/NN non/NN dose/NN leads/VBZ psychopathological/VB similar/JJ those/DT observed/VBN schizophrenia/NN
ketamine/NN exacerbates/VBZ supporting/VBG hypothesis/NNS dysfunction/NN glutamatergic/JJ
ketamine/NN exacerbates/VBZ supporting/VBG hypothesis/NNS dysfunction/NN
ketamine/NN exacerbates/VBZ patients/NNS schizophrenia/NN
Ketamine/NNP induces/VBZ similar/JJ those/DT observed/VBN patients/NNS schizophrenia/NN
NMDA/NNP dysfunction/NN pathophysiology/NN schizophrenia/NN
glycine/JJ antagonist/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN muscle/NN
glycine/JJ antagonist/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN
5/CD decreased/VBD haloperidol/NN rigidity/NN muscle/NN
5/CD decreased/VBD haloperidol/NN rigidity/NN
7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN muscle/NN
7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN
dichlorokynurenic/JJ acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN muscle/NN
dichlorokynurenic/JJ acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN
acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN muscle/NN
acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN
5/CD acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN muscle/NN
5/CD acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN
7/CD 5/CD acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN muscle/NN
7/CD 5/CD acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN
DCKA/NNP 5/CD acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN muscle/NN
DCKA/NNP 5/CD acid/NN 7/CD 5/CD decreased/VBD haloperidol/NN rigidity/NN
Valsartan/NNP antagonist/NN treatment/NN hypertension/NN
angiotensin/NNP antagonist/NN treatment/NN hypertension/NN
II/NNP antagonist/NN treatment/NN hypertension/NN
amlodipine/NN efficacy/NN study/NN Valsartan/NNP antagonist/NN treatment/NN hypertension/NN
valsartan/NN receive/VB allocated/VBN outpatients/NNS hypertension/NN
amlodipine/NN valsartan/NN receive/VB allocated/VBN outpatients/NNS hypertension/NN
valsartan/NN amlodipine/JJ treatment/NN hypertension/NN
amlodipine/JJ treatment/NN hypertension/NN
levofloxacin/NN treatment/NN sinusitis/NNS
levofloxacin/NN efficacy/NN evaluate/VB treating/VBG sinusitis/NNS
levofloxacin/JJ mg/NN treatment/NN sinusitis/NNS
cAMP/NN aggregation/NN platelet/NN
cAMP/NN aggregation/NN
ifosfamide/NN induced/VBN cystitis/NNS hemorrhagic/JJ
ifosfamide/NN induced/VBN cystitis/NNS
mesna/NN administration/NN subcutaneous/VBZ prevent/VB ifosfamide/NN induced/VBN cystitis/NNS hemorrhagic/JJ
mesna/NN administration/NN subcutaneous/VBZ prevent/VB ifosfamide/NN induced/VBN cystitis/NNS
ifosfamide/NN toxicity/NN cystitis/NNS Hemorrhagic/JJ
ifosfamide/NN toxicity/NN cystitis/NNS
mesna/NN administering/VBG prevented/VBN toxicity/NN
ifosfamide/NN toxicity/NN
mesna/NN administering/VBG prevented/VBN toxicity/NN cystitis/NNS Hemorrhagic/JJ
mesna/NN administering/VBG prevented/VBN toxicity/NN cystitis/NNS
mesna/NN concentrations/NNS risk/NN emesis/NNS
mesna/NN taking/VBG patient/NN emesis/NNS
ifosfamide/NN experiences/VBZ mesna/NN taking/VBG patient/NN emesis/NNS
fluorouracil/NN underwent/VBD cancer/NN colorectal/JJ
fluorouracil/NN underwent/VBD cancer/NN
catecholamines/NNS levels/NNS contributed/VBN development/NN ABS/NNP
catecholamines/NNS neuropeptides/NNS caused/VBN diagnosis/NN cancer/NN
prazosin/JJ antagonized/JJ rigidity/NN muscular/JJ
prazosin/JJ antagonized/JJ rigidity/NN
iodixanol/NN osmolar/NN study/NN comparing/VBG effects/NNS nephrotoxic/JJ
creatinine/NN concentrations/NNS involved/VBD diabetes/NN
iodixanol/NN used/VBN patients/NNS high/JJ develop/VB likely/JJ CONCLUSIONS/NNS Nephropathy/NNP
isoproterenol/NN demand/NN hypotension/NN
oxygen/NN supply/NN mismatch/NN vs/VBP unknown/JJ damage/NN myocardial/JJ
oxygen/NN supply/NN mismatch/NN vs/VBP unknown/JJ damage/NN
oxygen/NN supply/NN mismatch/NN vs/VBP unknown/JJ demand/NN hypotension/NN hyperactivity/NN myocardial/JJ
oxygen/NN supply/NN mismatch/NN vs/VBP unknown/JJ demand/NN hypotension/NN hyperactivity/NN
oxygen/NN supply/NN mismatch/NN vs/VBP unknown/JJ demand/NN hypotension/NN
vincristine/NN treated/VBN Lymphoma/NNP patients/NNS Non/NNP
vincristine/NN treated/VBN Lymphoma/NNP Hodgkin/NNP
vincristine/NN treated/VBN Lymphoma/NNP Hodgkin/NNP '/POS
vincristine/NN treated/VBN Lymphoma/NNP s/NNP
vincristine/NN treated/VBN Lymphoma/NNP
vincristine/NN effects/NNS evaluate/VB investigated/VBN patients/NNS Non/NNP
vincristine/NN effects/NNS evaluate/VB investigated/VBN patients/NNS Lymphoma/NNP Hodgkin/NNP
vincristine/NN effects/NNS evaluate/VB investigated/VBN patients/NNS Lymphoma/NNP Hodgkin/NNP '/POS
vincristine/NN effects/NNS evaluate/VB investigated/VBN patients/NNS Lymphoma/NNP s/NNP
vincristine/NN effects/NNS evaluate/VB investigated/VBN patients/NNS Lymphoma/NNP
vincristine/NN dose/NN reversible/JJ signs/NNS neuropathy/NN
vincristine/JJ neuropathy/NN
fluocinolone/JJ implants/NNS treated/VBN pressure/NN patients/NNS uveitis/NNS
acetonide/NN implants/NNS treated/VBN pressure/NN patients/NNS uveitis/NNS
fluocinolone/JJ implant/NN treated/VBN uveitis/NNS
acetonide/NN implant/NN treated/VBN uveitis/NNS
FA/NNP implant/NN treated/VBN uveitis/NNS
diatrizoate/NN fibrillation/VBN Ventricular/NNP
diatrizoate/NN fibrillation/VBN
Renografin/VBG toxicity/NN
76/CD %/NN Renografin/VBG toxicity/NN
%/NN Renografin/VBG toxicity/NN
Hypaque/VBG that/DT compared/VBN toxicity/NN
76/CD %/NN Hypaque/VBG that/DT compared/VBN toxicity/NN
%/NN Hypaque/VBG that/DT compared/VBN toxicity/NN
Renografin/NNP occurred/VBD suggesting/VBG contribute/VBP toxicity/VB
Renografin/NNP occurred/VBD fibrillation/NNP Ventricular/NNP
Renografin/NNP occurred/VBD fibrillation/NNP
carteolol/JJ hydrochloride/NN effect/NN induced/VBN catalepsy/RB
hydrochloride/NN effect/NN induced/VBN catalepsy/RB
propranolol/NN those/DT studied/VBN effects/NNS carteolol/NN beta/NN induced/VBN catalepsy/RB
biperiden/NN propranolol/NN those/DT studied/VBN effects/NNS carteolol/NN beta/NN induced/VBN catalepsy/RB
carteolol/NN beta/NN induced/VBN catalepsy/RB
propranolol/NN Carteolol/NNP inhibited/VBD haloperidol/NN induced/VBN catalepsy/RB
biperiden/NN propranolol/NN Carteolol/NNP inhibited/VBD haloperidol/NN induced/VBN catalepsy/RB
Carteolol/NNP inhibited/VBD haloperidol/NN induced/VBN catalepsy/RB
dopamine/NN receptor/NN evoke/VB stimulating/VBG signs/NNS stereotypy/NN hyperlocomotion/NN
Carteolol/NNP evoke/VB stimulating/VBG signs/NNS stereotypy/NN hyperlocomotion/NN
haloperidol/NN induced/VBN adrenoceptor/VB expected/VBN effective/JJ treatment/NN akathisia/NN
carteolol/NN improves/VBZ haloperidol/NN induced/VBN catalepsy/RB
dopamine/JJ activity/NN due/JJ induced/VBN induced/VBN adrenoceptor/VB expected/VBN effective/JJ treatment/NN akathisia/NN
carteolol/NN improves/VBZ haloperidol/NN induced/VBN adrenoceptor/VB expected/VBN effective/JJ treatment/NN akathisia/NN
dopamine/JJ activity/NN due/JJ induced/VBN induced/VBN catalepsy/RB
corticosterone/NN effects/NNS related/VBN Dose/NNP induced/VBN neuropathy/NN
organophosphorus/NNS related/VBN Dose/NNP induced/VBN neuropathy/NN
corticosterone/NN concentrations/NNS induced/VBN neuropathy/JJ
TOTP/NNP %/NN hr/VBP 24/CD Neurotoxic/NN
organophosphorous/NNS compounds/NNS chickens/NNS measured/VBN values/NNS %/NN hr/VBP 24/CD Neurotoxic/NN
DFP/NNP TOTP/NNP %/NN hr/VBP 24/CD Neurotoxic/NN
tris/NN administration/NN shown/VBN protect/VB effects/NNS hepatotoxic/JJ
salt/NN administration/NN shown/VBN protect/VB effects/NNS hepatotoxic/JJ
CS/NNP administration/NN shown/VBN protect/VB effects/NNS hepatotoxic/JJ
cholesteryl/JJ administration/NN shown/VBN protect/VB effects/NNS hepatotoxic/JJ
hemisuccinate/JJ administration/NN shown/VBN protect/VB effects/NNS hepatotoxic/JJ
carbon/NN tetrachloride/NN adriamycin/JJ non/NN toxicity/NN
tetrachloride/NN adriamycin/JJ non/NN toxicity/NN
gamma/NN form/NN non/NN toxicity/NN
cholesteryloxybutyric/JJ acid/NN gamma/NN form/NN non/NN toxicity/NN
acid/NN gamma/NN form/NN non/NN toxicity/NN
adriamycin/JJ non/NN toxicity/NN
CS/NNP cytoprotection/NN mechanism/NN understanding/NN further/VB examined/VBD abilities/NNS non/NN toxicity/NN
CS/NNP abilities/NNS non/NN toxicity/NN
CS/NNP form/NN non/NN toxicity/NN
tris/JJ salt/NN form/NN non/NN toxicity/NN
salt/NN form/NN non/NN toxicity/NN
CSE/NNP salt/NN form/NN non/NN toxicity/NN
galactosamine/JJ chloroform/JJ toxicity/NN
chloroform/JJ toxicity/NN
acetaminophen/NN salt/NN form/NN non/NN toxicity/NN
CS/NNP dose/NN resulted/VBN protection/NN effects/NNS hepatotoxic/JJ
adriamycin/NN administration/NN effect/NN pretreatment/NN' pretreatment/NN dose/NN resulted/VBN protection/NN effects/NNS hepatotoxic/JJ
CHCl/NNP CCl/NNP effects/NNS protection/NN resulted/VBN dose/NN pretreatment/NN pretreatment/NN' effect/NN cardiotoxic/JJ
3/CD CHCl/NNP CCl/NNP effects/NNS protection/NN resulted/VBN dose/NN pretreatment/NN pretreatment/NN' effect/NN cardiotoxic/JJ
acetaminophen/CD CHCl/NNP CCl/NNP effects/NNS protection/NN resulted/VBN dose/NN pretreatment/NN pretreatment/NN' effect/NN cardiotoxic/JJ
CCl/NNP effects/NNS protection/NN resulted/VBN dose/NN pretreatment/NN pretreatment/NN' effect/NN cardiotoxic/JJ
4/CD CCl/NNP effects/NNS protection/NN resulted/VBN dose/NN pretreatment/NN pretreatment/NN' effect/NN cardiotoxic/JJ
galactosamine/NN CCl/NNP effects/NNS protection/NN resulted/VBN dose/NN pretreatment/NN pretreatment/NN' effect/NN cardiotoxic/JJ
CS/NNP dose/NN pretreatment/NN pretreatment/NN' effect/NN cardiotoxic/JJ
CS/NNP protection/NN mechanism/NN appear/VB dependent/JJ reactive/NN intermediate/JJ light/NN protection/NN observed/VBN hepatotoxicity/NN
edaravone/NN effect/NN vestibulotoxicity/NN
edaravone/NN induced/VBN vestibulotoxicity/RB
Edaravone/NNP has/VBZ used/VBN treat/VB infarction/NN cerebral/JJ
Edaravone/NNP has/VBZ used/VBN treat/VB infarction/NN
edaravone/NN suppresses/VBZ streptomycin/NN induced/VBN vestibulotoxicity/RB
misoprostol/NN effect/NN induced/VBN dysfunction/NN renal/JJ
misoprostol/NN effect/NN induced/VBN dysfunction/NN
misoprostol/NN Addition/NNP minimize/VB affecting/VBG control/NN pain/NN
misoprostol/NN Addition/NNP minimize/VB impairment/NN renal/JJ
misoprostol/NN Addition/NNP minimize/VB impairment/NN
ketoconazole/NN gentamicin/NN administration/NN aggravate/VB toxicity/NN
gentamicin/NN administration/NN aggravate/VB toxicity/NN
amphothericin/NNP B/NNP gentamicin/NN administration/NN potential/NN nephrotoxic/JJ
B/NNP gentamicin/NN administration/NN potential/NN nephrotoxic/JJ
CSA/NNP administration/NN aggravate/VB toxicity/NN
CSA/NNP toxicity/NN
amphothericin/NNP B/NNP gentamicin/NN administration/NN aggravate/VB toxicity/NN
B/NNP gentamicin/NN administration/NN aggravate/VB toxicity/NN
ketoconazole/NN gentamicin/NN administration/NN potential/NN nephrotoxic/JJ
gentamicin/NN administration/NN potential/NN nephrotoxic/JJ
Gentamicin/NNP increased/VBD nephrotoxicity/RB
Tiapride/NNP movements/NNS involuntary/JJ
Tiapride/NNP movements/NNS
metoclopramide/VB related/VBN derivative/NN Tiapride/NNP induced/VBN disease/NN Parkinson/NNP idiopathic/JJ
metoclopramide/VB related/VBN derivative/NN Tiapride/NNP induced/VBN disease/NN Parkinson/NNP
metoclopramide/VB related/VBN derivative/NN Tiapride/NNP induced/VBN disease/NN Parkinson/NNP '/POS
metoclopramide/VB related/VBN derivative/NN Tiapride/NNP induced/VBN disease/NN s/JJ
metoclopramide/VB related/VBN derivative/NN Tiapride/NNP induced/VBN disease/NN
Tiapride/NNP induced/VBN movements/NNS involuntary/JJ
Tiapride/NNP induced/VBN movements/NNS
metoclopramide/VB related/VBN derivative/NN Tiapride/NNP induced/VBN movements/NNS involuntary/JJ
metoclopramide/VB related/VBN derivative/NN Tiapride/NNP induced/VBN movements/NNS
levodopa/NN Tiapride/NNP induced/VBN disease/NN Parkinson/NNP idiopathic/JJ
levodopa/NN Tiapride/NNP induced/VBN disease/NN Parkinson/NNP
levodopa/NN Tiapride/NNP induced/VBN disease/NN Parkinson/NNP '/POS
levodopa/NN Tiapride/NNP induced/VBN disease/NN s/JJ
levodopa/NN Tiapride/NNP induced/VBN disease/NN
benzamide/NN derivative/NN Tiapride/NNP induced/VBN movements/NNS involuntary/JJ
benzamide/NN derivative/NN Tiapride/NNP induced/VBN movements/NNS
Tiapride/NNP induced/VBN disease/NN Parkinson/NNP idiopathic/JJ
Tiapride/NNP induced/VBN disease/NN Parkinson/NNP
Tiapride/NNP induced/VBN disease/NN Parkinson/NNP '/POS
Tiapride/NNP induced/VBN disease/NN s/JJ
Tiapride/NNP induced/VBN disease/NN
benzamide/NN derivative/NN Tiapride/NNP induced/VBN disease/NN Parkinson/NNP idiopathic/JJ
benzamide/NN derivative/NN Tiapride/NNP induced/VBN disease/NN Parkinson/NNP
benzamide/NN derivative/NN Tiapride/NNP induced/VBN disease/NN Parkinson/NNP '/POS
benzamide/NN derivative/NN Tiapride/NNP induced/VBN disease/NN s/JJ
benzamide/NN derivative/NN Tiapride/NNP induced/VBN disease/NN
Tiapride/NNP had/VBD effect/NN period/NN dystonia/NN
levodopa/NN effect/NN period/NN dystonia/NN
dopamine/JJ receptors/NNS group/NN overstimulation/NN caused/VBN levodopa/NN dyskinesias/NNS
ASA/NNP administered/VBN strains/NNS Dawley/NNP Sprague/NNP results/NNS compare/VB test/VB confounds/VBZ toxicity/NN gastrointestinal/JJ
ASA/NNP administered/VBN strains/NNS Dawley/NNP Sprague/NNP results/NNS compare/VB test/VB confounds/VBZ toxicity/NN
ASA/NNP malformations/NNS detection/NN confounds/VBZ toxicity/NN gastrointestinal/JJ
ASA/NNP malformations/NNS detection/NN confounds/VBZ toxicity/NN
ASA/NNP induces/VBZ focused/VBD suggested/VBD induce/VB defects/NNS defects/NNS midline/JJ
ASA/NNP induces/VBZ focused/VBD suggested/VBD induce/VB defects/NNS defects/NNS
ASA/NNP induces/VBZ focused/VBD suggested/VBD induce/VB defects/NNS defects/NNS MDs/NNP
ASA/NNP induces/VBZ focused/VBD suggested/VBD induce/VB defects/NNS defects/NNS rats/NNS MDs/NNP
benzodiazepine/JJ lorazepam/NN controlled/VBN Akathisia/NNP
lorazepam/NN controlled/VBN Akathisia/NNP
oxygen/NN saturations/NNS range/NN %/NN mean/VBP associated/VBN incidence/NN bradycardia/NN
sulindac/NN difluoromethylornithine/NN trial/NN audiograms/VBZ prevention/NN adenomas/NNS colorectal/JJ
sulindac/NN difluoromethylornithine/NN trial/NN audiograms/VBZ prevention/NN adenomas/NNS
difluoromethylornithine/NN trial/NN audiograms/VBZ prevention/NN adenomas/NNS colorectal/JJ
difluoromethylornithine/NN trial/NN audiograms/VBZ prevention/NN adenomas/NNS
difluoromethylornithine/NN months/NNS treatment/NN assessed/VBD recurrence/NN polyps/NNS adenomatous/JJ
difluoromethylornithine/NN months/NNS treatment/NN assessed/VBD recurrence/NN polyps/NNS
DFMO/NNP difluoromethylornithine/NN months/NNS treatment/NN assessed/VBD recurrence/NN polyps/NNS adenomatous/JJ
DFMO/NNP difluoromethylornithine/NN months/NNS treatment/NN assessed/VBD recurrence/NN polyps/NNS
sulindac/JJ assessed/VBD recurrence/NN polyps/NNS adenomatous/JJ
sulindac/JJ assessed/VBD recurrence/NN polyps/NNS
DFMO/NNP treatment/NN toxicity/NN
DFMO/NNP treatment/NN toxicity/NN loss/NN hearing/NN
DFMO/NNP treatment/NN toxicity/NN loss/NN
DFMO/NN subjects/NNS proportion/NN difference/NN group/NN experienced/VBD loss/NN hearing/NN
DFMO/NN subjects/NNS proportion/NN difference/NN group/NN experienced/VBD loss/NN
alcohol/NN use/VB interval/NN men/NNS interval/NN suffer/VB fever/NN hay/NN
alcohol/NN use/VB interval/NN men/NNS interval/NN suffer/VB fever/NN
alcohol/NN use/VB interval/NN men/NNS interval/NN suffer/VB fever/NN asthma/NN
ibuprofen/NN agents/NNS use/NN age/NN history/NN gout/NN
ibuprofen/NN agents/NNS use/NN age/NN preexisting/VBG disease/NN renal/JJ
ibuprofen/NN agents/NNS use/NN age/NN preexisting/VBG disease/NN
ibuprofen/NN agents/NNS use/NN age/NN history/NN stones/NNS kidney/NN
ibuprofen/NN agents/NNS use/NN age/NN history/NN stones/NNS
KF/NNP administration/NN ameliorated/VBD responses/NNS cataleptic/JJ
17837/CD KF/NNP administration/NN ameliorated/VBD responses/NNS cataleptic/JJ
adenosine/NN administration/NN agonist/NN manner/NN induced/VBN responses/NNS cataleptic/JJ
KF/NNP 17837/NNP reduced/VBD catalepsy/NN
17837/NNP reduced/VBD catalepsy/NN
KF/NNP 17837/NNP drug/NN treatment/NN parkinsonism/NN
17837/NNP drug/NN treatment/NN parkinsonism/NN
Serotonin/NN gene/NN psychosis/NNS
serotonin/NN receptor/NN targeted/JJ HT/VBP amphetamine/NN induced/VBN hyperactivity/RB
5/CD serotonin/NN receptor/NN targeted/JJ HT/VBP amphetamine/NN induced/VBN hyperactivity/RB
HT/NNP 5/CD serotonin/NN receptor/NN targeted/JJ HT/VBP amphetamine/NN induced/VBN hyperactivity/RB
5/CD use/NN corrected/VBN rats/NNS induced/VBN hyperactivity/RB
HT/VBP amphetamine/NN induced/VBN hyperactivity/RB
olanzapine/NN clozapine/NN such/JJ targeted/JJ HT/VBP amphetamine/NN induced/VBN hyperactivity/RB
d/SYM targeted/JJ HT/VBP amphetamine/NN induced/VBN hyperactivity/RB
amphetamine/NN induced/VBN hyperactivity/RB
clozapine/NN such/JJ targeted/JJ HT/VBP amphetamine/NN induced/VBN hyperactivity/RB
5/CD altered/VBD suggests/VBZ considered/VBN reflect/VB symptoms/NNS schizophrenia/NN
HT/NNP receptors/NNS involved/VBN considered/VBN reflect/VB symptoms/NNS schizophrenia/NN
5/CD altered/VBD suggests/VBZ considered/VBN involved/VBN pathophysiology/NN disorders/NNS psychotic/JJ
5/CD altered/VBD suggests/VBZ considered/VBN involved/VBN pathophysiology/NN disorders/NNS
HT/NNP receptors/NNS involved/VBN pathophysiology/NN disorders/NNS psychotic/JJ
HT/NNP receptors/NNS involved/VBN pathophysiology/NN disorders/NNS
methamphetamine/NN symptoms/NNS similar/JJ those/DT schizophrenia/NN paranoid/JJ
methamphetamine/NN symptoms/NNS similar/JJ those/DT schizophrenia/NN type/NN
methamphetamine/NN symptoms/NNS similar/JJ those/DT schizophrenia/NN
METH/NNP methamphetamine/NN symptoms/NNS similar/JJ those/DT schizophrenia/NN paranoid/JJ
METH/NNP methamphetamine/NN symptoms/NNS similar/JJ those/DT schizophrenia/NN type/NN
METH/NNP methamphetamine/NN symptoms/NNS similar/JJ those/DT schizophrenia/NN
5/CD induced/VBN psychosis/NNS
HT/NNP gene/NN 5/CD induced/VBN psychosis/NNS
ketamine/NN Injections/NNS produced/VBD depression/NN
dopamine/JJ receptors/NNS induce/VB catalepsy/RB
dopamine/JJ antagonists/NNS induced/VBN catalepsy/NN
dopamine/JJ antagonists/NNS induced/VBN catalepsy/NN tested/VBN determined/VBN subtypes/NNS involved/VBN catalepsy/NN
dopamine/JJ subtypes/NNS determined/VBN tested/VBN catalepsy/NN
dopamine/JJ subtypes/NNS involved/VBN catalepsy/NN
Dopamine/JJ fluphenazine/NN sulpiride/NN induced/VBN catalepsy/RB
SKF/NNP 38393/NNS D/NNP decreased/VBD catalepsy/NN
38393/NNS D/NNP decreased/VBD catalepsy/NN
quinpirole/NN decreased/VBD catalepsy/NN
SKF/NNP Combination/NNP cause/VB catalepsy/NN
38393/CD SKF/NNP Combination/NNP cause/VB catalepsy/NN
quinpirole/NN Combination/NNP cause/VB catalepsy/NN
dopamine/JJ antagonists/NNS induced/VBN catalepsy/NN
isoflurane/VB exposure/NN Acute/VB hepatitis/NN cholestatic/JJ
isoflurane/VB exposure/NN Acute/VB hepatitis/NN
isoflurane/NN exposure/NN hepatitis/NN cholestatic/JJ
isoflurane/NN exposure/NN hepatitis/NN
dipyrone/NN analgesia/NN
Isoflurane/NNP cause/VB hepatitis/NN cholestatic/JJ
Isoflurane/NNP cause/VB hepatitis/NN
metoprolol/NN Effect/NN glucagon/NN induced/VBN ischemia/NN myocardial/JJ
metoprolol/NN Effect/NN glucagon/NN induced/VBN ischemia/NN
metoprolol/NN metoprolol/NN Effect/NN glucagon/NN induced/VBN ischemia/NN myocardial/JJ
metoprolol/NN metoprolol/NN Effect/NN glucagon/NN induced/VBN ischemia/NN
metoprolol/NN attenuates/VBZ evidence/NN ischemia/NN myocardial/JJ
metoprolol/NN attenuates/VBZ evidence/NN ischemia/NN
epinephrine/NN mepivacaine/VB seen/VBN addition/NN damage/NN muscle/NN
epinephrine/NN mepivacaine/VB seen/VBN addition/NN damage/NN
lithium/NN toxicity/NN regurgitation/NN Tricuspid/JJ
lithium/NN toxicity/NN regurgitation/NN valve/NN
lithium/NN toxicity/NN regurgitation/NN
carbonate/NN toxicity/NN regurgitation/NN Tricuspid/JJ
carbonate/NN toxicity/NN regurgitation/NN valve/NN
carbonate/NN toxicity/NN regurgitation/NN
lithium/NN toxicity/NN
carbonate/NN toxicity/NN
lithium/NN level/NN newborn/JJ regurgitation/NN failure/NN congestive/JJ
lithium/NN level/NN newborn/JJ regurgitation/NN failure/NN heart/NN
lithium/NN level/NN newborn/JJ regurgitation/NN failure/NN
lithium/NN level/NN newborn/JJ regurgitation/NN tricuspid/JJ
lithium/NN level/NN newborn/JJ regurgitation/NN
lithium/NN level/NN newborn/JJ regurgitation/NN flutter/NN atrial/JJ
lithium/NN level/NN newborn/JJ regurgitation/NN flutter/NN
lithium/NN compounds/NNS exposed/VBN infants/NNS described/VBD disease/NN cardiac/JJ
lithium/NN compounds/NNS exposed/VBN infants/NNS described/VBD disease/NN
lithium/NN compounds/NNS exposed/VBN infants/NNS described/VBD patient/NN manifest/VB regurgitation/NN tricuspid/JJ
lithium/NN compounds/NNS exposed/VBN infants/NNS described/VBD patient/NN manifest/VB regurgitation/NN
lithium/NN compounds/NNS exposed/VBN infants/NNS described/VBD patient/NN manifest/VB regurgitation/NN flutter/NN atrial/JJ
lithium/NN compounds/NNS exposed/VBN infants/NNS described/VBD patient/NN manifest/VB regurgitation/NN flutter/NN
Lithium/NNP carbonate/NNP factor/NN incidence/NN disease/NN congenital/JJ
Lithium/NNP carbonate/NNP factor/NN incidence/NN disease/NN heart/NN
Lithium/NNP carbonate/NNP factor/NN incidence/NN disease/NN
carbonate/NNP factor/NN incidence/NN disease/NN congenital/JJ
carbonate/NNP factor/NN incidence/NN disease/NN heart/NN
carbonate/NNP factor/NN incidence/NN disease/NN
thallium/NN correlation/NN severity/NN stenosis/NNS coronary/JJ
thallium/NN correlation/NN severity/NN stenosis/NNS
dipyridamole/NN had/VBD 12/CD dogs/NNS stenosis/NNS coronary/JJ
dipyridamole/NN had/VBD 12/CD dogs/NNS stenosis/NNS
Thallium/NNP induced/VBN hyperemia/NN
valdecoxib/NN placebo/NN events/NNS patients/NNS arthritis/NN
valdecoxib/NN placebo/NN events/NNS thrombotic/JJ
valdecoxib/NN data/NNS arthritis/NN rheumatoid/JJ
valdecoxib/NN data/NNS arthritis/NN
valdecoxib/NN data/NNS inhibitor/NN patients/NNS osteoarthritis/NNS
diclofenac/NN bid/NN NSAID/NNP valdecoxib/NN data/NNS osteoarthritis/NNS
naproxen/NN bid/NN bid/NN NSAID/NNP valdecoxib/NN trials/NNS rheumatoid/JJ
naproxen/NN bid/NN bid/NN NSAID/NNP valdecoxib/NN trials/NNS arthritis/NN
valdecoxib/NN trials/NNS rheumatoid/JJ
valdecoxib/NN trials/NNS arthritis/NN
ibuprofen/NN tid/NN bid/NN NSAID/NNP valdecoxib/NN analyzing/VBG determined/VBN incidence/NN events/NNS thrombotic/JJ
ibuprofen/NN tid/NN bid/NN NSAID/NNP valdecoxib/NN analyzing/VBG determined/VBN incidence/NN cardiac/JJ thrombotic/NN
ibuprofen/NN tid/NN bid/NN NSAID/NNP valdecoxib/NN trials/NNS rheumatoid/JJ
ibuprofen/NN tid/NN bid/NN NSAID/NNP valdecoxib/NN trials/NNS arthritis/NN
diclofenac/NN bid/NN NSAID/NNP valdecoxib/NN trials/NNS rheumatoid/JJ
diclofenac/NN bid/NN NSAID/NNP valdecoxib/NN trials/NNS arthritis/NN
valdecoxib/NN data/NNS osteoarthritis/NNS
ibuprofen/NN tid/NN bid/NN NSAID/NNP valdecoxib/NN data/NNS osteoarthritis/NNS
naproxen/NN bid/NN bid/NN NSAID/NNP valdecoxib/NN data/NNS osteoarthritis/NNS
valdecoxib/NN analyzing/VBG determined/VBN incidence/NN events/NNS thrombotic/JJ
valdecoxib/NN analyzing/VBG determined/VBN incidence/NN cardiac/JJ thrombotic/NN
naproxen/NN bid/NN bid/NN NSAID/NNP valdecoxib/NN analyzing/VBG determined/VBN incidence/NN events/NNS thrombotic/JJ
naproxen/NN bid/NN bid/NN NSAID/NNP valdecoxib/NN analyzing/VBG determined/VBN incidence/NN cardiac/JJ thrombotic/NN
diclofenac/NN bid/NN NSAID/NNP valdecoxib/NN analyzing/VBG determined/VBN incidence/NN events/NNS thrombotic/JJ
diclofenac/NN bid/NN NSAID/NNP valdecoxib/NN analyzing/VBG determined/VBN incidence/NN cardiac/JJ thrombotic/NN
valdecoxib/NNP similar/JJ Crude/NN incidences/NNS events/NNS thrombotic/JJ
valdecoxib/JJ dose/NN similar/JJ risk/NN events/NNS thrombotic/JJ
valdecoxib/NN aspirin/NN nonusers/NNS higher/JJR risk/NN Thrombotic/JJ
valdecoxib/NN doses/NNS therapeutic/JJ treatment/NN associated/VBN incidence/NN events/NNS patients/NNS rheumatoid/JJ
valdecoxib/NN doses/NNS therapeutic/JJ treatment/NN associated/VBN incidence/NN events/NNS patients/NNS arthritis/NN
valdecoxib/NN doses/NNS therapeutic/JJ treatment/NN associated/VBN incidence/NN events/NNS osteoarthritis/NNS
valdecoxib/NN doses/NNS therapeutic/JJ treatment/NN associated/VBN incidence/NN events/NNS thrombotic/JJ
bromocriptine/JJ received/VBN inhibition/NN
bromocriptine/JJ received/VBN inhibition/NN lactation/NN of/IN
bromocriptine/JJ received/VBN inhibition/NN lactation/NN
bromocriptine/JJ received/VBN seen/VBN patients/NNS history/NN psychiatric/JJ
Bromocriptine/NNP associated/VBN psychosis/NNS patients/NNS receiving/VBG drug/NN disease/NN Parkinson/NNP
Bromocriptine/NNP associated/VBN psychosis/NNS patients/NNS receiving/VBG drug/NN disease/NN Parkinson/NNP '/POS
Bromocriptine/NNP associated/VBN psychosis/NNS patients/NNS receiving/VBG drug/NN disease/NN s/JJ
Bromocriptine/NNP associated/VBN psychosis/NNS patients/NNS receiving/VBG drug/NN disease/NN
nitric/JJ oxide/NN levels/NNS gene/NN headache/NN patients/NNS tension/NN
nitric/JJ oxide/NN levels/NNS gene/NN type/NN
nitric/JJ oxide/NN levels/NNS gene/NN type/NN headache/NN
oxide/NN levels/NNS gene/NN headache/NN patients/NNS tension/NN
oxide/NN levels/NNS gene/NN type/NN
oxide/NN levels/NNS gene/NN type/NN headache/NN
nitric/JJ oxide/NN induced/VBN headache/NN headaches/NNS primary/JJ
nitric/JJ oxide/NN induced/VBN headache/NN headaches/NNS
oxide/NN induced/VBN headache/NN headaches/NNS primary/JJ
oxide/NN induced/VBN headache/NN headaches/NNS
NO/RB oxide/NN induced/VBN headache/NN headaches/NNS primary/JJ
NO/RB oxide/NN induced/VBN headache/NN headaches/NNS
NO/DT donor/NN glyceryl/JJ trinitrate/NN induced/VBN patients/NNS tension/NN
NO/DT donor/NN glyceryl/JJ trinitrate/NN induced/VBN headache/NN headache/NN type/NN
NO/DT donor/NN glyceryl/JJ trinitrate/NN induced/VBN headache/NN headache/NN
glyceryl/JJ trinitrate/NN induced/VBN patients/NNS tension/NN
glyceryl/JJ trinitrate/NN induced/VBN headache/NN headache/NN type/NN
glyceryl/JJ trinitrate/NN induced/VBN headache/NN headache/NN
trinitrate/NN induced/VBN patients/NNS tension/NN
trinitrate/NN induced/VBN headache/NN headache/NN type/NN
trinitrate/NN induced/VBN headache/NN headache/NN
GTN/NNP trinitrate/NN induced/VBN patients/NNS tension/NN
GTN/NNP trinitrate/NN induced/VBN headache/NN headache/NN type/NN
GTN/NNP trinitrate/NN induced/VBN headache/NN headache/NN
Levodopa/NNP induced/VBN dystonia/NN palsy/NN progressive/JJ
Levodopa/NNP induced/VBN dystonia/NN palsy/NN supranuclear/NN
Levodopa/NNP induced/VBN dystonia/NN palsy/NN
Levodopa/NNP induced/VBN reported/VBN disease/NN atrophy/NN multiple/JJ
Levodopa/NNP induced/VBN reported/VBN disease/NN atrophy/NN system/NN
Levodopa/NNP induced/VBN reported/VBN disease/NN atrophy/NN
Levodopa/NNP induced/VBN reported/VBN disease/NN Parkinson/NNP
Levodopa/NNP induced/VBN reported/VBN disease/NN Parkinson/NNP '/POS
Levodopa/NNP induced/VBN reported/VBN disease/NN s/JJ
Levodopa/NNP induced/VBN reported/VBN disease/NN
Levodopa/NNP induced/VBN reported/VBN dyskinesias/NNS
levodopa/NN case/NN describe/VBP dystonia/NNP patient/NN PSP/NNP
levodopa/NN case/NN describe/VBP highlight/VB importance/NN recognizing/VBG complication/NN management/NN PSP/NNP
levodopa/NN case/NN describe/VBP dystonia/NNP Oromandibular/NNP
levodopa/NN case/NN describe/VBP dystonia/NNP
levodopa/NN case/NN describe/VBP dystonia/NNP OMD/NNP
VPA/NNP treatment/NN tonic/NN
VPA/NNP convulsions/NNS clonic/JJ
VPA/NNP convulsions/NNS
VPA/NNP administration/NN consider/VBP result/NN combination/NN factors/NNS weakness/NN
VPA/NNP administration/NN consider/VBP result/NN combination/NN factors/NNS weakness/NN system/NN of/IN
VPA/NNP administration/NN consider/VBP result/NN combination/NN factors/NNS weakness/NN system/NN the/DT
VPA/NNP administration/NN consider/VBP result/NN combination/NN factors/NNS weakness/NN system/NN central/JJ
VPA/NNP administration/NN consider/VBP result/NN combination/NN factors/NNS weakness/NN system/NN nervous/JJ
VPA/NNP administration/NN consider/VBP result/NN combination/NN factors/NNS weakness/NN system/NN
furosemide/NN effect/NN nephropathy/NN
furosemide/NN efficacy/NN determine/VB fluids/NNS prevention/NN nephropathy/NN
creatinine/NN rise/NN pretreated/VBD function/NN Renal/JJ
creatinine/NN rise/NN pretreated/VBD function/NN
creatinine/NN rise/NN pretreated/VBD function/NN deteriorated/VBN significantly/RB
creatinine/NN rise/NN pretreated/VBD function/NN deteriorated/VBN
furosemide/NN associated/VBN failure/NN Renal/JJ
furosemide/NN associated/VBN failure/NN
furosemide/NN associated/VBN loss/NN weight/NN
furosemide/NN associated/VBN loss/NN
Furosemide/NNP deleterious/VBN prevention/NN nephropathy/NN
amphetamine/NN cocaine/NN use/NN stroke/NN hemorrhagic/JJ ischemic/JJ
cocaine/NN use/NN stroke/NN hemorrhagic/JJ ischemic/JJ
Pyrazinamide/NNP have/VB effects/NNS disorders/NNS toxicity/NN hyperuricemia/NN
Pyrazinamide/NNP have/VB effects/NNS disorders/NNS hepatic/JJ
Pyrazinamide/NNP have/VB effects/NNS disorders/NNS toxicity/NN
lovastatin/NN Efficacy/NN women/NNS hypercholesterolemia/NN
lovastatin/NN efficacy/NN evaluate/VB women/NNS hypercholesterolemia/NN
creatine/JJ elevations/NNS symptoms/NNS defined/VBN rare/JJ Myopathy/RB
Lovastatin/NNP effective/JJ therapy/NN hypercholesterolemia/NN
dopamine/JJ agonist/NN use/NN 86929/CD study/NN levodopa/NN parkinsonian/NN
A/NNP agonist/NN use/NN 86929/CD study/NN levodopa/NN parkinsonian/NN
86929/CD study/NN levodopa/NN parkinsonian/NN
levodopa/NN parkinsonian/NN
dopamine/JJ agonists/NNS utility/NN treatment/NN disease/NN Parkinson/NNP
dopamine/JJ agonists/NNS utility/NN treatment/NN disease/NN Parkinson/NNP '/POS
dopamine/JJ agonists/NNS utility/NN treatment/NN disease/NN s/JJ
dopamine/JJ agonists/NNS utility/NN treatment/NN disease/NN
dopamine/JJ agonists/NNS utility/NN treatment/NN disease/NN PD/NNP
DA/NNP agonists/NNS utility/NN treatment/NN disease/NN Parkinson/NNP
DA/NNP agonists/NNS utility/NN treatment/NN disease/NN Parkinson/NNP '/POS
DA/NNP agonists/NNS utility/NN treatment/NN disease/NN s/JJ
DA/NNP agonists/NNS utility/NN treatment/NN disease/NN
DA/NNP agonists/NNS utility/NN treatment/NN disease/NN PD/NNP
A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
86929/NNP -LSB-/NNP A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
86929/NNP -LSB-/NNP A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
-LSB-/NNP A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
-RSB-/NNP A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
-LSB-/CD 5/CD aR/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
5/CD aR/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
aR/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
11/CD -RSB-/NNS aR/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
bS/NN -RSB-/NNS aR/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
-RSB-/NNS aR/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
4/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
5/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
5/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
a/NNP b/NNS A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
6/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
7/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
11/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
b/NNS A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
hexahydro/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
2/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
propyl/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
3/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
thia/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
5/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
+/JJ azacyclopent/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
++/JJ azacyclopent/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
azacyclopent/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
1/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
ena/CD -LSB-/CD 1/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
-LSB-/CD 1/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
c/SYM 1/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
-RSB-/RB phenathrene/JJ 1/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
phenathrene/JJ 1/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
9/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
10/CD A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
diol/NN A/NNP 0/CD doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
-LSB-/NNP A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
-RSB-/NNP A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
-LSB-/CD 5/CD aR/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
5/CD aR/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
aR/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
11/CD -RSB-/NNS aR/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
bS/NN -RSB-/NNS aR/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
-RSB-/NNS aR/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
4/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
5/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
5/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
a/NNP b/NNS A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
6/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
7/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
11/CD b/NNS A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
b/NNS A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
hexahydro/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
2/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
propyl/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
3/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
thia/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
5/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
+/JJ azacyclopent/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
++/JJ azacyclopent/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
azacyclopent/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
1/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
ena/CD -LSB-/CD 1/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
-LSB-/CD 1/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
c/SYM 1/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
-RSB-/RB phenathrene/JJ 1/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
phenathrene/JJ 1/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
9/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
10/CD A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
diol/NN A/NNP 0/CD doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
1/CD study/NN dose/NN conducted/VBD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
phenyl/NNP -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
-/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
1/CD -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
2/CD -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
3/CD -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
6/CD -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
tetrahydropyridine/NN -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
1/CD study/NN dose/NN conducted/VBD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
phenyl/NNP -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
-/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
1/CD -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
2/CD -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
3/CD -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
6/CD -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
tetrahydropyridine/NN -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
MPTP/NNP tetrahydropyridine/NN -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN dyskinesias/NNS
MPTP/NNP tetrahydropyridine/NN -/NNP 4/CD methyl/NN exposed/VBN monkeys/NNS primed/VBN induced/VBN evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
DA/NNP D/NNP doses/NNS evaluate/VB induced/VBN dyskinesias/NNS
DA/NNP D/NNP doses/NNS evaluate/VB locomotor/NN effects/NNS dyskinetic/JJ
LY/NNP levodopa/NNP induced/VBN parkinsonism/NN
171555/CD efficacious/JJ alleviating/VBG MPTP/NNP induced/VBN parkinsonism/NN
LY/NNP with/IN efficacious/JJ alleviating/VBG MPTP/NNP induced/VBN parkinsonism/NN
171555/CD 86929/CD efficacious/JJ alleviating/VBG MPTP/NNP induced/VBN parkinsonism/NN
A/NNP administration/NN 86929/CD efficacious/JJ induced/VBN dyskinesias/NNS
86929/CD efficacious/JJ induced/VBN dyskinesias/NNS
MPTP/NNP alleviating/VBG efficacious/JJ induced/VBN dyskinesias/NNS
A/NNP administration/NN 86929/CD efficacious/JJ alleviating/VBG MPTP/NNP induced/VBN parkinsonism/NN
86929/CD efficacious/JJ alleviating/VBG MPTP/NNP induced/VBN parkinsonism/NN
LY/NNP levodopa/NNP induced/VBN MPTP/NNP alleviating/VBG efficacious/JJ induced/VBN dyskinesias/NNS
171555/CD efficacious/JJ induced/VBN dyskinesias/NNS
LY/NNP with/IN efficacious/JJ induced/VBN dyskinesias/NNS
171555/CD 86929/CD efficacious/JJ induced/VBN dyskinesias/NNS
levodopa/NNP induced/VBN parkinsonism/NN
levodopa/NN reproduce/VB likely/JJ efficacious/JJ alleviating/VBG MPTP/NNP induced/VBN parkinsonism/NN
levodopa/NN challenge/NN 171555/CD 86929/CD efficacious/JJ alleviating/VBG MPTP/NNP induced/VBN parkinsonism/NN
A/NNP efficacy/NN duration/NN 86929/CD agents/NNS tools/NNS PD/NNP
86929/CD agents/NNS tools/NNS PD/NNP
DA/NNP agents/NNS tools/NNS PD/NNP
fluoxetine/NN exposure/NN induces/VBZ hypertension/NN fetal/JJ
fluoxetine/NN exposure/NN induces/VBZ hypertension/NN pulmonary/JJ
fluoxetine/NN exposure/NN induces/VBZ hypertension/NN
fluoxetine/JJ exposure/NN resulted/VBD hypertension/NN fetal/JJ
fluoxetine/JJ exposure/NN resulted/VBD hypertension/NN pulmonary/JJ
fluoxetine/JJ exposure/NN resulted/VBD hypertension/NN
acetaminophen/NN NSAID/NN g/NN starting/VBG diagnosis/NN SAH/NNP aneurysmal/JJ
acetaminophen/VBN g/NN starting/VBG diagnosis/NN SAH/NNP aneurysmal/JJ
ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN aneurysmal/JJ
ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN subarachnoid/JJ
ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN
ketoprofen/NN receive/VB randomized/VBN Patients/NNS SAH/NNP
ketoprofen/NN NSAID/NN g/NN starting/VBG diagnosis/NN SAH/NNP
ketoprofen/VBN ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN aneurysmal/JJ
ketoprofen/VBN ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN subarachnoid/JJ
ketoprofen/VBN ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN
ketoprofen/VBN ketoprofen/NN receive/VB randomized/VBN Patients/NNS SAH/NNP
ketoprofen/VBN ketoprofen/NN NSAID/NN g/NN starting/VBG diagnosis/NN SAH/NNP
acetaminophen/NN NSAID/NN ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN aneurysmal/JJ
acetaminophen/NN NSAID/NN ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN subarachnoid/JJ
acetaminophen/NN NSAID/NN ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN
acetaminophen/NN NSAID/NN ketoprofen/NN receive/VB randomized/VBN Patients/NNS SAH/NNP
acetaminophen/NN NSAID/NN g/NN starting/VBG diagnosis/NN SAH/NNP
acetaminophen/VBN g/NN NSAID/NN ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN aneurysmal/JJ
acetaminophen/VBN g/NN NSAID/NN ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN subarachnoid/JJ
acetaminophen/VBN g/NN NSAID/NN ketoprofen/NN receive/VB randomized/VBN Patients/NNS hemorrhage/NN
acetaminophen/VBN g/NN NSAID/NN ketoprofen/NN receive/VB randomized/VBN Patients/NNS SAH/NNP
acetaminophen/VBN g/NN starting/VBG diagnosis/NN SAH/NNP
ketoprofen/NN NSAID/NN g/NN starting/VBG diagnosis/NN SAH/NNP aneurysmal/JJ
ketoprofen/VBN ketoprofen/NN NSAID/NN g/NN starting/VBG diagnosis/NN SAH/NNP aneurysmal/JJ
adenosine/JJ diphosphate/NN microM/NN induced/VBN aggregation/NN platelet/NN
adenosine/JJ diphosphate/NN microM/NN induced/VBN aggregation/NN
diphosphate/NN microM/NN induced/VBN aggregation/NN platelet/NN
diphosphate/NN microM/NN induced/VBN aggregation/NN
acetaminophen/NN group/NN increased/VBD aggregation/NN platelet/NN
acetaminophen/NN group/NN increased/VBD aggregation/NN
acetaminophen/NN group/NN increased/VBD results/NNS platelet/JJ
acetaminophen/NN group/NN increased/VBD results/NNS aggregation/NN
Ketoprofen/JJ platelet/NN function/VBP patients/NNS SAH/NNP
acetaminophen/RB impaired/JJ Ketoprofen/JJ platelet/NN function/VBP patients/NNS SAH/NNP
ketoprofen/NN used/VBN surgery/NN aneurysms/NNS artery/NN
ketoprofen/NN used/VBN surgery/NN aneurysms/NNS
ketoprofen/NN used/VBN pose/VB hemorrhage/NN
dopamine/NNP blockade/NN result/NN thought/VBN syndrome/NN Neuroleptic/JJ
dopamine/NNP blockade/NN result/NN thought/VBN syndrome/NN malignant/JJ
dopamine/NNP blockade/NN result/NN thought/VBN syndrome/NN
risperidone/NN impart/VB frequency/NN symptoms/NNS extrapyramidal/JJ
risperidone/NN impart/VB frequency/NN symptoms/NNS
Quinidine/RB responsible/JJ hepatitis/NN
cytosine/NN treatment/NN patient/NN leukemia/NN acute/JJ
cytosine/NN treatment/NN patient/NN leukemia/NN myeloid/JJ
cytosine/NN treatment/NN patient/NN leukemia/NN
arabinoside/NN treatment/NN patient/NN leukemia/NN acute/JJ
arabinoside/NN treatment/NN patient/NN leukemia/NN myeloid/JJ
arabinoside/NN treatment/NN patient/NN leukemia/NN
cytosine/NN arabinoside/NN high/JJ toxicity/NN
arabinoside/NN high/JJ toxicity/NN
cytosine/NN arabinoside/NN high/JJ toxicity/NN recognized/VBN reported/VBN toxicity/NN
arabinoside/NN high/JJ toxicity/NN recognized/VBN reported/VBN toxicity/NN
cytosine/JJ arabinoside/NN toxicity/NN reported/VBN recognized/VBN toxicity/NN
arabinoside/NN toxicity/NN reported/VBN recognized/VBN toxicity/NN
cytosine/JJ arabinoside/NN toxicity/NN
arabinoside/NN toxicity/NN
cytosine/NN arabinoside/NN high/JJ course/NN resulted/VBD complained/VBD numbness/NNS
arabinoside/NN high/JJ course/NN resulted/VBD complained/VBD numbness/NNS
methylprednisolone/VB responded/VBD worsened/VBD development/NN graft/NN
methylprednisolone/VB responded/VBD worsened/VBD versus/CC
methylprednisolone/VB responded/VBD worsened/VBD worsened/VBD' disease/NN -/IN
methylprednisolone/VB responded/VBD worsened/VBD worsened/VBD' disease/NN host/NN
methylprednisolone/VB responded/VBD worsened/VBD worsened/VBD' disease/NN
methylprednisolone/VB responded/VBD worsened/VBD resolving/VBG neuropathy/NN
Sorafenib/NNP induced/VBN due/JJ infarction/NN myocardial/JJ
Sorafenib/NNP induced/VBN due/JJ infarction/NN
nicorandil/NN Addition/NNP reduced/VBD maintained/VBD status/NN stable/JJ
nicorandil/NN Addition/NNP reduced/VBD maintained/VBD status/NN angina/NN
acetaminophen/NN overdose/NN
fenfluramine/NN users/NNS disease/NN valvular/NN
fenfluramine/NN users/NNS disease/NN heart/NN
fenfluramine/NN users/NNS disease/NN
dexfenfluramine/NN fenfluramine/NN users/NNS disease/NN valvular/NN
dexfenfluramine/NN fenfluramine/NN users/NNS disease/NN heart/NN
dexfenfluramine/NN fenfluramine/NN users/NNS disease/NN
fenfluramine/NN users/NNS %/NN had/VBD disease/NN valvular/NN
fenfluramine/NN users/NNS %/NN had/VBD disease/NN
dexfenfluramine/NN fenfluramine/NN users/NNS %/NN had/VBD disease/NN valvular/NN
dexfenfluramine/NN fenfluramine/NN users/NNS %/NN had/VBD disease/NN
fenfluramine/NN users/NNS abnormalities/NNS valvular/NN
fenfluramine/NN users/NNS abnormalities/NNS
dexfenfluramine/NN fenfluramine/NN users/NNS abnormalities/NNS valvular/NN
dexfenfluramine/NN fenfluramine/NN users/NNS abnormalities/NNS
phentermine/NN developed/VBN disease/NN valvular/NN
phentermine/NN developed/VBN disease/NN heart/NN
phentermine/NN developed/VBN disease/NN
fenfluramine/NN receiving/VBG patients/NNS RESULTS/NNS phentermine/NN developed/VBN disease/NN valvular/NN
fenfluramine/NN receiving/VBG patients/NNS RESULTS/NNS phentermine/NN developed/VBN disease/NN heart/NN
fenfluramine/NN receiving/VBG patients/NNS RESULTS/NNS phentermine/NN developed/VBN disease/NN
D/NNP treated/VBN cirrhosis/NNS primary/JJ
D/NNP treated/VBN cirrhosis/NNS biliary/NN
D/NNP treated/VBN cirrhosis/NNS
penicillamine/VBP case/NN cirrhosis/NNS primary/JJ
penicillamine/VBP case/NN cirrhosis/NNS biliary/NN
penicillamine/VBP case/NN cirrhosis/NNS
D/NNP used/VBN diseases/NNS rheumatologic/JJ
D/NNP used/VBN diseases/NNS
penicillamine/NN D/NNP used/VBN diseases/NNS rheumatologic/JJ
penicillamine/NN D/NNP used/VBN diseases/NNS
D/NNP used/VBN limits/VBZ toxicity/NN
penicillamine/NN D/NNP used/VBN limits/VBZ toxicity/NN
D/NNP complications/NNS one/CD develop/VB dermatomyositis/NNS
penicillamine/VBP Polymyositis/NNS develop/VB dermatomyositis/NNS
D/NNP receiving/VBG developed/VBD cirrhosis/NNS primary/JJ
D/NNP receiving/VBG developed/VBD cirrhosis/NNS biliary/NN
D/NNP receiving/VBG developed/VBD cirrhosis/NNS
penicillamine/JJ therapy/NN D/NNP receiving/VBG developed/VBD cirrhosis/NNS primary/JJ
penicillamine/JJ therapy/NN D/NNP receiving/VBG developed/VBD cirrhosis/NNS biliary/NN
penicillamine/JJ therapy/NN D/NNP receiving/VBG developed/VBD cirrhosis/NNS
D/NNP dermatomyositis/VBZ
penicillamine/JJ therapy/NN followed/VBN D/NNP dermatomyositis/VBZ
atenolol/NN resolved/VBD arrhythmia/NN
atenolol/NN week/NN stopping/VBG disappeared/VBD arrhythmia/NN
salbutamol/NN agonist/NN beta/NN known/VBN induce/VB tachycardia/NN
atenolol/NN blocker/NN beta/NN relieve/VB swallowing/VBG originating/VBG reflexes/NNS trigger/NN beta/NN known/VBN induce/VB tachycardia/NN
imipenem/NN therapy/NN activity/NN Seizure/JJ
imipenem/JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN cerebral/JJ
imipenem/JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN vascular/NN
imipenem/JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN
//JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN cerebral/JJ
//JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN vascular/NN
//JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN
cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN cerebral/JJ
cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN vascular/NN
cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN
imipenem/JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN CVA/NNP
//JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN CVA/NNP
cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN accident/NN CVA/NNP
imipenem/JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN head/NN
imipenem/JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN
//JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN head/NN
//JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN
cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN head/NN
cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN
imipenem/JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN evidence/NN disease/NN renal/JJ
imipenem/JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN evidence/NN disease/NN
//JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN evidence/NN disease/NN renal/JJ
//JJ cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN evidence/NN disease/NN
cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN evidence/NN disease/NN renal/JJ
cilastatin/NN doses/NNS receiving/VBG developed/VBD patients/NNS history/NN trauma/NN evidence/NN disease/NN
phenytoin/NN doses/NNS controlled/VBN seizures/NNS
beta/NN doses/NNS received/VBN antibiotics/VBZ evidence/NN activity/NN seizure/NN
lactam/NN antibiotics/VBZ evidence/NN activity/NN seizure/NN
steroids/NNS using/VBG seen/VBN tumors/NNS liver/NN
steroids/NNS using/VBG seen/VBN tumors/NNS
digoxin/NN group/NN patients/NNS capacity/NN selected/VBN patients/NNS rheumatic/JJ
digoxin/NN group/NN patients/NNS capacity/NN selected/VBN patients/NNS heart/NN
digoxin/NN group/NN patients/NNS capacity/NN selected/VBN patients/NNS disease/NN
lithium/NN therapy/NN secondary/JJ developed/VBN attacks/NNS syncopal/JJ
lithium/NN therapy/NN secondary/JJ developed/VBN attacks/NNS
lithium/NN levels/NNS remained/VBD attacks/NNS syncopal/JJ
lithium/NN levels/NNS remained/VBD attacks/NNS
Vancomycin/NNP curative/JJ %/NN patients/NNS infection/NN
aminoglycoside/NN receiving/VBG patients/NNS confined/VBN nephrotoxicity/NN
aminoglycoside/NN receiving/VBG patients/NNS confined/VBN nephrotoxicity/NN ototoxicity/NN
vancomycin/NN aminoglycoside/NN receiving/VBG patients/NNS confined/VBN nephrotoxicity/NN
aminoglycoside/NN receiving/VBG patients/NNS confined/VBN occurred/VBD Thrombophlebitis/NNS
vancomycin/NN constitutes/VBZ infections/NNS
6/CD man/NN leukemia/NN acute/JJ
6/CD man/NN leukemia/NN lymphocytic/JJ
6/CD man/NN leukemia/NN
thioguanine/VBN year/NN man/NN leukemia/NN acute/JJ
thioguanine/VBN year/NN man/NN leukemia/NN lymphocytic/JJ
thioguanine/VBN year/NN man/NN leukemia/NN
Unfractionated/NNP sodium/NN BACKGROUND/NNP used/VBN prevent/VB thrombosis/NNS
heparin/NN sodium/NN BACKGROUND/NNP used/VBN prevent/VB thrombosis/NNS
sodium/NN BACKGROUND/NNP used/VBN prevent/VB thrombosis/NNS
UFH/NNP sodium/NN BACKGROUND/NNP used/VBN prevent/VB thrombosis/NNS
low/JJ sodium/NN BACKGROUND/NNP used/VBN prevent/VB thrombosis/NNS
molecular/JJ heparin/NN used/VBN prevent/VB thrombosis/NNS
weight/NN heparin/NN used/VBN prevent/VB thrombosis/NNS
heparin/NN used/VBN prevent/VB thrombosis/NNS
heparin/NN induced/VBN negative/JJ test/NN platelet/JJ
heparin/NN induced/VBN negative/JJ test/NN aggregation/NN
dobutamine/JJ infusion/NN managed/VBN admitted/VBN patient/NN known/VBN have/VB cardiomyopathy/NN hypertrophic/JJ
dobutamine/JJ infusion/NN managed/VBN admitted/VBN patient/NN known/VBN have/VB cardiomyopathy/NN
dobutamine/JJ infusion/NN managed/VBN admitted/VBN failure/NN biventricular/NN
dobutamine/JJ infusion/NN managed/VBN admitted/VBN failure/NN
propofol/JJ infusion/NN continued/VBN available/JJ detect/VB hyperthermia/NN malignant/JJ
propofol/JJ infusion/NN continued/VBN available/JJ detect/VB hyperthermia/NN
butylated/JJ hydroxyanisole/NN induced/VBN rats/NNS carcinogenesis/NNS acetate/NN effect/NN carcinogenic/JJ
hydroxyanisole/NN induced/VBN rats/NNS carcinogenesis/NNS acetate/NN effect/NN carcinogenic/JJ
retinyl/JJ acetate/NN carcinogenesis/NNS forestomach/JJ
retinyl/JJ acetate/NN carcinogenesis/NNS
acetate/NN carcinogenesis/NNS forestomach/JJ
acetate/NN carcinogenesis/NNS
retinyl/JJ acetate/NN effect/NN carcinogenic/JJ
acetate/NN effect/NN carcinogenic/JJ
retinyl/JJ acetate/NN effect/NN hydroxyanisole/NN tumorigenesis/NNS forestomach/NN
retinyl/JJ acetate/NN effect/NN hydroxyanisole/NN tumorigenesis/NNS
acetate/NN effect/NN hydroxyanisole/NN tumorigenesis/NNS forestomach/NN
acetate/NN effect/NN hydroxyanisole/NN tumorigenesis/NNS
RA/NNP effect/NN hydroxyanisole/NN tumorigenesis/NNS forestomach/NN
RA/NNP effect/NN hydroxyanisole/NN tumorigenesis/NNS
RA/VBG %/NN animals/NNS observed/VBN BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN papilloma/NN squamous/JJ
RA/VBG %/NN animals/NNS observed/VBN BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN papilloma/NN cell/NN
RA/VBG %/NN animals/NNS observed/VBN BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN papilloma/NN
RA/NNP given/VBN group/NN increased/VBD incidence/NN papilloma/NN squamous/JJ
RA/NNP given/VBN group/NN increased/VBD incidence/NN papilloma/NN cell/NN
RA/NNP given/VBN group/NN increased/VBD incidence/NN papilloma/NN
BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN papilloma/NN squamous/JJ
BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN papilloma/NN cell/NN
BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN papilloma/NN
BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN papilloma/NN carcinoma/NN
BHA/NNP given/VBN groups/NNS increased/VBD %/NN 9/CD rats/NNS carcinoma/NN
BHA/NNP given/VBN groups/NNS increased/VBD %/NN 3/CD 20/CD rat/NN carcinoma/NN
RA/VBG %/NN animals/NNS observed/VBN BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN tumors/NNS forestomach/JJ
RA/VBG %/NN animals/NNS observed/VBN BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN tumors/NNS
RA/NNP given/VBN group/NN increased/VBD incidence/NN tumors/NNS forestomach/JJ
RA/NNP given/VBN group/NN increased/VBD incidence/NN tumors/NNS
RA/VBG %/NN animals/NNS observed/VBN BHA/NNP given/VBN groups/NNS increased/VBD incidence/NN papilloma/NN carcinoma/NN
RA/VBG %/NN animals/NNS observed/VBN BHA/NNP given/VBN groups/NNS increased/VBD %/NN 9/CD rats/NNS carcinoma/NN
RA/VBG %/NN animals/NNS observed/VBN BHA/NNP given/VBN groups/NNS increased/VBD %/NN 3/CD 20/CD rat/NN carcinoma/NN
RA/NNP given/VBN group/NN increased/VBD incidence/NN papilloma/NN carcinoma/NN
RA/NNP given/VBN group/NN increased/VBD %/NN 9/CD rats/NNS carcinoma/NN
RA/NNP given/VBN group/NN increased/VBD %/NN 3/CD 20/CD rat/NN carcinoma/NN
BHA/NNP given/VBN rats/NNS showed/VBD dose/NN induced/VBN hyperplasia/NN epithelial/JJ
BHA/NNP given/VBN rats/NNS showed/VBD dose/NN induced/VBN hyperplasia/NN
BHA/NNP development/NN enhancing/VBG dependent/JJ dose/NN induced/VBN hyperplasia/NN epithelial/JJ
BHA/NNP development/NN enhancing/VBG dependent/JJ dose/NN induced/VBN hyperplasia/NN
RA/NNP co/NNP showed/VBD dose/NN induced/VBN hyperplasia/NN epithelial/JJ
RA/NNP co/NNP showed/VBD dose/NN induced/VBN hyperplasia/NN
RA/RB 0/NNP rats/NNS rat/NN %/NN administration/NN induced/VBN Tumors/NNS papillomas/NNS
RA/NNP co/NNP %/NN administration/NN induced/VBN Tumors/NNS papillomas/NNS
RA/RB 0/NNP rats/NNS rat/NN %/NN administration/NN induced/VBN Tumors/NNS
RA/NNP co/NNP %/NN administration/NN induced/VBN Tumors/NNS
RA/NNP acted/VBD indicate/VBP forestomach/VBP
RA/NNP acted/VBD indicate/VBP forestomach/VBP carcinogenesis/NNS
crack/NN abusers/NNS endorsing/VBG CIP/NN
cocaine/NN abusers/NNS endorsing/VBG CIP/NN
crack/NN abusers/NNS endorsing/VBG CIP/NN group/NN denied/VBD CIP/NNP
cocaine/NN abusers/NNS endorsing/VBG CIP/NN group/NN denied/VBD CIP/NNP
crack/NN addicts/NNS group/NN CIP/NN
crack/NN addicts/NNS group/NN denied/VBD CIP/NNP
crack/NN abusers/NNS group/NN distinguish/VB able/JJ Measures/NNS oscillation/NN pupillary/JJ
crack/NN abusers/NNS group/NN distinguish/VB able/JJ Measures/NNS oscillation/NN
cocaine/NN abusers/NNS group/NN distinguish/VB able/JJ Measures/NNS oscillation/NN pupillary/JJ
cocaine/NN abusers/NNS group/NN distinguish/VB able/JJ Measures/NNS oscillation/NN
crack/NN addicts/NNS group/NN CIP/NN endorsing/VBG abusers/NNS group/NN distinguish/VB able/JJ Measures/NNS oscillation/NN pupillary/JJ
crack/NN addicts/NNS group/NN CIP/NN endorsing/VBG abusers/NNS group/NN distinguish/VB able/JJ Measures/NNS oscillation/NN
Amiodarone/NNP represents/VBZ drug/NN cardioversion/NN recent/JJ fibrillation/NN atrial/JJ
Amiodarone/NNP represents/VBZ drug/NN cardioversion/NN recent/JJ fibrillation/NN
Amiodarone/NNP represents/VBZ drug/NN cardioversion/NN recent/JJ AF/NNP
amiodarone/NN loading/NN initiation/NN experienced/VBD fibrillation/NN atrial/JJ
amiodarone/NN loading/NN initiation/NN experienced/VBD fibrillation/NN
salicylates/NNS association/NN lack/NN disappearing/VBG syndrome/NN Reye/JJ
salicylates/NNS association/NN lack/NN disappearing/VBG syndrome/NN
Penicillamine/NNP induced/VBN arthritis/NN rheumatoid/JJ
Penicillamine/NNP induced/VBN arthritis/NN
D/NNP months/NNS presented/VBN arthritis/NN rheumatoid/JJ
D/NNP months/NNS presented/VBN arthritis/NN
penicillamine/JJ treatment/NN woman/NN arthritis/NN rheumatoid/JJ
penicillamine/JJ treatment/NN woman/NN arthritis/NN
D/NNP course/NN case/NN emphasizes/VBZ need/NN sediment/NN proteinuria/NN
penicillamine/JJ treatment/NN emphasizes/VBZ need/NN sediment/NN proteinuria/NN
hepatitis/NNP antigen/NN stick/VB assess/VB examined/VBN globulin/NN Hepatitis/NNP
hepatitis/NNP antigen/NN stick/VB assess/VB examined/VBN globulin/NN B/NNP
B/NNP antigen/NN stick/VB assess/VB examined/VBN globulin/NN Hepatitis/NNP
B/NNP antigen/NN stick/VB assess/VB examined/VBN globulin/NN B/NNP
surface/NN antigen/NN stick/VB assess/VB examined/VBN globulin/NN Hepatitis/NNP
surface/NN antigen/NN stick/VB assess/VB examined/VBN globulin/NN B/NNP
antigen/NN stick/VB assess/VB examined/VBN globulin/NN Hepatitis/NNP
antigen/NN stick/VB assess/VB examined/VBN globulin/NN B/NNP
hepatitis/NNP antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP type/NN
hepatitis/NNP antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP B/NNP
hepatitis/NNP antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP
B/NNP antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP type/NN
B/NNP antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP B/NNP
B/NNP antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP
surface/NN antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP type/NN
surface/NN antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP B/NNP
surface/NN antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP
antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP type/NN
antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP B/NNP
antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP
HBsAG/NNP antigen/NN stick/VB assess/VB examined/VBN globulin/NN Hepatitis/NNP
HBsAG/NNP antigen/NN stick/VB assess/VB examined/VBN globulin/NN B/NNP
HBsAG/NNP antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP type/NN
HBsAG/NNP antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP B/NNP
HBsAG/NNP antigen/NN stick/VB assess/VB preventing/VBG hepatitis/NNP
Nimodipine/NNP prevents/VBZ impairment/NN hypotension/NN
Nimodipine/NNP prevents/VBZ impairment/NN memory/NN
Nimodipine/NNP prevents/VBZ impairment/NN
nimodipine/NN administered/VBN tested/VBD preserve/VB hypotension/NN
NIMO/NNP nimodipine/NN administered/VBN tested/VBD preserve/VB hypotension/NN
NIMO/NNP saline/NN injected/VBN those/DT showed/VBD Mice/NNS subjected/VBN hypotensive/VB
NIMO/NNP attenuated/VBD caused/VBD improve/VB absence/NN hypotension/NN
NIMO/NNP effect/NN attributable/JJ hypotension/NN
calcium/NN homeostasis/NNS preservation/NN attributable/JJ hypotension/NN
gamma/NN synthesis/NN attributed/VBD induced/VBN tachycardia/NN bradycardia/NN
aminobutyric/JJ acid/NN gamma/NN synthesis/NN attributed/VBD induced/VBN tachycardia/NN bradycardia/NN
acid/NN gamma/NN synthesis/NN attributed/VBD induced/VBN tachycardia/NN bradycardia/NN
GABA/NNP gamma/NN synthesis/NN attributed/VBD induced/VBN tachycardia/NN bradycardia/NN
gamma/NN synthesis/NN attributed/VBD induced/VBN doses/NNS hypotension/NN
aminobutyric/JJ acid/NN gamma/NN synthesis/NN attributed/VBD induced/VBN doses/NNS hypotension/NN
acid/NN gamma/NN synthesis/NN attributed/VBD induced/VBN doses/NNS hypotension/NN
GABA/NNP gamma/NN synthesis/NN attributed/VBD induced/VBN doses/NNS hypotension/NN
gamma/NN synthesis/NN attributed/VBD induced/VBN tachycardia/NN
aminobutyric/JJ acid/NN gamma/NN synthesis/NN attributed/VBD induced/VBN tachycardia/NN
acid/NN gamma/NN synthesis/NN attributed/VBD induced/VBN tachycardia/NN
GABA/NNP gamma/NN synthesis/NN attributed/VBD induced/VBN tachycardia/NN
isoniazid/JJ hypotension/NN doses/NNS induced/VBN tachycardia/NN
urethane/NN chloralose/NN anaesthetised/VBN rats/NNS determined/VBN induced/VBN enhancement/NN isoniazid/NN bradycardia/NN
chloralose/NN anaesthetised/VBN rats/NNS determined/VBN induced/VBN enhancement/NN isoniazid/NN bradycardia/NN
hexamethonium/NN increased/VBD' increased/VBD bradycardia/NN
propranolol/JJ increased/VBD bradycardia/NN
clonidine/NN increased/VBD bradycardia/NN
atenolol/JJ propranolol/JJ increased/VBD bradycardia/NN
labetalol/JJ propranolol/JJ increased/VBD bradycardia/NN
pindolol/JJ propranolol/JJ increased/VBD bradycardia/NN
carbachol/NN hexamethonium/NN increased/VBD' increased/VBD bradycardia/NN
Valproic/JJ acid/NN given/VBN patients/NNS epileptic/JJ
acid/NN given/VBN patients/NNS epileptic/JJ
VPA/NNP acid/NN given/VBN patients/NNS epileptic/JJ
angiotensin/NN proteins/NNS altered/VBN rats/NNS syndrome/NN nephrotic/JJ
angiotensin/NN proteins/NNS altered/VBN rats/NNS syndrome/NN
angiotensin/NN proteins/NNS altered/VBN rats/NNS syndrome/NN NS/NNP
tobramicyn/NN regimen/NN effect/NN evaluate/VB concentrations/NNS toxicity/NN
creatinine/NN observed/VBN evidence/NN nephrotoxicity/NN
Doxorubicin/NN cardiomyopathy/NN Wilms/NNP
Doxorubicin/NN cardiomyopathy/NN Wilms/NNP tumor/NN
anthracycline/NN cardiomyopathy/NN
anthracycline/NN cardiomyopathy/NN experienced/VBD bed/NN tumor/NN
anthracycline/NN cardiomyopathy/NN experienced/VBD children/NNS tumor/NN Wilms/NNP
anthracycline/NN cardiomyopathy/NN experienced/VBD children/NNS tumor/NN
doxorubicin/NN bed/NN tumor/NN
doxorubicin/NN bed/NN experienced/VBD children/NNS tumor/NN Wilms/NNP
doxorubicin/NN bed/NN experienced/VBD children/NNS tumor/NN
doxorubicin/NN interaction/NN fact/NN include/VBP fields/NNS tumor/NN Wilms/NNP
doxorubicin/NN interaction/NN fact/NN include/VBP fields/NNS tumor/NN
doxorubicin/NN dosage/NN restricted/VBN tumor/NN Wilms/NNP
doxorubicin/NN dosage/NN restricted/VBN tumor/NN
lithium/JJ sex/NN duration/NN respect/VBG had/VBD relative/NN disease/NN thyroid/NN
lithium/JJ sex/NN duration/NN respect/VBG had/VBD relative/NN disease/NN
lithium/NN therapy/NN receiving/VBG disorder/NNP bipolar/NNP
lithium/NN therapy/NN receiving/VBG disorder/NNP
lithium/NN therapy/NN years/NNS hypothyroidism/NN onset/NN accelerated/VBN patients/NNS having/VBG first/JJ relatives/NNS affected/VBN illness/NN thyroid/NN
lithium/NN therapy/NN years/NNS hypothyroidism/NN onset/NN accelerated/VBN patients/NNS having/VBG first/JJ relatives/NNS affected/VBN illness/NN
lithium/NN therapy/NN onset/NN years/NNS hypothyroidism/NN onset/NN accelerated/VBN patients/NNS having/VBG first/JJ relatives/NNS affected/VBN illness/NN thyroid/NN
lithium/NN therapy/NN onset/NN years/NNS hypothyroidism/NN onset/NN accelerated/VBN patients/NNS having/VBG first/JJ relatives/NNS affected/VBN illness/NN
lithium/NN therapy/NN factor/NN illness/NN thyroid/NN
lithium/NN therapy/NN factor/NN illness/NN
lithium/NN therapy/NN factor/NN hypothyroidism/NN hypercalcemia/NN
Doxorubicin/NN cardiomyopathy/NN induced/VBN attenuated/VBN inflammation/NNS
doxorubicin/NN use/NN limited/VBN effects/NNS cardiotoxic/JJ
DOX/NNP doxorubicin/NN use/NN limited/VBN effects/NNS cardiotoxic/JJ
anthracycline/JJ doxorubicin/NN use/NN limited/VBN effects/NNS cardiotoxic/JJ
DOX/NNP cardiomyopathy/NN development/NN elucidate/VB studied/VBD B/NNP mice/NNS investigating/VBG inflammation/NNS
DOX/NNP induction/NN investigating/VBG inflammation/NNS
DOX/NNP mice/NNS showed/VBD dysfunction/NN cardiac/JJ
DOX/NNP mice/NNS showed/VBD dysfunction/NN
DOX/NNP mice/NNS improved/VBN dysfunction/NN cardiac/JJ
DOX/NNP mice/NNS improved/VBN dysfunction/NN
DOX/NNP mice/NNS improved/VBN dysfunction/NN cardiac/JJ
DOX/NNP mice/NNS improved/VBN dysfunction/NN
ephedrine/NN study/NN placebo/NN induced/VBN dysfunction/NN sexual/JJ
ephedrine/NN study/NN placebo/NN induced/VBN dysfunction/NN
ephedrine/NN has/VBZ effects/NNS dysfunction/NN sexual/JJ
ephedrine/NN has/VBZ effects/NNS dysfunction/NN
ephedrine/NN effects/NNS study/NN cross/JJ controlled/JJ measures/NNS women/NNS sexually/RB
ephedrine/NN effects/NNS study/NN cross/JJ controlled/JJ measures/NNS women/NNS dysfunctional/JJ
Pilocarpine/JJ age/NN seizures/NNS
Pilocarpine/NNP induced/VBN resulted/VBD loss/NN seizures/NNS
Pilocarpine/NNP induced/VBN resulted/VBD had/VBD loss/NN seizures/NNS
baclofen/NN muscimol/NN drugs/NNS jerks/NNS myoclonic/JJ
baclofen/NN muscimol/NN drugs/NNS jerks/NNS
benzodiazepines/NNS drugs/NNS jerks/NNS myoclonic/JJ
benzodiazepines/NNS drugs/NNS jerks/NNS
clonazepam/NN found/VBN blocking/VBG jerks/NNS myoclonic/JJ
clonazepam/NN found/VBN blocking/VBG jerks/NNS
diazepam/NN potent/JJ found/VBN blocking/VBG jerks/NNS myoclonic/JJ
diazepam/NN potent/JJ found/VBN blocking/VBG jerks/NNS
benzodiazepines/NNS found/VBN blocking/VBG jerks/NNS myoclonic/JJ
benzodiazepines/NNS found/VBN blocking/VBG jerks/NNS
5/CD fact/NN found/VBN beneficial/JJ management/NN myoclonus/NNS
HTP/NNP found/VBN beneficial/JJ management/NN myoclonus/NNS
5/CD fact/NN found/VBN seems/VBZ myoclonus/NNS
HTP/NNP found/VBN seems/VBZ myoclonus/NNS
benzodiazepines/NNS HTP/NNP found/VBN beneficial/JJ management/NN myoclonus/NNS
benzodiazepines/NNS HTP/NNP found/VBN seems/VBZ myoclonus/NNS
MK/NNP value/NN myoclonus/NNS
212/NNP value/NN myoclonus/NNS
baclofen/NN value/NN myoclonus/NNS
phenytoin/NN administration/NN safe/JJ child/NN hypothermic/JJ
phenytoin/NN administered/VBN part/NN surgery/NN prophylaxis/NNS seizure/NN
atropine/VB refractory/VBG developed/VBD bradycardia/NN
adrenaline/VB atropine/VB refractory/VBG developed/VBD bradycardia/NN
phenytoin/NN hypothermia/NN
phenytoin/NN presence/NN hypothermia/NN
doxorubicin/NN induced/VBN cardiotoxicity/RB
fat/JJ diet/NN sensitive/JJ doxorubicin/NN induced/VBN cardiotoxicity/RB
doxorubicin/NN sensitive/JJ rats/NNS obese/NN
doxorubicin/NN chemotherapy/NN limited/VBN life/NN threatening/VBG cardiotoxicity/RB
Adriamycin/NNP doxorubicin/NN chemotherapy/NN limited/VBN life/NN threatening/VBG cardiotoxicity/RB
doxorubicin/NN induced/VBN cardiotoxicity/RB
doxorubicin/NN sensitizes/NNS rats/NNS diet/NN feeding/VBG intervention/NN induced/VBN cardiotoxicity/RB
fat/JJ diet/NN feeding/VBG intervention/NN induced/VBN cardiotoxicity/RB
doxorubicin/NN sensitizes/NNS rats/NNS diet/NN induces/VBZ obesity/RB
doxorubicin/NN dose/NN administered/VBN day/NN regimen/NN led/VBN absence/NN toxicity/NN renal/JJ
doxorubicin/NN dose/NN administered/VBN day/NN regimen/NN led/VBN absence/NN toxicity/NN renal/JJ or/CC
doxorubicin/NN dose/NN administered/VBN day/NN regimen/NN led/VBN absence/NN toxicity/NN renal/JJ hepatic/JJ
doxorubicin/NN dose/NN administered/VBN day/NN regimen/NN led/VBN absence/NN toxicity/NN
doxorubicin/NN dose/NN administered/VBN day/NN regimen/NN led/VBN cardiotoxicity/NN
doxorubicin/NN dose/NN administered/VBN day/NN regimen/NN led/VBN cardiotoxicity/NN mortality/NN rats/NNS obese/JJ
doxorubicin/NN dose/NN administered/VBN day/NN regimen/NN led/VBN cardiotoxicity/NN mortality/NN rats/NNS OB/NNP
doxorubicinol/NN doxorubicin/NN accumulation/NN change/NN fed/NN revealed/VBD OB/VBP
Doxorubicin/JJ studies/NNS revealed/VBD OB/VBP
doxorubicin/NN accumulation/NN change/NN fed/NN revealed/VBD OB/VBP
ATP/NNP levels/NNS drop/NN leading/VBG stress/VBP revealed/VBD sensitized/VBN rats/NNS OB/NNP
ATP/NNP levels/NNS drop/NN leading/VBG upregulation/NN uncoupling/VBG proteins/NNS downregulation/NN proliferators/NNS oxidation/NN min/NN min/NN heart/NN OB/NNP
ATP/NNP ratio/NN accompanied/VBN levels/NNS drop/NN leading/VBG stress/VBP revealed/VBD sensitized/VBN rats/NNS OB/NNP
ATP/NNP ratio/NN accompanied/VBN levels/NNS drop/NN leading/VBG upregulation/NN uncoupling/VBG proteins/NNS downregulation/NN proliferators/NNS oxidation/NN min/NN min/NN heart/NN OB/NNP
doxorubicin/NN administration/NN ratio/NN accompanied/VBN levels/NNS drop/NN leading/VBG stress/VBP revealed/VBD sensitized/VBN rats/NNS OB/NNP
doxorubicin/NN administration/NN ratio/NN accompanied/VBN levels/NNS drop/NN leading/VBG upregulation/NN uncoupling/VBG proteins/NNS downregulation/NN proliferators/NNS oxidation/NN min/NN min/NN heart/NN OB/NNP
AMP/NNP decreased/VBN oxidation/NN proliferators/NNS downregulation/NN proteins/NNS uncoupling/VBG upregulation/NN leading/VBG stress/VBP revealed/VBD sensitized/VBN rats/NNS OB/NNP
AMP/NNP decreased/VBN oxidation/NN min/NN min/NN heart/NN OB/NNP
ADP/NNP ratio/NN accompanied/VBN levels/NNS drop/NN leading/VBG stress/VBP revealed/VBD sensitized/VBN rats/NNS OB/NNP
ADP/NNP ratio/NN accompanied/VBN levels/NNS drop/NN leading/VBG upregulation/NN uncoupling/VBG proteins/NNS downregulation/NN proliferators/NNS oxidation/NN min/NN min/NN heart/NN OB/NNP
ATP/NN generation/NN downregulating/VBG induced/VBN HFD/NNP induced/VBN sensitized/JJ rats/NNS obese/JJ
doxorubicin/NN sensitized/JJ induced/VBN HFD/NNP induced/VBN cardiotoxicity/RB
doxorubicin/NN sensitized/JJ rats/NNS obese/JJ
ATP/NN generation/NN downregulating/VBG induced/VBN cardiotoxicity/RB
testosterone/NN concentration/NN increased/VBD affected/VBN hyperprolactinemia/NN
risperidone/NNP started/VBN occurred/VBD fractures/NNS
Diazepam/RB remains/VBZ ketamine/VB buffers/VBZ decreases/VBZ duration/NN hallucinations/NNS
haloperidol/NN potentiation/NN induced/VBN hyperactivity/RB
apomorphine/NN prevention/NN catalepsy/NN
steroids/NNS protect/VBP acid/NN seizures/NNS epilepticus/NNS status/NN
steroids/NNS protect/VBP acid/NN seizures/NNS epilepticus/NNS
steroids/NNS protect/VBP acid/NN seizures/NNS
deoxycorticosterone/NN progesterone/NN metabolites/NNS seizures/NNS
3/CD alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
hydroxy/JJ pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
21/CD pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
diol/NN 21/CD pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
20/CD diol/NN 21/CD pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
ones/NNS 21/CD pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
progesterone/NN metabolites/NNS seizures/NNS
3/CD alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
hydroxy/JJ pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
20/CD pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
ones/NNS 20/CD pregnane/NN alpha/NNS progesterone/NN metabolites/NNS seizures/NNS
N/NNP metabolites/NNS seizures/NNS
methyl/NN metabolites/NNS seizures/NNS
D/NNP methyl/NN metabolites/NNS seizures/NNS
aspartate/NN metabolites/NNS seizures/NNS
NMDA/NNP aspartate/NN metabolites/NNS seizures/NNS
Steroids/NNS induced/VBZ seizures/NNS epilepticus/NNS status/NN
Steroids/NNS induced/VBZ seizures/NNS epilepticus/NNS
Steroids/NNS induced/VBZ seizures/NNS
benzodiazepine/JJ clonazepam/NN potent/JJ protecting/VBG seizures/NNS
benzodiazepine/JJ clonazepam/NN potent/JJ had/VBD values/NNS TD/NNP divided/VBN protection/NN seizure/NN
clonazepam/NN potent/JJ had/VBD values/NNS indicating/VBG have/VB toxicity/NN
clonazepam/NN values/NNS indicating/VBG have/VB toxicity/NN
benzodiazepine/JJ clonazepam/NN potent/JJ had/VBD values/NNS indicating/VBG have/VB toxicity/NN
steroids/NNS potent/JJ had/VBD values/NNS indicating/VBG have/VB toxicity/NN
steroids/NNS had/VBD values/NNS indicating/VBG have/VB toxicity/NN
steroids/NNS have/VB toxicity/NN
steroids/NNS potent/JJ protecting/VBG seizures/NNS
steroids/NNS potent/JJ had/VBD values/NNS TD/NNP divided/VBN protection/NN seizure/NN
steroids/NNS had/VBD potent/JJ protecting/VBG seizures/NNS
steroids/NNS had/VBD values/NNS TD/NNP divided/VBN protection/NN seizure/NN
steroids/NNS have/VB indicating/VBG values/NNS had/VBD potent/JJ protecting/VBG seizures/NNS
steroids/NNS have/VB indicating/VBG values/NNS TD/NNP divided/VBN protection/NN seizure/NN
clonazepam/NN potent/JJ protecting/VBG seizures/NNS
clonazepam/NN potent/JJ had/VBD values/NNS TD/NNP divided/VBN protection/NN seizure/NN
clonazepam/NN values/NNS had/VBD potent/JJ protecting/VBG seizures/NNS
clonazepam/NN values/NNS TD/NNP divided/VBN protection/NN seizure/NN
pilocarpine/JJ seizures/NNS protecting/VBG potent/JJ had/VBD values/NNS indicating/VBG have/VB toxicity/NN
Steroids/NNS produced/VBD onset/NN seizures/NNS
Steroids/NNS produced/VBD protect/VB seizures/NNS
steroid/NN dose/NN administered/VBN However/RB obtained/VBN seizures/NNS epilepticus/NNS status/NN
steroid/NN dose/NN administered/VBN However/RB obtained/VBN seizures/NNS epilepticus/NNS
steroid/NN dose/NN administered/VBN However/RB obtained/VBN seizures/NNS
steroids/NNS caused/VBD protect/VB seizures/NNS
NMDA/NNP delay/NN dose/NN induced/VBN caused/VBD protect/VB seizures/NNS
NMDA/NNP seizures/NNS
steroids/NNS effective/JJ protecting/VBG acid/NN seizures/NNS epilepticus/NNS status/NN
steroids/NNS effective/JJ protecting/VBG acid/NN seizures/NNS epilepticus/NNS
steroids/NNS effective/JJ utility/NN treatment/NN forms/NNS epilepticus/NNS status/NN
steroids/NNS effective/JJ utility/NN treatment/NN forms/NNS epilepticus/NNS
steroids/NNS effective/JJ protecting/VBG acid/NN seizures/NNS
heparin/NN therapy/NN thrombophlebitis/NNS
oxacillin/NN treated/VBN man/NN year/NN developed/VBD failure/NN lesions/NNS purpuric/JJ
oxacillin/NN treated/VBN man/NN year/NN developed/VBD failure/NN lesions/NNS
oxacillin/NN week/NN bacteremia/NN Staphylococcus/NNP
oxacillin/NN week/NN bacteremia/NN aureus/NN
oxacillin/NN week/NN bacteremia/NN
cyanoacrylate/JJ doxorubicin/NN toxicity/NN renal/JJ
cyanoacrylate/JJ doxorubicin/NN toxicity/NN
doxorubicin/NN toxicity/NN renal/JJ
doxorubicin/NN toxicity/NN
adriamycin/NN doxorubicin/NN toxicity/NN renal/JJ
adriamycin/NN doxorubicin/NN toxicity/NN
doxorubicin/NN nanoparticle/NN explored/VBN rats/NNS glomerulonephritis/NNS
doxorubicin/NN nanoparticle/NN explored/VBN toxicity/NN renal/JJ
doxorubicin/NN nanoparticle/NN explored/VBN toxicity/NN
DX/NNP died/VBD given/VBN rats/NNS rats/NNS glomerulonephritis/NNS
DX/NNP killed/VBD toxicity/NN renal/JJ
DX/NNP killed/VBD toxicity/NN
naloxazone/NN Pretreatment/NNP blocked/VBD morphine/VB analgesia/NN catalepsy/NN
morphine/VB analgesia/NN
naloxazone/NN Pretreatment/NNP blocked/VBD morphine/VB analgesia/NN
naloxazone/NN Pretreatment/NNP blocked/VBD morphine/VB analgesia/NN hypothermia/NN
naloxazone/NN attenuated/VBN bradycardia/NN
morphine/JJ bradycardia/NN induced/VBN hypotension/NN depression/NN respiratory/JJ
morphine/JJ bradycardia/NN induced/VBN hypotension/NN depression/NN
morphine/JJ induced/VBN hypotension/NN depression/NN respiratory/JJ
morphine/JJ induced/VBN hypotension/NN depression/NN
naloxazone/NN attenuated/VBN bradycardia/NN induced/VBN hypotension/NN
naloxazone/NN attenuated/VBN bradycardia/NN induced/VBN hypotension/NN depression/NN respiratory/JJ
naloxazone/NN attenuated/VBN bradycardia/NN induced/VBN hypotension/NN depression/NN
methylprednisolone/NN dose/NN reviews/VBZ mechanisms/NNS death/NN sudden/JJ
methylprednisolone/NN dose/NN reviews/VBZ mechanisms/NNS death/NN
IVMP/NNP methylprednisolone/NN dose/NN reviews/VBZ mechanisms/NNS death/NN sudden/JJ
IVMP/NNP methylprednisolone/NN dose/NN reviews/VBZ mechanisms/NNS death/NN
Amiodarone/NNP proved/VBN treatment/NN tachyarrhythmias/NNS
amiodarone/JJ treatment/NN due/JJ hepatitis/NN patient/JJ cholestatic/JJ
amiodarone/JJ treatment/NN due/JJ hepatitis/NN
amiodarone/NN hepatotoxicity/NN review/NN given/VBN presented/VBN hepatitis/NN patient/JJ cholestatic/JJ
amiodarone/NN hepatotoxicity/NN review/NN given/VBN presented/VBN hepatitis/NN
amiodarone/JJ treatment/NN due/JJ injury/NN exists/VBZ concluded/VBN alterations/VBZ hepatitis/NN alcoholic/JJ
amiodarone/JJ treatment/NN due/JJ injury/NN exists/VBZ concluded/VBN alterations/VBZ hepatitis/NN
amiodarone/JJ treatment/NN due/JJ injury/NN exists/VBZ concluded/VBN alterations/VBZ hepatitis/NN hepatitis/NN cholestatic/JJ
amiodarone/JJ treatment/NN due/JJ injury/NN exists/VBZ concluded/VBN alterations/VBZ hepatitis/NN hepatitis/NN
apomorphine/NN infusion/NN induced/VBN state/NN dyskinetic/JJ
apomorphine/NN infusion/NN induced/VBN state/NN modification/NN result/VB investigated/VBD Using/VBG area/NN group/NN patients/NNS disease/NN Parkinson/JJ
apomorphine/NN infusion/NN induced/VBN state/NN modification/NN result/VB investigated/VBD Using/VBG area/NN group/NN patients/NNS disease/NN
azidothymidine/NN erythropoietin/NN colonies/NNS Sensitivity/NNP treated/VBD mice/NNS immunodeficient/JJ
AZT/NNP due/JJ determine/VB BM/VBP used/VBN model/NN AIDS/NNP
AZT/NNP due/JJ determine/VB BM/VBP infection/NN
AZT/NNP due/JJ determine/VB BM/VBP leukaemia/NN
phenylhydrazine/NN compared/VBN observed/VBD degree/NN anaemia/NN
PHZ/NNP phenylhydrazine/NN compared/VBN observed/VBD degree/NN anaemia/NN
PHZ/NNP AZT/NNP treated/VBN degrees/NNS anaemia/NN
AZT/NNP observed/VBN anaemia/NN degree/NN inappropriate/JJ reticulocytosis/NNS
amisulpride/NN unmasked/VBD Pheochromocytoma/NNP
tiapride/NN amisulpride/NN unmasked/VBD Pheochromocytoma/NNP
amisulpride/NN treated/VBN patient/NN describe/VB unmasking/NN pheochromocytoma/NN
tiapride/NN amisulpride/NN treated/VBN patient/NN describe/VB unmasking/NN pheochromocytoma/NN
nicardipine/NN recovered/VBD discontinued/VBN CASE/NN man/NN headache/NN
verapamil/NN treatment/NN nicardipine/NN recovered/VBD discontinued/VBN CASE/NN man/NN hypertension/NN
verapamil/NN treatment/NN nicardipine/NN recovered/VBD discontinued/VBN CASE/NN man/NN headache/NN
nicardipine/NN recovered/VBD discontinued/VBN CASE/NN man/NN hypertension/NN
verapamil/NN treatment/NN nicardipine/NN recovered/VBD discontinued/VBN CASE/NN man/NN headache/NN vomiting/NN
nicardipine/NN recovered/VBD discontinued/VBN CASE/NN man/NN headache/NN vomiting/NN
benzamide/NN drugs/NNS use/NN associated/VBN symptoms/NNS pheochromocytoma/NN
amisulpride/JJ crisis/NN patient/NN pheochromocytoma/NN
tiapride/JJ amisulpride/JJ crisis/NN patient/NN pheochromocytoma/NN
barbiturate/NN melatonin/NN effects/NNS narcosis/NNS
barbiturate/NN narcosis/NNS
barbiturate/JJ narcosis/NNS
barbiturate/JJ mechanism/NN specific/JJ seems/VBZ action/NN melatonin/NN narcosis/NNS
pegylated/JJ alpha/NNS patient/NN chronic/JJ
pegylated/JJ alpha/NNS patient/NN hepatitis/NNP
pegylated/JJ alpha/NNS patient/NN C/NNP
interferon/NN alpha/NNS patient/NN chronic/JJ
interferon/NN alpha/NNS patient/NN hepatitis/NNP
interferon/NN alpha/NNS patient/NN C/NNP
alpha/NNS patient/NN chronic/JJ
alpha/NNS patient/NN hepatitis/NNP
alpha/NNS patient/NN C/NNP
2/CD b/NNS case/NN parasitosis/NNS patient/NN chronic/JJ
2/CD b/NNS case/NN parasitosis/NNS patient/NN hepatitis/NNP
2/CD b/NNS case/NN parasitosis/NNS patient/NN C/NNP
b/NNS case/NN parasitosis/NNS patient/NN chronic/JJ
b/NNS case/NN parasitosis/NNS patient/NN hepatitis/NNP
b/NNS case/NN parasitosis/NNS patient/NN C/NNP
ribavirin/JJ treatment/NN b/NNS case/NN parasitosis/NNS patient/NN chronic/JJ
ribavirin/JJ treatment/NN b/NNS case/NN parasitosis/NNS patient/NN hepatitis/NNP
ribavirin/JJ treatment/NN b/NNS case/NN parasitosis/NNS patient/NN C/NNP
ribavirin/NN interferon/NN treatment/NN patients/NNS chronic/JJ
ribavirin/NN interferon/NN treatment/NN patients/NNS hepatitis/NNP
ribavirin/NN interferon/NN treatment/NN patients/NNS C/NNP
MPTP/NNP dyskinesias/NNS
L/NNP drugs/NNS Effect/VBG dopa/NN dyskinesias/NNS
dopa/NN dyskinesias/NNS
L/NNP tested/VBN see/VB modified/VBN movements/NNS dyskinetic/JJ
DOPA/NNP tested/VBN see/VB modified/VBN movements/NNS dyskinetic/JJ
dopamine/NN neurotransmitters/NNS acting/VBG agents/NNS series/NN tested/VBN see/VB modified/VBN movements/NNS dyskinetic/JJ
clonidine/NN reduced/VBD cost/NN return/NN symptomatology/NN parkinsonian/NN
methysergide/NN clonidine/NN reduced/VBD movements/NNS dyskinetic/JJ
5/CD methysergide/NN clonidine/NN reduced/VBD movements/NNS dyskinetic/JJ
MDOT/NN clonidine/NN reduced/VBD movements/NNS dyskinetic/JJ
physostigmine/NN clonidine/NN reduced/VBD movements/NNS dyskinetic/JJ
MK/NN MDOT/NN clonidine/NN reduced/VBD cost/NN return/NN symptomatology/NN parkinsonian/NN
801/CD clonidine/NN reduced/VBD cost/NN return/NN symptomatology/NN parkinsonian/NN
propranolol/NN MDOT/NN clonidine/NN reduced/VBD movements/NNS dyskinetic/JJ
methysergide/NN clonidine/NN reduced/VBD cost/NN return/NN symptomatology/NN parkinsonian/NN
propranolol/NN MDOT/NN clonidine/NN reduced/VBD cost/NN return/NN symptomatology/NN parkinsonian/NN
5/CD methysergide/NN clonidine/NN reduced/VBD cost/NN return/NN symptomatology/NN parkinsonian/NN
MDOT/NN clonidine/NN reduced/VBD cost/NN return/NN symptomatology/NN parkinsonian/NN
clonidine/NN reduced/VBD movements/NNS dyskinetic/JJ
physostigmine/NN clonidine/NN reduced/VBD cost/NN return/NN symptomatology/NN parkinsonian/NN
MK/NN MDOT/NN clonidine/NN reduced/VBD movements/NNS dyskinetic/JJ
801/CD clonidine/NN reduced/VBD movements/NNS dyskinetic/JJ
yohimbine/NN reduced/VBD movements/NNS dyskinetic/JJ
meperidine/NN yohimbine/NN reduced/VBD movements/NNS dyskinetic/JJ
Baclofen/NNP useful/JJ monkey/NN form/NN dyskinesia/NN
Baclofen/NNP useful/JJ monkey/NN form/NN dystonic/JJ
Atropine/NNP converted/VBD movements/NNS dystonic/JJ
Atropine/NNP converted/VBD chorea/NN
3/CD shown/VBN known/VBN lesions/NNS neurotoxic/NN
3/CD shown/VBN known/VBN lesions/NNS
4/CD 3/CD shown/VBN known/VBN lesions/NNS neurotoxic/NN
4/CD 3/CD shown/VBN known/VBN lesions/NNS
methylenedioxymethamphetamine/NN 4/CD 3/CD shown/VBN known/VBN lesions/NNS neurotoxic/NN
methylenedioxymethamphetamine/NN 4/CD 3/CD shown/VBN known/VBN lesions/NNS
MDMA/NNP methylenedioxymethamphetamine/NN 4/CD 3/CD shown/VBN known/VBN lesions/NNS neurotoxic/NN
MDMA/NNP methylenedioxymethamphetamine/NN 4/CD 3/CD shown/VBN known/VBN lesions/NNS
ecstasy/NN MDMA/NNP methylenedioxymethamphetamine/NN 4/CD 3/CD shown/VBN known/VBN lesions/NNS neurotoxic/NN
ecstasy/NN MDMA/NNP methylenedioxymethamphetamine/NN 4/CD 3/CD shown/VBN known/VBN lesions/NNS
MDMA/NNP HT/NNP consequences/NNS long/JJ lesions/NNS neurotoxic/NN
MDMA/NNP HT/NNP consequences/NNS long/JJ lesions/NNS
serotonin/NN neurons/NNS damage/VB shown/VBN known/VBN lesions/NNS neurotoxic/NN
serotonin/NN neurons/NNS damage/VB shown/VBN known/VBN lesions/NNS
5/CD neurons/NNS damage/VB shown/VBN known/VBN lesions/NNS neurotoxic/NN
5/CD neurons/NNS damage/VB shown/VBN known/VBN lesions/NNS
HT/NNP 5/CD neurons/NNS damage/VB shown/VBN known/VBN lesions/NNS neurotoxic/NN
HT/NNP 5/CD neurons/NNS damage/VB shown/VBN known/VBN lesions/NNS
5/CD HT/NNP consequences/NNS long/JJ lesions/NNS neurotoxic/NN
5/CD HT/NNP consequences/NNS long/JJ lesions/NNS
HT/NNP consequences/NNS long/JJ lesions/NNS neurotoxic/NN
HT/NNP consequences/NNS long/JJ lesions/NNS
5/CD functions/NNS known/VBN lesions/NNS neurotoxic/NN
5/CD functions/NNS known/VBN lesions/NNS
HT/NNP involved/VBN 5/CD functions/NNS known/VBN lesions/NNS neurotoxic/NN
HT/NNP involved/VBN 5/CD functions/NNS known/VBN lesions/NNS
testosterone/JJ fat/NN effects/NNS carcinogenesis/VBZ
testosterone/NN implanted/VBN rats/NNS developed/VBD interval/NN %/NN developed/VBN tumors/NNS
testosterone/NN implanted/VBN rats/NNS developed/VBD interval/NN %/NN included/VBD tumors/NNS
5/CD toxicity/NNP Cardiac/NNP
5/CD toxicity/NNP
fluorouracil/NN toxicity/NNP Cardiac/NNP
fluorouracil/NN toxicity/NNP
5/CD presented/VBD metastasis/NNS
fluorouracil/JJ administration/NN metastasis/NNS
5/CD administration/NN metastasis/NNS
FU/NNP 5/CD administration/NN metastasis/NNS
5/CD presented/VBD metastasis/NNS patient/NN carcinoma/NN colon/NN
5/CD presented/VBD metastasis/NNS patient/NN carcinoma/NN
fluorouracil/JJ administration/NN metastasis/NNS patient/NN carcinoma/NN colon/NN
fluorouracil/JJ administration/NN metastasis/NNS patient/NN carcinoma/NN
5/CD administration/NN metastasis/NNS patient/NN carcinoma/NN colon/NN
5/CD administration/NN metastasis/NNS patient/NN carcinoma/NN
FU/NNP 5/CD administration/NN metastasis/NNS patient/NN carcinoma/NN colon/NN
FU/NNP 5/CD administration/NN metastasis/NNS patient/NN carcinoma/NN
nifedipine/NN resolved/VBN pain/NN chest/NN
nifedipine/NN resolved/VBN pain/NN
nifedipine/NN resolved/VBN similar/JJ observed/VBD angina/NN Prinzmetal/NNP
nifedipine/NN resolved/VBN similar/JJ observed/VBD angina/NN Prinzmetal/NNP '/POS
nifedipine/NN resolved/VBN similar/JJ observed/VBD angina/NN s/JJ
nifedipine/NN resolved/VBN similar/JJ observed/VBD angina/NN
calcium/NN antagonists/NNS used/VBN cause/NN due/JJ cardiotoxicity/RB
calcium/NN antagonists/NNS used/VBN cause/NN suggest/VBP cardiotoxicity/JJ
calcium/NN antagonists/NNS used/VBN cause/NN spasm/NN coronary/JJ
calcium/NN antagonists/NNS used/VBN cause/NN spasm/NN
5/CD due/JJ cause/NN spasm/NN coronary/JJ
5/CD due/JJ cause/NN spasm/NN
FU/NNP cause/NN spasm/NN coronary/JJ
FU/NNP cause/NN spasm/NN
5/CD prevention/NN used/VBN cause/NN spasm/NN coronary/JJ
5/CD prevention/NN used/VBN cause/NN spasm/NN
FU/NNP cardiotoxicity/JJ suggest/VBP cause/NN spasm/NN coronary/JJ
FU/NNP cardiotoxicity/JJ suggest/VBP cause/NN spasm/NN
5/CD due/JJ cardiotoxicity/RB
FU/NNP cause/NN due/JJ cardiotoxicity/RB
5/CD due/JJ cause/NN suggest/VBP cardiotoxicity/JJ
FU/NNP cause/NN suggest/VBP cardiotoxicity/JJ
5/CD prevention/NN used/VBN cause/NN due/JJ cardiotoxicity/RB
FU/NNP cardiotoxicity/JJ suggest/VBP cause/NN due/JJ cardiotoxicity/RB
5/CD prevention/NN used/VBN cause/NN suggest/VBP cardiotoxicity/JJ
FU/NNP cardiotoxicity/JJ
paroxetine/NN treatment/NN day/NN exhibited/VBD tremors/NNS
paroxetine/NN treatment/NN day/NN exhibited/VBD retardation/NN rigidity/NN muscle/NN
paroxetine/NN treatment/NN day/NN exhibited/VBD retardation/NN rigidity/NN
paroxetine/NN treatment/NN day/NN exhibited/VBD retardation/NN psychomotor/NN
paroxetine/NN treatment/NN day/NN exhibited/VBD retardation/NN
alprazolam/NN paroxetine/NN treatment/NN day/NN exhibited/VBD tremors/NNS
alprazolam/NN paroxetine/NN treatment/NN day/NN exhibited/VBD retardation/NN rigidity/NN muscle/NN
alprazolam/NN paroxetine/NN treatment/NN day/NN exhibited/VBD retardation/NN rigidity/NN
alprazolam/NN paroxetine/NN treatment/NN day/NN exhibited/VBD retardation/NN psychomotor/NN
alprazolam/NN paroxetine/NN treatment/NN day/NN exhibited/VBD retardation/NN
penicillamine/JJ therapy/NN effects/NNS patient/NN arthritis/NN rheumatoid/JJ
penicillamine/JJ therapy/NN effects/NNS patient/NN arthritis/NN
penicillamine/JJ therapy/NN complications/NNS recorded/VBN patients/NNS arthritis/NN rheumatoid/JJ
penicillamine/JJ therapy/NN complications/NNS recorded/VBN patients/NNS arthritis/NN
penicillamine/NN treated/VBN arthritis/NN reported/VBN serpiginosa/NN perforans/VBZ resembled/VBD lesion/NN skin/NN
penicillamine/NN treated/VBN arthritis/NN reported/VBN serpiginosa/NN perforans/VBZ resembled/VBD lesion/NN
penicillamine/NN treated/VBN arthritis/NN rheumatoid/JJ
penicillamine/NN treated/VBN arthritis/NN
penicillamine/NN treated/VBN arthritis/NN reported/VBN serpiginosa/NN perforans/VBZ elastosis/NNS
penicillamine/NN treated/VBN arthritis/NN reported/VBN serpiginosa/NN perforans/VBZ
penicillamine/NN treated/VBN arthritis/NN reported/VBN serpiginosa/NN
penicillamine/NN treated/VBN arthritis/NN reported/VBN effect/NN patients/NNS disease/NN Wilson/NNP
penicillamine/NN treated/VBN arthritis/NN reported/VBN effect/NN patients/NNS disease/NN Wilson/NNP '/POS
penicillamine/NN treated/VBN arthritis/NN reported/VBN effect/NN patients/NNS disease/NN s/JJ
penicillamine/NN treated/VBN arthritis/NN reported/VBN effect/NN patients/NNS disease/NN
chloramphenicol/NN beginning/VBG undergoing/VBG extraction/NN cataract/NN
chloramphenicol/NN treatment/NN report/NN reported/VBN cases/NNS hypoplasia/NN bone/NN
chloramphenicol/NN treatment/NN report/NN reported/VBN cases/NNS hypoplasia/NN marrow/NN
chloramphenicol/NN treatment/NN report/NN reported/VBN cases/NNS hypoplasia/NN
chloramphenicol/NN associated/VBN toxicity/NN ocular/NN
chloramphenicol/NN associated/VBN toxicity/NN
ifosfamide/NN Hallucinations/NNS induced/VBN neurotoxicity/RB
ifosfamide/NN effect/NN symptom/NN neurotoxicity/NN
ifosfamide/NN hallucinations/NNS occur/VB signs/NNS neurotoxicity/NN
haloperidol/NN neuroleptics/NNS becomes/VBZ agitation/NN
prostaglandin/NN synthetase/NN Effect/NN inhibitors/VBZ induced/VBG convulsions/NNS
prostaglandins/NNS induction/NN seizure/NN
prostaglandins/NNS induction/NN effects/NNS inhibitors/NNS convulsions/NNS
PGs/NNP prostaglandins/NNS induction/NN seizure/NN
PGs/NNP prostaglandins/NNS induction/NN effects/NNS inhibitors/NNS convulsions/NNS
PGs/NNP involved/VBN fluorthyl/NN induced/VBN convulsions/NNS
PGs/NNP involved/VBN fluorthyl/NN convulsions/NNS
azidothymidine/NN induced/VBN impairment/NN activity/NN immunodeficiency/JJ
Benzylacyclouridine/NNP reverses/VBZ azidothymidine/NN induced/VBN suppression/NN marrow/NN
Benzylacyclouridine/NNP reverses/VBZ azidothymidine/NN induced/VBN suppression/NN
Benzylacyclouridine/NNP reverses/VBZ azidothymidine/NN induced/VBN impairment/NN activity/NN immunodeficiency/JJ
azidothymidine/JJ vitro/NN inhibition/NN concentrations/NNS cells/NNS impairment/NN activity/NN immunodeficiency/JJ
AZT/NNP azidothymidine/JJ vitro/NN inhibition/NN concentrations/NNS cells/NNS impairment/NN activity/NN immunodeficiency/JJ
uridine/NN concentrations/NNS cells/NNS impairment/NN activity/NN immunodeficiency/JJ
Urd/NNP uridine/NN concentrations/NNS cells/NNS impairment/NN activity/NN immunodeficiency/JJ
benzylacyclouridine/NN ability/NN effect/NN AZT/NNP induced/VBN anemia/NN
BAU/NNP ability/NN effect/NN AZT/NNP induced/VBN anemia/NN
benzylacyclouridine/NN ability/NN effect/NN AZT/NNP induced/VBN anemia/NN leukopenia/NN
BAU/NNP ability/NN effect/NN AZT/NNP induced/VBN anemia/NN leukopenia/NN
AZT/NNP effect/NN ability/NN assessed/VBN toxicities/NNS
benzylacyclouridine/NN ability/NN assessed/VBN toxicities/NNS
BAU/NNP ability/NN assessed/VBN toxicities/NNS
Urd/NN administration/NN associated/VBN toxicities/NNS
Urd/NN administration/NN associated/VBN toxicities/NNS assessed/VBN ability/NN effect/NN AZT/NNP induced/VBN anemia/NN leukopenia/NN
Urd/NN administration/NN associated/VBN toxicities/NNS assessed/VBN ability/NN effect/NN AZT/NNP induced/VBN anemia/NN
Urd/NNP catabolism/NNP inhibits/VBZ toxicity/NN
Urd/NNP concentration/NN increases/VBZ inhibits/VBZ toxicity/NN
Urd/NNP manner/NN toxicity/NN
BAU/NN reversed/VBD rendered/VBN anemic/JJ
BAU/NN reversed/VBD induced/VBN anemia/NN
BAU/NN reversed/VBD rendered/VBN anemic/JJ leukopenic/JJ
BAU/NN reversed/VBD induced/VBN anemia/NN leukopenia/NN
BAU/NN reversed/VBD rendered/VBN mice/NNS increased/VBD improved/VBD megaloblastosis/NNS
AZT/NNP administration/NN rendered/VBN mice/NNS increased/VBD improved/VBD megaloblastosis/NNS
AZT/NNP administration/NN water/NN drinking/VBG days/NNS reversed/VBD rendered/VBN mice/NNS increased/VBD improved/VBD megaloblastosis/NNS
AZT/NNP induced/VBN reversed/VBD rendered/VBN mice/NNS increased/VBD improved/VBD megaloblastosis/NNS
BAU/NNP reduced/VBD AZT/NNP induced/VBN toxicity/NN marrow/NN
BAU/NNP reduced/VBD AZT/NNP induced/VBN toxicity/NN
levodopa/NN overflow/NN dyskinesias/NNS disease/NN Parkinson/NNP
levodopa/NN overflow/NN dyskinesias/NNS disease/NN Parkinson/NNP '/POS
levodopa/NN overflow/NN dyskinesias/NNS disease/NN s/JJ
levodopa/NN overflow/NN dyskinesias/NNS disease/NN
levodopa/NN therapy/NN complications/NNS assessed/VBD coordination/NN hand/NN disease/NN Parkinson/NNP
levodopa/NN therapy/NN complications/NNS assessed/VBD coordination/NN hand/NN disease/NN Parkinson/NNP '/POS
levodopa/NN therapy/NN complications/NNS assessed/VBD coordination/NN hand/NN disease/NN s/JJ
levodopa/NN therapy/NN complications/NNS assessed/VBD coordination/NN hand/NN disease/NN
levodopa/NN complications/NNS assessed/VBD coordination/NN hand/NN disease/NN Parkinson/NNP
levodopa/NN complications/NNS assessed/VBD coordination/NN hand/NN disease/NN Parkinson/NNP '/POS
levodopa/NN complications/NNS assessed/VBD coordination/NN hand/NN disease/NN s/JJ
levodopa/NN complications/NNS assessed/VBD coordination/NN hand/NN disease/NN
levodopa/NN with/IN studied/VBD groups/NNS patients/NNS Parkinson/NNP
levodopa/NN with/IN studied/VBD groups/NNS patients/NNS Parkinson/NNP '/POS
levodopa/NN with/IN studied/VBD groups/NNS patients/NNS s/JJ
levodopa/NN with/IN studied/VBD groups/NNS patients/NNS disease/NN
levodopa/NN with/IN LID/VBP +/NN Parkinson/NNP
levodopa/NN with/IN LID/VBP +/NN Parkinson/NNP '/POS
levodopa/NN with/IN LID/VBP +/NN s/JJ
levodopa/NN with/IN LID/VBP +/NN disease/NN
levodopa/NN dyskinesias/NNS disease/NN Parkinson/NNP
levodopa/NN dyskinesias/NNS disease/NN Parkinson/NNP '/POS
levodopa/NN dyskinesias/NNS disease/NN s/JJ
levodopa/NN dyskinesias/NNS disease/NN
levodopa/JJ assessed/VBN lift/VBP score/NN Scale/NNP Parkinson/NNP
levodopa/JJ assessed/VBN lift/VBP score/NN Scale/NNP Parkinson/NNP '/POS
levodopa/JJ assessed/VBN lift/VBP score/NN Scale/NNP s/NNP
levodopa/JJ assessed/VBN lift/VBP score/NN Scale/NNP Disease/NNP
levodopa/NN increased/VBN LID/NNP Parkinson/NNP
levodopa/NN increased/VBN LID/NNP Parkinson/NNP '/POS
levodopa/NN increased/VBN LID/NNP s/NNS
levodopa/NN increased/VBN LID/NNP disease/NN
mangiferin/NN Role/NNP infarction/NN myocardial/JJ
mangiferin/NN Role/NNP infarction/NN
creatine/JJ phosphokinase/JJ isoenzymes/NNS dehydrogenase/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN myocardial/JJ
creatine/JJ phosphokinase/JJ isoenzymes/NNS dehydrogenase/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN
uric/JJ level/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN myocardial/JJ
uric/JJ level/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN
acid/NN level/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN myocardial/JJ
acid/NN level/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN
lactate/NN dehydrogenase/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN myocardial/JJ
lactate/NN dehydrogenase/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN
iron/NN capacity/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN myocardial/JJ
iron/NN capacity/NN activity/NN determined/VBN heart/NN caused/VBD damage/NN
ISPH/NNP injection/NN caused/VBD damage/NN myocardial/JJ
ISPH/NNP injection/NN caused/VBD damage/NN
triphenyl/JJ chloride/NN test/NN used/VBN assay/NN myocardium/NN ischemic/JJ
triphenyl/JJ chloride/NN test/NN used/VBN assay/NN myocardium/NN
tetrazolium/NN chloride/NN test/NN used/VBN assay/NN myocardium/NN ischemic/JJ
tetrazolium/NN chloride/NN test/NN used/VBN assay/NN myocardium/NN
chloride/NN test/NN used/VBN assay/NN myocardium/NN ischemic/JJ
chloride/NN test/NN used/VBN assay/NN myocardium/NN
TTC/NNP chloride/NN test/NN used/VBN assay/NN myocardium/NN ischemic/JJ
TTC/NNP chloride/NN test/NN used/VBN assay/NN myocardium/NN
mangiferin/NN role/NN analyzed/VBN chloride/NN test/NN used/VBN assay/NN myocardium/NN ischemic/JJ
mangiferin/NN role/NN analyzed/VBN chloride/NN test/NN used/VBN assay/NN myocardium/NN
Vitamin/NNP C/NNP dismutase/NN enzymes/NNS altered/VBN rats/NNS MI/NNP
C/NNP dismutase/NN enzymes/NNS altered/VBN rats/NNS MI/NNP
glutathione/JJ peroxidase/NN dismutase/NN enzymes/NNS altered/VBN rats/NNS MI/NNP
glutathione/JJ transferase/NN dismutase/NN enzymes/NNS altered/VBN rats/NNS MI/NNP
glutathione/JJ activities/NNS transferase/NN dismutase/NN enzymes/NNS altered/VBN rats/NNS MI/NNP
glutathione/JJ levels/NNS dismutase/NN enzymes/NNS altered/VBN rats/NNS MI/NNP
Vitamin/NNP E/NNP dismutase/NN enzymes/NNS altered/VBN rats/NNS MI/NNP
E/NNP dismutase/NN enzymes/NNS altered/VBN rats/NNS MI/NNP
superoxide/JJ dismutase/NN enzymes/NNS altered/VBN rats/NNS MI/NNP
dimethyl/JJ sulphoxide/NN ml/NN suspended/VBN weight/NN pretreatment/NN given/VBN rats/NNS MI/NNP
sulphoxide/NN ml/NN suspended/VBN weight/NN pretreatment/NN given/VBN rats/NNS MI/NNP
mangiferin/NN pretreatment/NN given/VBN rats/NNS MI/NNP
mangiferin/NN administration/NN rose/VBD ISPH/NNP induced/VBN rats/NNS MI/NNP
mangiferin/NN exerts/VBZ due/JJ MI/NNP
ISPH/NNP exerts/VBZ due/JJ potential/NN regulated/VBN system/NN damage/NN cardiac/JJ
ISPH/NNP exerts/VBZ due/JJ potential/NN regulated/VBN system/NN damage/NN
mangiferin/NN exerts/VBZ due/JJ potential/NN regulated/VBN system/NN damage/NN cardiac/JJ
mangiferin/NN exerts/VBZ due/JJ potential/NN regulated/VBN system/NN damage/NN
CCNU/JJ toxicity/NN
lomustine/NN toxicity/NN
1/CD receiving/VBG dogs/NNS tumour/NN toxicities/NNS haematological/JJ
1/CD receiving/VBG dogs/NNS tumour/NN toxicities/NNS haematological/JJ renal/JJ
1/CD receiving/VBG dogs/NNS tumour/NN toxicities/NNS haematological/JJ hepatic/JJ
1/CD receiving/VBG dogs/NNS tumour/NN toxicities/NNS haematological/JJ and/CC
1/CD receiving/VBG dogs/NNS tumour/NN toxicities/NNS haematological/JJ gastrointestinal/JJ
1/CD receiving/VBG dogs/NNS tumour/NN toxicities/NNS
2/CD toxicities/NNS haematological/JJ
2/CD toxicities/NNS haematological/JJ renal/JJ
2/CD toxicities/NNS haematological/JJ hepatic/JJ
2/CD toxicities/NNS haematological/JJ and/CC
2/CD toxicities/NNS haematological/JJ gastrointestinal/JJ
2/CD toxicities/NNS
chloroethyl/NN 2/CD toxicities/NNS haematological/JJ
chloroethyl/NN 2/CD toxicities/NNS haematological/JJ renal/JJ
chloroethyl/NN 2/CD toxicities/NNS haematological/JJ hepatic/JJ
chloroethyl/NN 2/CD toxicities/NNS haematological/JJ and/CC
chloroethyl/NN 2/CD toxicities/NNS haematological/JJ gastrointestinal/JJ
chloroethyl/NN 2/CD toxicities/NNS
3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ
3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ renal/JJ
3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ hepatic/JJ
3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ and/CC
3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ gastrointestinal/JJ
3/CD describe/VB incidence/NN toxicities/NNS
cyclohexyl/JJ nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ
cyclohexyl/JJ nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ renal/JJ
cyclohexyl/JJ nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ hepatic/JJ
cyclohexyl/JJ nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ and/CC
cyclohexyl/JJ nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ gastrointestinal/JJ
cyclohexyl/JJ nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS
1/CD nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ
1/CD nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ renal/JJ
1/CD nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ hepatic/JJ
1/CD nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ and/CC
1/CD nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ gastrointestinal/JJ
1/CD nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS
nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ
nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ renal/JJ
nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ hepatic/JJ
nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ and/CC
nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ gastrointestinal/JJ
nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS
CCNU/NNP nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ
CCNU/NNP nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ renal/JJ
CCNU/NNP nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ hepatic/JJ
CCNU/NNP nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ and/CC
CCNU/NNP nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS haematological/JJ gastrointestinal/JJ
CCNU/NNP nitrosourea/NN 3/CD describe/VB incidence/NN toxicities/NNS
CCNU/NNP treated/VBN dogs/NNS met/VBD class/NN toxicity/NN
CCNU/NNP used/VBN treatment/NN lymphoma/NN
CCNU/NNP used/VBN treatment/NN lymphoma/NN lymphoma/NN epitheliotropic/JJ
CCNU/NNP used/VBN treatment/NN lymphoma/NN lymphoma/NN
CCNU/NNP used/VBN treatment/NN lymphoma/NN tumour/NN mast/JJ
CCNU/NNP used/VBN treatment/NN lymphoma/NN tumour/NN cell/NN
CCNU/NNP used/VBN treatment/NN lymphoma/NN tumour/NN
CCNU/NNP used/VBN treatment/NN lymphoma/NN tumour/NN brain/NN
CCNU/NNP used/VBN treatment/NN lymphoma/NN tumour/NN
CCNU/NNP used/VBN treatment/NN lymphoma/NN tumours/NNS histiocytic/JJ
CCNU/NNP used/VBN treatment/NN lymphoma/NN tumours/NNS
alanine/NN transaminase/NN toxicity/NN
CCNU/NNP CONCLUSIONS/NNS common/JJ toxicity/NN
quipazine/NN aggressiveness/NN
quipazine/NN aggressiveness/NN induced/VBN deprivation/NN REM/NNP
quipazine/NN aggressiveness/NN induced/VBN deprivation/NN sleep/NN
quipazine/NN aggressiveness/NN induced/VBN deprivation/NN
quipazine/NN aggressiveness/NN induced/VBN deprivation/NN REMD/NNP
apomorphine/NN deprivation/NN REM/NNP
apomorphine/NN deprivation/NN sleep/NN
apomorphine/NN deprivation/NN
apomorphine/NN deprivation/NN REMD/NNP
apomorphine/NN deprivation/NN induced/VBN twitches/NNS head/NN
apomorphine/NN deprivation/NN induced/VBN twitches/NNS
quipazine/JJ increased/VBN reduced/VBN increased/VBN induced/VBN aggressiveness/NN
quipazine/JJ increased/VBN reduced/VBN increased/VBN hr/NN REMD/NNP
quipazine/JJ increased/VBN reduced/VBN immediately/RB completing/VBG REMD/NNP
quipazine/JJ hr/NN REMD/NNP
apomorphine/JJ increased/VBN hr/NN REMD/NNP
apomorphine/JJ increased/VBN reduced/VBN immediately/RB completing/VBG REMD/NNP
apomorphine/JJ increased/VBN reduced/VBN increased/VBN quipazine/JJ hr/NN REMD/NNP
apomorphine/JJ increased/VBN reduced/VBN twitches/NNS head/NN
apomorphine/JJ increased/VBN reduced/VBN twitches/NNS
oestrogen/NN Long/NNP increased/VBD increase/VB risk/NN cancer/NN breast/NN
oestrogen/NN Long/NNP increased/VBD increase/VB risk/NN cancer/NN
amine/NN Effects/NNPS pretreatment/VBP catatonia/NN
catecholamines/NNS role/NN idolamines/NNS catatonia/NN
norepinephrine/NN pretreatment/NN did/VBD increased/VBD duration/NN catatonia/NN
adriamycin/NN effects/NNS Cardiotoxic/JJ
anthracycline/NN induced/VBN cardiomyopathy/RB
anthracycline/NN found/VBD resembled/VBD lesions/NNS myocardial/JJ
anthracycline/NN found/VBD resembled/VBD lesions/NNS
adriamycin/NN cardiotoxin/NN consequence/NN leukemia/NN
daunorubicin/NN sarcoma/NN Kaposi/NNP
daunorubicin/NN sarcoma/NN Kaposi/NNP '/POS
daunorubicin/NN sarcoma/NN s/JJ
daunorubicin/NN sarcoma/NN
daunorubicin/NN efficacy/NN assess/VB treatment/NN AIDS/NNP
daunorubicin/NN efficacy/NN assess/VB treatment/NN AIDS/NNP related/VBN sarcoma/NN Kaposi/NNP
daunorubicin/NN efficacy/NN assess/VB treatment/NN AIDS/NNP related/VBN sarcoma/NN Kaposi/NNP '/POS
daunorubicin/NN efficacy/NN assess/VB treatment/NN AIDS/NNP related/VBN sarcoma/NN s/JJ
daunorubicin/NN efficacy/NN assess/VB treatment/NN AIDS/NNP related/VBN sarcoma/NN
daunorubicin/NN agent/NN treatment/NN sarcoma/NN Kaposi/NNP
daunorubicin/NN agent/NN treatment/NN sarcoma/NN Kaposi/NNP '/POS
daunorubicin/NN agent/NN treatment/NN sarcoma/NN s/JJ
daunorubicin/NN agent/NN treatment/NN sarcoma/NN
Mesna/NNP adding/VBG precise/JJ frequency/NN hematuria/NN
Mesna/NNP adding/VBG infusate/NN patients/NNS hematuria/NN
cyclophosphamide/NN associated/VBN cancer/NN urothelial/JJ
cyclophosphamide/NN associated/VBN cancer/NN
Amisulpride/VB symptoms/NNS schizophrenic/NN
risperidone/NN antipsychotics/NNS treated/VBN disorders/NNS Tic/NNP
risperidone/NN antipsychotics/NNS treated/VBN disorders/NNS
ziprasidone/NN risperidone/NN antipsychotics/NNS treated/VBN disorders/NNS Tic/NNP
ziprasidone/NN risperidone/NN antipsychotics/NNS treated/VBN disorders/NNS
olanzapine/NN risperidone/NN antipsychotics/NNS treated/VBN disorders/NNS Tic/NNP
olanzapine/NN risperidone/NN antipsychotics/NNS treated/VBN disorders/NNS
quetiapine/NN occurring/VBG show/VBP tic/NN
quetiapine/NN occurring/VBG like/IN
quetiapine/NN occurring/VBG symptoms/NNS
clozapine/NN quetiapine/NN occurring/VBG show/VBP tic/NN
clozapine/NN quetiapine/NN occurring/VBG like/IN
clozapine/NN quetiapine/NN occurring/VBG symptoms/NNS
amisulpride/JJ treatment/NN months/NNS movements/NNS year/NN schizophrenic/NNS
amisulpride/JJ treatment/NN months/NNS movements/NNS year/NN schizophrenic/NNS developed/VBD eye/NN involuntary/JJ
amisulpride/JJ treatment/NN months/NNS movements/NNS year/NN schizophrenic/NNS developed/VBD eye/NN
amisulpride/JJ treatment/NN months/NNS movements/NNS blinking/JJ
amisulpride/JJ treatment/NN months/NNS movements/NNS
quetiapine/JJ occur/VB suggests/VBZ tic/NN
quetiapine/JJ occur/VB symptoms/NNS like/JJ
quetiapine/JJ occur/VB symptoms/NNS
clozapine/JJ quetiapine/JJ occur/VB suggests/VBZ tic/NN
clozapine/JJ quetiapine/JJ occur/VB symptoms/NNS like/JJ
clozapine/JJ quetiapine/JJ occur/VB symptoms/NNS
acetic/JJ acid/NN induced/VBN writhing/VBG
acid/NN induced/VBN writhing/VBG
acetic/JJ acid/NN paw/NN model/NN edema/NN
acid/NN paw/NN model/NN edema/NN
